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Abstract 
 
The emergence of antimicrobial resistance is a severe threat to global health and new 
classes of antibiotics are desperately needed. Peptoids, or oligo-N-substituted glycines, 
are a group of peptidomimetics with increased structural stability and resistance to 
protease degradation compared to peptide analogues. In Chapter 1, peptoids are 
introduced and their antimicrobial properties reported to date are summarised. The 
synthesis and characterisation of one of the largest library of antimicrobial peptoids in 
existence is outlined in Chapter 2, comprising linear sequences and cyclic compounds. 
The development of synthetic methodology that allows the on-resin synthesis of novel 
peptoids containing both lysine- and arginine-type monomers is also described. In 
Chapter 3, the antiparasitic activity of the peptoid library is assessed against a variety of 
clinically relevant protozoan targets; including Leishmania mexicana, the causative agent 
of the neglected tropical disease cutaneous leishmaniasis. Active peptoids were identified 
against the insect and mammalian life stages of this parasite, including several with low 
micromolar potency against L. mexicana infected macrophages, an in vivo model of the 
disease. Additionally, peptoids that have selective activity at sub-micromolar 
concentrations against Plasmodium falciparum have been identified. Chapter 4 discusses 
the potent antibacterial and antifungal properties of the peptoid library against 
planktonic bacteria and also against mixed species, cross kingdom biofilms using a new 
quantitative polymerase chain reaction approach. Evaluation of peptoid toxicity to 
mammalian cells is also considered and conjugation of active sequences to the lantibiotic 
nisin is evaluated as a method to increase peptoid selectivity. To rationalise the activity 
of the peptoid library, Chapter 5 investigates the relationship between peptoid 
hydrophobicity, secondary structure and biological activity using circular dichroism 
spectroscopy and partitioning experiments. Finally, the antimicrobial mode of action is 
also examined using confocal fluorescence microscopy. 
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Chapter 1 
An Introduction to Peptoids 
 
1.1 Antimicrobial peptides 
The discovery and deployment of antibiotics has had a dramatic positive impact on 
human and animal health since the introduction of penicillin in the 1940s. However, our 
ability to effectively treat bacterial diseases has gradually been eroded by the emergence 
of ‘superbugs’ that display resistance to multiple first line antibiotics. Increasing 
resistance, coupled with a dearth of new therapeutic molecules means the development 
of alternative antibacterial agents is imperative to prevent the onset of a post-antibiotic 
era where infection is rampant.1  
Over the last few decades, an emerging class of molecules called antimicrobial peptides 
(AMPs) have been studied as potential antibiotic compounds. AMPs, also known as host-
defense peptides, are found in nature and are part of the innate immune response of 
many organisms, as summarised by Table 1.1. They have been found to kill a large range 
of pathogens; including bacterial, fungal and parasitic species. In mammals, AMPs like 
the defensins and cathelicidin are found in leukocytes and are secreted by epithelia in skin 
and mucosal surfaces as part of the body’s innate immune response. AMPs are also 
involved in other roles, such as wound repair, angiogenesis, inflammation responses and 
in the adaptive immune system. The potential applications of AMPs are already well 
reviewed, and these peptides have been recognised as highly selective and efficacious 
compounds.2-4 
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Peptide Origin Structure Number of 
amino acids 
1 Magainin 2 Frog α-helical 23 
2 Cecropin A Insect α-helical 37 
3 Cathelicidin  Mammal 
(human) 
α-helical 37 
4 α-defensins Mammal 
(human) 
β-sheet 29-35 
5 β-defensin Mammal 
(human) 
β-sheet 36-47 
6 Protegrin 1 Mammal (pig) β-sheet 18 
7 Indolicin Mammal 
(bovine) 
Extended 
structure 
13 
8 Lactoferricin Mammal 
(bovine) 
Loop (one 
disulphide) 
25 
9 Nisin Bacteria Polycyclic 34 
Table 1.1. Examples of naturally occurring AMPs isolated from different sources with 
varying secondary structures.5 
 
AMPs are short peptides (typically between ten and fifty amino acids) often with an 
amphipathic structure that allows permeabilisation of bacterial cytoplasmic membranes, 
leading to apoptosis. Many AMPs have α-helical domains and most are cationic with a 
high content of the amino acids lysine and/or arginine. Structure activity relationship 
studies have shown that factors such as sequence, size, helical content, charge and 
overall hydrophobicity can all affect the potency of AMPs. Understanding these related 
factors is key to designing new AMPs with increased potency and selectivity.6,7  
AMPs often display greater selectivity towards bacterial membranes than eukaryotic 
membranes as their cationic character selectively targets prokaryotic membranes, which 
have a high proportion of negatively charged phospholipids. Perhaps the greatest 
advantage of AMPs over traditional small molecule drugs is that they are much less likely 
to be affected by bacterial resistance as they have been in use by nature for thousands of 
years without resistance emerging. Conventional antibiotics usually target specific 
bacterial processes, like cell wall synthesis, protein synthesis or replication. Bacteria 
undergo mutations rapidly and so can render entire classes of antibiotics ineffective in a 
short time period.8,9  
Although the exact mechanisms are still debated within the field, antimicrobial peptides 
are thought to disrupt the cytoplasmic membrane, either causing the formation of 
aggregates, ‘barrel-stave’, ‘carpet’ or ‘toroidal’ pores that lead to cell lysis and apoptosis 
(see Figure 1.1). Alternatively, AMPs may permeate the membrane and target anionic 
intracellular substances like DNA, mRNA or specific proteins and interrupt cellular 
processes. Although bacteria have evolved certain strategies such as increased protease 
production, active efflux or modification of groups on the surface of bacterial 
membrane*, many AMPs are able to evade these resistance mechanisms. As specific 
                                                     
*
 For example, surface polysaccharides may capture cationic AMPs before they reach the cell membrane. 
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receptors are not necessarily involved and an adaptation to alter the bacterial membrane 
composition is a substantial evolutional change, AMPs are thought to be less susceptible 
to the development of bacterial resistance than typical small molecule antibiotics.2,3,10-16 
 
Figure 1.1. Proposed mechanism of action of AMP against a bacterial cell membrane, 
represented by the lipid bilayer. Peptides are represented by the blue and red helicies 
(although it should be noted that not all AMPs are helical, and not all are amphipathic) 
which suggest hydrophobic and hydrophilic regions of the peptide. 1: aggregate model; 2: 
toroidal pore model; 3: barrel-stave model; 4: carpet model. 
 
More than 1,000 natural cationic peptides that display broad-spectrum activity have been 
identified to date.† Approved peptide therapeutics include antibiotics such as cyclic 
daptomycin17, gramicidin18 or the food preservative nisin (9).19 Although about 140 
peptides are being evaluated in the clinical trial process for various applications, few of 
these are antimicrobial peptides.20 AMPs often show potent antimicrobial activity in vitro 
in controlled experiments, but there are many challenges in the clinical application of 
candidate peptides. For example, AMPs generally have poor oral bioavailability, a short 
half-life in vivo due to protease action and are rapidly excreted through the liver and 
kidneys so AMP drugs are usually unsuitable for systemic administration and tend to be 
proposed in topical applications only. Additionally, the synthesis of peptide based 
therapeutics can be costly which reduces their feasibility.2,3,6,21-23 
Of the AMPs that pharmaceutical companies are developing, most are relatively small 
and the most cost-effective molecules which contain only the biologically active 
fragment of a larger parent peptide. AMPs have reached various stages of drug 
development, from preclinical studies to phase III trials (see Table 1.2 for compounds 
10–15 that are currently in clinical trials, 16 and 17 are in preclinical trials). However, 
despite encouraging results, as of 2015, no AMPs have been granted Food and Drug 
Administration (FDA) approval for clinical use.5,20,24-26 
 
                                                     
†
 The majority of these are documented in a variety of online databases, for example the Antimicrobial 
Peptide Database (URL: http://aps.unmc.edu/AP/main.php). 
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Peptide Clinical 
Trial 
Phase 
Number of 
amino 
acids 
Description and proposed 
use 
10 Pexiganan acetate 
 
III 22 Synthetic analogue of magainin 2; 
topical antibiotic for diabetic 
ulcers 
11 Iseganan III 17 Protegrin 1 analogue; prevention 
of oral mucositis 
12 Omiganan  II/III 12 Synthetic cationic derivative of 
indolicidin; topical antiseptic for 
prevention of catheter infection 
13 OP-145 II 24 LL-37 derivative for binding to 
lipopolysaccharides or 
lipoteichoic acid for the treatment 
of middle ear infection 
14 LTX-109 I/II 3 Peptidiomimetic compound as a 
topical antibiotic for nasally 
colonised MRSA 
15 hLF1-11 I/II 11 Lactoferrin analogue for the 
prevention of bacteria in the 
blood and fungal infections 
16 Arenicin preclinical 21 Rich in arginine and hydrophobic 
residues for use against multidrug 
resistant Gram positive bacteria 
17 IMX924 preclinical 5 Synthetic peptide for use against 
both Gram positive and Gram 
negative bacteria 
Table 1.2. Promising AMP candidates in clinical trials, as of 2015.5,25 
 
Many groups have sought to optimise AMPs and their analogues in the pursuit of novel 
antimicrobial drugs, aiming to achieve improved metabolic stability and bioavailability, 
whilst retaining the activity and selectivity of the original peptide. For example, AMPs 
have been formulated as prodrugs or compounds have been developed that are 
structurally similar but distinct to peptides - these are collectively known as 
peptidomimetics.27 Peptidomimetics can have additional advantageous properties, such 
as reduced rates of enzymatic degradation, the possibility to conformationally restrict 
the structure and enhance binding at desired receptors or provide the opportunity to add 
hydrophobic residues that can increase transport through cellular membranes. 
Common strategies to improve peptide stability are summarised in Figure 1.2. These 
include cyclisation; the use of unnatural amino acids, for example, D- or β-amino acids; 
peptide stapling28; the addition of extra moieties to the peptide sequence, i.e. 
lipidation29, methylation of sidechains30,31 or PEGylation32; and modification of the 
peptide backbone such as use of N-acylated-N-aminoethyl amino acids‡,33 or peptoids.34 
Additionally, many varied hybrid peptide-peptidomimetics have been synthesised to 
date. In particular the use of peptoids, oligomers of N-substituted glycine units, is 
becoming increasingly popular and the focus of this work.  
                                                     
‡
 α-AA peptides are based on the chiral peptide nucleic acid backbone. 
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Figure 1.2. Common strategies to stabilise linear peptoids and examples of 
peptidomimetics that improve the in vivo stability of the compound compared to the 
parent peptide. 
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1.2 Peptoid structure 
Peptoids are a class of peptidomimetics and as such share certain structural similarities 
with peptides, as illustrated in Figure 1.3. However, some aspects of peptoid structure 
are considerably different to that of peptides. In a peptoid, the polymer backbone 
consists of amide bonds where the side chain functionality is bonded to the nitrogen, 
rather than the α-carbon, so the repeating monomer of a peptoid is an N-substituted 
glycine. This means there are no stereogenic centres on the backbone of peptoids, 
compared to peptides that have a chiral backbone.10,35 
 
Figure 1.3. A comparison of the structures of generic α-peptoid and peptide oligomers. 
β-peptoids and β-peptides with the extra methylene unit in the backbone are also 
shown. 
 
The lack of an amide hydrogen (due to the N-substitution) has several important effects 
on the structure of peptoids. In peptides and proteins, amide protons can undergo intra-
chain hydrogen bonding which is key for the formation of the secondary structural 
motifs, such as α-helices and β-sheets. In peptoids, the absence of this amide proton 
leads to greater chain flexibility compared to peptides and prevents intra- and inter-
chain hydrogen bonding. In addition, the lack of a hydrogen bonding donor on the 
backbone prevents backbone driven aggregation which can help to increase 
bioavailability. Therefore peptoid secondary structures are formed almost exclusively 
through electrostatic and steric interactions. As such peptoids are protease resistant and 
are not denatured by solvent changes or increased temperatures that usually disrupt 
hydrogen bonding patterns in peptides. Further discussion about peptoid secondary 
structure and strategies to stabilise such structures can be found in Chapter 2.36  
The structures of generic alpha-peptoids and peptides are shown in Figure 1.3. Several 
research groups have also documented the synthesis and study of beta-peptoids, with an 
extra methylene group in the peptoid backbone.37-39 The structure of β-peptoids is also 
shown above. Although they appear less frequently in the literature than the α-peptoids, 
β-peptoids will be considered briefly.  
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Due to their improved stability to proteases, peptoids have been used in a wide variety of 
biomedical applications, ranging from inhibitors of protein-protein interactions40,41, 
molecular scaffolds42,43, nucleic acid binders44,45, lung surfactant protein mimics46, 
biomimetic materials43,47-50 or molecular transporters for drug delivery.51-53 Example 
peptoids 18–21 for these applications are shown in Figure 1.4. 
In particular, there is a wealth of literature detailing the antimicrobial activities of 
peptoids, with certain sequences displaying potent anti-infective properties against a 
wide variety of clinically relevant pathogens. This review seeks to summarise the field 
and will evaluate the antibacterial and antifungal properties of this exciting class of 
peptidomimetic molecules. The focus will be upon linear sequences but cyclic, lipidated 
peptoids, β-peptoids and hybrid peptoid-peptides will also be considered briefly.10,54,55  
Figure 1.4. Selected examples of peptoid structures and their varied applications. 
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1.3 Antibacterial peptoids 
1.3.1 Linear sequences 
The Barron group have conducted several structure-activity studies of peptoids against a 
wide variety of bacterial targets to probe the effect of characteristics such as chirality, 
chain length, overall sequence charge and hydrophobicity on the potency of peptoids as 
anti-infective compounds. In one study, peptoids were designed to mimic helical AMPs 
based broadly around a (NLysNspeNspe)-motif (see Figure 1.5) and these peptoids were 
shown to have broad-spectrum activity with the best MICs of 1.6 µM for E. coli and 
0.78 µM for B. subtilis.  
 
Figure 1.5. (NLysNspeNspe)-motif within the antimicrobial peptoids synthesised by the 
Barron group.56 
 
The hydrophobicity of the peptoids was altered by incorporation of different monomers; 
for example, Nssb monomers in peptoid 23 were replaced by the more hydrophobic 
monomers Nsmb and Nsna in peptoids 28 and 29 respectively in Table 1.3. The increased 
hydrophobicity of the side chains in peptoids 28 and 29 led to greater antibacterial 
activity (MIC against E. coli decreases from 31 µM to 7 µM in peptoids 28 and 29). 
However, incorporation of these more hydrophobic monomers also increased the 
hemolytic activity of the peptoids and the group also found that longer peptoid 
sequences are more cytotoxic against lung epithelial cells. The inclusion of the NHis 
chain§ in compound 31, gave a peptoid with substantially decreased cytotoxicity in vitro 
and only a small reduction in antibacterial activity. To investigate the effect of charge, 
NLys and NGlu monomers were used.  
The lytic activity of peptoids against human erythrocytes was determined as a crude 
measure of selectivity. The most active peptoids showed good antibacterial activity 
against B. subtillis and E. coli and were also not significantly hemolytic, so the library was 
                                                     
§
 The imidazole group of the NHis monomer is polar, but mostly uncharged at physiological pH with an 
isoelectric point of approximately pH 7.59. 
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extended in the group’s later work (see Table 1.3).  Successful compounds were then 
screened against six further clinically relevant bacterial pathogens and gave similar 
activities to pexiganan, 35, a peptide optimised for biomedical applications.  
It was demonstrated that the antimicrobial activity of these compounds was improved by 
moderate hydrophobicity, but high hydrophobicity and amphipathicity (i.e. peptoids 27, 
31 or 32) led to poorly selective, hemolytic compounds. In addition, it was shown that 
that not only the hydrophobic, but also the positively charged side chains, have a great 
influence on the antibacterial potency; replacement of the positively charged side chain 
amines by carboxylic acids resulted in almost inactive compounds (see NGlu containing 
peptoid 33). 12 residue sequences were identified as the optimal length for antibacterial 
activity – shorter peptoids were less potent and longer ones showed only an increase in 
hemolysis; for example, compare 9 reside peptoid 26 to 12 residue peptoid 22 with MIC 
values against E. coli of 9.1 µM to 3.5 µM respectively.  
The overall peptoid helix stability was only slightly important for antimicrobial activity; 
the handedness of a helix does not alter its activity or selectivity as peptoids with the α-
chiral monomer Nspe and Nrpe have the same activity (i.e. compound 22 and 24 both 
have equal MIC values against both E. coli and B. subtilis). Peptoids with strong and 
weak helical CD spectra all showed potent activity. Given that the peptoids which were 
strongly helical and amphipathic also had greater hemolytic activity, the overall 
sequence helicity should be considered when designing selective, antimicrobial peptoids 
in the future.56 
Further sequences were made to mimic magainin-2 amide (1) and hits within this library 
gave MICs between 5.4–49 µM for E. coli and 0.82–7.8 for B. subtilis.57 
   
 
10 
Table 1.3. A summary of selected peptoids and their associated antibacterial data from the Barron group. The selectivity ratio = 10 % hemolytic 
dose/MIC E. coli. The MIC values are obtained in assays with serum. The peptoid monomers used are also shown. All peptoids had C terminal 
amide groups.56 
 Linear Sequence Net 
Charge 
MIC (µM) Selectivity 
Ratio 
 
   E. coli B. subtilis  
22 (NLysNspeNspe)4 + 4 3.5 0.88 6.0 
23 (NLysNssbNspe)4 + 4 31 3.9 > 3.9 
24 (NLysNrpeNrpe)4 + 4 3.5 0.88 4.6 
25 (NLysNspeNspe)2 + 2 27 27 > 8.1 
26 (NLysNspeNspe)3 + 3 9.1 1.2 > 16 
27 (NLysNspeNspe)5 + 5 5.5 1.4 0.55 
28 (NLysNsmbNspe)4 + 4 7.4 0.95 > 16 
29 (NLysNssbNspeNLysNssbNsna)2 + 4 7.2 0.93 7.6 
30 (NLysNspeNspeNLysNspeNsna)2 + 4 3.3 1.6 1.2 
31 (NLysNspeNspeNLysNspeNHis)2 + 4 3.5 6.9 > 31 
32 (NLysNspeNspeNGluNspeNsna)2 0 > 110 6.9 < 0.17 
33 (NGluNspeNspe)4 - 4 > 219 > 219 n/a 
34 (NLysNpheNphe)4 + 4 12.5 1.6 14 
35 Pexiganan (GIGKFLKKAKKFGKAVKILKK-NH2) + 9 3.1 1.6 24 
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In other studies, peptoids related to the Barron group’s initial study into helical AMP 
mimics were shown to be active against clinically relevant targets, 
Pseudomonas aeruginosa biofilms and Mycobacterium tuberculosis which are causes of 
pulmonary infection (see Table 1.4).58,59  
These peptoids were shown to reduce the viability of established P. aeruginosa biofilms 
at their MICs, whereas antibiotics commonly used to treat this infection only showed 
comparable results at concentrations 8 to 30 times greater than their MIC. The most 
active peptoid tested, 22, (NLysNspeNspe)4 had an MIC value of 12.5 µM, compared to 
12.5–25 µM  for pexiganan (35) which was used as a control. It was shown that the 
peptoids prevent biofilm formation by killing planktonic cells and the hydrophobic tail 
on the most active sequence, peptoid 38, was proposed to act like a surfactant and 
interact strongly with the hydrophobic polysaccharide matrix on the cell surface, 
allowing the peptoid to penetrate deeper into the cell.59 
The peptoids in Table 1.4 showed appreciable activity against both M. tuberculosis and 
M. tuberculosis bacille Calmette-Guérin and displayed moderate toxicity against 
mammalian cells at their MIC. Similarly to the P. aeruginosa study, the cationic 
surfactant-like peptoid containing the C13 chain, 38, was the least cytotoxic and most 
active peptoid.58 
Table 1.4. Activities of selected peptoids against P. aeruginosa and M. tuberculosis and 
comparisons with their LD50 against murine macrophages.
58,59 
 
Peptoids have also been proven to interact synergistically with antimicrobial peptides, 
suggesting a similar mechanism of action.60 
A SAR study from the Shin group synthesised a peptoid analogue of a known 
tryptophan-rich antimicrobial peptide (see 39 in Figure 1.6). The cell selectivity of the 
peptide and peptoid were investigated against Gram positive and Gram negative 
bacteria, as well as their hemolytic activity against human red blood cells. Leakage of dye 
from liposomes designed to mimic the plasma membrane of bacteria was also measured 
to compare the mode of action between the peptide and peptoids. The peptoid and 
peptide tested showed very similar antimicrobial activities, with MIC ranging between 2 
 Linear Sequence MIC  
(µM) 
LD50 
(µM) 
  P. aeruginosa M. tuberculosis  
22 (NLysNspeNspe)4 12.5 14.1 20 
36 (NLysNspeNspe)3NLysNspe 12.5–25 14.46 40 
37 (NLysNspeNspe)2NLysNspe-LPro-NLysNspeNspe 25–50 14.5 40 
38 Ntridec-NLysNspeNspeNLys 12.5–25 6.6 n/a 
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µM to 8 µM against a broad range of bacteria and neither showed significant hemolytic 
activity, even at 800 µM. Overall, the peptoid caused less dye leakage than the peptide 
and it was suggested that the target of both peptide and peptoid was intracellular rather 
than the cell membrane.61 
 
Figure 1.6. The tryptophan rich peptoid, 39, synthesised by Shin et al. 40 is also shown, 
the GN2 peptoid made by Jenssen et al., of which derivatives were used in an SAR study 
on antimicrobial peptoids.61,62 
 
The Jenssen group built upon the Shin study of the tryptophan rich peptoid by 
synthesising 22 cationic, amphipathic peptoids. These sequences were direct 
transformations of known typtophan rich antimicrobial peptides (see Figure 1.6 for 
peptoid 40, GN2) and the relationship between charge and hydrophobicity upon activity 
and cytotoxicity was examined. Screening against E. coli, P. aeruginosa and S. aureus 
showed MICs within the range of 2–64 µg mL-1 with moderate or improved activity in 
comparison to related antimicrobial peptides. It was shown that peptoids with high 
hydrophobicity (measured via HPLC retention time) are not always the most potent 
compounds against the Gram negative bacteria screened, but a linear relationship is seen 
for S. aureus. Furthermore, an increase in hydrophobicity (typically introduced by the 
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inclusion of highly aromatic residues like N-(2,2-diphenylethyl)glycine residues) reduces 
selectivity and increases toxicity against mammalian cells.62  
The synthesis and characterisation of antibacterial tripeptoids found by screening of 
combinatorial chemistry libraries has identified peptoids with moderate activities against 
different bacteria strains.63,64 The antimicrobial properties of peptoids have also been 
studied computationally, providing consistent results with biological testing65 or via a 
mixture of modelling and NMR structural characterisation.66 Another study compared 
the activity of a peptoid library using in silico, in vitro and in vivo techniques. In this 
study a QSAR model was able to correlate the antimicrobial activity (via MIC) of a 
peptoid from its structure.67 
Finally, antimicrobial peptoids have also been immobilized onto titanium dioxide 
surfaces and shown to damage the cell membrane of adherent E. coli within 2 hours. In 
these systems both active antimicrobial peptoid and a passive antifouling peptoid 
coating was added with the view to use in implantable medical devices.43 
 
1.3.2 Cyclic antimicrobial peptoids 
Macrocyclisation enforces conformational ordering so reduces entropy losses upon 
binding to a biological target compared to a linear analogue and this is often linked to 
increased antimicrobial activity; for example, cyclic peptides like gramicidin are potent 
AMPs. An increased hydrophobic surface area in cyclic compounds compared to linear 
analogues and loss of charged termini is often attributed to an improvement in 
antimicrobial activity, via increased membrane permeability. In addition, the challenge 
of creating stable and defined secondary structures in linear peptoids due to their cis-
trans isomerism means macrocyclisation is an attractive route. Therefore, there has been 
significant interest in the synthesis of cyclic peptoids as anti-infective agents, particularly 
because peptoids have been shown to cyclise more efficiently than peptides.68-70 
The first cyclic peptoids with documented antimicrobial properties were synthesised by 
the De Riccardis lab. A small library of linear peptoids and their cyclised analogues was 
made to investigate activity against clinically relevant bacterial and fungal targets 
(E. coli, S. aureus, Candida albicans and Cryptococcus neoformans). Both protected and 
deprotected compounds were included in the study. Enhanced antimicrobial potency 
was seen following macrocyclisation and the moderate activity of cyclic molecules 41–46 
are summarised in Table 1.5. Overall, their library showed better activity against the 
fungal targets compared to the bacteria and the antifungal potency increased with a 
greater number of charged amino groups, but this increased charge inhibited 
antimicrobial activity against both bacterial strains. It was also demonstrated that the 
amphiphilicity of the peptoids impacts significantly on the antimicrobial activity. The 
cyclic peptoids also show a selectivity against fungal strains and negligible toxicity to 
human red blood cells at the concentrations tested.71 
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Cyclic Peptoid MIC (µM) 
  E. coli S. aureus C. albicans 
41 cyclo (NLysNOBnNOBn)2 392 392 196 
42 cyclo (NLysNLysNOBn)2 383 383 184 
43 cyclo (NpheNpheNphe)2 > 1000 > 1000 > 1000 
44 cyclo (NLysNpheNphe)2 465 465 232 
45 cyclo (NLysNLysNphe)2 786 > 1000 12 
46 cyclo (NLysNLysNLys)2 > 1000 > 1000 5 
Table 1.5. The antibacterial and antifungal properties of selected cyclic peptoids. The 
structure and side chains of the peptoids are also shown.71 
 
The Kirschenbaum group have synthesised a large number of potent antimicrobial 
peptoids. The library was informed by X-ray crystal structures and designed with 
alternating cationic and hydrophobic monomers to lead to an amphiphillic structure 
with defined cationic/hydrophobic faces on opposing faces of the planar macrocycle. 
This was suggested to improve biological activity and may help cyclic peptoids to target 
cell membranes.69,72  
Some peptoids screened were found to be inactive, but others showed potent 
antimicrobial properties; in particular peptoid 57 in Table 1.6 with alternating phenyl 
and aminopropyl residues (NapNphe)5 had MIC values of 0.5 µg mL
-1 and 7.8 µg mL-1 for 
B. subtilis and E. coli/S. aureus respectively. The potency of cyclic peptoids was 
compared to the activity of their linear precursors and as before, it was shown that 
cyclisation improves antibacterial properties. This is shown in Table 1.6 and illustrated 
by Figure 1.7 where it can be seen that the MIC values are lower for cyclic peptoids 
relative to their linear analogues.72  
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Figure 1.7. The MIC values for selected peptoids against E. coli (sequences shown in 
Table 1.6) and the increase in activity against shown by lower MIC values upon 
cyclisation.72 
 
Longer peptoid sequences had increased activity in both cyclic and linear cases and the 
Kirshenbaum group concluded that there is a strong correlation between the 
hydrophobic surface area of a peptoid and activity by comparing sequences with side 
chains of varying hydrophobic surface area. For example, when comparing the napthyl, 
phenyl and diphenyl substituted peptoids (compounds 50, 48 and 52 respectively) the 
napthyl peptoids have the greatest activity. However, increasing the hydrophobic area 
often also increases the hemolytic activity, so there should always be a balance between 
activity and selectivity. Finally in a resistance study using a potent cyclic peptoid, 
S. aureus was not able to develop resistance over a 21 day period, indicating the potential 
that peptoids provide as novel antimicrobials.72 
The cyclic peptoids summarised in Table 1.6 did not readily induce hemolysis of human 
erythrocytes (HC50 > 250 mg mL
-1 for all compounds**) so were a promising starting point 
in the production of antibacterial peptoids.  
 
 
 
 
 
 
                                                     
**
 Where HC50 is the hemolytic concentration at which 50 % of the erythrocytes in solution are lysed. 
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Peptoid Sequence MIC (µM) 
S. aureus E. coli 
47 linear Ac(NapNdp)3 15.6 15.6 
48 cyclo (NapNdp)3 7.8 15.6 
49 linear Ac(NapNnap)3 125 62.5 
50 cyclo (NapNnap)3 31.3 31.3 
51 linear Ac(NapNphe)4 250 250 
52 cyclo (NapNphe)4 31.3 31.3 
53 linear Ac(NapNphe)3 62.5 31.3 
54 cyclo (NapNphe)3 7.8 7.8 
55 linear Ac(NdpNLeuNArgNVal-Pro)2 500 250 
56 cyclo (NdpNLeuNArgNVal-Pro)2 62.5 31.3 
57 linear Ac(NapNphe)5 62.5 31.3 
58 cyclo (NapNphe)5 7.8 7.8 
Table 1.6. Selected peptoids from the Kirschenbaum study are tabulated to compare the 
effect of macrocyclisation. Peptoid monomers used are also illustrated.72 
 
Further work from the Kirshenbaum group looked at the mode of action of cyclic 
antimicrobial peptoids against S. aureus. A new library of 5 and 6 residue cyclic peptoids 
was designed (see Table 1.7) to extend the previous library and these compounds 
included a greater variety of aromatic side chains for a more detailed SAR study.73 
9 out of the 25 peptoids showed moderate or good antimicrobial activities and the 
relationship between hydrophobic surface area and activity was reinforced; i.e. for 
example, napthyl-based residues give higher potency than the phenyl-type monomers. 
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When comparing peptoids with diphenyl groups (i.e Ndp monomer), sequences with 
three Ndp residues show much better activity than those containing only two Ndp 
monomers (i.e. scaffolds A/C 59 and 61 versus scaffold B 60). Often compounds with 
increased hydrophobicity show increased toxicity towards host cells through non-
specific interactions with mammalian membranes. However, most peptoids in this study 
had a good selectivity and moderate to low hemolysis (HD10 values in the range of 30–
100 µM and selectivity ratios between 8 and 30).73 
 
 R Group Scaffold MIC 
(µM) 
 
 R Group Scaffold MIC 
(µM) 
 
59 
60 
61 
 
A 
B 
C 
3.9 
250 
3.9 
66 
67 
 
A 
B 
3.9 
> 500 
62 
63 
 
A 
B 
> 500 
> 500 
68 
 
A 15.6 
64 
 
A 31.3 69 
 
A 3.9 
65 
 
A 3.9 70 
 
A 3.9 
Table 1.7. Peptoids from the Kirschenbaum study are tabulated with their MIC values 
against S. aureus. The cyclic scaffolds are shown above, with the ‘R’ groups shown in the 
table entries.73 
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Scanning electron microscopy (SEM) was used to confirm that the membrane of the 
bacteria, in this case S. aureus, was damaged upon treatment with cyclic peptoid. In 
Figure 1.8, it can be seen that pores and craters have been created in the bacterial cell 
walls in the cells treated with peptoid 59 at its MIC concentration.73 
 
 
Figure 1.8. Scanning electron microscopy images to show the action of cyclic peptoids 
on bacterial cell membranes. A untreated cells; B–F cells incubated with peptoid 59 at 
the MIC value of 3.9 µM for 18 hours. Reprinted with permission, copyright 2013 John 
Wiley and Sons.††,73 
 
The Kirschenbaum group have also used osmoprotective polymer additives to investigate 
the mechanism of action at the cell surface in more detail. It has been suggested that the 
creation of pores in a cell membrane leads to osmotic shock and the subsequent cell lysis 
and death. Adding osmoprotective layers to cells (in this case, polyethylene glycol) can 
prevent the influx of water that occurs after pore formation and therefore can protect 
against this process.  
Both moderately active and potent cyclic peptoids were added to polymer protected 
methicillin-resistant S. aureus and SEM used to study morphological changes. Initial 
pores formed by the cyclic peptoids in the absence of osmoprotectant were between 2.0–
3.8 nm in diameter but expanded to > 200 nm over 24 hours. After adding the 
osmoprotectant, the antimicrobial potency of the peptoids was diminished but pores 
were still seen via SEM. It is suggested by the authors that the polymer is able to protect 
the cells from the expansion of lethal pores attenuating the MIC and that the cell 
membrane of the MRSA is a primary target of their antimicrobial peptoids.74 
                                                     
††
 Image adapted from Huang et al, Eur. J. Org. Chem., 2013, 17, 3560. 
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1.3.3 Lipopeptoids 
Lipopeptides, such as daptomycin, or the polymyxin and echinocandin related 
antibiotics are becoming increasingly important antimicrobial peptides. These molecules 
all possess fatty acid chains that have been shown to be vital for their activities.75 
Lipopeptoids with different sequences and lipid tails have been synthesised to mimic 
these successful antimicrobial peptides and their toxicity and activity against both Gram 
positive and Gram negative bacteria strains studied by several groups.  
The Barron group has taken linear peptoid sequences, previously used in their 
antibacterial studies, and added lipid-type chains to the N termini of the sequence with 
alkyl tails either 5, 10 or 13 carbons in length. A selection of these lipopeptoids and their 
activities against bacterial and fungal species have been summarised in  
Table 1.8. It was found that the 12 residue peptoid 22 (NLysNspeNspe)4 with known 
antibacterial activity loses its activity against bacteria as the chain length of the lipid tail 
increases, i.e. C5 chain on peptoid 70 yields an MIC of 15.5 µM against E. coli whereas 
with the C10 chain of compound 73 has an MIC value of 31.6 µM. However, the longer 
alkyl chains do shows display increased antifungal properties, with lower MIC values 
against C. albicans. It is suggested that the higher hydrophobicity needed for activity 
against fungal species stems from differences between zwitterionic eukaryotic 
membranes and the more anionic bacterial cell membranes.76 
For the shorter peptoid sequences that were lipidated, an increased antimicrobial 
potency is seen against both bacteria and fungi compared to the analogous unalkylated 
peptoid 22 (i.e. peptoid 74 has lower MIC values of 8.8 µM against E. coli and C. albicans 
and MIC value of 2.2 µM against B. subtilis). Significantly, lipopeptoids as short as five 
residues showed good antimicrobial activity with promising selectivity ratios against 
human erythrocytes, with peptoid 74 having a selectivity ratio of 17.76  
As expected, the longer lipid tails lead to more hydrophobic molecules with a higher 
toxicity towards eukaryotic cells. However, alkylation does not always cause detrimental 
hemolytic activity as the 5 residue Ndec peptoid 75 showed potent activity against Gram 
positive bacteria but negligible lysis of red blood cells at concentrations as high as 
200 µg mL-1. To extend the study, 38, Ntridec-NLysNspeNspeNLys was tested against a 
wide variety of clinically relevant pathogens including multi-drug resistant strains and 
showed broad spectrum activity.76 
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Table 1.8. A summary of selected lipopeptoids and their associated antibacterial and antifungal properties. The selectivity ratio = 10 % 
hemolytic dose/B. subtilis MIC. The peptoid monomers are also summarised, where Ndec = 10 carbon decane alkyl chain, Ntridec = 13 carbon 
tridecyl chain and Npent = 5 carbon pentane chain. All peptoids had C terminal amide groups.76 
 
 
 
 Peptoid Sequence MIC (µM) HD10 (µM) Selectivity 
Ratio 
  E. coli B. subtilis C. albicans   
22 (NLysNspeNspe)4 14.7 3.7 14.7 33 8.9 
70 Npent(NLysNspeNspe)4 15.5 3.9 15.5 37 9.5 
71 Npent(NLysNspeNspe)3 30.8 1.8 23.7 100 56 
72 Npent(NLysNspeNspe)2 > 266 4.1 133 > 266 > 65 
73 Ndec(NLysNspeNspe)4 31.6 4.0 4.0 13 3.3 
74 Ndec(NLysNspeNspe)2 8.8 2.2 8.8 37.8 17 
75 Ndec-NLysNspeNspeNLys > 108 6.8 108 > 215 > 32 
38 Ntridec-NLysNspeNspeNLys 14.0 1.8 14.0 73 41 
35 Pexiganan (GIGKFLKKAKKFGKAVKILKK-NH2) 7.8 3.9 124 181 46 
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A separate study looked into the effect of lipidation on a library of 19 very short 
antimicrobial peptoids. The sequences chosen were all based upon KKK, RRR, KGK or 
RGR tripeptides‡‡ and therefore were cationic, made of NLys or NhArg residues. 
Sequences made exclusively of the cationic monomers had an overall charge of +3 and 
the sequences with a glycine between the two cationic residues had a net charge of +2. 
The lipid tails chosen are summarised in Figure 1.9; C11, C14, C16, C20 or F11 chains (where 
the F11 backbone is comprised of CF2 groups rather than CH2).
77 
 
 
Figure 1.9. The short, three reside peptoids prepared by the Schweizer group with lipid 
tail groups.77 
 
 
                                                     
‡‡
 Where K is the amino acid lysine, R is arginine and G is glycine. 
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The compounds were tested against a variety of reference and clinical bacterial strains§§ 
and were found to be moderately active against both Gram positive bacteria (MICs from 
8 µg mL-1 for S. aureus and MRSA) and Gram negative species (for example, MICs from 
16 µg mL-1 for E. coli, 64 µg mL-1 for P. aeruginosa and 16 µg mL-1 for K. pneumoniae). In 
comparison to the positive control (cetrimide, a cationic disinfectant), their most active 
peptoids were less able to inhibit Gram positive bacteria, but had a greater potency 
against the Gram negative bacteria.77  
It was found that E. coli species were particularly susceptible to peptoids with the C16 
chain. Overall, the fluorinated F11 chain was less effective than the C14 analogue on a mass 
basis and the homoarginine peptoids were more active but also more toxic than their 
analogous lysine peptoids. The hemolytic activity of compounds within the peptoid 
library was proportional to their antimicrobial activity, but the most hemolytic peptoids 
were still slightly less toxic than the cetrimide control. The antimicrobial assays were 
also repeated in the presence of bovine serum albumin (BSA) since hydrophobic proteins 
such as BSA are known to cause a reduction in antimicrobial activity through binding 
interactions. Both the control compound and the lipopeptoids were similarly inhibited 
with a reduction in antimicrobial potency.77 
Other peptidomimetic structures based upon peptoids have also been lipidated to 
increase their antimicrobial activity, such as the α-AApeptides synthesised and tested by 
the Cai group.78,79  
 
1.3.4 Peptide-peptoid hybrids 
Several groups have tried to overcome the poor stability of peptides in vivo by 
synthesising peptoid-peptide hybrids. In one study using apidaecin Ib, 76, an AMP with 
three arginine residues which are important for its antibacterial activity, single arginine 
or leucine residues were replaced with the equivalent peptoid residues. Basic residues 
often represent the attack site for trypsin-like enzymes so the mutation to a peptoid 
monomer had the potential to increase the half-life in vivo.80  
The hybrids synthesised had arginine residues in one or more positions of the sequence 
replaced by NArg N-(3-guanidinopropyl) glycine*** or NnArg N-(2-guanidinoethyl) 
glycine††† at residue 17, 12 or 4, as shown in Table 1.9. These compounds were more 
resistant to proteolysis than unmodified apidacecin, which has a half-life of less than 60 
minutes in a trypsin digest. No significant degradation of the peptide-peptoid hybrids 
76–81 was detected after a 24 hour incubation with trypsin. Additionally, the hemolytic 
activity of the hybrids was shown to be less than 2 % at 300 µM for all compounds and as 
long as the C terminal residues were not altered, MIC values between 16–32 µM were 
achievable against E. coli.80 
                                                     
§§
 Data not shown 
***
 i.e. compounds 77, 78 and 79 in Table 1.9. 
†††
 i.e. compound 81 in Table 1.9. 
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 Sequence MIC (µM) Hemolytic activity (%) 
E. coli 
76 Apidaecin Ib 
GNNRPVYIPQPRPPHPRL 
8 1.2 
77 GNNRPVYIPQPRPPHPNArgL > 128 0.44 
78 GNNRPVYIPQPNArgPPHPRL 16 2 
79 GNNNArgPVYIPQPRPPHPRL 16 0.06 
80 GNNRPVYIPQPRPPHPRNLeu > 128 nd 
81 GNNRPVYIPQPNnArgPPHPRL 16–32 1.31 
Table 1.9. Apidaecin analogues substituted with peptoid residues and their associated 
antibacterial activity against E. coli and the hemolytic activity against human 
erythrocytes at 300 µM. Peptoid residues are highlighted in bold.80 
 
Some groups have incorporated a small number of peptoid resides into a peptide 
sequence for a specific purpose. For example, a synthetic mimic of naturally occurring 
AMPs papiliocin and magainin 2, 82, was designed to have high antimicrobial activity. 
This peptide contained the N terminal residues of both peptides joined by a proline 
hinge, however caused significant lysis of human erythrocytes at 100 µM due to the rigid 
structure. By substituting this proline residue with the more conformationally flexible 
lysine peptoid residue in compound 83 the hemolytic activity was reduced so selectivity 
was increased two-fold; from 19 for the parent peptide 82 to 35 for 83, as seen in Table 
1.10.81  
Proline residues play a critical role in determining peptide secondary structure and in 
other peptide-peptoid hybrids, proline residues have also been substituted by a peptoid 
monomer to reduce cytotoxicity (see Table 1.10). For example piscidin 1, 84, is a cationic 
and cytotoxic peptide with α-helical secondary structure. Replacing the proline at 
position 8 with a peptoid lysine residue (85) reduces the rigidity of the sequence and 
leads to a hybrid compound with similar antibacterial activity but much increased 
selectivity compared to the parent peptide (selectivity ratio 1.6 for 84 compared to 140 for 
85).82  
Additionally, proline residues in the tryptophan/proline-rich AMPs cathelicidin 86 and 
indolicidin 87 were substituted with the peptoid residue NLys to increase the therapeutic 
index of the parent peptides. The minimal hemolytic concentrations (MHCs) of the NLys 
peptide-peptoid hybrids, 88 and 89, were drastically increased to > 200 µM, leading to 
improved selectivity indices in excess of 150 (86 and 87 have selectivity factors of 59 and 
7 respectively). It was proposed that these compounds have an intracellular target 
mechanism as no visible membrane depolarisation was seen when cells were treated at 
the MIC level.83 
 
 24 
 
 Sequence MIC (µM) Minimal hemolytic 
concentration (µM) 
Selectivity 
E. coli S. aureus 
82 Synthetic papiliocin/magainin 2 mimic 
RWKIFKKIPKFLHSAKKF 
2 4 100 19 
83 RWKIFKKINLysKFLHSAKKF 2 4 200 35 
84 Piscidin 1 
FFHHIFRGIVHVGKTIHRLVTG 
2 1 3.1 1.6 
85 FFHHIFRNLysIVHVGKTIHRLVT 2 4 > 200 140 
86 Cathelicidin  
KKFPWWWPFKK 
4 1 100 59 
87 Indolicidin 
ILPWLWPWWPWRR 
8 1 25 7 
88 KKFNLysWWWNLysFKK 1 1 > 200 235 
89 ILNLysWLWNLysWWNLysWRR 4 1 >200 182 
90 Melittin 
GIGAVLKVLTTGLPALISWIKRKRQQ 
2 0.5 0.78 0.6 
91 GIGAVNAlaKVLTTGNAlaPALISWNAlaKRKRQQ 16 16 > 100 14 
92 GIGAVNLeuKVLTTGNLeuPALISWNLeuKRKRQQ 4 4 > 100 50 
93 GIGAVNpheKVLTTGNphePALISWNpheKRKRQQ 4 2 > 100 71 
94 GIGAVNLysKVLTTGNLysPALISWNLysKRKRQQ 4 2 > 100 71 
Table 1.10. Other peptide-peptoid hybrids and their associated biological activity against bacteria.  The concentration at which minimal 
hemolytic activity is seen is also shown with a selectivity factor. Peptoid residues are highlighted in bold.81,82,84,85  
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Single peptoid residues were also introduced into the AMP melittin (90) to form other 
peptoid-peptide hybrids (compounds 91–94 in Table 1.10). Melittin, 90, found in bee 
venom, is known to form an amphipathic structure with a leucine zipper motif that is 
thought to promote self-association and facilitate the formation of a transmembrane 
pore in cell membranes. Peptoid residues were substituted into key positions of the 
leucine zipper and showed strong antimicrobial activity against bacteria, even though 
CD studies showed that the helical structure was distorted by inclusion of these peptoid 
residues. Although the MIC values of the hybrid compounds against clinical isolates of 
MRSA‡‡‡ were greater than the MIC of wild-type melittin (MIC = 2–8 µM and 2 µM 
respectively), the peptoid analogues 91–94 were far less hemolytic than melittin, with 
MHC values of > 100 µM compared to melittin itself that has an MHC of 0.78 µM. In 
particular substitution of leucine, phenylalanine or lysine for their peptoid counterparts 
in the leucine zipper  were suggested as strategies to improve the antimicrobial action of 
peptides (i.e. NLeu in 92, Nphe in 93 or NLys in 94).84  
In another study, a library of lysine-peptoid hybrids was synthesised as short analogues 
of cationic AMPs. All compounds incorporated the peptoid fragment 95 in Figure 1.10 
and multiple lysine residues were added at the C or N terminus and a selection of these 
sequences are shown in Table 1.11. The peptide-peptoid hybrids 96–100 exhibited broad-
spectrum antimicrobial activity against clinically relevant bacteria. MIC values for the 
most active compounds in the library ranged between 2–8 µM and 4–20 µM for S. aureus 
and E. coli respectively. The hemolytic activity of these compounds at 50 µM was low in 
compounds with three or more lysine residues, for example 98–100. In extension to the 
original study, more antibacterial lysine-peptoid hybrids based upon this structure were 
identified from a positional scanning combinatorial library.86-88 
 
 
Figure 1.10. The peptoid fragment 95, used in the Hansen study. Lysine residues were 
added either at the C or N terminus to form the peptide-peptoid hybrids.86-88 
                                                     
‡‡‡
 MIC values of compounds 91–94 against clinical isolates of MRSA are not shown in Table 1.10. 
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Table 1.11. Selected antimicrobial activities of some lysine-peptoid hybrids and hemolytic 
activity at 50 µM. All sequences were amidated at the C terminus.86-88 
 
The peptide-peptoid hybrid 100 with five C terminal lysine peptide residues was used to 
investigate the mode of action against S. aureus. At concentrations much greater than 
the MIC, the compound disrupts the cell membrane and causes ATP leakage from the 
cells. At concentrations nearer the MIC the S. aureus growth is inhibited without ATP 
leakage. The hybrid can also bind to DNA, inhibiting DNA gyrase and topoisomerase IV 
causing the SOS response in S. aureus which indicates that this peptide-peptoid hybrid 
may have a dual mode of action.89 
The Robinson group have reported the synthesis of macrocyclic peptide-peptoid 
compounds that have a β-hairpin backbone conformation. These antibiotics display 
antimicrobial activities against both Gram positive and Gram negative bacteria and have 
low hemolytic activity against human erythrocytes. The exchange of peptoid residues for 
peptide residues is shown to have no detrimental effect on biological activity or to the 
secondary structure.90,91 
In another study, the cytotoxicity of peptide-peptoid hybrids was investigated. The 
library was comprised of sequences with alternating cationic amino acids and 
hydrophobic peptoid residues of varying lengths. Moderate activity against Gram 
positive strains was seen for those compounds with chiral peptoid residues, however, the 
presence of α-chiral side chains in the peptoid monomers was found to increase 
cytotoxicity. Both chiral and achiral peptoid monomers gave moderate activity against 
Gram negative E. coli with one compound having an MIC of 1 µM.92 
Peptoid Sequence MIC (µM) Hemolysis (%) 
  S. aureus E. coli  
96 Fragment 95-K 6.25 23 100 
97 Fragment 95-KK 6.25 21 51 
98 Fragment 95-KKK 3.12 17 5 
99 Fragment 95-KKKK < 1.6 15 2 
100 Fragment 95-KKKKK < 1.6 15 3 
101 Ampicillin 1.25 62.5 nd 
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1.3.5 β-peptoids 
Several groups have also incorporated beta-peptoid residues into antimicrobial peptoids 
(i.e. poly-N-substituted β-alanine). These structures are isosteres of β-peptides and are 
similarly stable to proteases as the α-peptoids discussed above. β-peptoids have very 
different secondary structures to the linear α-peptoids described above and although 
many natural AMPs are helical, it has been shown that compounds without an 
amphiphillic, helical structure can also function as potent antimicrobials   
Work by Du Pont in 2006 documented the synthesis of antimicrobial β-peptoids. In this 
study, 21 compounds between 9 and 18 residues in length were synthesised and tested 
against E. coli. In the library, functionalities included hydrophobic groups such as benzyl 
or isobutyl and cationic chains, such as aminoethyl, aminobutyl and 4-
dimethylaminopyridine to probe effects like charge, the importance of overall side-chain 
composition and positioning of cationic and hydrophobic residues on their biological 
activity. A selection of these peptoids were shown to have moderate activity against 
E. coli, with the best sequence having an MIC of 128 µg mL-1.37 
A large number of antimicrobial β-peptoids have since been made by the Olsen group. In 
an early study, a library of β-peptoid α-peptide oligomers were made with α-chiral 
phenethyl side chains (β-Nspe) and either the cationic amino acids lysine or arginine. A 
variety of both chiral and achiral containing β-peptoid residues were included in the 
sequence and the length of the chimeras varied between 10 and 16 residues (see Figure 
1.11, peptoids 102–110). For preliminary screening these compounds were tested against a 
range of Gram positive and negative bacteria93 and also against the causative agent of 
malaria, Plasmodium falciparum.94  
Later, an extended library was synthesised to test against a wider variety of pathogens, 
including drug resistant bacteria and the fungal species C. albicans.95 This larger library 
included similar α-peptide β-peptoid motifs with the addition of the aliphatic monomer 
N-(S)-1-cyclohexylethyl-β-alanine (see Figure 1.11, peptoids 111 and 112) to probe the 
effects of lipophilicity on activity.95  
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Figure 1.11. Example antimicrobial α-peptide β-peptoid hybrids synthesised by the Olsen 
group.93-95 
 
Peptoid MIC (µg/mL) 
 E. coli B. subtilis S. aureus MRSA VRE P. aeruginosa. C. albicans 
102 63 63 > 200 500 250 63 125 
103 63   250 125 31 63 
104 31   125 63 16 63 
105 16 16 125 16 16 63 125 
106 16   9 9 37 148 
107 16   16 8 31 31 
108 4 8 32 67 17 67 33 
109 16   64 16 64 32 
110 34   64 9 34 34 
111 8   8 4 64 16 
112 32   16 8 128 32 
Table 1.12. The biological activity for selected α-peptide β-peptoid dodecamers against a 
variety of resistant Gram positive and negative bacteria.93-95  
 
Peptoids 102–110 were screened against P. falciparum and low IC50 values were recorded 
for selected guanidinylated peptoids (IC50 4–6 µM for compounds 103 and 104). Although 
the compounds showed considerably lower activity than the chloroquinine control, these 
peptoids were able to inhibit parasite growth at concentrations that AMPs magainin 1 
and 2 could not. Most peptoids showed low hemolytic activity, but some erythrocyte 
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alterations could be seen at the IC50 value using microscopy. Additionally, the most 
active peptoids 103 and 104 showed hemolytic activity at concentrations near their IC50 
values.94 
Peptoids 102, 105 and 108 were also moderately active against E. coli, B. subtilis and 
S. aureus (see Table 1.12). Sequences with arginine exhibited improved potencies to the 
lysine chimeras and the achiral β-Nphe containing peptoid 108 is more potent to all 
bacteria tested than the chiral β-Nspe variant 105, suggesting that chirality is not 
necessarily required for antimicrobial action in these hybrid compounds. The chimeras 
were highly stable towards proteolysis and also showed no significant hemolysis of 
human red blood cells at concentrations up to 500 µg mL-1.93  
The results shown in Table 1.12 demonstrate that longer oligomers generally resulted in 
improved biological activities towards most of the species tested (i.e. compare 12 residue 
102 to 16 residue 104). However, in the case of E. coli this trend was either diminished or 
reversed and some of the shorter compounds showed the most promising activities, for 
example peptoid 108 has more potent activity than the longer analogues 109 or 110. 
Guanidino-functionalised sequences (105/108) showed a similarly better potency than 
the amino compounds (102) for all pathogens except P. aeruginosa. The link between 
secondary structure and biological activity was investigated using circular dichroism 
spectroscopy. Compounds with α-chiral β-peptoid residues show a greater degree of 
order than the achiral variants, so it was suggested that these compounds interact with 
cell membranes via an unstructured conformation. Peptoid 111 with higher lipophilic 
character showed at least a two fold increase in activity compared to the aromatic 
analogue 105 against all species tested. However, this was accompanied by an increase in 
hemolytic activity.95  
Interestingly, C. albicans was significantly more susceptible to peptoids without α-chiral 
peptoid monomers (i.e. 108) whereas methicillin-resistant S. aureus was more sensitive 
to those peptoids with more order, i.e. sequences containing α-chiral residues (i.e. 102 or 
105). All other pathogens showed no significant difference in activity between 
compounds with a higher or lower degree of order via CD. Toxicity against HeLa cells 
was also studied and all compounds were less hemolytic than pexiganan (35) which was 
used as a clinical comparison.95  
Peptoids 102–110 in Table 1.12 were also studied in more detail against both planktonic 
and biofilm cultures of S. epidermis using susceptibility and time-kill assays and confocal 
laser scanning microscopy respectively. At their minimum inhibitory concentration, all 
the α-peptide β-peptoids tested inhibited biofilm formation and at greater 
concentrations between 80–160 µg mL-1, 6 hour old biofilms could be eradicated. As 
before, peptidomimetics containing guanidio functionalities and chiral β-peptoid 
residues (i.e. compound 105) showed the best and fastest antimicrobial potencies and 
antibiofilm behaviour compared to those that with lysine and achiral peptoid residues. 
There was a clear relationship between increased sequence length and an increased 
antimicrobial activity and increased cytotoxicity, a trend that was more evident in 
amino-functionalised compounds than the guanidio-rich peptoids.96 
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Insertion assay experiments were performed using peptoids 102 and 105 and Langmuir 
monolayers to show that guanidino-containing peptide-peptoid hybrids are more readily 
able to compromise membrane integrity of monolayers that mimic Gram positive 
bacteria than amino-functionalised analogues. However, for the lipopolysaccharide 
monolayers that were used to represent a Gram negative system, the same trend was not 
observed.97 Additionally, fluorescently labelled α-peptide β-peptoid chimeras related to 
102, 105 and 108 have been studied in cellular uptake studies and it was shown that these 
compounds were taken up more efficiently than the arginine rich peptide Tat47-57
§§§
 and 
subsequently localised in vesicular compartments.98 
Finally, two of these α-peptide β-peptoid chimeras (compounds 102 and 105 in Table 
1.12) were used to determine the potentiation of their antibacterial activity by human 
blood plasma. The activity of AMPs can be considered to be negatively impacted by the 
high salt content of blood plasma. However, in this study it was found that the 
antimicrobial activity of these peptidomimetics in 50 % blood plasma was increased 
(MIC improved by up to one order of magnitude) with respect to Gram negative E. coli; 
no effect was seen with Gram positive S. aureus. This enhancement of antibacterial 
activity is a promising characteristic of these peptidomimetics for therapeutic 
applications.99  
 
 
1.4 Antifungal peptoids 
Fungal infections are often more difficult to treat than infections caused by bacteria due 
to the limited number and greater toxicity of antifungal drugs. Additionally, infections 
caused by the fungal species C. albicans or C. neoformans are particularly common in at 
risk patient groups, such as the elderly or those with immunodeficiency. As with 
antibacterial drugs, resistance is developing against many of the currently available 
antifungal treatments.100,101 
In combination with the Barron group, the Larabell research group have used soft X-ray 
tomography to study the cellular response of C. albicans to peptoids.102 This technique 
allows imaging of the subcellular changes that occur due to phenotypic switching**** and 
also to monitor changes resultant from antimicrobial treatment. In this study two 
peptoids 22 and 38 were used that had been previously used in antibacterial studies. The 
structures of these molecules are shown in Figure 1.12.  
 
 
                                                     
§§§
 Tat is HIV-1 transactivating protein; Tat47-57 sequence: YGRKKRRQRRR. 
****
 In phenotypic switching the cellular type changes from a benign to an invasive, multi-cellular phenotype. 
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Figure 1.12. Peptoids used in the soft X-ray tomography study. Peptoid 22 and peptoid 38 
have structural similarities to AMPs and were previously shown to have potent 
antifungal activities.56,57 
 
Treatment with peptoids inhibited the formation of the pathogenic hyphal phenotype of 
C. albicans and led to significant changes in the cell and organelle morphology, 
particularly in the nucleus where lipidic bodies were seen to be embedded in the 
nucleus. Nucleoli in cells treated with peptoid also appeared to contain at least one hole 
that passed directly through the organelle in all cells imaged. The authors do not suggest 
a function or the consequences of this, but is a noteworthy addition to peptidomimetic 
research.102 
Peptoids have also been shown to be promising antifungal candidates against plant 
pathogens, Fusarium virguliforme and Fusarium lateritium which both cause sudden 
death syndrome in soybean and are a threat to global food security. A library of 36 
peptoids was designed to mimic ultrashort lipopeptides and synthesised using an Ugi 
four-component reaction. The peptoids have a tetrapeptoid backbones and an N-
terminal palmitoyl residue, as shown by fragment 113 in Figure 1.13. In general 
F. virguliforme was more susceptible to the lipopeptoids and most compounds showed 
measurable antifungal activities against either or both F. virguliforme and F. solani, with 
MIC values ranging from 7–38 µM via a broth microdilution method (compared to a 
control commercial antifungal Benomyl that has an MIC of 2 µM).103 
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Figure 1.13. 113, the general structure for the antifungal peptoids, with a selection of 
possible side chains which were employed in varying combinations. The C terminus of 
the peptoids was varied from acid, amide, ester to phosphoester.103  
 
The group of Hansen have also studied antifungal properties of peptoids and developed 
their initial antibacterial studies previously described in section 1.3.1. Their lysine 
containing peptide-peptoid hybrids were tested against two common fungal species in 
immunocompromised patients; C. albicans and C. neoformans.  
The potent antibacterial activity of this library has already been described above and 
these compounds were also active against the fungal targets. Most peptoids contained 
the central motif shown in Figure 1.10, with differing numbers of lysine residues at N- 
and C-termini or within the motif in varying combintions. In general, C. neoformans was 
more susceptible to the peptoids than amphotericin resistant C. albicans with MICs for 
active compounds in the range 1.6–6.25 µM and 3.1–12.5 µM respectively. The trends 
between active and less active compounds followed the trends described for the Gram 
positive bacteria and in most cases, an increased activity was seen with an increase in 
charge (i.e. for compounds with a greater number of lysine residues included in the 
sequence).88
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More recently, another potent antifungal peptoid has been identified against 
C. neoformans, with a similar potency to antifungal agents in current clinical use. The 
structure of this tripeptoid 114 is shown in Figure 1.14. The peptoid identified was shown 
to have excellent stability, moderate cytotoxicity in mammalian cells (toxicity NIH-3T3 
murine fibroblasts IC50 48.6 µg/mL; toxicity HPLIA human peripheral lung epithelial 
cells IC50 36.3 µg/mL) and a low hemolytic activity to human erythrocytes 
(HC10 68.7 µg mL
-1). Against the C. neoformans lab strains, 114 had MIC values of 
6.3 µg mL-1 and the compound was also evaluated against several clinical isolates and 
favourable MIC values between 12.5–65 µg mL-1 were recorded.104 
 
Figure 1.14. Structure of the antifungal peptoid 114. MIC and IC50 values against 
C. neoformans H99S are shown.104 
 
 
1.5 Conclusions and Project Aims 
It has been shown that peptoids show significant promise in biomedical applications that 
is not just limited to their antimicrobial activity. Such applications are wide ranging from 
inhibitors for protein-protein interactions40,41, lung surfactants46, molecular scaffolds42,43, 
biomimetic materials like collagen for biomedical devices and tissue engineering 43,47-50 or 
as molecular transporters for drug delivery.51-53 Although a comprehensive review of such 
medicinal uses is not possible here, the area has been reviewed extensively by others.10,105 
Peptoids have also been proven as a novel class of anti-infective agents, displaying potent 
antibiotic, antifungal properties with advantageous properties such as their stability 
in vivo. 
Some peptoids act via an amphiphilic arrangement of side chains in the folded state, 
others can mimic the side chains in natural protein surfaces. Structure-based design, 
combinatorial libraries with high throughput screening and sequence-based design have 
all been used to discover peptoids with useful biological activities. In some cases, a 
defined secondary structure was necessary to elicit a potent biological response but in 
other cases, potent compounds had no defined solution state secondary structure in the 
absence of cell membranes.  
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However, there are many challenges that must be addressed before biomedically useful 
peptoids can become a reality. Problems with selectivity or other side effects, such as 
immunogenicity, have not been fully evaluated and manufacture on a large scale may 
prove to be challenging or costly.  
Whilst the secondary structure prediction of peptoids has advanced dramatically over 
the last few decades, our understanding of peptoid sequence-structure relationships are 
still not good enough to predict the secondary structure of complicated peptoids from 
scratch. Computational methods that can accurately predict peptoid conformations are 
in their infancy and improvements are needed urgently. Additionally, there is a lack of 
data concerning peptoid conformation in the literature; certain CD spectra published by 
other groups suggest that related peptoid sequences can form a range of stable helical 
conformations (the literature is examined in more detail in Chapter 2), however these 
have yet to be elucidated and characterised in detail. More information regarding 
peptoid secondary structure would allow the diversity of peptoid libraries to be 
improved. It is known that α-chiral substituents can induce helicity, but the requirement 
for approximately half of side chains to be bulky α-chiral monomers106-108 places certain 
restrictions on the synthesis of diverse peptoid libraries. Future studies should look for 
novel side chain types that can stabilise peptoid folding to allow a more through 
exploration of chemical space. 
The optimisation of the pharmacological properties of peptoids will be important in the 
future. Although peptoids have better stability than peptides in vivo, their oral 
availability will need to be improved for enteral administration and the fast excretion 
rates currently recorded109 would have to be reduced for peptoids to be considered as 
pharmaceuticals. The ease of peptoid synthesis, the high cell permeability, in vivo 
stability among other pharmacokinetic properties are significant advantages in the 
search for peptoid pharmaceuticals. However, the issues outlined above need to be 
addressed before peptoids can be considered as viable drug candidates. A balance 
between activity and selectivity must also be achieved to avoid unwanted toxicity of any 
potentially useful pharmaceutical peptoids. As our understanding of the conformational 
control of peptoids increases, it is expected that many more promising pharmaceutical 
candidates will emerge which can be taken forward into clinical studies.10,34,55,105  
Given the aforementioned points, the main aim of this research project was to build 
upon the work already undertaken into the antibiotic and antifungal properties of 
peptoids and to explore peptoids in more detail as a new class of anti-infective 
compounds.  
In particular, a focus was placed upon developing peptoids as antiparasitic agents since 
no comprehensive investigation had yet been undertaken into the action of peptoids 
against protozoa. Our aim was to synthesise a large peptoid library, with increased 
chemical and biological stability compared to peptides. Following biological evaluation 
of this library, it was intended that active compounds against parasite targets would be 
identified and the structure activity relationships analysed to determine the most 
important features of antiparasitic peptoids. 
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Since peptoids are proposed to act against cell membranes, it was anticipated that 
peptoids that displayed potent antiparasitic activity would also be potential antibiotic 
compounds. Therefore, we planned to test the peptoid library against a variety of 
bacteria and fungi, particularly in their biofilm form due to limited studies into the 
fungicidal and bactericidal activity of peptoids against biofilms. This data would further 
help to elucidate the factors that contribute towards good antimicrobial activity in 
peptoid sequences. 
Additionally, it has been highlighted that the mode of action of peptoids has not yet 
been conclusively determined and that the selectivity of many peptoids in the literature 
has either not been stated or has proven problematic. Therefore, a final objective was to 
examine the mode of action of peptoids in further detail using biophysical 
characterisation techniques and fluorescent microscopy experiments. In particular, the 
secondary structure of a wide variety of peptoids would be studied via circular dichroism 
spectroscopy to fill some of the aforementioned gaps in the literature and help to 
rationalise the biological activity of the library. It was hoped that these investigations 
would assist in the design of selective and potent antimicrobial peptoids, help to 
elucidate their mode of action and would strengthen the position of peptoids as a novel 
and promising class of compound, with potential antimicrobial applications within the 
pharmaceutical industry. 
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Chapter 2 
Peptoid Synthesis and Characterisation 
 
2.1  The synthesis of α-peptoids 
Peptoids were first made in the late 1980s as novel candidates for the drug discovery 
process by Protos Corporation. Ever since, there has been increasing interest and 
numerous developments in the field of peptoid synthesis.1 In many respects, the 
synthesis of peptoids is very similar to that of peptides. Most often, the peptoid is built 
on resin using solid phase synthesis. This has the obvious advantage that using an excess 
of reagents can help to drive the reaction and that unused reagents and by-products are 
easily washed out after the reaction. Following synthesis of the whole sequence, acidic 
cleavage conditions remove the peptoid from the solid support to allow purification. 
Due to their repetitive structure and high stability, the synthesis of many peptoids is 
fairly simple and can be automated. In early attempts at peptoid synthesis, a solid-phase 
monomer approach was taken. Later, an improved sub-monomer method was 
developed. Solution syntheses have also been attempted but will not be reviewed here. 
 
2.1.1 Monomer approach  
The synthesis of peptoid oligomers was first attempted using the monomer approach, 
where Fmoc protected monomers are incorporated into the growing peptoid chain on an 
insoluble, solid support using conventional coupling activators. The Fmoc group is then 
removed, analogous to peptide synthesis, and the next monomer added. The chain is 
built from the carboxy (C) to amino terminus (N), as illustrated by Scheme 2.1.2 
These syntheses were successful on a wide variety of monomers. However, the Fmoc 
protected N-substituted glycine monomers are often very arduous and time consuming 
to make and the time needed to produce Fmoc-protected monomers often greatly 
exceeded the time taken to synthesise an entire library of peptoids on solid support.1  
Ch. 2 Peptoid Synthesis and Characterisation 
40 
 
 
Scheme 2.1. The synthesis of a peptoid via the monomer approach, using Fmoc 
protected N-substituted glycine monomers; i. coupling using activating agent; ii. 
deprotection with 20 % piperidine in DMF.1 
 
2.1.2 Submonomer approach  
Due to the restrictions of the monomer approach, a sub-monomer method was 
developed in 1992 by Zuckermann et al., and was a major breakthrough in peptoid 
synthesis. This approach involves acylation by a haloacetic acid (for example, bromo or 
chloroacetic acid) followed by a displacement step using a primary amine to introduce 
the side chain, as summarised in Scheme 2.2.3  
 
 
 
 
 
Scheme 2.2. The submonomer approach to peptoid synthesis; i. acylation with 
appropriate coupling agent and haloacetic acid (where X = Br or Cl); ii. SN2 displacement 
with a primary amine.3 
Generally, bromoacetic acid is used in the acylation step with an activating agent like 
N,N'-diisopropylcarbodiimide (DIC). However, for amines where there are unprotected 
heteroatoms on the side chain (for example, imidazoles or pyridines) chloroacetic acid is 
preferred because it is a poorer alkylating agent and prevents unwanted alkylation at side 
chain heteroatoms. The use of chloroacetic acid slows down the subsequent 
displacement step with the amine, but can be countered by addition of iodide, which 
forms a reactive iodoacetamide by Finklestein halide exchange in situ.1,4-6  Importantly, 
protecting groups are generally not required* (except for certain amine side chain 
functionalities) and there are a large variety of inexpensive amines commercially 
available. Many new submonomers have been made for incorporation into peptoids. For 
example, chemical functionalities have been introduced that allow chemoselective 
                                                     
*
 i.e. compared to the Fmoc-protected amino acids used in standard solid-phase peptide synthesis. 
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conjugation and efficient ligations between peptoids.7,8 Therefore, there are significant 
advantages to using this method as a vast range of chemical moieties can easily be 
introduced into peptoid libraries; potentially a much greater variety of side chains can be 
added than in traditional peptide chemistry. However, protecting group methodologies 
for peptoid side chains are not as advanced in peptoid studies, which can cause problems 
for many functionalities.  
Today, the submonomer method is the most commonly used method for peptoid 
synthesis by the scientific community. The submonomer approach significantly 
increased the diversity of side chains available, increased efficiency in the reactions and 
improved synthetic yields. It has been shown that peptoids about 50 monomers long can 
be made, with yields for each coupling cycle in excess of 99 %.1 
 
2.2  Synthesis of β-peptoids 
Poly-N-alkylated β-alanines (or β-peptoids) have an extra methylene unit in the amide 
backbone compared to α-peptoids and this presents several challenges in the synthesis of 
these compounds. For an α-peptoid, the submonomer method of peptoid synthesis is 
very efficient. However, efficiency in the synthesis of β-peptoids is not as well established 
and may explain why β-peptoids appear less frequently in the literature than their α-
peptoid equivalents  
To date, two main synthetic routes to linear β-peptoids have been developed. The first 
utilises an aza-Michael reaction between a resin-bound acryloyl group and the required 
amine submonomer. For longer compounds, coupling protected building blocks on solid 
phase is often more sucessful.9,10  
The aza-Michael addition (Scheme 2.3) first described by Hamper et al.11, is a two-step 
submonomer approach. First, acryloyl chloride is used to acylate the resin. A subsequent 
conjugate aza-Michael reaction with a primary amine installs the required amine 
submonomer. However, this strategy is less efficient for the synthesis of β-peptoids 
greater than four monomers in length or that contain α-chiral amines, as poor yields are 
often achieved even with optimised reaction conditions.9-12 
 
Scheme 2.3. A submonomer approach for the synthesis of β-peptoids using aza-Michael 
addition; i. acryloyl chloride with pyridine in DCM; ii. primary amine in THF/H2O, 
60 ˚C.11  
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Similar to the monomer approach of synthesis for α-peptoids, coupling protected β-
peptoid building blocks on solid phase has been used by several groups to synthesise 
longer β-peptoid oligomers.12-15 Typically Fmoc protected di- or tripeptoids are prepared, 
as Fmoc protection is a well-developed strategy in peptide synthesis. These can be 
prepared either via the solid-phase aza-Michael addition described above, or in solution 
via a cycle of aza-Michael reactions. In the latter approach, t-butyl acrylate is used as the 
starting material and intermediates are purified at each stage by flash chromatography 
(see Scheme 2.4). The final di/tripeptoids are then Fmoc-protected and the t-butyl 
protection removed to yield components for use in the synthesis of longer β-peptoid 
oligomers.9,10,13,14 
 
Scheme 2.4. Synthesis of an Fmoc-protected β-peptoid and its use in the solid phase 
synthesis of longer β-peptoid oligomers; i. aza-Michael addition with primary amine in 
THF/H2O; ii. acryloyl chloride with pyridine in DCM; iii. aza-Michael addition with 
primary amine in THF/H2O; iv. Fmoc protection using Fmoc-Cl; v. t-butyl deprotection 
using formic acid; vi. activating agent (i.e. HATU) with DIPEA in DMF at RT; vii. Fmoc 
deprotection using piperidine in DMF; viii. second coupling of Fmoc-protected 
monomer to extend sequence.9,10,13,14 
 
Finally, efficient co-polymerisation of β-peptoids has also been reported, however the 
nature of this polymerisation means sequence specific compounds cannot be 
prepared.16,17 
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2.3  Cyclisation of linear peptoids 
The syntheses discussed so far have all concerned the synthesis of linear peptoid 
structures. Whilst the first examples of cyclic peptoids only emerged in 2007, there has 
been significant interest within the scientific community to produce cyclic peptoids, and 
a wide variety of α-peptoid18-22 and β-peptoid23 macrocycles have been reported. Many 
cyclic peptoids are synthesised for their antibacterial properties because restricting the 
conformational flexibility of the peptoids often enhances biological activity and stability. 
A number of peptide macrocycles show potent antimicrobial activities and research 
groups are looking to mimic these with peptoid residues.5,21,23-27   
It has been demonstrated that cyclisation can organise the peptoid side chains onto the 
opposite sides of a planar macrocycle, leading to an amphiphilic structure with well-
defined lipophilic and cationic surfaces. This mimics natural antimicrobial peptides and 
therefore cyclic peptoids have the ability to be potent antimicrobials. Possibly because of 
this amphiphilic structure, cyclic peptoids may penetrate further into the lipid 
hydrophobic core of bacterial membranes than their linear equivalents and so show 
promise for use in drug discovery. 28  
Many examples of cyclic α- or β-peptoids have been documented and several methods to 
cyclise linear peptoids have been demonstrated, including head to tail cyclisation of the 
linear precursors in solution or side chain reactions on-resin. These are summarised in 
Scheme 2.5. 
Head to tail cyclisation is currently the most common method used to synthesise these 
molecules, partly because mild conditions can be used in efficient reactions and give 
high yields.  Typically in head to tail cyclisation, the linear precursors are synthesised on 
resin via the sub-monomer procedure, the peptoids cleaved from the resin and then 
cyclised in solution with a traditional coupling agent (see Scheme 2.5). In most cases, 
the terminal secondary amine of the peptoid chain is cyclised with a carboxylic acid 
formed following cleavage from the resin. Care needs to be taken to ensure that any 
reactive amine side chains are masked with appropriate protecting groups.  Cyclisation of 
oligiomers from pentamer to 20mer lengths occurs very efficiently, with typical yields in 
excess of 90 %, due to the facile cis-trans isomerisation of the N-substituted amides. 
Interestingly, there is no requirement for high dilution, as the cyclisation reactions have 
been shown to proceed within 5 minutes at a 70 mM concentration. However, ring 
closures of tetramers have yet to be optimised and often leads to low yields (< 12 %).27-29  
Similar to peptide chemistry, cyclisation of peptoids can also be achieved through 
chemoselective ligation of the side chains. Depending on where the reacting side chains 
are located in the sequence, truly cyclic peptoids or bridged compounds can be made.  
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Scheme 2.5. A summary of the common methods of peptoid cyclisation and stapling. a) via head to tail cyclisation in solution; b) ring 
closing metathesis; c) azide-alkyne cycloaddition; d) amide bond formation. 
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One example of this is the formation of an amide bond, summarised in Scheme 2.5d. 
The formation of covalent bonds, for example, amides, disulphides or the use of sulphur 
as a nucleophile in SN2 ring closing reactions are all well established. In one recent study, 
linear peptoids were synthesised and a covalent lactam bridge introduced by the 
formation of an amide bond, with the aim of stabilising the folding of helical peptoids in 
aqueous and organic solvents. When the reacting side chains were placed at positions i 
and i + 3, stabilisation of a helical secondary structure could be achieved.30,31 Normally, 
helical secondary structures are formed by the inclusion of many aromatic α-chiral 
substituents in the peptoid sequence. However, this can restrict the diversity of a 
peptoid. The amide bond cyclisation strategy avoids the use of a high number these α-
chiral substituents, allowing the peptoids to have a greater structural diversity. This has 
been particularly useful for the synthesis of helical peptoids with a large range of side 
chains for biological study.30,32,33 
Another approach to cyclise peptoids via the covalent reaction of side chains is ring 
closing metathesis (RCM). In olefin metathesis a carbon-carbon bond is formed, usually 
using alkene groups on the substrate in combination with a ruthenium catalyst and has 
been used in many chemical reactions and in industry for many years. Although RCM is 
still challenging in solid-phase reactions, the cyclisation of peptoids (as in Scheme 2.5b) 
has been optimised through choice of the resin, solvent and catalyst. It was shown that 
ring sizes of 16–25 could be successfully made via this approach. 20 
Finally, click chemistry has also been used to ligate peptoid side chains and to form 
cyclic structures. This copper (I) catalysed [3+2] cycloaddition is shown in Scheme 2.5c 
and is regiospecific and high yielding under mild conditions. The formation of the 
triazole linkages and the macrocycle is assisted if the structure is preorganised so that 
the reactive groups are across one face of the helical secondary structure, i.e. at positions 
i and i +3.34-38 
Due to the increased conformational ordering, many of these cyclised products have 
been crystallised†, allowing X-ray diffraction structures of the cyclic peptoids to be 
obtained.21,23,27-29,39   
 
 
 
                                                     
†
 A comprehensive collection of all peptoid crystal structures can be found on the Peptoid Databank 
(maintained by the Kirshenbaum group at New York University) URL: 
https://wp.nyu.edu/kirshenbaumlab/peptoid-data-bank/  
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2.4  Common peptoid secondary structures 
As seen in nature, a large variety of well-defined and ordered structures can be formed 
by peptides and proteins. For peptoids, there is a great deal of conformational diversity 
in their secondary structures due to the flexibility of their backbones and lack of 
hydrogen bonding capacity. Currently, the folding of peptoids into global hierarchical 
structures is not completely understood. However, if the secondary structure of a 
particular peptoid can be predicted or controlled, the biological function and properties 
of these molecules can be exploited and enhanced.  
Many of the mechanisms that allow the folding of normal peptides are absent in 
peptoids. Peptoids cannot undergo extensive hydrogen bonding which stabilises the 
secondary structures of peptides. As the peptoid backbone has no chiral centres, 
peptoids have no inherent handedness and their secondary structures are usually 
controlled by non-covalent local interactions, such as steric and electronic effects. 
Despite the lack of hydrogen bond donors and the achirality of the peptoid backbone, 
stable secondary structures in solution have been achieved. Within the area of peptoid 
chemistry, common structural motifs in peptide chemistry have been seen like helices or 
turns for α-peptoids. Defined structures have also been designed for β-peptoids but will 
not be discussed for brevity.40-42 
 
2.4.1 Stable peptoid helices 
By far the most studied peptoid secondary structure is the peptoid helix. The chemistry 
of such structures is well established and these helices show excellent chemical and 
thermal stability.43 Chemists can now design helical peptoids as AMP mimics with 
specific functions, as it is possible to predict which sequences will form stable helices in 
solution. 
It has been shown that bulky, chiral side chain groups adjacent to the nitrogen on the 
main chain can induce a helical structure in peptoids as short as 5 residues long in 
solution.44 Several common monomers used for this purpose are shown in Figure 2.1. 
Helices can also be stabilised by side chain reactions that effectively staple peptoid 
chains to enforce a helical structure  
 
Figure 2.1. Common α-chiral sub-monomers used to induce a helical secondary 
structure in peptoid oligomers. 
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Peptoid helices have been shown to contain 3 residues per turn and have a pitch of about 
6 Å (however, the pitch can vary by as much as 10 % depending on the specific side 
chains used). A model structure for a peptoid helix of compound 115 is shown in Figure 
2.2. These helices have similar structures to the type-I polyproline (PPI) peptide helices 
that are commonly seen in proteins and contain all cis-amide bonds. The direction of 
this helix in peptoids is usually controlled by the handedness of the chiral building 
blocks used.44-46  
Helical peptoids are regularly studied using circular dichroism (CD) spectroscopy (see 
section 2.5). Normally, greater helical characteristics are observed if the bulky side chain 
contains an aromatic group at the i and i + 3 positions, but heterooligomeric peptoids 
can fold into stable helices if at least 50 % of the monomers contain a chiral centre.33 
Furthermore, the helices are stabilised if the C-terminal residue is α-chiral and also as 
the peptoid chain increases in length, i.e. decamers and longer.32,33,44,45,47 
 
Figure 2.2. A representative model of the peptoid helix for peptoid 115, Nspe10. The 
structure has been generated using molecular mechanics. The backbone is highlighted in 
green. Image adapted and reprinted with permission from The Royal Society of 
Chemistry.‡,47 
 
Where sequences contain aromatic, α-chiral monomers, the peptoid helix is induced as 
the large groups significantly reduce the conformational freedom of the peptoid 
backbone. The backbone is limited to a certain range of angles to prevent electronic 
repulsions with the aromatic rings of the side chain and neighbouring carbonyl groups of 
the peptoid backbone. Therefore, the helix formation is largely controlled by the steric 
and electronic properties of the submonomers used. 32,33,44,45,48-50 
                                                     
‡
 Image reproduced from Fowler and Blackwell, Org. Biomol. Chem., 2009, 7, 1508. 
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More recently, it was shown that the peptoid helix could also be controlled using the 
electronic properties of the side chains, which can affect an electronic n → π* interaction 
and alter the cis/trans ratio of the backbone amide bonds.49,51-53 In the PPI-type helix, all 
the amide bonds should be present as the cis isomer in order to achieve a homogeneous 
helix. The less common type II polyproline helix has also been synthesised, which 
contains all trans amide bonds from repeated N-aryl glycine residues (see Figure 2.3) 
that cause a greater steric clash with the corresponding backbone carbonyls..51  
 
 
Figure 2.3. N-aryl glycine peptoid monomer, shown to induce a PPI-II helix with trans 
amide bonds.51 
 
This cis/trans amide bond ratio is attributed to a balance between n → π* interactions 
between the backbone carbonyl and aromatic side chain or the carbonyl to carbonyl n → 
π* interaction of the amide bond, favouring the cis amide and trans amide isomers 
respectively. Therefore, including an electron deficient substituent submonomer can 
enhance the proportion of cis conformations in a peptoid by lowering the HOMO (n) – 
LUMO (π*) gap. Whereas an electron rich substituent will favour the trans conformation 
as the n → π*Ar interactions become less favourable. These interactions are shown in 
Figure 2.4 and could be exploited in the design of new peptoid structures.49,52,54  
Figure 2.4. The n → π* interactions are shown between a) the carbonyls of the backbone 
stabilising the trans amide conformation; b) the backbone carbonyl and the aromatic 
residue stabilising the cis conformation. The nitrogen of the amide is shown in blue and 
oxygen in red. Adapted with permission, copyright 2007 American Chemical Society§,52 
                                                     
§
 Image reproduced from Gorske et al., J. Am. Chem. Soc., 2007, 129, 8928. 
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For example, in model peptoids the Kcis/trans ratio was examined by Blackwell et al. Values 
for selected dipeptoids (in this case capped with piperidine or a methyl group) are shown 
in Table 2.1. The model peptoid structures and monomers utilised are shown in Figure 
2.5.52 Relative to the Nspe dipeptoid (116), electron withdrawing groups on the aromatic 
ring (i.e. pentafluoro-functionalised Npfe in compound 117 or nitro-functionalised Nsnp 
residue in 118) stabilise the cis amide, suggesting the influence of n → π*Ar interactions. 
In comparison, inclusion of the sterically bulkier cyclohexyl peptoid (120) or more 
electron-rich phenolate monomer (Nmph in 121) cause a decrease in the cis amide 
rotamer population compared to the analogous Nspe dipeptoid, 119.52 
 
Figure 2.5. The structure of the model dipeptoids synthesised to study the effect of 
monomer functionalisation on the cis/trans amide ratio. The different resides utilised in 
the R* position are also shown. 
 
 
 
 
 
 
Table 2.1. Model dipeptoids containing monomers with different steric and electronic 
characters and the associated cis/trans ratio and free energy. 
 
 
 R1 R2 Kcis/trans ΔGcis/trans 
(kcal mol-1) 
116 Npip Nspe 2.04 - 0.42 
117 Npip Nsnp 3.43 - 0.73 
118 Npip Npfe 3.84 - 0.79 
119 Me Nspe 2.12 - 0.44 
120 Me Nche 1.30 - 0.15 
121 Me Nmph 1.25 - 0.13 
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2.4.2 The ‘threaded loop’ conformation 
In previous studies of peptoid helices, an anomalous result had been seen in the CD 
spectra of a group of peptoid nonamers. The CD spectra were distinct from the peptoid 
helices with a single broad peak at 203 nm, suggesting a novel structure type. NMR 
spectroscopy studies in d3-acetonitrile revealed a new structure with well-defined local 
interactions, known as the ‘threaded loop’ conformation, where the C- and N-termini of 
the peptoid are held in close proximity by hydrogen bonds.47,55  
 
Figure 2.6. The NMR structure of the threaded loop conformation of peptoid 122, Nspe9, 
structure obtained in d3-acetonitrile. Hydrogen bonds shown in blue. Image adapted and 
reprinted with permission from The Royal Society of Chemistry.**,47 
 
So far, the threaded loop conformation has been found to be unique for peptoid 
nonamers with α-chiral side chains, such as 122, and it is stabilised by four 
intramolecular hydrogen bonds, as shown in Figure 2.6. Three of these hydrogen bonds 
are between the backbone carbonyl groups of residue 5, 7 and 9 to the N-terminal 
secondary amine and the fourth is from the carbonyl of residue 2 to the C-terminal 
primary amide. The threaded loop contains four cis and four trans amide bonds.55 In the 
threaded loop conformation, solvophobic interactions direct the polar amide bonds to 
the interior of the loop. This secondary structure can be easily converted into a helix by 
the addition of a polar solvent that can disrupt the hydrogen bonding patterns (e.g. 
methanol) showing that the strength of hydrogen bonding is very important in 
stabilising the threaded loop conformation.  
 
 
 
                                                     
**
 Image reproduced from Fowler and Blackwell, Org. Biomol. Chem., 2009, 7, 1508. 
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The Blackwell group has also manipulated the secondary structure of this peptoid 
‘threaded loop’ using electronic effects, for example with the nitro-aromatic residues 
Nsnp and Ns2ne (Figure 2.7). By placing these monomers at strategic points in the 
peptoid nonamer, the hydrogen bonding at key positions in the structure can be 
modulated and the loop structure stabilised or disassembled.54,56-58 
 
 
Figure 2.7. Nitro-aromatic residues used in the Nspe9 threaded loop by Blackwell et al. 
Placement of the Nsnp in an N-terminal position stabilises the threaded loop, whereas 
inclusion of Ns2ne destabilises the structure. 
 
 
2.4.3 Turn structures 
Peptoid turn structures are not as well studied as the two motifs already discussed, 
however progress has been made to manipulate peptoid structures in this way. In the 
literature, turns have been achieved either by macrocyclisation (techniques for 
cyclisation are discussed in detail in section 2.3) or by the introduction of a heterocyclic 
turn-inducing monomer.21,47,59-61 
Firstly, the head-to-tail macrocyclisation of achiral peptoids can form units which 
resemble native peptide β-turns. For hexamer and octamer peptoids with alternating 
aromatic and alkyl sub-monomers, the two types of side chain are segregated to opposite 
faces of the macrocycle, as illustrated in Figure 2.8A. The enforced cyclic structure 
closely resembles both type I and type III β-turns. The two amide bonds in the turn 
region are both cis, and trans in the rest of the structure.21,47,58  
An alternative way to induce a peptoid turn in a linear oligomer is through the use of 
specific monomer units that mimic turn structures. Triazole monomers have been used 
for this purpose, as shown by compound 124 in Figure 2.9. The triazole is geometrically 
constrained and introduces a tight turn in peptoid structures. If bulky α-chiral groups 
neighbour the triazole ring, the structural stability can be further increased by rigidifying 
the turn. Other monomers have also been used to create the same effect. For example, 
N-aryl side chains with hydrogen bond donors in the ortho position can form hydrogen 
bonds to the peptoid backbone and enable an acyclic peptoid reverse-turn structure.47,59-
61 
Ch. 2 Peptoid Synthesis and Characterisation 
52 
 
 
Figure 2.8. a) The X-ray crystal structure of an example cyclic hexamer 123; b) the 
backbone of the cyclic peptoid, shown in green, is overlaid with a peptide type I (left) 
and type III β-turn (right), both shown in grey; c) chemical structure of the peptoid 
macrocycle 123. Image adapted and reprinted with permission from The Royal Society of 
Chemistry. ††,47 
 
Figure 2.9. The NMR structure of the highly ordered turn induced by the triazole unit in 
compound 124, where the peptoid backbone is highlighted in green. The structure of 
peptoid 124 is also shown, with the triazole moiety highlighted in blue. Image adapted 
and reprinted with permission from The Royal Society of Chemistry.‡‡,47 
                                                     
††
 Image reproduced from Fowler and Blackwell, Org. Biomol. Chem., 2009, 7, 1508. 
‡‡
 Image reproduced from Fowler and Blackwell, Org. Biomol. Chem., 2009, 7, 1508. 
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Ch. 2 Peptoid Synthesis and Characterisation 
53 
2.4.4 Self-assembly of peptoid nanostructures 
Another peptoid structural motif that has been well documented by the Zuckermann 
group is peptoid nanosheets and related nanotubes, which were discovered well over a 
decade later than peptoid helices. Nanosheets have been suggested as β-sheet mimetics 
and are typically comprised of amphiphillic diblock copolymers.62-64 To form these 
nanosheets, chain-chain interactions are necessary and this introduces a greater level of 
complexity into the design of peptoid nanosheets as peptoid backbones cannot undergo 
intramolecular hydrogen bonds like peptides. 
The Zuckermann group synthesised the first peptoid nanosheet which was formed of two 
separate, oppositely charged 36 residue peptoids that self-assemble into a bilayer in high 
yield under aqueous conditions. The two amphiphilic 36mers alternated a polar ionic 
sub-monomer and nonpolar aromatic monomer and this regular sequence was repeated. 
These nanosheets were characterised by atomic force microscopy, X-ray diffraction and 
transmission electron microscopy to show that the layers were 3 nm thick and consistent 
with a bilayer model, where hydrophobic groups are buried in the interior of the sheet 
and ionic groups exposed to the surface. This two dimensional structure is shown in 
Figure 2.10. The bilayers were stable over a broad pH range and various temperatures, 
but dissolve in the presence of greater than 50 % acetonitrile.8,62,65-68 
The sheet formation was found to be highly dependent on the two-fold periodicity (i.e. 
three and four-fold repeating units didn’t lead to self-assembling polymers) and also on 
peptoid chain lengths; in general, the longer the chain the more stable the nanosheets 
formed.  
 
Figure 2.10. a) The structure of the two dimensional nanosheet described, as taken from 
molecular modelling. Oxygen is shown in red, nitrogen in blue and carbon in yellow. b) 
The chemical structure of the two, oppositely charged amphiphilic peptoids 125 and 126, 
i.e. the positively charged peptoid 125 (NaeNphe)18 and the negatively charged peptoid 
126 (NceNphe)18.
65,67 Image adapted and reprinted with permission, copyright 2010 
Nature Publishing Group. §§ 
 
                                                     
§§
 Image of nanosheet reproduced from Nam et al., Nat. Mater., 2010, 9, 454. 
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More sophisticated nanosheets have also been made by the Zuckermann group, who 
sought to form a nanosheet from a single peptoid chain. They combined the critical 
design elements from the first nanosheets to successfully form a block charge structure 
(NaeNphe)9(NceNphe)9 and also a peptoid with alternating charge (NaeNpheNceNphe)9. 
Both designs formed nanosheets and as expected the block charge motif had the best 
stability against pH change and chemical denaturation.65,67  
Additionally, monodisperse amphiphillic diblock polypeptoids have also recently been 
shown to spontaneously assemble into hollow, crystalline nanotubes.69 Such structures 
have no central hydrophobic core, which is dissimilar to the nanosheets described above 
and van der Waals interactions provide the dominant interaction. The motif used in 
these nanosheets contains a hydrophobic block of poly-N-decylglycines and a 
hydrophilic domain made of 2-(20(2-methoxyethoxy)ethoxy)ethylglycine monomers. 
The ethyleneoxy and aliphatic packing interactions are strong enough to crystallise the 
thin nanotube domains, with significant curvature and provide materials that can be 
adapted for many potential applications in the nanotechnology or pharmaceutical 
fields.69 
 
2.5  Characterisation of peptoid secondary structure 
Mass spectrometry is usually used to confirm the sequence of peptoids but 
characterising the secondary structure of peptoids needs further analytical techniques 
which are briefly explained below. In particular, circular dichroism spectroscopy (CD), 
X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy have been 
regularly used and other techniques such as fluorescence resonance energy transfer 
(FRET) or computational methods have also been used. 
CD spectroscopy is probably the most commonly used procedure to study the secondary 
structures of peptoids as measurements are quick to obtain and only require low sample 
concentrations (typically 1–10 mg mL-1). CD spectroscopy can be used to evaluate the 
stability as well as conformation of the peptoids under many conditions such as 
temperature, solvents or the effect of denaturants. A source of circularly polarised light is 
used and for optically active samples the left and right components of circularly 
polarised light are absorbed to different extents leading to characteristic absorption 
bands.70  
CD spectroscopy is used extensively to study helical peptoids, as intense and 
characteristic absorption signals due to low energy electronic transitions within the N-
substituted amide backbone can be seen (corresponding to n → π* and π0 → π* 
transitions). Peptoids as short as five residues long can exhibit helical CD spectra, 
although the signals intensify as chain length increases. In helical peptoids with α-chiral 
aromatic side chains, well-defined double minima are seen around 202 and 218 nm, 
similar to peptide helices and it is suggested that these helicies are structurally similar to 
a type-I polyproline helix.32,33,50,71  
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The handedness of helices is controlled by the chirality of the monomers chosen, so 
peptoids with side-chains of opposing handedness exhibit mirror-image CD spectra. 
Only molecules without a plane of symmetry show the characteristic absorptions, 
therefore in peptides the chirality in the backbone allows measurements to be taken 
regardless of the sequence. However, with peptoids, if no α-chiral sub-monomers are 
present, CD measurements cannot be obtained.32,33,50,71 
Where it has been possible to crystallise peptoids, single crystal X-ray diffraction 
techniques have been used to study their conformation. The first crystal structure of a 
peptoid (an N-(1-cyclohexylethyl)glycine pentamer) was reported in 2003.50 Linear 
peptoids tend to be difficult to crystallise due to their flexibility, therefore far more X-ray 
structures have been solved for conformationally restrained cyclic peptoids than linear 
ones.21,32,33,50 
Finally, NMR spectroscopy has also been used to characterise peptoid secondary 
structures, often in combination with CD spectroscopy or X-ray structures. Often 2D-
NMR is used to gain a better understanding of the solution state conformations of 
peptoids; NOESY was used to confirm the n → π*Ar interactions discussed earlier. 
1H–13C 
HSQC spectra have also been used to show that there is more than one helical 
conformation in solution, as far more peaks are seen on the proton-carbon correlation 
than expected. This arises due to the lack of backbone hydrogen bonding in peptoids, 
which means that the amide bonds can readily populate cis and trans forms. In general, 
in longer peptoids, the cis form is favoured. The ratio between cis and trans states can be 
altered by inclusion of monomers with different steric or electronic character (as 
discussed in section 2.4.1) and the ratio Kcis/trans can be determined via integration of the 
NMR spectra.32,33,50,52,72,73 
Overall, great progress has been made in understanding and synthesising new peptoid 
structures over the last decade. Common motifs from peptide chemistry have been 
copied and successfully transferred into peptoids, such as the helix and more 
complicated structures such as self-assembling microspheres and nanosheets. It has been 
shown that subtle sequence variations can influence long-range structural interactions, 
giving chemists a handle to help design peptoids for specific applications.66,74 
Several groups have accurately predicted the structure of peptoids from their sequence, 
but there is still much work to be completed in this area. In the future, the de novo 
design of functional peptoids, for example for biological applications, will depend upon 
the ability to predict the structure of peptoids from their sequence. As peptoids lack 
regular hydrogen bonding patterns, this is very challenging. To date, steric, hydrophobic, 
electrostatic and stereoelectronic effects have all been implicated in the folding of 
peptoids and these additional forces all vary greatly for the hundreds of potential peptoid 
side chains. Further research is needed to thoroughly understand the complicated 
molecular interactions that are necessary to fold peptoids into helices, turns and larger 
global structures that would resemble peptoid protein mimics.46,72 
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2.6  Peptoid library synthesis 
Over 200 peptoids have been synthesised as part of this project, this includes simple 
linear peptoids including those that have been lipidated or PEG-ylated, sequences with 
novel chemical functionalities and cyclic compounds. The synthesis of these compounds 
will be discussed, including the development of novel methodology for the synthesis of 
sequences containing both lysine- and arginine-type monomers, a new class of peptoid. 
The synthesis of fluorescently tagged peptoids will be discussed in Chapter 5, where they 
are used to facilitate investigations into peptoid mode of action.  
 
2.6.1 Library design 
Our initial peptoid library was designed to incorporate three key properties known to 
lead to biological activity in antimicrobial peptides (AMPs); positive charge, 
amphipathicity and a defined secondary structure. By mimicking these key attributes of 
AMPs, it was hoped that potent anti-infective behaviours could also be replicated in the 
peptoid sequences. 
Firstly, most sequences included residues that could provide an overall cationic charge to 
the sequence. In naturally occurring AMPs, inclusion of lysine and arginine is highly 
conserved as they facilitate interaction with bacterial cell membranes. Both bacterial and 
parasitic cell membranes tend to be more negatively charged than mammalian cells as 
they have a greater proportion of phospholipids on their surface. It was hoped that 
cationic peptoids may have a greater selectivity to pathogenic cells over mammalian 
cells.  
A large proportion of potent AMPs are helical, so sequences within this library were 
designed to encourage the formation of peptoid helicies. Given the lack of backbone 
chirality and the amide bound proton that can undergo hydrogen bonding to stabilise 
peptide secondary structure, bulky, aromatic residues were included in the peptoid 
sequences in order to induce a helical secondary structure, as described in section 2.4.1 
Many of our peptoids include the N-(S-phenylethyl)glycine residue (Nspe) as this has 
been shown to induce a helical peptoid conformation. CD studies on our library*** 
confirm that most sequences display at least some helical character.75-77 
Typically sequences used a repeat motif of three residues, i.e. (NxNyNz)n where Nx is 
typically a charged or hydrophilic monomer. Ny/z is usually a hydrophobic monomer 
such as the Nspe monomer so the motif often was similar to that shown in Figure 2.11. 
Peptoid helices are reported to be wound slightly tighter than the typical peptide α-helix, 
with 3.0 residues per turn. Use of the three monomer motif in Figure 2.11 should 
encourage the formation of an amphiphilic structure where all the hydrophilic groups 
                                                     
***
 Data in section 2.10 
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are positioned on the same side of the helix. This has often been shown to aid 
antimicrobial action in AMPs.47,77 
 
Figure 2.11. Typical repeating peptoid motif of hydrophilic monomer, Nx, followed by 
two hydrophobic monomers, Ny and Nz (that don't necessarily have to be the same). 
 
In initial peptoid syntheses, a limited variety of monomers were incorporated into the 
library using cheap and commercially available amines, including aromatics like 
substituted-benzylamines and simple alkyl amines. Successive generation libraries were 
designed to add differing functionalities and to expand the chemical space achieved by 
the peptoid sequences. For example, residues containing heteroatoms reminiscent of 
natural amino acids were included (i.e. histidine, tryptophan or cysteine-type 
monomers) or those with suspected beneficial pharmacokinetic properties (i.e. fluorine 
containing monomers). Figure 2.12 shows a representative selection of the wide variety 
of peptoid residues included in our library.  
By including a wide variety of side chain functionalities in the peptoid library, structure-
activity relationship investigations have been investigated against a variety of biological 
targets.  
As well as examining the effect of different monomer functionalisation, other features 
were designed into the sequences to investigate other attributes that are necessary for 
potent, anti-infective peptoids. These alterations will be discussed as specific compounds 
are introduced, but include changes such as:  
– Peptoid sequence length 
– Overall peptoid charge 
– Placement of charge in the peptoid sequence 
– Length and nature of hydrophilic side chains 
– The effect of α-chiral monomers 
– Differing motifs (i.e.  pattern of hydrophilic and hydrophobic residues) 
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Figure 2.12. Representative selection of the most common monomers used as an example of the chemical diversity within the library. 
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2.6.2 Peptoid nomenclature 
Within the scientific literature, there exists many different ways to name a single peptoid 
sequence. Unlike peptides, where each amino acid in the sequence has a distinctive 
name and one letter amino acid code, the naming of peptoid monomers is far more 
ambiguous. In part, this is due to the great diversity within peptoid sequences and also 
because no group has yet published guidelines for the naming of peptoids. As such, 
different research groups use different terminology for the same peptoid monomer.  
In an effort to implement a consistent nomenclature across peptoid building blocks 
within this project, the following conventions have been adopted. Peptoid monomers are 
typically named after the amine that they are derived from (unless the side chains are 
reminiscent of a natural amino acid). Building blocks with side chains analogous to those 
of amino acids are named after the corresponding amino acid if the N-terminal nitrogen 
of the building block bears those atoms attached to the alpha carbon of the 
corresponding amino acid (not including the alpha carbon), e.g. NArg. Building blocks 
with side chains analogous to those of amino acids but differing by one carbon are 
named after the corresponding amino acid with 'h' (homo) preceding the amino acid 
code if the building block contains one carbon extra, e.g. NhArg, or 'n' (nor) preceding 
the amino acid code if the building block contains one carbon less, e.g. NnArg (see 
Figure 2.13). Capitalization within building blocks is in line with the literature where 
possible and amino acid components of peptoid building block names are capitalized. 
 
Figure 2.13. Nomenclature for peptoid monomers similar to the peptide amino acid 
arginine. 
 
Where possible, this building block nomenclature has been chosen to be as similar as 
possible to that found in the literature. While some building block names may differ 
from those found in the literature in some cases, it is envisaged that the naming scheme 
chosen will result in more consistent and understandable naming. In collaboration with 
Sam Lear (Cobb group, Durham University), this nomenclature has been used in an 
online web utility for the calculation of peptoid molecular weights and assignment of 
mass spectrometry data. This site can be found at www.pep-calc.com/peptoid and also 
includes residues not used in this project, but commonly found in the literature.78 
Additionally, a table to show peptoid monomers and the primary amine they are derived 
from can be found in the Appendix. 
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2.6.3 Synthesis of linear peptoids  
All peptoids were made using solid-phase synthesis and the submonomer procedure 
pioneered by Zuckermann et al introduced in section 2.1.2.3  A schematic for the 
synthesis and cleavage from the resin is shown in Scheme 2.6. In the submonomer 
method, the peptoid is built up sequentially to form a monodisperse sequence by 
acylation of the resin using a haloacetic acid and subsequent displacement by a primary 
amine. The submonomer procedure is then repeated until a peptoid of the required 
sequence and length has been achieved.  
 
 
Scheme 2.6. The sub-monomer synthesis of a peptoid on solid phase; i. acylation step; ii. 
displacement using a primary amine; iii/iv. repetition of submonomer method; iv. acidic 
cleavage from the resin using TFA. ‘R’ represents the side-chains and where necessary, 
monomers are protected by a suitable protecting group. 
 
Typically, bromoacetic acid was chosen as the acetylating agent and N,N’-
diisopropylcarbodiimide (DIC) as the activator in the first coupling. For certain 
sequences where side chain functionality included unprotected heteroatoms, 
chloroacetic acid was used instead. The chloroacetic acid was used to synthesise the 
peptoids using amines with unprotected side-chains such as imidazole, indole or pyridyl 
groups. 
Due to the unprotected heteroatoms, there is the potential for sequence propagation on 
the side chain heterocycles as shown in Scheme 2.7. It is expected that activated 
bromoacetic acid will temporarily acylate most side chain aromatic nitrogens. However, 
this reaction is readily reversed in the presence of base and because the second step of 
the submonomer procedure involves a high concentration of amine, unwanted side 
products from acylation are removed. Bromoacetic acid can also alkylate the unprotected 
heteroatoms. Normally, this side reaction is not observed on the propagating chain 
because acylation of an N-terminal secondary amine is not reversible and is 
approximately 1,000 times faster than alkylation. However, the reversibility of side-chain 
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heterocycle acylation allows accumulation of the irreversible alkylation byproduct. To 
avoid this, chloroacetic acid was used in the acylation step when monomers were used 
that had unprotected heteroatoms.4  
Scheme 2.7. The two potential side reactions that can occur at unprotected, side chain 
heteroatoms when treated with an activated haloacetic acid; acylation (transient) and 
alkylation (irreversible). 
 
Chloroacetic acid is a poorer alkylating agent than bromoacetic acid so reduces the 
unwanted alkylation reaction, but it also slows down the following displacement 
reactions. Therefore, in syntheses using chloroacetic acid, the displacement steps were 
extended to 90 minutes. After the synthesis, a final piperidine deprotection ensured that 
any side-products from acylation were removed.  
Following successful acylation, in the second step of the submonomer method, a variety 
of primary amines were used to undertake the SN2 displacement of the halide atom to 
form the peptoid monomer. All coupling steps were undertaken in DMF as both 
haloacetic acids, DIC and most amines have good solubility in DMF, although NMP was 
used to solubilise certain amines that had poor solubility in DMF. 
Most amines were commercially available, either as protected amines (i.e. Nae from N-
Boc-1,2-diaminoethane) or could be used without protection. Several monomers needed 
treatment before use in peptoid synthesis and are shown in Figure 2.14. The glutamic 
acid peptoid residue NGlu was derived from tBu-protected β-alanine which is purchased 
as a hydrochloride salt and must be free-based prior to synthesis to give 127. In order to 
add a cysteine monomer, commercially available thioethylamine was trityl protected to 
yield 128. The NLys monomer was derived from N-Boc-1,4-diaminobutane, compound 
129, which was either synthesised from the unprotected diamine (as described in section 
2.6.4), or purchased from commercial sources. Protocols for monomer preparation can 
be found in the Experimental chapter. 
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Figure 2.14. Protected monomers synthesised for use in the submonomer method of 
peptoid synthesis. 
 
Typically, Rink Amide resin was used to build the peptoids from the C terminus, as it is a 
versatile resin and following cleavage from the resin results in a C terminal 
carboxamidine. However, in the synthesis of cyclic precursors or specialised sequences 
(discussed in section 2.6.5) other resins were chosen. Removal of the final compound 
from the resin is undertaken using acidic cleavage conditions that depend on the 
particular resin chosen (see Chapter 7).  
In general, the peptoids in this library were cleaved for no longer than 90 minutes (most 
commonly 45–60 minutes) due to the potential for acid induced degradation of the N-
(S/R-phenylethyl)glycine residue monomer. In comparison to peptide synthesis where 
cleavages of 6 hours are routine, this is a much shorter time period but provided 
peptoids in the greatest purity with adequate overall yield. 
Peptoids were synthesised both manually in the Cobb Group††† and using a customised, 
automated parallel synthesiser in the Zuckermann lab‡‡‡ using different conditions (see 
Table 2.2).  A list of peptoids synthesised in this peptoid library and detailed 
experimental procedures for these syntheses can be found in the Experimental chapter. 
All peptoids were purified to > 95 %, as characterised by analytical RP-HPLC. 
At the outset of this project, most synthetic peptoid papers referenced the original 1992 
submonomer paper from the Zuckermann  group2 and a statement was made that adapted 
conditions were used but these were rarely stated. Therefore, there was no overall 
consensus within the literature on the exact method that should be used for the synthesis 
of generic peptoids. The literature suggested that the time taken for the addition of each 
submonomer (both acylation and displacement) can vary between several minutes and 
several hours, dependent on the amines used, which becomes problematic in the 
synthesis of longer peptoids. It had been shown that couplings occurred faster when the 
reactions were heated; either manually or using microwave irradiation. In particular, 
microwave heating is reported to be useful for α-branched primary amines and where 
electronically deactivated amines are used. In these cases, gentle microwave heating was 
                                                     
†††
 At Durham University 
‡‡‡
 At the Molecular Foundry, Lawrence Berkeley National Laboratory, USA 
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reported to give a modest increase in purity relative to control experiments carried out at 
room temperature.79,80  
Table 2.2 summarises the three reactions conditions used for the synthesis of linear 
peptoids. Due to the suggestion that conventional or microwave heating could aid the 
submonomer synthesis of peptoids; early syntheses in this project used a heated shaker 
platform or microwave to accelerate reactions. In heated reactions, 15 minute couplings 
at 50 ˚C (condition 1) were chosen to balance the time of reaction and product purity 
(crude product purity between 40 and 70% by RP-analytical HPLC). Pure samples were 
obtained following HPLC using these conditions, however additions and deletions were 
seen in the crude products and it was anticipated that the yields could be improved with 
optimisation.  
At this point, the synthesis of peptoids was undertaken using an automated peptoid 
synthesiser that had no heating element, so other conditions were necessary. In 
automated syntheses the acylation and displacement steps were carried out at room 
temperature for 20 minutes and 60 minutes respectively (condition 2), following advice 
from the Zuckermann group. The longer coupling times and lower concentration of 
bromoacetic acid led to high yielding, clean syntheses with crude purities approximated 
between 75–95 % by RP-analytical HPLC. Final purification was substantially easier using 
condition 2a so subsequent manual syntheses also followed the optimised conditions 
used in the automated syntheses. 
In syntheses using chloroacetic acid (condition 3), the crude products were not as clean 
and had crude purities between 50–75 % by RP-analytical HPLC. However, enough 
material was obtained following preparative HPLC at > 95 % purity for biological testing 
so the reactions were not optimised further. 
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 Condition 1 Condition 2 Condition 3 
M
a
n
u
a
l 
S
y
n
th
e
si
s 
    
Heated shaker  Microwave (power 20W)  Shaker platform Shaker platform 
50 ˚C  50 ˚C Room temperature Room temperature 
 
Acylation 15 min 
     8 eq. 2 M BrAA in DMF 
     8 eq. 2 M DIC in DMF 
Acylation 15 min 
     8 eq. 2 M BrAA in DMF 
     8 eq. 2 M DIC in DMF 
Acylation 20 min 
     1 mL 0.6 M BrAA in DMF 
     0.20 mL 50 % DIC in DMF v/v 
  
Acylation 20 min 
     1 mL 0.6 M ClAA in DMF 
     0.20 mL 50 % DIC in DMF v/v 
Displacement 15 min 
     4 eq. 1 M amine in DMF 
Displacement 15 min 
     4 eq. 1 M amine in DMF 
Displacement 60 min 
     1 mL 0.8–2.0 M amine in DMF  
 
Displacement 90 min 
     1 mL 0.8–2.0 M amine in DMF  
 
A
u
to
m
a
te
d
 S
y
n
th
e
si
s 
  Robot  Robot  
  Room temperature 
 
Room temperature 
 
  Acylation 20 min 
     1 mL 0.6 M BrAA (or ClAA) in DMF 
     0.18 mL 50 % DIC in DMF v/v 
 
Acylation 20 min 
     1 mL 0.6 M ClAA in DMF 
     0.18 mL 50 % DIC in DMF v/v 
 
  Displacement 60 min 
     1 mL 0.8 – 2.0M amine in DMF 
 
Displacement 90 min 
     1 mL 0.8–2.0 M amine in DMF 
 
 
Table 2.2. A comparison of manual and automated synthesis procedures. NMP is used as a solvent for poorly soluble amines, BrAA is 
bromoacetic acid and ClAA is chloroacetic acid. Condition 2 is recommended for all syntheses (or condition 3 where residues containing 
unprotected heteroatoms are introduced). 
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2.6.4 Boc protection of 1,4-diaminobutane 
The lysine-mimetic NLys submonomer is derived from 1,4-diaminobutane, which must 
be mono-protected to prevent unwanted reactions and chain propagation along the side 
chain groups. 
Boc (tert-butyloxycarbonyl) protection was chosen, similar to the Boc protection of 
Fmoc-Lys(Boc)-OH used in peptide synthesis, as the Boc group can be removed under 
the same acidic conditions used to cleave products from the resin. A literature procedure 
was followed to achieve the synthesis of mono-N-Boc-1,4-diaminobutane, 129.81  
The reaction shown in Scheme 2.8 uses high-dilution synthesis; large volumes of 
solvent, low temperatures and slow addition of Boc anhydride to the 10-fold excess of 1,4-
diaminobutane to encourage formation of the mono-protected product over the di-
substituted amine. Unreacted 1,4-diaminobutane is readily removed from the product by 
washing with water. Following extraction and solvent removal, 129 is found as a 
colourless oil and ready for use in solid phase synthesis, without further purification. 
 
 
 
Scheme 2.8. Mono-Boc protection of 1,4-diaminobutane using high dilution synthesis. 
 
Later in the project, it was decided to purchase N-Boc-1,4-diaminobutane (129) from 
commercial sources to save time and reduce reagent costs. Although 129 synthesised in 
house looked identical to the commercially bought compound via 1H and 13C NMR 
spectroscopy, the purchased amine was less viscous, therefore easier to handle and more 
soluble in DMF (the solvent used in the sub-monomer synthesis of peptoids) which was 
advantageous. 
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2.6.5 Cyclic peptoids 
As previously explained in Chapter 1, cyclisation often increases the biological activity of 
molecules. This is attributed in part to a more rigid structure, therefore conformational 
entropy losses are minimised upon target binding. When considering peptides and 
peptoids, cyclisation also removes charged termini which can increase membrane 
permeability.82 
A small library of cyclic peptoids was synthesised in this project to investigate if these 
compounds would have an improved biological activity compared to their linear 
analogues. The five cyclic peptoids synthesised as part of this project are summarised in 
Figure 2.15. Since the cyclisation itself enforces a defined secondary structure inclusion 
of the α-chiral N-(S-phenylethyl)glycine residue monomer, which was used frequently in 
the linear sequences to achieve a stable secondary structure, was unnecessary. 
Figure 2.15. The cyclic peptoids synthesised with a range of cationic functionalities 
represented. 
 
Peptoids 130 and 131 with the NxNyNy  motif were synthesised as direct comparisons to 6 
residue peptoids from the linear library, (NLysNpheNphe)2  and (NLysNpfbNpfb)2.  
However, X-ray diffraction data collected from various cyclic peptoids in the literature 
show that if the linear sequence has alternating hydrophobic/phillic residues, the 
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hydrophobic chains are organised onto one face of the macrocycle and the hydrophilic 
chains will be directed towards the opposite face. This should form an amphiphilic 
structure with well-defined lipophilic and cationic surfaces.28,29 Therefore, three peptoids 
based upon an alternating NxNy motif, 132, 133 and 135 were also synthesised. As well as 
being more highly charged, it was anticipated that these peptoids may have more distinct 
hydrophobic and hydrophilic faces compared to 130 and 131, which may increase 
biological activity. 
A wide variety of techniques have been developed for the cyclisation of peptoids 
(summarised in 2.3). In this project, a head-to-tail cyclisation strategy was employed. As 
shown in Scheme 2.9, the linear precursor peptoid is made using the submonomer 
procedure on solid phase, cleaved from the resin and then cyclised in solution.28,39   
 
 
Scheme 2.9. A schematic to represent the stages involved in the cyclisation of linear 
peptoids, where ‘P’ represents protected side-chains. i. cleavage from resin under mildly 
acidic conditions; ii. cyclisation using an activating agent; iii. removal of side-chain 
protecting groups. 
 
In order to facilitate a head-to-tail cyclisation, 2-chlorotrityl chloride resin was used for 
the synthesis of linear precursors. This resin produces a C-terminal carboxylic acid group 
upon cleavage from the solid-support, which can be easily activated to facilitate 
cyclisation. To load the resin, bromoacetic acid and DIPEA are used and all subsequent 
couplings follow as for Rink Amide resin. As this resin contains a fairly acid and moisture 
sensitive linker and because a concentrated bromoacetic acid solution is used in the 
acylation step, couplings were undertaken at room temperature. These conditions were 
adequate to produce a crude peptoid that didn’t need purification before cyclisation.  
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To cleave the peptoid from the resin, hexafluoroisopropanol, HFIP (20 % v/v in DCM) was 
used. This cocktail causes cleavage under mild conditions that does not remove protecting 
groups on the side-chain amino groups (i.e. Boc protection remains intact). This is 
necessary to prevent unwanted side-reactions upon cyclisation.  
Cyclisation was carried out on the crude, protected peptoids using PyBOP and DIPEA in 
DMF, which form an activated ester to assist the head-to-tail attack of the terminal amine. 
Finally, the Boc groups are removed from the NLys residues using a TFA cocktail. Full 
conditions for the cleavage, cyclisation and deprotection of 130 are shown in Scheme 
2.10.  
 
Scheme 2.10. The synthesis of the cyclic peptoid 130. The linear precursor is made on 2-
chlorotrityl chloride resin as previously described; i. cleavage from the resin; ii. 
cyclisation under high-dilution synthesis conditions; iii. deprotection of Boc groups. 
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For small molecules, intramolecular reactions should be much faster than intermolecular 
processes. Although literature precedents28,39 suggested that there was no need for high-
dilution conditions to encourage cyclisation over the formation of oligomers, reactions 
were carried out in a larger volume of solvent than necessary (typically 10 mL for 
100 µmol peptoid) and the peptoid solution was added dropwise over several hours.  
DMF was used in initial cyclisations, but as it has a boiling point of 153 ˚C it is difficult to 
remove at the end of the reaction in vacuo, so a trial cyclisation was carried out in DCM. 
However, no appreciable cyclic product was seen on the crude reaction mixture via LC-
MS or recovered following work up so further reactions continued using DMF.  
Purification was necessary following the cyclisation and also a final purification was 
undertaken after Boc deprotection to yield the peptoids in > 95 % purity (see Figure 
2.16). See Experimental chapter for further detail regarding the cyclisation.  
 
 
Figure 2.16. Analytical RP-HPLC traces for a) 130 cyclo (NLysNpheNphe)2; b) 132 
cyclo (NLysNphe)3; c) 133 cyclo (NhArgNphe)3; d) 134 cyclo (NLysNpheNhArgNphe 
NLysNphe). See Experimental chapter for gradient and solvent conditions.  
 
Crystallisation of the peptoids 130–134 was attempted to investigate their structural 
conformation further. This was carried out using a sitting drop method in a sparse 
matrix crystallisation screen with 24 different buffers, pH conditions and salts or 
additives conditions§§§. The crystallisation was attempted with several peptoid 
concentrations and with plates stored at room temperature and in various temperature 
fridges. However, to date, no suitable crystals have been produced.  
                                                     
§§§
 Using a crystallisation screen developed for peptides by Dr Ehmke Pohl, Durham University. 
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A collaboration with the laboratory of Professor Kent Kirshenbaum (New York State 
University, USA) provided an additional library of ten cyclic peptoids synthesised by 
Alan-Yao Liu to compliment those synthesised in Durham. Compounds 135-144 expand 
the library of cyclic peptoids and include larger ring sizes (6, 8 and 10 residue peptoids) 
and differently functionalised monomers to form very different scaffolds to those made 
as part of this project. These cyclic products are shown in Figure 2.17 and were also 
synthesised by the head-to-tail cyclisation of linear precursor peptoids.28 
Figure 2.17. The structure of the ten cyclic peptoids provided by the Kirshenbaum Group 
and synthesised by Alan-Yao Liu. 
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2.7  Novel chemical methodology for the introduction of arginine-type 
monomers 
As seen in Chapter 1, antimicrobial peptoids are often designed to mimic naturally 
occurring AMPs and contain a mixture of hydrophobic and cationic monomers to mimic 
the amphipathic structures of many AMPs. The presence of cationic side chains within 
the peptoid sequence can provide a degree of selectivity between zwitterionic 
mammalian cell membranes and the more negatively charged prokaryotic cell 
membranes. In biologically active peptoids, either lysine- or arginine-type monomers 
provide this net positive charge and there are many examples within the literature of 
cationic anti-infective peptoids that contain either lysine-type or arginine-type 
monomers (see Figure 2.18).28,77,83-86 
 
Figure 2.18. A representation of the amino functionalised lysine-type monomers and 
guanido functionalised arginine-type monomers, where different length side chains are 
possible and n = 1-6. 
 
Beyond their anti-infective applications, cationic peptoids have been applied in other 
areas of medicinal chemistry. For example, peptoids rich in guanidine functionalised 
arginine monomers have been used as molecular transporters,87-89 cell-penetrating 
vehicles,29,89-91 heparin binding agents,92 and as analogues of Lung Surfactant Protein B.93 
It has been shown that cellular uptake can be affected by the use of either lysine or 
arginine type monomers; in general guanidine containing peptoids can translocate into 
the cell more quickly than their amino analogues. Additionally, it has been suggested 
that sequences including arginine-type monomers may have an increased biological 
activity, however this is typically accompanied by an increased toxicity towards 
mammalian cells.94 
Therefore, it would be advantageous to investigate the biological activities of peptoids 
that contain mixtures of lysine- or arginine-type monomers in order to fine tune the 
balance between toxicity and activity. However, with the exception of one example,95 all 
of the peptoids investigated to date have sequences consisting exclusively of either the 
amino functionalised lysine monomer or the guanido functionalised arginine residues 
exclusively.**** The lack of a suitable synthetic route to prepare such mixed cationic 
                                                     
****
 Although peptoid-peptide hybrids have been made with mixed cationic functionality introduced using 
the amino acids lysine and arginine. 
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peptoids has meant that their biological potential has remained almost largely 
unexplored.96,97  
Polyarginine-type peptoids reported in the literature have mostly been synthesised using 
the method developed by Rothbard and co-workers.98 This approach uses pyrazole-1-
carboxamidine to transform lysine-type monomers into their arginine-type analogues 
(i.e. an amino to guanido transformation) in a post-synthetic modification of 
unprotected amino moieties. This reaction can only be carried out after the peptoid has 
been cleaved from the resin and Boc protecting groups removed. Therefore, it is not 
possible to use this approach to synthesise sequences containing both amino (i.e. NLys) 
and guanido (i.e. NArg) functionalities as every lysine-type residue with the peptoid 
chain is transformed into an arginine-type residue. 
The Zuckermann group has previously synthesised a PMC (2,2,5,7,8-
pentamethylchroman-6-sulphonyl) protected guanidinopropyl amine monomer.17 Barron 
et al., attempted to use this PMC protected monomer in the on-resin synthesis of a linear 
peptoid functionalised with both amino and guanidine cationic groups.95  However, poor 
solubility of the PMC protected monomer in solvents commonly used for on-resin 
reactions led to a low coupling efficiency in the submonomer method. The extended 
cleavage times necessary for this protecting group also proved problematic, causing acid-
induced degradation of the mixed peptoid (in particular, deterioration of the commonly 
used Nspe monomer) preventing the full isolation and purification of the target peptoid 
sequences with both arginine/lysine-type residues.  
Therefore to the best of our knowledge an efficient generally applicable method for the 
synthesis of mixed arginine/lysine-type peptoids was yet to be reported.  In this work, an 
effective synthetic route was developed that allowed novel linear and cyclic cationic 
peptoids to be synthesised that contained both lysine-type and arginine-type monomers 
within the same sequence.99 This has allowed the biological activity of this novel class of 
peptoids to be investigated; in particular, the relationship between antimicrobial 
properties and cytotoxicity probed in more detail (discussion in Chapters 3 and 4).  
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2.7.1 Synthesis of Dde-protected amine submonomers 
In order to incorporate both amino and guanido functionalised side chains (lysine-type 
and arginine-type monomer residues respectively) within the same sequence using solid 
phase synthesis, it was planned to utilise orthogonal protection of monomers. 
Commonly, N-Boc protected amines are used in peptoid synthesis for the protection of 
amino groups; for example N-Boc-1,4-diaminobutane. For the other protecting group, 
Dde (N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl) was chosen.  
Dde is commonly used to protect free primary amines in peptide synthesis and provides 
orthogonal protection to the acid cleavable Boc group.100,101 The Dde group is removed 
using 2 % hydrazine in DMF which allows these residues to be selectively deprotected 
(leaving the Boc protection on the other lysine-type monomers intact). Following 
complete synthesis of the peptoid using the submonomer method, selective deprotection 
of the Dde amine on-resin enables the guanidinylation reaction at specific positions 
using pyrazole-1-carboxamidine. Finally, cleavage from the resin under acidic conditions 
simultaneously deprotects the remaining Boc protected amino chains to yield a mixed 
peptoid, containing both lysine-type and arginine-type peptoid residues (See Scheme 
2.12, steps iv. to vi.). 
A variety of mono-N-Boc protected amines are available to purchase from commercial 
sources, or can be made in high dilution syntheses using Boc anhydride and the required 
diamine, as for 129.23 Initially, it was planned to synthesise a mono Dde-protected amine 
in a similar manner so it could be synthesised in bulk and used directly in the 
submonomer procedure.  
In the first attempt to synthesise N-Dde-1,4-diaminobutane, the literature procedure81 
previously used to synthesise mono-Boc protected diamines in this project (section 2.6.4) 
was followed under similar high-dilution conditions with 1,4 diaminobutane and 2-
acetyldimedone (Dde-OH). Several conditions, as summarised by Table 2.3, were used 
to attempt the synthesis of mono N-Dde-1,4-diaminobutane (145). However, in all cases 
the major product of the reaction and the only compound isolated was the doubly 
protected amine (146), shown in Scheme 2.11. Therefore, this procedure was deemed to 
be ineffective as the protection of the amines with Dde-OH was so efficient and an 
alternative route to mixed arginine/lysine peptoids using on-resin protection of the 
amine was developed. 
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Scheme 2.11. The attempted synthesis of N-Dde-1,4-diaminobutane using high dilution 
synthesis. 
 
Table 2.3. Conditions used in the attempted solution synthesis of N-Dde-1,4-
butanediamine.  
 
Coupling conditions were developed that permitted an unprotected diamine to be added 
to the peptoid sequence during the displacement stage of the sub-monomer method. 
One extra step was then introduced to protect this free amine on resin using Dde-OH (2-
acetyldimedone). This is shown in Scheme 2.12, steps i. to iii. 
Adding the Dde group on resin has been used in peptide synthesis, but has never been 
used to make mixed arginine- and lysine-type peptoid residues as far as we are 
aware.100,101 Addition of Dde-OH to the free amine on resin was complete by LC-MS after 
60 minutes at room temperature (10 eq. Dde-OH with respect to the resin, in the 
minimum volume of DMF necessary to dissolve the reagent fully). The submonomer 
procedure could then be resumed to lengthen the peptoid chain successfully as the Dde-
protected sidechains are stable to the conditions used in the submonomer method. 
Following completion of the sequence, selective deprotection of the Dde enables the on-
resin guanidinylation reaction to take place at specific positions in the sequence. 
 
 
Reaction Equivalents 
diaminobutane 
Equivalents 
Dde-OH 
Solvent Addition 
Time (hours) 
Reaction 
Time (hours) 
1 
10 1 
CHCl3 
1 18 
2 6 18 
3 10 18 
4 
CH2Cl2 
6 18 
5 10 18 
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Scheme 2.12. The method used to synthesise mixed arginine/lysine peptoids, where x and y = 1-5; i. standard displacement step in the 
submonomer method with diamine, 1.5 M in DMF, 60 min, RT; ii. addition of Dde-OH, 10 eq. wrt resin in minimum volume DMF, 60 min at 
RT to protect free amine; iii. further additions to extend the peptoid chain, using the normal sub-monomer procedure; iv. deprotection of 
Dde using 2 % hydrazine in DMF 4 x 3 min; v. guanidinylation of free amine, on resin, using 6 eq. pyrazole-1-carboxamidine per free amine 
and 6 eq. DIPEA per free amine in the minimum volume DMF, 60 min, RT; vi. acidic cleavage from the resin and deprotection of Boc groups. 
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2.7.2 On resin guanidinylation 
Following the on-resin protection of specific amine submonomers with Dde and 
completion of the peptoid sequence on resin, the Dde group was deprotected using a 2 % 
hydrazine solution in DMF. This yields free amino groups that can be selectively 
transformed into guanido groups, or arginine-type monomers. 
Pyrazole-1-carboxamidine is a convenient reagent for the guanidinylation of simple 
primary amines that leaves secondary amines unaffected, even when used in large excess 
and is therefore suitable for use with peptoid side chains.102 The guanidinylation reaction 
with pyrazole-1-carboxamidine previously reported by Rothbard et al. must be carried 
out on fully deprotected peptoids in solution and additionally, water was used as a 
solvent with sodium bicarbonate as a base. The procedure developed as part of this 
project uses reaction conditions which are more compatible with solid-phase synthesis 
(e.g. DMF with DIPEA). Carrying out the guanidinylation reaction on resin is preferable 
as the excess reagents used can be washed away at the end of the synthesis making the 
final purification easier. Finally, cleavage from the resin simultaneously deprotects lysine 
chains and yields the mixed peptoid, containing both lysine and arginine peptoid 
residues. 
Additionally, this approach benefits from being compatible with the submonomer solid-
phase synthesis of peptoids, which is utilised by the majority of the scientific 
community. Although not reported here, the methodology developed should be well-
suited for use with automated peptoid synthesisers as it adds only one step to the 
commonly used sub monomer method and the Dde group is easily introduced under 
room temperature conditions. 
To demonstrate the versatility and synthetic utility of the methodology, a library of 
linear peptoids containing both amino and guanido moieties within the same sequence 
were synthesised (see Table 2.4 and Figure 2.19 for monomer abbreviations). To 
illustrate Dde addition, deprotection and guanidinylation steps this process, mass 
spectra taken from each stage of the synthesis of two peptoids can be found in the 
Appendix. 
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 Peptoid Sequence 
M
ix
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d
 
L
y
si
n
e
/A
rg
in
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e
  147 (NLysNspeNspe)2(NhArgNspeNspe)2 
148 (NhArgNspeNspe)2(NLysNspeNspe)2 
149 (NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2 
150 [(NhArgNspeNspe)(NLysNspeNspe)]2 
151 [(NnArgNspeNspe)(NLysNspeNspe)]2 
134 cyclo (NLysNpheNhArgNpheNLysNphe) 
A
ll
 
A
rg
in
in
e
  152 (NhArgNspeNspe)4 
153 (NhArgNmfbNmfb)4 
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 
155 (NnArgNspeNspe)4 
Table 2.4. Sequences of the all arginine-type and the mixed lysine- /arginine-type 
peptoids prepared in this study.  
 
Figure 2.19. Monomers used in the synthesis of the arginine-containing peptoids 147–
155. The NhArg and NnArg monomers were formed from a post-synthetic 
transformation, all other monomers were introduced from standard displacement step in 
the submonomer method of peptoid synthesis. 
 
Initially, ‘mixed’ lysine/arginine-type peptoids (Table 2.4, 147–150) were prepared with 
monomers containing 4 carbons in the side chain (i.e. NLys and NhArg monomers 
derived from 1,4-diaminobutane). The Dde group was introduced at a variety of positions 
within the sequence. It was found that the Dde protection reaction on resin was efficient, 
it could be carried out near the resin linker at the C terminus and other Dde-protected 
residues in the same sequence were tolerated. The synthesis was also carried out using 
the shorter, 2 carbon amine monomer (Nae, Table 2.4, 151) to highlight that the 
methodology works with side chains of varying lengths (i.e. Nae and NnArg, derived 
from 1,2-diaminoethane). 
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Four all arginine-type peptoids were also synthesised on resin using the Dde protection 
strategy developed (Table 2.4, 152–155). Carrying out the guanidinylation reaction on 
resin significantly simplified the final purification of these peptoids compared to those 
made using the Rothbard method. The preparation of these mixed peptoids illustrates 
that the Dde methodology is compatible not just with Nphe and Nspe but also with other 
commonly used amine monomers (i.e. Nmfb and Namy). 
A cyclic peptoid (134) with both lysine- and arginine-type residues was also synthesised 
via a Dde-protected linear precursor (Scheme 2.13). The linear peptoid protected by the 
Dde-group was successfully cleaved from 2-chlorotrityl chloride resin and cyclised in a 
solution phase head-to-tail cyclisation, as in section 2.6.5. Subsequent Dde-deprotection 
of the cyclic peptoid allowed guanidinylation in solution, prior to a final acidic TFA 
deprotection of remaining Boc-protected amines. Despite the bulky nature of the Dde 
group, the cyclisation still occurred efficiently at room temperature. 
 
Scheme 2.13. The synthesis of a cyclic peptoid 134, containing both arginine/lysine-type 
residues; i. linear precursor made on 2-chlorotrityl chloride resin using sub-monomer 
method and cleaved under mildly acidic conditions (20 % HFIP in DCM, 20 min); ii. 
head-to-tail cyclisation of peptoid in solution (6 eq. PyBOP, 6 eq. DIPEA in DMF), 
6 hours; iii. deprotection of Dde (2 % hydrazine in DMF, 4 x 3 mins);  iv. guanidinylation 
in solution (6 eq. pyrazole carboxamidine per free amine in the minimum volume of 
DMF, 6 eq. DIPEA, RT, 60 min); v. deprotection of N-Boc groups (TFA, 60 min). 
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Analytical RP-HPLC purification of all final compounds was undertaken, to yield the 
peptoids in > 95 % purity, as shown by Figure 2.20 where chromatograms for 
representative compounds from the library are shown (the chromatogram for the mixed 
cyclic compound 134 is shown in Figure 2.16d). 
 
 
Figure 2.20. Analytical RP-HPLC chromatograms for selected peptoids; a) 
148 (NhArgNspeNspe)2(NLysNspeNspe)2; b) 153 (NhArgNmfbNmfb)4; c) 151 
[(NnArgNspeNspe)(NLysNspeNspe)]2; d) 155 (NnArgNspeNspe)4. Gradient 0–100 % 
solvent B (solvent A = 95 % H2O, 5 % MeCN, 0.1 % TFA; solvent B = 95 % MeCN, 5 % 
H2O, 0.1 % TFA); column oven at 40 ˚C; λ = 220 nm. 
 
In conclusion, a practical synthetic procedure has been developed that can synthesise 
linear and cyclic peptoids that contain both arginine- and lysine-type residues within the 
same sequence. This has enabled the preparation of a small library of peptoids that 
contain combinations of peptoid monomers not previously reported in the literature. 
The methodology developed uses orthogonal N-Boc and N-Dde protection and pyrazole-
1-carboxamidine as a guanidinylation reagent. The final identities of all peptoids was 
confirmed using accurate QToF mass spectrometry and the peptoids were all estimated 
to be > 95 % pure by RP-analytical HPLC. Significantly, this process is amenable for use 
with acid sensitive monomers (i.e. Nspe) and it is compatible with the commonly used 
submonomer method of peptoid synthesis.  
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2.8  Expanding peptoid chemical space: end group modification 
In an attempt to enhance the efficacy of the peptoid sequences synthesised, 
modifications were made to the termini. In particular, moieties similar to simple lipid 
chains were added to either the C or N terminus of a peptoid to mimic lipopeptides, 
biologically active peptide derivatives often found in nature.  
Lipopeptides are typically comprised of an aliphatic, fatty acid-derived chain, covalently 
linked to a the N terminus of a short linear or cyclic oligopeptide. A large structural 
diversity of lipid chains can be found in nature, with chains between 6 and 18 carbon 
units in length, including branched and non-branched, saturated and unsaturated 
chains. In nature, these lipopeptides are synthesised nonribosomally in bacteria and 
fungi and can be highly active against multidrug resistant species of bacteria and fungi.103 
Compounds like daptomycin, micafungin or colistin are all approved lipopeptide 
antibiotics. A range of isolated lipopeptides are now being used in research into novel 
antimicrobials; particularly relevant to this project are several families of lipopeptides, 
such as the ciliatamides or dragonamides, that have been shown to display potent anti-
leishmanial activities less than 10 µM.104,105  
In addition to use as commercial antibiotics, certain lipopeptides are now being 
increasingly used in areas such as the cosmetics industry for their surfactant properties 
or as emulsifiers in certain food technology applications.  The mode of action of 
lipopeptides on microorganisms has been suggested to include disruption of the plasma 
cell membrane as well as targeting specific processes, like inhibition of ATPases or D-
glucan synthase used in fungal cell wall synthesis. This dual mode of action may help to 
explain the low number of reported cases of bacterial resistance in lipopeptide 
antibiotics compared to traditional small molecule drugs.103,106,107 
Despite the attractive characteristics of the lipopeptides, they are still limited by the in 
vivo stability of their peptide components. Although certain cyclic lipopeptides are 
proteolytically stable, the majority of linear sequences are not, therefore the 
development of novel, lipopeptide analogues that are resistant to proteolysis is a rapidly 
increasing area of research. As with peptides, one potential strategy for stabilisation is 
the introduction of N-substituted glycine monomers. Indeed, to date a few peptoids with 
lipid tails have also been made to mimic these successful antimicrobial lipopeptides.  
As described in Chapter 1 (Lipopeptoids), the Barron group has added lipid-type chains 
of either 5, 10 or 13 carbons in length to the N-terminus of linear peptoid sequences and 
found sequences with potent antimicrobial activities.108 A separate study looked into the 
effect of lipidation on a library of 19 very short antimicrobial peptoids based upon KKK, 
RRR, KGK or RGR tripeptides and therefore were cationic with NLys or NhArg 
(homoarginine) residues. The compounds were tested against a variety of reference and 
clinical bacterial strains and were found to be moderately active against both Gram 
positive bacteria and Gram negative species.94  
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Another common strategy used to enhance the antimicrobial action of therapeutics is 
the addition of polyethylene glycol (PEG) polymer chains, known as PEGylation. Many 
PEGylated pharmaceuticals now exist on the market since the covalent addition of PEG 
to a compound, has multiple advantageous effects and typically improves the 
pharmacokinetic profile of a drug. PEG is FDA approved, non-toxic and non-
immunogenic, PEGylation can mask a pharmaceutical from the host immune system, 
can increase the circulatory time of a drug by increasing retention time in the blood and 
minimising renal excretion and the addition of the PEG chains imparts water solubility 
to hydrophobic sequences.109-111 
Although peptoids are not susceptible to proteolysis like peptides, reduction of 
immunogenicity, reduced renal excretion or increased solubility may be advantageous 
for any future medicinal applications. A handful of PEGylated peptoids have been 
previously reported in materials applications.112,113 Additionally, it has been reported that 
the addition of a short PEG chain to a peptide-peptoid hybrid had no detrimental effect 
on the antibacterial profile of a peptoid.114 
 
2.8.1 Synthesis of lipopeptoids and PEG-ylation of sequences 
To enhance the chemical space of our peptoids and in an attempt to modulate their 
biological activity and toxicity, a suite of lipopeptoids were synthesised. The two peptoid 
sequences chosen were identified as having good antibacterial and antiparasitic activity, 
which is discussed in more detail in Chapters 3 and 4. Peptoid 156 (NaeNspeNspe)4 and 
peptoid 157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 were both lipidated and PEGylated to 
give the compounds listed in Table 2.5. Example structures are provided in Figure 2.21. 
The lipid-like amines added to the peptoid sequences were heptylamine (158, 163, 168, 
173), dodecylamine (160, 165, 170, 175), hexadecylamine (161, 166, 171, 176) and 
cycloheptylamine (159, 164, 169, 174). As no specific target was specified, this variety of 
amines introduced a range of saturated, unbranched lipid chain lengths (C7 to C16), as 
well as a cyclic moiety to examine the SAR. The C16 chains were chosen because of their 
previously proven activity94 against E. coli and the shorter chains for their potential to 
give good selectivity ratios.108 2-2(2-methoxyethoxy)ethoxy ethylamine was also chosen 
to represent a short chain PEG-mimic to determine the effect of PEGylation on peptoid 
antimicrobials (peptoids 162, 167, 172, 177). 
Adding these five amines to both the C and N terminus of the two peptoid sequences 
afforded 20 novel lipopeptoids. The synthesis of sequences with a lipid head or tail group 
is shown by Scheme 2.14. Whilst the addition of lipid tail groups is standard practice, as 
far as we are aware, this is the first time that lipid groups have been added to the C 
terminus of a peptoid sequence. 
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Compound number Sequence 
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s 158 NC7(NaeNspeNspe)4 
159 NcycloC7(NaeNspeNspe)4 
160 NC12(NaeNspeNspe)4 
161 NC16(NaeNspeNspe)4 
162 Nte(NaeNspeNspe)4 
163 NC7[(NLysNpfbNpfb)(NLysNspeNspe)]2 
164 NcycloC7[(NLysNpfbNpfb)(NLysNspeNspe)]2 
165 NC12[(NLysNpfbNpfb)(NLysNspeNspe)]2 
166 NC16[(NLysNpfbNpfb)(NLysNspeNspe)]2 
167 Nte[(NLysNpfbNpfb)(NLysNspeNspe)]2 
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 168 (NaeNspeNspe)4-C7H15 
169 (NaeNspeNspe)4-C7H13 
170 (NaeNspeNspe)4-C12H25 
171 (NaeNspeNspe)4-C16H33 
172 (NaeNspeNspe)4-C9H21O3 
173 [(NLysNpfbNpfb)(NLysNspeNspe)]2-C7H15 
174 [(NLysNpfbNpfb)(NLysNspeNspe)]2-C7H13 
175 [(NLysNpfbNpfb)(NLysNspeNspe)]2-C12H25 
176 [(NLysNpfbNpfb)(NLysNspeNspe)]2-C16H33 
177 [(NLysNpfbNpfb)(NLysNspeNspe)]2-C9H21O3 
Table 2.5. Peptoid sequences modified with C and N terminal lipid or PEG chains. 
 
 
Figure 2.21. Example structures of the lipopeptoids synthesised. 163 shows the heptyl 
amine tagged to the N terminus and 169 is an example of peptoid with cycloheptane lipid 
head group. 
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Scheme 2.14. The synthesis of lipidated peptoids 158–177 with a) peptoid tail groups; b) lipid head groups. The four lipoamines and the short 
PEG-type amine introduced are shown in the box. 
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For the N terminal tagged sequences 158–167, the lipoamines were added to the sequence 
using an on resin coupling using Rink Amide resin. Following acylation with 
bromoacetic acid, the lipoamine was introduced in the displacement step of the 
submonomer method. All couplings were undertaken under standard conditions; 60 
minute displacement, 1–2 M amine concentration at RT. However, the hexadecylamine 
was added at 0.5 M in 50 % DCM in DMF v/v due to a decreased solubility compared to 
the other amines. Following acidic resin cleavage, the lipopeptoids were obtained as a 
crude powder. 
To add a lipid head group to a peptoid C terminus (peptoids 168-177) the sequence was 
synthesised on 2-chlorotrityl chloride resin and cleaved from the support using 50 % 
HFIP in DCM, to afford a C-terminal carboxy-functionalised peptoid sequence. Using 
these cleavage conditions, the Boc protection of lysine monomers remains intact. 
Subsequently, the crude material was used in a solution phase coupling between the 
peptoid and the lipoamine in DMF, with PyBOP as an activator. 4 equivalents of PyBOP 
with respect to the crude peptoid were used with DIPEA (4 equivalents) and the amine 
(4 equivalents), as in Scheme 2.14b. 
Using these conditions, all coupling reactions had reached completion after 90 minutes 
by LC-MS, without further optimisation. A subsequent organic/aqueous extraction 
removed excess primary amine from the mixture and the Boc protection of the peptoid 
side chains was removed using TFA.  
The compounds shown in Table 2.5 were purified by RP-HPLC to afford the material in 
> 95 % purity for biological evaluation. Figure 2.22 shows a representative selection of 
analytical HPLC traces for the lipopeptoids.  
As explained in more detail in Chapter 7, the purification used a linear gradient from 0–
100 % solvent B (where solvent A = 95 % water, 5 % acetonitrile, 0.1 % TFA; solvent B = 
95 % acetonitrile, 5 % water, 0.1 % TFA). Typically, in the purification of linear peptoids a 
gradient is set up from 0–100 % solvent B over 60 minutes, dependent on the exact 
sequence and purity of the crude sequence. However, due to the hydrophobic nature and 
reduced solubility of peptoids with lipid chains of 12 or 16 carbons in length (peptoids 
160/161, 165/166, 170/171, 175/176), injections were made to the column during an 
isocratic step at 40 % solvent B and the following gradient to 100 % B was undertaken 
over 60 minutes. 
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Figure 2.22. Analytical RP-HPLC chromatograms for selected compounds from the 
lipopeptoid library so show peptoids with lipid head and tail groups. One of example of a 
peptoid with each lipid chain is shown; a) 158  NC7(NaeNspeNspe)4; 
b) 169 (NaeNspeNspe)4-C7H13; c) 165  NC12[(NLysNpfbNpfb)(NLysNspeNspe)]2; 
d) 170  (NaeNspeNspe)4-C12H25; e) 162  Nte(NaeNspeNspe)4; 
f) 176  [(NLysNpfbNpfb)(NLysNspeNspe)]2-C16H33. Gradient 0–100 % solvent B (solvent A 
= 95 % H2O, 5 % MeCN, 0.1 % TFA; solvent B = 95 % MeCN, 5 % H2O, 0.1 % TFA); 
column oven at 40 ˚C; λ = 220 nm. 
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2.9  Peptoid proteolytic stability 
Stability testing using MALDI described in this section was undertaken by Dr Yu Luo and 
Dr Fionnuala Lundy (Queen’s University, Belfast). The stability investigation using HPLC 
was assisted by Emily Corlett (undergraduate project student at Durham University). 
 
Many groups are investigating peptoids for biomedical or materials applications due to 
their reported stability against proteolysis. This gives peptoids longer half-lives in vivo 
when compared to a given peptide sequence. However, very few studies within the 
literature have data to support the increased enzymatic stability and pharmacokinetic 
properties of peptoids.43,115  
In pharmacokinetic studies of labelled peptoids, it was shown that peptoids are largely 
absorbed in the liver, similar to other high molecular weight drugs. If the peptoids were 
made less hydrophobic, increased kidney uptake could be achieved. Although peptoids 
show similarly poor bioavailability to peptides when administered orally, their passage 
through the gastrointestinal tract is slower and peptoids are generally excreted whole in 
urine rather than being broken down by proteases.116,117 
The main paper published to date investigating the superior stability of peptoids tested 
L-peptides, D-peptides and peptoids against a range of enzymes from the four major 
classes of proteases; metallo, cysteine, aspartyl and serine proteases. Hexa- or 
tetrapeptide and peptoid sequences were prepared for each enzyme, including retro 
sequences to cover both possible reading frames, and were incubated with the enzymes 
under approximate physiological conditions. All L-peptides designed were indeed 
substrates for their respective enzymes, whereas the D-peptides displayed only minimal 
degradation to 3 of the 6 enzymes tested. The peptoids were unaffected by all enzymes 
tested and this data has formed the evidence for increased peptoid stability to 
proteolysis.43 
Due to the lack of data available in the literature, as a proof of concept stability assays 
were undertaken to check that the specific sequences synthesised in this peptoid library 
were also stable to degradation. A small selection of representative peptoids were tested 
in a quantitative enzymatic HPLC assay and the digestion profile of a peptoid was 
examined via mass spectrometry.  
The stability of peptoids and peptides were first compared by a chymotrypsin digestion 
assay using RP-HPLC. Chymotrypsin, a digestive enzyme which is found in the 
pancreatic juice to perform proteolysis, is known to preferentially cleave peptide amide 
bonds at aromatic residues like tyrosine, tryptophan or phenylalanine which fit into a 
hydrophobic pocket in the enzyme. All peptoid sequences tested contained peptoid 
monomers equivalent to phenylalanine N-(S-phenylethyl)glycine residue or N-benzyl 
glycine (Nspe or Nphe) and a variety of sequences and building blocks were analysed in 
this study. In this assay, a solution of chymotrypsin was added to the peptoid samples 
and time-points taken approximately every 2 hours over a 24 hour period. Experiments 
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were performed in triplicate to ensure that a robust data set was taken. The absorbance 
of the peptoid or peptide was quantitatively monitored by RP-HPLC at 215 nm 
(corresponding to absorbance of the amide backbone).  
As seen in Figure 2.23, within the bounds of error (not shown), the peptoids are stable to 
chymotrypsin as the overall amount of peptoid does not change over time. Half-lives 
could not be calculated as no decay, exponential or otherwise, was seen during the 
experiment. In comparison, a native p53 peptide†††† (178) was degraded rapidly, so time 
points could only be collected for approximately 4 hours. The resultant half-life of the 
native p53 peptide was calculated to be 58 minutes ± 6 minutes.  
Additionally, collaborators at Queens University Belfast have compared the digestion 
profile of peptoid 180 (NaeNpheNphe)4 by trypsin against a naturally occurring α-helical 
antimicrobial peptide, LL-37 compound (179), derived from human cathelicidin.‡‡‡‡ 
Trypsin is another enzyme typically found in the mammalian digestive system and 
belongs to the family of serine proteases. In contrast to chymotrypsin, trypsin cleaves 
peptides primarily at the C terminal side of lysine or arginine residues – peptoid 180 
tested has four Nae lysine-mimetic residues within the sequence. 
The samples were treated with trypsin for 24 hours and their MALDI spectra compared 
to the untreated sample. As seen in Figure 2.24 peptoid 180 at m/z = 1596 showed no 
appreciable degradation, whereas the peptide 179 showed complete loss of the parent ion 
at m/z = 4492 and was degraded into many smaller molecular weight peptide fragments. 
 
Figure 2.23. The results of the stability assay (absorbance monitored via RP-HPLC at 215 
nm) show that all six peptoids tested are stable to chymotrypsin as no degradation is 
seen over time. In comparison, p53 peptide 178 has a half-life of approximately 1 hour. 
                                                     
††††
 178 native p53 peptide sequence: LTFCHYWCQLTS-NH2 
‡‡‡‡
 179 LL-37 peptide sequence: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-NH2 
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Figure 2.24. Tryptic degradation profile of a) peptoid (NaeNpheNphe)4 180 and b) 
peptide LL-37, compound 179. 180 shows no degradation after 24 hours in trypsin, 
whereas peptide 179 shows complete loss of parent ion and degradation into many 
smaller molecular weight peptide fragments. 
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2.10  Analysis of peptoid library secondary structure 
Circular dichroism (CD) spectroscopy was introduced in section 2.4 and this technique 
has previously been used by the Barron group, among others, to identify helical peptoids. 
The secondary structures of a number of peptoids synthesised within this library were 
characterised in order to help rationalise the biological activity of the sequences, as it is 
known that helical peptoids may have increased biological activities.50,77 
For simple first round analysis, all spectra were collected at 50 µM concentration in 
1 mol dm-3 phosphate buffered saline solution§§§§ (PBS). This low concentration was 
chosen to prevent intermolecular interactions which may affect the CD values obtained. 
CD data for a small selection of peptoids are shown in Figure 2.25 and Figure 2.26 as an 
example of the characteristic CD spectra for helical peptoids. Data is presented in mean 
residue ellipticity units which take into account the chain length and concentration of 
samples. 
The CD spectra of peptoids 186–188 without a chiral reporter do not show any 
discernible secondary structure as shown in Figure 2.25, where the ellipticity values are 
all around zero across the wavelength range studied. The lack of secondary structure 
seen could arise due to the samples forming random conformations in solution or 
because any helices formed are racemic and therefore signals for left-handed and right-
handed helices cancel each other out. However, it should be noted that even if a 
compound doesn’t show helicity in solution, it may spontaneously self-assemble into a 
helix when in contact with a cell membrane.  
At 50 µM, the CD spectra of compounds in Figure 2.26 show two minima at 
approximately 202 nm and 218 nm, which indicate that these peptoids are forming PPI-
type helices in solution. This data matches results reported by the Barron group.32,33 For 
the 6 residue peptoid, there are small minima at 202 nm and 218 nm, suggesting 25 
(NLysNspeNspe)2 is weakly helical. As peptoid helices have 3.0 residues per turn, it is 
unsurprising that a 6 residue peptoid only shows weak helicity as it is too short to form a 
fully stabilised helix. The ellipticity values are more negative for the longer peptoids 
(26/22), suggesting that longer chains stabilise the helices formed.  
CD data has been collected for other selected sequences (data in the electronic 
supplementary information). Most sequences containing α-chiral monomers show a 
defined folded structure, suggestive of a peptoid helix. This will be discussed in more 
detail in Chapter 5 where a greater investigation of peptoid secondary structure is 
undertaken. 
 
 
 
                                                     
§§§§
 pH 7.4 
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Figure 2.25. CD spectra for peptoid sequences of different lengths containing the achiral 
Nphe monomer, peptoids 186–188. Data collected at 50 µM in PBS (pH 7.4) at 22 ˚C. The 
structure of the 12 residue sequence 186 is shown. The secondary structure of these 
samples in solution cannot be determined – described in text. 
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Figure 2.26. CD spectra for peptoid sequences of different lengths containing the α-
chiral Nspe monomer, peptoids 22, 25, 26. Data collected at 50 µM in PBS (pH 7.4) at 
22 ˚C. The structure of the 12 residue sequence 22 is shown. The samples show 
characteristic signals of peptoid helicies. 
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Chapter 3 
Antiparasitic Peptoids  
 
Neglected tropical diseases (NTDs) represent a significant global health burden, affecting 
approximately one-sixth of the world’s population.1 The illnesses classified as NTDs by 
the World Health Organisation (WHO) include diverse conditions that have historically 
been overlooked by international public health efforts, leading to insufficient prevention 
and treatment options. Currently, seventeen NTDs have been prioritised by the WHO 
and are caused by a variety of pathogens, including protozoa, bacteria, viruses or 
helminths, as summarised in Table 3.1.1  
 
Table 3.1. The seventeen neglected tropical diseases prioritised by the WHO. The 
conditions are split to illustrate the causative pathogen, where the protozoa are 
unicellular eukaryotes and the helminth are multicellular eukaryotes.1 
 
 
Prokaryotic Eukaryotic Viral 
Protozoa Helminth 
Treponematoses 
(yaws) 
Human African 
Trypanosomiasis 
Dracunculiasis (guinea-worm 
disease) 
Dengue 
Leprosy Chagas Lymphatic Filariasis Rabies 
Trachoma Leishmaniases Onchocerciasis (river 
blindness) 
 
Buruli ulcer  Echinococcosis  
  Foodbourne trematodiases  
  Schistosomiasis  
  Soil-transmitted helminthiases  
  Taeniasis/cysticercosis  
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These conditions present a severe threat to global health and they affect the world’s 
poorest populations, particularly in tropical and sub-tropical regions, as illustrated by 
Figure 3.1. NTDs are typically endemic in resource-poor, developing countries where 
populations have limited access to healthcare, deprived living conditions and a lack of 
resources to tackle the disease. In addition to the mortality of these diseases, they can 
cause long-term disability and have significant social and economic consequences. 
Often treatments for these NTDs are limited in their efficacy, cause severe side effects 
that can be detrimental to patient compliance and increasingly face problems such as 
drug resistance, so many NTDs may become untreatable in the future.1,2 Given the lack of 
licensed vaccines and the disadvantages associated with many of the current drugs on 
the market, there is a clear need for the development of new therapies for NTDs. This 
urgency is highlighted by recent initiatives such as the 2012 London Declaration on 
Neglected Tropical Diseases that encourages partnerships between public and private 
institutions, with the aim of eradicating and controlling neglected diseases. In 2015, the 
Ross Fund was announced by the UK government, providing over £1 billion to combat 
serious disease, including NTDs, and antimicrobial resistance in developing counties.3,4 
 
 
Figure 3.1. A map to illustrate the global burden of neglected tropical diseases. Data is 
taken from 2010 estimates of global endemicity of the 17 WHO classified NTDs.  
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Research into the development of vaccines against parasitic tropical diseases has mainly 
been focused on malaria but despite this, only one vaccine has been licensed for malaria 
to date.5-7 With no vaccines approved for clinical use against parasitic NTDs, eradication 
of their transmission vector is the main preventative strategy. If infection does occur, the 
frontline treatments in current use often have significant limitations and severe side 
effects. In addition, increasing drug resistance to many of the available treatments means 
that these diseases may become untreatable in the near future.8-12  
Access to the genome sequences of many clinically relevant parasites opens the 
possibility for drug discovery based upon the identification of novel molecular drug 
targets. For example, trypanothione reductase has been identified as a potential target 
for the kinetoplastids13, a selection of kinases for Plasmodium falciparum9 and very 
recently the inhibition of the kineoplastid proteasome has been muted as a potential 
conserved target across Leishmania, and Trypanosoma species.14 Despite the fact that 
many potential, parasite specific biochemical targets and pathways have now been 
identified for the treatment of infections caused by protozoa, adequate treatments for 
many of these NTDs are still elusive. Bringing new treatments to market for diseases 
caused by protozoa is challenging because of the complicated lifecycle of these parasites, 
with multiple stages that have drastic differences in their membrane composition and 
that exhibit distinct metabolic processes or protein expression.9,15  
This project focussed on the development of peptoids as novel antiparasitic agents 
against Leishmania species, the causative agents of the NTD leishmaniasis. Other vector-
borne protozoa were also considered, such as those that cause malaria or the NTDs 
Chagas disease and African sleeping sickness and these will also be discussed in the 
following chapter. 
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3.1 Leishmanaisis 
Leishmaniasis is one of the WHO’s classified neglected tropical diseases and is caused by 
insect vector-borne protozoan parasites of the genus Leishmania. Endemic in over 80 
countries worldwide, it is estimated that there are 1.3 million new cases each year, 
causing 20,000 to 30,000 deaths annually. In 2010, it was approximated that 12 million 
people were infected and a further 350 million at risk of disease across five continents.16,17  
Leishmaniasis has three main clinical forms; visceral leishmaniasis (VL) which causes life 
threatening organ damage and is typically accompanied by fever; cutaneous 
leishmaniasis (CL) which leads to significant scarring and mucosal damage and 
mucocutaneous leishmaniasis (MCL) which causes the partial or total destruction of 
mucous membranes (see Figure 3.2).  
VL is typically fatal in approximately 95 % of untreated cases and is characterised by 
irregular bouts of fever, enlargement of the liver and spleen, dramatic weight loss and 
anaemia. The visceral form is highly endemic in the Indian subcontinent and East Africa, 
with over 90 % of cases occurring in Bangladesh, Brazil, India, Ethiopia, South Sudan 
and Sudan. CL is the most common form of the disease, causing mild to severe skin 
infections that can cause disfigurement and life-long disability. 95 % of CL infections are 
found in America, the Middle East, Central Asia and more recently southern Europe. 
Although CL is not fatal itself, it can lead to complications from secondary infections. 
Most cases of MCL occur in Bolivia, Brazil and Peru and if untreated can progress to the 
ulcerative destruction of the nose and mouth area.17,18  
 
 
Figure 3.2. a) and b) skin ulcers caused by cutaneous leishmaniasis; c) destruction of the 
mouth and nose area by mucocutaneous leishmaniasis.* 
 
                                                     
*
 Images reproduced from a) https://www.emaze.com/@AIIWFRCF/Leishmaniasis; b) 
https://en.wikipedia.org/wiki/Leishmaniasis c) http://www.medicalrealm.net/what-is-
microbiology---leishmaniasis.html 
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Leishmaniasis typically affects the poorest people around the globe and is often 
associated with malnutrition, poor access to housing and healthcare and population 
mobility, as illustrated by the recent explosion of CL cases in the Middle East due to the 
refugee crisis.19 As well as the physical symptoms of the disease, patients often suffer 
from long-term disability and social exclusion. Leishmaniasis is particularly problematic 
where patients have Leishmania-HIV coinfection since patients are more likely to 
develop a serious disease and display high relapse and fatality rates.18,20 
 
3.1.1 Life cycle 
As a vector-borne disease, leishmaniasis is transmitted by the bite of a female 
phlebotomine sandfly. Leishmania are digenetic parasites with distinct life stages 
involving two hosts, both insect and vertebrate, as shown in Figure 3.3. 
In a mammalian host, Leishmania are present as intracellular amastigotes, and multiply 
within various tissue cells or macrophages and the presence of these amastigotes causes 
the clinical symptoms of leishmaniasis. Host cells with a large parasite burden are often 
prone to lysis which release the amastigotes and can lead to the infection of further 
macrophages. Upon taking a blood meal from an infected mammalian host, a sandfly 
may ingest infected macrophages.  As these are digested in the gut of the insect vector, 
the Leishmania parasites undergo a transformation into the promastigote stage. In this 
phenotype, the parasite survives as a motile extracellular parasite with a single flagellum. 
Promastigotes divide in the insect midgut and migrate to the proboscis, where the 
metacyclic promastigotes can be transferred back to a mammalian host during feeding 
and cause further infection in the new host.21,22 
There are substantial differences between the promastigote and pathogenic amastigote 
forms of the parasite, including significant modifications to the cell surface which are 
suspected to cause different susceptibilities when treated with drugs and AMPs. The 
insect stage promastigotes are surrounded by a thick glycocalyx layer composed of 
macromolecules; mainly lipophosphoglycan (LPG) and also cell surface 
proteophosphoglycan (PPG). The LPG layer is made of anionic phosphorylated 
disaccharides and bound to the cell membrane via a glycosylphosphoinositol (GPI) 
anchor. In contrast, in the mammalian form of the parasite expression of both LPG and 
PPG is down-regulated so amastigotes display very low or negligible cell surface 
quantities of LPG and PPG.23-25 
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Recent work by our group with mutant Leishmania mexicana has shown that the 
presence of PPG is a major factor that contributes to promastigote sensitivity to a family 
of AMPs, whereas the presence of LPG has little effect on the sensitivity of the protozoa 
to treatment. It is suggested that the anionic charge of the PPG helps to attract the 
cationic AMPs and may help to explain why the pathogenic amastigotes (that have a lack 
of PPG on their cell surface) often display greater resistance to treatment than the insect 
stage promastigotes. Although this work is not discussed in detail here, a publication 
resulting from this work can be found in the Appendicies.26 
Figure 3.3. Lifecycle of Leishmania spp. including promastigote stage inside the insect 
vector and transformation to the mammalian amastigote form inside mammalian 
macrophages. 
 
3.1.2 Current treatments for leishmaniasis 
Preventative measures deployed against leishmaniasis commonly use vector control, 
such as the use of insecticides, the culling of animal reservoir populations or the use of 
insecticide-treated nets. However, these tactics are commonly ineffective since control of 
the disease involves a complex biological system, involving human host, multiple 
parasite life stages, a sandfly vector and various animal reservoir hosts.  
Currently, there is no approved vaccine for the prevention of either CL or VL in humans, 
although several promising candidates are in development.12,27 There has been extensive 
investigation into vaccines using killed or attenuated parasites, second generation 
vaccines based upon recombinant or antigenic proteins and a third generation of 
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immunisations derived from antigen-encoding DNA plasmids. Those based upon 
recombinant protein or antigen-encoding plasmids have given very promising results 
and a few vaccines have now been licensed for use against visceral leishmaniasis in 
canines. Several candidate vaccines have made phase I and II clinical trials, and others 
are currently ongoing.12,27-30 It seems very likely that a vaccine for leishmaniasis in 
humans will be developed in the near future. However, even with a successful vaccine in 
hand, deployment to affected populations will take time and considerable expense.  
 
Chemotherapy is the basis for current treatment in all three major forms of 
leishmaniasis; VL, CL and MCL. The main treatments in clinical use are shown in Figure 
3.4 and have already been well reviewed.31,32 These treatments are often unsatisfactory 
with high toxicity, long durations of treatment and severe side effects that lead to poor 
patient compliance, as summarised in Table 3.2. Additionally, the distinct species of 
Leishmania have very different susceptibilities to the drugs in current use; for example, 
paramomycin (193), a drug effective against VL in India shows poor efficacy against VL in 
East Africa.33 
Options include the use of the pentavalent antimonials like sodium stibogluconate (189) 
or meglumine antimoniate (190), which have been in clinical use since the 1940s. This 
class of drugs contains antimony and have very severe side effects, including 
cardiotoxicity. Pentavalent antimonials must also be administered intravenously, which 
is a disadvantage in areas where Leishmaniasis is prevalent because patients often have 
poor access to healthcare.11,20,31,32,34,35   
Amphotericin B (191) is a widely used antifungal polyene that is also commonly used 
drug in the fight against leishmanaisis and binds to the parasite specific sterol, 
ergosterol. However, the drug also has toxic side effects and must be administered 
parenterally. Amphotericin B formulations (in particular the liposomal form) were 
developed to reduce these adverse effects and lead to improvements in pharmacokinetic 
properties. However these have limitations for use in developing countries since they are 
costly and unstable at higher temperatures.11,20,31,32,34,35 
Miltefosine (192) is another front-line treatment for Leishmaniasis. Although this drug 
can be administered orally, it must be refrigerated and is also a teratogen so cannot be 
prescribed to pregnant women. With resistance to this drug developing in the Indian 
sub-continent and high levels of treatment failure, this drug also has severe 
disadvantages.11,20,31,32,34,35   
Paromomycin (193) is an alternative drug but is also associated with severe toxicity. 
Pentamidine (194) has an unknown mechanism of action and is only used infrequently 
due to the appearance of resistant cases of leishmaniasis. It is highly toxic and can trigger 
severe side effects, such as diabetes mellitus or severe hypoglycaemia. Typically it is only 
recommended when used in combination therapy.11,20,31,32,34,35  
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Figure 3.4. Chemical structures of the frontline treatments in clinical use for 
leishmaniasis. 
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Table 3.2. A summary of the current anti-leishmanial drugs in clinical use, administration routes, evidence of drug resistance and their 
associated toxicity.31,32 
Structure(s) Drug Administration Side effects Resistance 
189 
190 
Pentavalent antimonials Intramuscular or 
Intravenous  
 
Severe cardiotoxicity, pancreatitis, toxic to liver 
and kidney, painful injection and stiff joints, 
gastrointestinal problems 
Common (> 65 % in India) 
Efficacy 35–95 % depending 
on area 
 
191 Amphotericin B  
 
 
 
Liposomal amphotericin B 
Intravenous  
 
 
 
Intravenous  
Must be stored 
below 25 ˚C 
 
Severe toxicity to kidney, high fever, potassium 
deficiency, bone pain, cardiac arrest (rare) 
 
 
Mild toxicity to kidney 
Seen in laboratory strains 
Efficacy > 90 % 
 
 
Not documented 
Efficacy > 97 % 
192 Miltefosine Oral 
Must be 
refrigerated 
 
Vomiting and diarrhoea, toxicity to liver and 
kidney, teratogenic  
Seen in laboratory strains 
L. braziliensis, L. guyanensis 
and L. mexicana are 
insensitive to miltefosine 
Efficacy 60–93 % in Africa; 
94 % in India 
 
193 Paromomycin Intramuscular  
for VL 
Topical for CL 
Severe toxicity to ear, liver and kidney, pain at 
injection site, abdominal cramp and diarrhoea 
Seen in laboratory strains 
against L. donovani 
Efficacy 46–85 % in Africa; 
94 % in India 
 
194 Pentamidine Intramuscular 
 
Hyperglycemia via pancreatic damage, 
hypotension, pain at injection site, death 
Resistance emerging, 
particularly with HIV-
coinfection 
Efficacy 35–96 % dependent 
on species 
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With developing drug resistance, toxicity issues and the requirement to treat diverse 
patient populations, there is a real need to develop new, improved therapeutics for 
leishmaniasis. However, bringing novel treatments to market for diseases caused by 
protozoa is challenging because of the complicated lifecycle of these parasites, with 
multiple stages that have drastic differences in their membrane composition and that 
exhibit distinct metabolic processes or protein expression. In particular, for 
leishmaniasis, the disease has several manifestations so is a complex disease, particularly 
in patients with co-infections. Additionally, the fact that Leishmania parasites residue 
inside a compartment within an intracellular target means there are many membranes 
that a potential drug must pass. Even for CL pharmacokinetics are complex since drugs 
must pass into the dermal layer, compared to bacterial of fungal infections that are 
present in the upper and more easily reachable epidermal skin layers.9,36 
In recent years, the development of safer, more effective treatments for VL has become a 
priority following the London Declaration in 2012. In contrast, CL remains relatively 
overlooked and new treatments are desperately needed. One rich source of potential 
drug scaffolds and pharmacophores are natural products. A wide variety of these have 
been shown to have mild anti-leishmanial activities, including plant-derived compounds 
such as alkaloids37, flavonoids32 or terpenes38,39 and products isolated from marine 
sponges.40,41 In particular, antimicrobial peptides (AMPs) have been proposed as targets 
for the development of new treatments for leishmaniasis due to their broad spectrum 
antimicrobial activities and as yet resistance has not emerged to these compounds.42,43 A 
wide variety of AMPs derived from mammalian sources,44-50 invertebrates,51-66 
amphibians26,43,67 or synthetic AMPs68,69 have been shown to have activity against 
protozoan species. These antiparasitic peptides include promising activity against 
Leishmania spp., from AMPs such as the cathelicidins, indolicidins, histatins and 
bombinins (see Table 3.3).42,43,70  
It is suspected that most cationic AMPs target the protozoan plasma membrane by 
association with the acidic phospholipids on the outer membrane of the protozoa, but 
other modes of action have been demonstrated such as interaction with intracellular 
targets, immunomodulatory effects or the induction of biochemical changes that lead to 
apoptosis. The relative specificity of the AMPs towards the parasite over host cells is 
accounted for by the more anionic cell membrane structure compared to mammalian 
cells.42,43,70 
Previous work in the Cobb group has shown that the temporins, a versatile group of 
AMPs, are effective against Leishmania mexicana, the causative agent of cutaneous 
leishmaniasis. The temporins are short AMPs isolated from frog skin secretions and they 
have an exceptionally low number of positively charged amino acids (net charges 
between neutral and +3). Temporin A, B and 1Sa were shown to have activity against 
L. mexicana in the low micromolar range for promastigotes, but poor activity against the 
clinically relevant amastigote form.67  
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However, the biological and chemical stability of short, linear peptides is often 
problematic for their application as pharmaceuticals. Peptides are rapidly degraded 
in vivo by the wide variety of proteases and peptidases in the body, leading to short 
biological half-lives and a low bioavailability.67 Therefore, this project aimed to 
investigate peptoids as potential improved antiparasitic agents against L. mexicana and 
cutaneous leishmaniasis. 
 
Table 3.3. A selection of anti-leishmanial AMPs, their peptide sequence in grey and their 
recorded antiparasitic activity. All peptides are amidated at the C terminus. pE 
represents pyroglutamic acid and RNH2 post-translational amidation of arginine.
70 
 
AMP Leishmania spp. IC50 
(µM) 
In
v
e
rt
e
b
ra
te
 
195 CA(1-8)M(1-18) 
KWKLFKKIGIGAVLKVLTTGLPALIS 
L. donovani promastigotes 1–5 
196 CA(1-7)M(2-9) 
KWKLFKKIGAVLKVL 
L. donovani and L. pifanoi 
axenic amastigotes 
< 1 
197 Oct-CA(1-7)M(2-9) 
Oct-KWKLFKKIGAVLKVL 
L. infantum blood circulating 
amastigotes 
< 1 
198 Gomesin 
pECRRLCYKQRCVTYCRGRNH2 
L. amazonensis promastigotes 2.5 
199 Sandfly defensin-1 
ATCDLLSAFGVGHAACAAHCIGHGYRGG
YCNSKAVCTCRR 
L. amazonensis and L. major 
promastigotes 
 
> 50 
 
A
m
p
h
ib
ia
n
 
200 Bombinin H2 and H4 
IIGPVLGLVGSALGGLLKKI 
L. donovani and L. pifanoi 
promastigotes/axenic 
amastigotes 
7/11 
201 Dermaseptin-S1  
ALWKTMLKKLGTMALHAGKAALGAAAD
TISQGTQ 
L. amazonensis and L. major 
promastigotes/amastigotes 
4.5/13.5 
202 Skin peptide-TyrTyr 
YPPKPESPGEDASPEEMNKYLTALRHYINL
VTRERY 
L. major 
promastigotes/amastigotes 
5.9/6.2 
203 Phylloseptin-1 
FLSLIPHAINAVSAIAKHN 
L. amazonensis promastigotes 0.5 
204 Temporin A 
FLPLIGRVLSGIL 
L. infantum and L. mexicana 
promastigotes/ amastigotes 
12/50 
 
M
a
m
m
a
li
a
n
 6 β-defensin-1 
DHYNCACMGG 
 
L. amazonensis and L. major 
promastigotes/amastigotes 
20/50 
205 Histatin 5 
DSHAKRHHGYKRKFHEKHHSHRGY 
 
L. donovani 
promastigotes/amastigotes 
7.3/14.2 
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3.2 Antiparasitic peptoids in the literature 
As discussed in Chapter 1, in recent years, a number of peptoids have been shown to be 
potent and promising antimicrobials against a wide variety of clinically relevant fungi, 
Gram negative and Gram positive bacteria with activities similar to leading AMPs.71-80 
However as yet, very few groups have investigated the effect of peptoids against parasites 
therefore there is little information available to aid the rational design of antiparasitic 
peptoids.  
A study from the Olsen group tested α-peptide β-peptoid chimeras against Plasmodium 
falciparum, one of the causative agents of malaria. The compounds were designed with 
alternating β-peptoids and α-amino acids to give lipophilicity and side-chain 
functionality respectively. For certain sequences, sub-hemolytic doses showed anti-
plasmodial activities, with the best IC50 of 3.6 µM for 206 shown in Figure 3.5, however it 
was noted that although these chimeras had low hemolytic activity, they caused severe 
membrane alterations in human red bloods cells observed via phase-contrast light 
microscopy.81  
Peptoids have also been investigated as inhibitors of trypanothione reductase, vital for 
Trypanosoma and Leishmania species. These parasites use trypanothione instead of the 
glutathione redox based defence system in mammalian organisms and as this enzyme is 
not present in mammals, selective inhibition of trypanothione reductase has been 
proposed as a drug target. The Douglas and Fairlamb groups had previously shown that 
peptides could act as strong inhibitors of trypanothione reductase and modelled 
peptoids on these leads. Successful inhibition was seen with several peptoids in kinetic 
enzymatic assays and the most successful peptoid (see 207 in Figure 3.5) only weakly 
inhibited glutathione reductase in human erythrocytes giving a promising selectivity 
ratio.82 
 
Figure 3.5. Structures of 206 the peptide-peptoid chimera with activity against 
P. falciparum and 207 the trypanothione reductase inhibitor.81,82 
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3.3 Determination of peptoid activity against Leishmania mexicana  
In order to assess the potential leishmanicidal activity of peptoids, the library 
synthesised in chapter 2 was screened against insect and mammalian stage parasites of 
Leishmania mexicana, the causative agent of CL. 
 
3.3.1 Leishmania testing 
The peptoids were screened against MYNC/BZ/62/M379 L. mexicana in a high 
throughput alamarBlue® assay with results described in sections 3.3.4, 3.3.5 and 3.3.6. 
This is the first time that peptoids have been tested in whole cell, phenotypic parasite 
cytotoxicity assays. Due to the vast differences between Leishmania lifestages, 
compounds were screened against both the procyclic promastigote and the axenic 
amastigotes. Promising compounds were also tested against mammalian macrophages 
infected with L. mexicana amastigotes in section 3.3.8 as a more realistic model of the 
disease in vivo.  
The detailed and optimised experimental protocol for these assays can be found in 
Chapter 7. However, in brief, compounds to be tested were added to 96 well plates in 
triplicate and serial dilutions carried out from 100 µM to 3 µM. Appropriate controls were 
also added to the plate; amphotericin B (191) as positive control, DMSO vector only 
negative controls and wells containing medium only to allow correction for background 
fluorescence. Parasites were subcultured, added to the plates in appropriate media and 
incubated with the peptoids for 60 minutes. After the incubation time, the wells were 
diluted ten-fold, followed by a further incubation of 24 hours. In order for quantitative 
results to be obtained at the end of the assay, the cell viability reagent alamarBlue® was 
added to each well† and incubated for 4 hours at the appropriate temperature for the 
parasite culture; 26 ˚C for promastigotes and 32 ˚C for amastigotes. 
 
 
Scheme 3.1. The reduction of resazurin to the fluorescent resorufin, used as the active 
ingredient in alamarBlue® cell viability reagent. 
                                                     
†
 10 % of well volume, following the recommended protocol from the manufacturer. 
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AlamarBlue® quantitatively assesses cell viability using the reducing activity of living 
cells via a fluorescent or colorimetric detection technique. The active ingredient of 
alamarBlue® is resazurin, a non-toxic and cell permeable compound that is blue and non-
fluorescent. When the dye enters living cells, the resazurin (208) is reduced to a red and 
highly fluorescent compound, resorufin (209) as shown by Scheme 3.1. The cell viability 
can then be calculated from the fluorescence emission intensity, larger values correlate 
to increased total metabolic activity from the cells.83 
Although the in vitro alamarBlue® assay has limitations (i.e. exposure times will be very 
different in vivo, pharmacokinetic factors such as excretion and tissue penetration are 
not considered and suppressed cell proliferation cannot be quantified) the assay was 
used for first round toxicity evaluation.  
Seeding tests and growth curves were also carried out to ensure that the seeding density 
and conditions were appropriate for the cell line. Since different amounts of foetal 
bovine serum (FBS) are required for the culture of promastigote and amastigotes‡, 
several peptoids were also tested in serum-free conditions in the first 60 minute 
incubation to determine the effect, if any, of FBS on antiparasitic activity. Results showed 
that the serum had little effect on the anti-leishmanial effect of the peptoids (see data in 
the Appendices) so future assays were all undertaken with serum as these conditions are 
more representative of biological conditions. This is in contrast to many previous studies 
with AMPs, where clear and measurable differences are seen between serum and serum-
free assays due to the higher susceptibility of AMPs to proteases.67,84,85 
 
3.3.2 Cytotoxicity assays against mammalian cell lines 
Alongside the parasite assays, the same high throughput alamarBlue® screening was 
adapted for two mammalian cell lines§ to determine the cytotoxicity of the peptoid 
library. The ultimate aim of this project is to develop compounds that could be used as 
new therapeutics, in the case of cutaneous leishmaniasis (CL) this would be as a topical 
application. Ideally, any drug should be selective to the target and balance desired 
activity with toxicity to human cells.  
Compounds in the peptoid library were tested against human epithelial cell lines, HaCaT 
and HepG2, to model toxicity against skin cells and liver cells respectively. The HaCaT 
line consists of spontaneously transformed aneuploid keratinocytes and the HepG2 are 
human liver carcinoma cells. Cultures of both cell lines are frequently used in in vitro 
studies of cytotoxicity or cell function as they are both immortal cell lines and because 
cells have high and reproducible proliferation and differentiation rates in vitro.86-89  
HaCaT or HepG2 cells were subcultured and prepared in 96 well plates prior to the assay 
then incubated in the presence of peptoid solutions in DMSO for 1 hour (concentrations 
                                                     
‡
 15 % FBS in pH 7.0 promastigote culture and 20 % FBS in pH 5.5 amastigote culture. 
§
 Specific adaptations used in mammalian cytotoxicity assay are summarised in the Experimental Chapter 7. 
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between 3 and 100 µM). Solutions were then removed from the plates, the cells washed 
with PBS and new medium added. Cells were incubated for a further 24 hours and the 
viability of cells measured by addition of alamarBlue®. DMSO vector controls were used 
and as with the results from the L. mexicana assays, all compounds were screened in 
triplicate on a minimum of two occasions to ensure that a robust data set was collected. 
 
3.3.3 Library design 
For initial screening purposes, the peptoid sequences were designed around a linear 
NxNyNy motif, which was repeated to give 6, 9 or 12 residue peptoids. This repeating 
motif was used as peptoid helices are reported to have 3.0 residues per turn. By placing a 
hydrophilic residue in the Nx position and hydrophobic monomers for Ny, the formation 
of an amphiphillic structure may be encouraged where all the hydrophilic groups are 
positioned on the same side of the helix. This has often been shown to aid antimicrobial 
action in AMPs.76,90  
Due to the lack of information available to aid in the design of antiparasitic peptoids, the 
initial peptoid library synthesised included only five monomers combined in the NxNyNy 
motif. In these sequences, the Ny monomer was either the chiral aromatic N-(S)-(1-
phenylethyl) glycine residue (Nspe) or the achiral N-(benzyl) glycine (Nphe). As 
discussed in Chapter 2, inclusion of sterically bulky and aromatic monomers in close 
proximity can favour the formation of a helical structure, another factor known to 
enhance activity in antimicrobial peptoids.91,92 For the hydrophilic Nx, cationic lysine-
type monomers were chosen with varying length of side chain; N-(2-aminoethyl) glycine, 
N-(4-aminobutyl) glycine or N-(6-aminohexyl) glycine (Nae, NLys and Nah with 2, 4 and 
6 carbons respectively as shown in Figure 3.6A). This first generation library93 allows the 
effect of overall sequence length, sequence chirality and the nature of the cationic Nx 
monomer on the anti-leishmanial activity to be determined.  
In a second generation library,94  a further 30 novel linear peptiods were synthesised to 
include a range of substituted aromatic and aliphatic monomers (monomer structures 
shown in Figure 3.6A). This library contains more varied side chain substituents to 
provide a more in depth investigation of structure activity relationships. To add extra 
diversity to these peptoids, sequences were also designed around four motifs (Figure 
3.6B). The first was the NxNyNy motif used in the first generation library, again repeated 
two, three or four times to give 6, 9 or 12 residue peptoids respectively. In a further 
iteration, a second hydrophobic building block was introduced into each sequence 
(motif 2), i.e. NxNyNz where Ny and Nz were either an aromatic or alkyl residue. To 
investigate if the sequence specific position if Ny or Nz influenced the activity, they were 
also placed in a co-block manner (motif 3). In the final motif 4, the overall charge of a 12 
residue peptoid was reduced by replacing one or two of the charged NLys residues with 
the uncharged Namy monomer. The five carbon Namy monomer has the same molecular 
weight and has a side chain five carbons in length, so differs only in the chemical 
functionality.  
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Figure 3.6. A The chemical structures of the monomers used in this peptoid library with 
their abbreviations; B Different structural motifs used in the SAR study are also shown 
with an example of the repeating trimer repeat. 
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3.3.4 First generation library screening: the effect of sequence length, 
chirality and cationic monomer on anti-leishmanial activity 
From the anti-leishmanial assay described in section 3.3.1, the parasite viabilities can be 
determined following treatment with peptoids of different concentrations. From this 
data, the effective median dose (ED50) for each compound can be calculated and this 
data is tabulated in Table 3.4 for the first generation peptoid library. The amphotericin B 
control used in the assay behaved as expected, with a reduction in nearly 100% of 
parasites at the lowest concentration tested to give an ED50 less than 2 µM. 
 
Compound ED50    L. mexicana (µM) ED50 mammalian cells 
(µM) 
Promastigotes Amastigotes HaCaT HepG2 
191 Amphotericin B < 2 < 2 > 100 > 100 
210 (NahNpheNphe)4 21 > 100 > 100 > 100 
211 (NahNpheNphe)3 > 100 > 100 > 100 > 100 
212 (NahNpheNphe)2 > 100 > 100 > 100 > 100 
186 (NLysNpheNphe)4 15 > 100 36 > 100 
187 (NLysNpheNphe)3 > 100 > 100 > 100 > 100 
188 (NLysNpheNphe)2 > 100 > 100 > 100 > 100 
180 (NaeNpheNphe)4 21 > 100 > 100 > 100 
213 (NaeNpheNphe)3 > 100 > 100 > 100 > 100 
214 (NaeNpheNphe)2 > 100 > 100 > 100 > 100 
215 (NahNspeNspe)4 11 > 100 23 41 
216 (NahNspeNspe)3 25 > 100 > 100 > 100 
217 (NahNspeNspe)2 > 100 > 100 > 100 > 100 
185 (NLysNspeNspe)4 8 > 100 20 29 
22 (NLysNspeNspe)3 15 > 100 > 100 > 100 
26 (NLysNspeNspe)2 > 100 > 100 > 100 > 100 
25 (NaeNspeNspe)4 7 17 26 41 
156 (NaeNspeNspe)3 10 > 100 > 100 > 100 
218 (NaeNspeNspe)2 > 100 > 100 > 100 > 100 
Table 3.4. Activity of the first generation peptoid library against L. mexicana pro and 
amastigotes, including their toxicity to mammalian cell lines. Please see the Appendices 
for side chain abbreviations. 
 
Effect of sequence length 
The results show that the longest peptoid sequences show the lowest ED50 values against 
L. mexicana and therefore the most potent activity with the activity increasing as the 
sequence is lengthened. For example, all of the shortest 6 residue peptoids (212, 188, 214, 
217, 25 and 219) were completely inactive against both promastigotes and amastigotes, 
even at the highest 100 µM concentration tested. The 9 residue peptoids show 
intermediate activity to the promastigotes, with some sequences with the chiral Nspe 
monomer showing good activity against the insect stage promastigotes (ED50 25 µM, 
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15 µM and 10 µM for 216, 26 and 218). Following this pattern, the 12 residue peptoids 
displayed the best leishmanicidal activities against the promastigotes, with peptoid 156 
being the only compound in this library to show any activity against the amastigotes 
(ED50 17 µM, structure as in Figure 3.7).  
 
 
Figure 3.7. Structure of peptoid 156 that shows activity against L. mexicana 
promastigotes ED50 7 µM and amastigotes ED50 17 µM. 
 
Effect of sequence chirality  
To examine the effect of chirality peptoids with the Nspe and the achiral Nphe 
monomers were compared and it can be concluded that those peptoid with the chiral 
monomer display better activity (data in Table 3.4). Amongst the 12 residue peptoids the 
Nspe analogues show significantly lower ED50 values than those containing Nphe; for 
example compare peptoids 22 and 186 (Nspe and Nphe respectively) with activity of 8 
µM and 15 µM or 156 and 180 with ED50 7 µM and 21 µM. However, the extra contribution 
to hydrophobicity from the additional methyl group of Nspe could also provide an 
explanation for this trend. Therefore, further investigations into the hydrophobicity of 
chiral and achiral peptoids was therefore undertaken to aid the rationalisation of the 
biological activity of our libraries and this is discussed in Chapter 5.  
 
Effect of cationic monomer choice 
The anti-leishmanial activity of the peptoids was also increased as the chain length of the 
cationic monomer in the Nx position is decreased. Therefore the Nae monomer has 
better activity against the L. mexicana than the NLys monomer, which itself has better 
activity than Nah. I.e. activity Nae > NLys > Nah, as evidenced by comparing 156, 22 and 
215 (Table 3.4). These differences in activity could stem from the greater flexibility of the 
longer side chains 
The Nae peptoid 218 is the most potent 9 residue peptoid in the library (ED50 10 µM), 
followed by the NLys analogue then the Nah sequence (ED50 of 15 µM for 26 and 25 µM 
for 216). Peptoid 156 (NaeNspeNspe)4 is the only member of the library to show activity 
against the axenic amastigotes with an ED50 of 17 µM. Analogous peptoids 22 (NLys) and 
215 (Nah) decrease parasite viability by 70 % and 80 % respectively at 100 µM but at 
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lower concentrations activity was negligible. Notably, the ED50 for 218 is similar to the 
activity recorded for AMPs against various amastigote-stage Leishmania spp.70  
All the peptoids are more potent against promastigotes (insect stage) than amastigotes 
(mammalian stage parasites) of L. mexicana. This trend was also seen in previous work 
from our group with the temporin family of antimicrobial peptides.67 Differences in the 
membrane structure of the two life stages could explain this behaviour since amastigotes 
have a minimalist surface glycocalyx and the LPG and PPG layer, found on 
promastigotes, is down-regulated. It is thought that the PPG layer may help to target 
cationic compounds to the cell membrane. Due to the significantly different behaviour of 
the compounds against the two parasitic life stages, mechanistically it is proposed that 
the peptoids act on the cell membranes, although further work is needed to confirm 
this.21 
 
Toxicity to mammalian cells 
Only the longest 12 residue sequences (186, 215, 22, 156) displayed a level of toxicity to 
either of the mammalian cell lines tested (Table 3.4). Most sequences showed no 
toxicity, even at the highest concentration tested (100 µM). Logically, the most active 
compounds in this library were those that were mildly cytotoxic. However in all cases, 
the peptoids showed a greater potency against L. mexicana than the mammalian cells. 
For example, the most active peptoid 156 (ED50 7 µM and 17 µM against promastigote and 
amastigote respectively) shows toxicity of 26 µM and 41 µM against HaCaT and HepG2 so 
some selectivity is seen in the peptoids. 
Photographs of the wells were taken before and after compound treatment to check 
whether cell growth was inhibited by compounds that were not toxic to the cells, as this 
is not always reflected in the results of the alamarBlue® assay. Figure 3.8 compares 
untreated cells before and after the assay when peptoid 156 is added at different 
concentrations.   
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Figure 3.8. Photographs taken of HaCaT in 96 well plates treated by DMSO (control) 
and peptoid 156; a) before treatment following a 24 hour subculture and b) after 1 hour 
incubation with compound, a PBS wash then further 24 hour incubation/recovery time. 
 
As shown by the photos taken of cells incubated with DMSO only, plates were seeded at 
a density that allowed cell growth over the course of the assay. Peptoid 156, shown to be 
cytotoxic (ED50 26 µM) allows the HaCaT to proliferate at 2 µM, similar to the growth 
seen in the control wells. At the ED50, it is noticeable that cell growth is reduced or 
stalled. Following peptoid treatment at 100 µM, far fewer cells are present in the well and 
although some cells are still alive**  they look very different to the healthy HaCaT; cells 
have a different morphology and granularities around the cell nuclei. 
 
                                                     
**
 As the cells are still adhered to the plate. 
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3.3.5 Second generation library screening: the effect of monomer 
substitutions to anti-leishmanial activity 
Peptoids synthesised as part of the extended, second generation library are shown in 
Table 3.5. In these compounds, the cationic monomer was NLys exclusively to allow 
comparison between the whole library and a variety of commercially available amines 
were incorporated into the sequences to provide sequence diversity. The peptoids 
prepared were also tested against both L. mexicana promastigotes and amastigotes, with 
many showing improved activity compared to the first generation library. 
 
Substitution of aromatic residues in the peptoid sequence 
The effect of substitution on the aromatic residues was investigated through the 
inclusion of Npmb, Npcb, Npfb and Nmfb monomers. Peptoids with the achiral Npmb 
(methoxy substitution in the para position) residue showed significantly reduced 
potency against the L. mexicana promastigotes (see Table 3.5). For the 12 residue 
sequence 220 the ED50 was 42 µM, which is a three-fold reduction in activity compared 
to the Nphe analogue (186 ED50 15 µM). The shorter 6 and 9 residue Npmb peptoids, 221 
and 222, did not show any activity to the promastigotes and no activity was found against 
the amastigotes for any sequence length of the Npmb peptoids. 
In contrast, the peptoids substituted with halogens on the aromatic monomers showed 
enhanced activity against the axenic amastigotes and maintained activity against the 
insect stage promastigotes (peptoids 184 and 223–230) cf the unsubstituted analogues 
(186–188 in Table 3.5). Peptoids with a chloro substitutent in the para position of the 
phenyl ring (Npcb) were all active against the promastigotes, but only the longer 9 and 12 
residue sequences, 223 and 184, showed any activity against the axenic amastigotes, with 
ED50 values of 85 and 44 µM respectively.  
For peptoids substituted with fluorine there is little overall effect on activity whether the 
fluorine atom is in the para or meta position (Npfb or Nmfb) and only the longest 12 
residue sequences showed any activity against the amastigotes (ED50 225 75 µM and 228 
69 µM in Table 3.5). However, these achiral fluorinated peptoids were efficacious against 
the promastigotes with similar potency to the chiral, non-halogenated sequences 186–
188. The 9 residue sequences 226 and 229 showed antiparasitic activity in the low 
micromolar range (19 µM and 17 µM), although the shortest 6 residue peptoids didn’t 
show any activity to either stage of the parasite. This provided compelling evidence that 
fluorination of peptoids may be a good strategy to increase the biological activity of 
sequences.
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Compound ED50  
L. mexicana 
(µM) 
ED50 
mammalian 
cells (µM) 
Pro Ama HaCaT HepG
2 
191 Amphotericin B < 2 < 2 > 100 > 100 
220 (NLysNpmbNpmb)4 42 > 100 41 >100 
221 (NLysNpmbNpmb)3 > 100 > 100   
222 (NLysNpmbNpmb)2 > 100 > 100   
184 (NLysNpcbNpcb)4 28 44 18 22 
223 (NLysNpcbNpcb)3 22 85 22 23 
224 (NLysNpcbNpcb)2 29 > 100   
225 (NLysNpfbNpfb)4 15 75 46 30 
226 (NLysNpfbNpfb)3 19 > 100 > 100 45 
227 (NLysNpfbNpfb)2 > 100 > 100   
228 (NLysNmfbNmfb)4 14 69 25 17 
229 (NLysNmfbNmfb)3 17 > 100 64 43 
230 (NLysNmfbNmfb)2 > 100 > 100   
183 (NLysNpfbNspe)4 8 27 20 26 
231 (NLysNpfbNspe)3 13 > 100 52 36 
232 (NLysNpfbNspe)2 > 100 > 100   
157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 6 21 78 55 
233 (NLysNspeNspe)(NLysNpfbNpfb)(NLysNspeNspe) 13 > 100 65 43 
234 (NLysNpfbNpfb)(NLysNspeNspe) > 100 > 100   
235 (NLysNnValNspe)4 > 100 > 100 > 100  
236 (NLysNnValNspe)3 > 100 > 100   
237 (NLysNnValNspe)2 > 100 > 100   
238 (NLysNLeuNspe)4 > 100 > 100 > 100  
239 (NLysNLeuNspe)3 > 100 > 100   
240 (NLysNLeuNspe)2 > 100 > 100   
182 (NLysNhLeuNspe)4 12 > 100 > 100  
241 (NLysNhLeuNspe)3 52 > 100   
242 (NLysNhLeuNspe)2 > 100 > 100   
243 (NamyNspeNspe)[(NLysNspeNspe)]3 8 21 12 15 
244 (NamyNspeNspe)2(NLysNspeNspe)2 11 16 20 18 
245 [(NamyNspeNspe)(NLysNspeNspe)]2 10 17   
246 (NLysNspeNspe)2(NamyNspeNspe)(NLysNspeNspe) 10 15 20 22 
Table 3.5. Activity of the second generation peptoid library against L. mexicana pro and 
amastigotes, including their toxicity to mammalian cell lines. 
 
From the data collected in the first screening, it was determined that peptoids with the 
chiral and aromatic Nspe monomer show better activity than those containing the 
achiral Nphe. Therefore, a further set of fluorinated peptoids were synthesised where 
Nspe was combined with the Npfb building block in two motifs (peptoids 183, 157 231–
234; motifs 2 and 3 in Figure 3.6). When comparing peptoids of the same length in these 
motifs, both versions had similar activity against both lifestages of L. mexicana. For 
example, 183 (NLysNpfbNspe)4 had an ED50 value of 8 µM against the promastigotes and 
the co-block peptoid 157 [(NLysNpfbNpfb)(NLysNspeNspe)]2  displayed an activity of 
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6 µM. This level of activity against the promastigotes is comparable to the unsubstituted, 
chiral peptoid 22 (NLysNspeNspe)4 that has an ED50 of 8 µM and is two-fold better than 
the sequence containing Npfb exclusively, peptoid 225, which had an ED50 of 15 µM. 
However, the activity between 183/157 and 22 against the axenic amastigotes was 
improved. The NspeNpfb peptoids showed good activities (ED50 27 µM and 21 µM 
respectively) but the Nspe-only peptoid was inactive and peptoid 225 showed only 
moderate activity of 75 µM.  
The toxicity data collected for these compounds is also shown in Table 3.5. From this 
data, it appears that sequences containing the Npcb residue are more toxic to 
mammalian cells than either Npfb or Nmfb. For example, when comparing the 12 residue 
peptoids 184 (NLysNpcbNpcb)4 and 225 (NLysNpfbNpfb)4, lower ED50 values are recorded 
for 225 against L. mexicana (28 µM cf 15 µM), yet the less active 184 has greater toxicity to 
both HaCaT and HepG2 than 225 (ED50 HaCaT 18 µM cf 46 µM; ED50 HepG2 22 µM cf 
30 µM). This trend also holds for the shorter sequences in the library and when 
comparing Npcb to Nmfb.  
In sequences where Nspe is used in combination with Npfb in motif 2, in general lower 
ED50 values are seen against the mammalian cell lines so these compounds are more 
cytotoxic (i.e. compare the 12 residue peptoids 225 with 183, ED50 against HaCaT 46 µM 
and 20 µM respectively). However, less toxicity is seen when these residues are combined 
in a coblock manner, as in motif 3. In this case, peptoid 157 is illustrative (see Figure 
3.9), with ED50 values of 76 µM for HaCaT and 55 µM against HepG2. 
 
 
Figure 3.9. Structure of peptoid 157 [(NLysNpfbNpfb)(NLysNspeNspe)]2, the most active 
compound screened from peptoids with substituted aromatic groups. 
 
Therefore, the combination of the chiral Nspe monomer with the fluorinated Npfb 
residue helps to improve the overall activity of the sequence against L. mexicana. In 
particular, combining these two monomers in a coblock manner (motif 3) can help to 
reduce toxicity to mammalian cells, whilst maintaining potent antiparasitic behaviour. 
Peptoid 157 was the most active compound from this part of the SAR study with an ED50 
of 6 µM (promastigotes) and 21 µM (axenic amastigotes).  
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The effect of alkyl peptoid monomers 
The second generation library also included sequences that combine one aromatic 
residue with one alkyl monomer; either a propyl, isobutyl or isopentyl pentyl side chain 
(NnVal, NLeu and NhLeu correspondingly). These peptoids were based upon motif 2, 
compounds 235–242. 
As shown by Table 3.5, none of these peptoids showed much activity against either life 
stage of L. mexicana. Only the 12 and 9 residue peptoids containing the NhLeu building 
block showed any activity (ED50 promastigotes: 182 12 µM and 241 52 µM). The toxicity of 
the longest 12 residue peptoids containing these alkyl monomer were also assessed 
against the HaCaT keratinocytes and none showed any effect at the highest 
concentration tested. 
The reduced activity of peptoids 235–242 to both L. mexicana and the mammalian cells 
could be due to a lack of stable helical structure. Only a third of residues in each 
sequence are aromatic and previous work has shown that sequences should have at least 
half aromatic residues, preferably α-chiral, to induce a helix.95  Alternatively, the poor 
biological activity may be explained by the reduced overall hydrophobicity of the 
compounds. This result highlights that as expected, the size and chemical functionality 
of peptoid monomers is highly important for anti-leishmanial efficacy. 
 
Reduction of overall sequence charge 
In the further design iteration of motif 4, NLys residues in the Nx position were replaced 
by the alkyl building block Namy. In peptoids 243–246, the terminal amino group of 
either one or two NLys monomers was replaced by a methyl group. Thus, the net positive 
charge of the peptoid is reduced but the overall molecular weight remains unchanged. 
Despite the poor activity seen when alkyl chains replaced an aromatic residue in motif 2, 
peptoids 243–246 following motif 4 were the most potent in the library. An example 
structure for these peptoids is shown in Figure 3.10. 
 
Figure 3.10. Structure of peptoid 244 (NamyNspeNspe)2(NLysNspeNspe)2 where several 
cationic monomers are replaced by the uncharged Namy residue. 
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For all compounds in the first and second generation library discussed so far, the 
promastigotes are more susceptible to peptoid treatment than the axenic amastigotes. As 
already mentioned, this is probably due to the large differences in the cell surface coat of 
each parasite.  However, for all four peptoids with a reduced net charge (243–246) there 
is a smaller difference between potencies against promastigotes and amastigotes, as seen 
by ED50 values in Table 3.5. For example, against the promastigotes ED50 values were 
between 8 µM and 10 µM for peptoids 243–246. The activity against the amastigotes for 
these peptoids was also in the low micromolar range (ED50 15–21 µM). These results 
suggest that the increased hydrophobicity and reduced charge of the Namy residue can 
increase the biological activity when compared to the amino groups found on NLys. No 
significant difference was seen if the overall positive charge was reduced by 1 or 2, or in 
which position the residue(s) were replaced. 
Unfortunately the four peptoids 243–246 also show elevated cytotoxicity against the 
mammalian cells (ED50 < 20 µM for all compounds against both HaCaT and HepG2). This 
indicates that the increase in efficacy is a generic effect. However, the sequences were 
still slightly more potent against L. mexicana than the mammalian cells. 
 
Initial summary 
In conclusion, following analysis of the first and second generation linear peptoid 
libraries active peptoids were identified against L. mexicana for the first time (Table 3.4 
and Table 3.5 respectively).93,94 Efficacious compounds were found against both 
promastigotes (insect-stage parasites) and against the axenic amastigotes (mammalian-
stage parasites). In this group of 50 peptoids, over 20 were identified with ED50 values in 
the low micromolar range against the promastigote stage of the parasite. Seven 
compounds also showed low micromolar potencies against the clinically relevant 
amastigotes, including peptoid 246, (NLysNspeNspe)2(NamyNspeNspe)(NLysNspeNspe),  
with the best ED50 of 15 µM (Table 3.5). 
A comparison of the active and inactive sequences shows that the overall length of a 
peptoid and the nature of the individual monomers have a large influence on biological 
activity. As the peptoid sequence length is increased more potent activity was observed 
against both lifestages of L. mexicana. The chiral aromatic monomer Nspe, known to 
stabilise the formation of a helical secondary structure in peptoids, was found to increase 
the antiparasitic effect compared to the achiral Nphe analogues. It is also clear that the 
more hydrophobic a compound is, the more potent it becomes, presumably due to 
greater membrane permeability. When examining the effect of different amino-
functionalised side chains, it was found that the shorter chain lengths (Nae) gave rise to 
the most active peptoids and the longest (Nah) had the least potent activity. 
The investigation also demonstrated a clear difference in the sensitivity of the two life 
stages of L. mexicana to treatment by peptoids, with amastigotes being significantly 
more resistant. This is also observed with AMPs and is highly likely caused by the 
different molecules displayed on each of the parasite membranes and how these 
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influence sensitivity to both peptoids and peptides.26,51,67  Due to this, it is probable that 
the active peptoids screened in this study target the cellular membrane of the parasites. 
Many sequences in the library display only mild or negligible toxicity to the mammalian 
cell lines tested. However, the most active peptoids also display the greatest toxicities, 
with 246 having an ED50 of 20 µM and 22 µM against HaCaT and HepG2 respectively. 
This is a point for improvement, however, in applications against L. mexicana, some level 
of toxicity in a topical treatment may be acceptable. These results provide a basis to 
begin further SAR studies to explore the activity, mode of action and toxicity of this new 
class of potential anti-leishmanial compounds. Conclusions drawn from the SAR data 
were used in the design of a third generation linear peptoid library, which provided an 
opportunity to further probe the therapeutic window of bioactive peptoids. 
 
3.3.6 Enlarging the chemical space of linear anti-leishmanial peptoids 
In a third generation library, most peptoids were prepared using automated synthesisers 
in collaboration with Professor Ron Zuckermann at the Lawrence Berkeley National 
Laboratory. This allowed a greater number of compounds to be synthesised with a much 
larger subset of peptoid monomers included in the sequences.  
In the third generation library, a focus was placed on 12 residue peptoids as this length of 
sequence was shown to have the best activity in the first and second generation libraries. 
Monomer abbreviations and chemical structures for the sequences outlined in Table 3.6 
are shown in Figure 3.11. Firstly, this library contained peptoids with arginine only or the 
peptoids synthesised by the methodology developed in Chapter 2 to synthesise mixed 
lysine- and arginine-type monomers within the same sequence.96 This allowed 
comparison of the biological activity of these sequences to the amino-only functionalised 
peptoids of the previous libraries (i.e Nae/NLys and NnArg/NhArg, peptoids 147–155).  
As fluorinated monomers showed increased efficacy, a variety of peptoids were 
synthesised containing fluorinated building blocks. For example, a variety of aliphatic 
fluorine monomers were introduced into achiral peptoids (peptoids 247–251) and chiral 
analogues of the previous Npfb library with the cationic Nae residue instead of NLys to 
further investigate the effect of the length of the cationic sidechain (252–258). Other 
fluorine containing monomers in peptoids 261–267 included the α-chiral fluorinated 
residue Nsfb, or achiral monomers such as Ndfb, Ntfe or Npfp that were used in 
combination with Nspe to induce an overall helical peptoid. 
As many of the monomers included in the library so far are not representative of natural 
amino acids, a variety of residues were added to sequences that have moieties seen in 
amino acids. Peptoids 284–292 include groups such as the imidazole of histidine 
(NhHis), phenolic group from tyrosine (NhTyr), the indole of tryptophan-mimic NhTrp 
or thiol from the cysteine-type monomer, NhCys. However, it should be noted that these 
resides have an extra methylene group in the sidechain compared to their peptide 
equivalents, which may cause significant differences in activity. 
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  Sequence Average viability  
L. mexicana (%) 
ED50 HaCaT  
(µM) 
147 (NLysNspeNspe)2(NhArgNspeNspe)2 84 > 100 
148 (NhArgNspeNspe)2(NLysNspeNspe)2 7 15 
149 (NLysNspeNspe)(NhArgNspeNspe) (NLysNspeNspe)2 61 33 
150 [(NhArgNspeNspe)(NLysNspeNspe)]2 50 33 
151 [(NnArgNspeNspe)(NaeNspeNspe)]2 76 35 
155 (NnArgNspeNspe)4 23 18 
247 (NaeNspeNdfea)(NaeNpheNdfea)3 100 > 100 
248 (NaeNspeNea)(NaeNpheNea)3 100 > 100 
249 (NaeNspeNea)4 100 > 100 
250 (NaeNpheNea)2(NaeNspeNea)(NaeNpheNea) 90 > 100 
251 (NaeNpheNdfea)2(NaeNspeNdfea)(NaeNpheNdfea) 100 > 100 
252 (NaeNpfbNspe)4 7 32 
253 [(NaeNpfbNpfb)(NaeNspeNspe)]2 84 7 
254 (NLysNpfbNLysNspe)3 95 > 100 
255 (NaeNpfbNaeNspe)3 89 > 100 
256 (NLysNpfbNrpe)4 55 11 
257 (NaeNpfbNrpe)4 16 34 
258 [(NaeNpfbNspe)(NLysNpfbNspe)]2 71 25 
259 (NLysNspe)6 100 > 100 
260 (NaeNspe)6 87 > 100 
261 (NLysNdfbNspe)4 23 25 
262 (NaeNdfbNspe)4 2 28 
263 (NLysNsfbNsfb)4 2 36 
264 (NaeNsfbNsfb)4 4 24 
265 (NLysNsfbNspe)4 38 34 
266 (NaeNtfeNspe)4 98 > 100 
267 (NaeNpfpNspe)4 42 52 
268 [(NGluNpfbNspe)(NLysNpfbNspe)]2  22 73 
269 (NGluNpfbNspe)(NLysNpfbNspe)3 40 37 
270 (NGluNspeNspe)(NLysNspeNspe)3 52 28 
271 (NGluNspeNspe)(NLysNspeNspe)2(NGluNspeNspe) 46 31 
272 (NLysNspeNspe)(NGluNspeNspe)2(NLysNspeNspe) 89 27 
273 (NGluNspeNspe)2(NLysNspeNspe)2 77 28 
274 (NGluNspeNspe)2(NaeNspeNspe)2 62 25 
275 (NGluNspeNspe)(NaeNspeNspe)2(NGluNspeNspe) 2 75 
276 (NaeNspeNspe)(NGluNspeNspe)2(NaeNspeNspe) 44 > 100 
277 (NGluNspeNspe)(NaeNspeNspe)3 0 8 
278 [(NGluNspeNspe)(NaeNspeNspe)]2 6 49 
279 [(NGluNspeNspe)(NLysNspeNspe)]2 8 26 
280 (NLysNbutNspe)4 100 > 100 
281 (NaeNbutNspe)4 100 > 100 
282 (NbutNspeNspe)2(NLysNspeNspe)2 1 25 
283 [(NbutNspeNspe)(NLysNspeNspe)]2 0 19 
284 (NLysNhHisNspe)4 100 > 100 
285 (NaeNhHisNspe)4 100 > 100 
286 [(NaeNspeNspe)(NaeNhHisNspe)]2 80 > 100 
287 (NaeNhTyrNspe)4 82 86 
288 (NLysNhTyrNspe)4 89 > 100 
289 [(NLysNspeNspe)(NLysNhTrpNspe)]2 65 18 
290 [(NaeNspeNspe)(NaeNhTrpNspe)]2 66 10 
291 [(NLysNspeNspe)(NLysNpyrNspe)]2 93 > 100 
292 (NLysNhCysNspe)4 100 > 100 
Table 3.6. Percentage viability L. mexicana amastigotes when treated with 100 µM 
peptoid. ED50 values against the mammalian HaCaT cell line also displayed. 
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It was previously recognised that a reduction in the charge of a peptoid may increase its 
antimicrobial properties against L. mexicana (i.e. the Namy peptoids 243–246). 
Therefore, peptoids 280–283 were synthesised with the Nbut monomer either in position 
Ny of motif 2, or replacing a cationic monomer in position Nx, as in motif 4. This was to 
examine whether reducing the charge of peptoids with this alkyl chain could retain 
activity but decrease toxicity to mammalian cells. A series of peptoids were also 
synthesised with the glutamic acid analogue NGlu to investigate the effect of 
substitution by an anionic residue (peptoids 268–279). 
Finally, in several peptoids, the repeating three residue repeat unit was changed, either 
to an alternating NxNy motif (i.e. peptoids 254, 255, 259 and 260) to examine the effect of 
this charge: hydrophobicity ratio on activity against L. mexicana. 
 
Figure 3.11. Monomers used in the third generation peptoid library and accompanying 
monomer abbreviations, as discussed in the text. 
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Following synthesis, cleavage and purification of the library as described in Chapter 2, 
the peptoids were initially tested in a screen against the L. mexicana amastigotes at 
100 µM. Assays were only undertaken against amastigotes as it had already been 
determined that sequences that were active against amastigotes would also almost 
certainly have some level of activity against the promastigotes, as promastigotes were 
more susceptible to peptoid treatment in all prior screening. 
Peptoids were tested as before in the alamarBlue® high-throughput assay at a 
concentration of 100 µM against the L. mexicana and the population viability reported 
following treatment compared to positive and negative controls. Additionally, 
cytotoxicity screening against the HaCaT keratinocytes was undertaken to identify 
compounds that merited further investigation. The results are shown in Table 3.6 as a 
percentage viability of L  mexicana amastigotes following treatment.  
As seen from the data in Table 3.6, varying activities are seen for the peptoid library 
against L. mexicana amastigotes and in general, the compounds that showed the greatest 
percentage reduction in parasite viability also tended to have lower ED50 values against 
HaCaT. Some of the SAR drawn from this testing agrees with the conclusions made 
previously. For example, as seen in the second generation library, (section 3.3.5) peptoids 
containing alkyl chains in motif 2 showed little activity (i.e. peptoids 247–251 and 280–
281).   
The fluorinated peptoids showed enhanced activities; in particular the inclusion of the α-
chiral Nsfb monomer seemed to increase activity. In peptoids 263 and 264 (in motif 1) 
the activity was significantly enhanced, decreasing parasite viability to 2 % and 4 %. In 
motif 2 i.e. compound 265, the Nsfb activity was not so strong but still reduced parasite 
viability to 38 % after 100 µM treatment. However, significant toxicity to the HaCaT was 
also recorded (ED50 of 36 µM, 24 µM and 34 µM respectively for 263, 264 and 265 
respectively). 
Similar to the peptoids with a reduced net charge, replacing cationic NLys or Nae 
monomers with either Nbut or NGlu residues yields peptoid sequences that can 
considerably reduce the viability of L. mexicana. In the peptoids with the NGlu 
monomers, the net charge is reduced due to the anionic charge of the carboxylic acid 
side chain and a range of activities were seen depending on the specific positioning of 
the NGlu residues. The most active peptoids reduced parasite viability by nearly 100 % 
when added at 100 µM (i.e. peptoids 277, 275, 278 and 279). Similar reductions in parasite 
viability were also seen for the Nbut peptoids 280 and 281. 
When considering the effect of monomers that mimic amino acids upon antiparasitic 
activity it can be seen that some of these peptoids display negligible toxicity to HaCaT 
but the parasite population is not greatly affected by treatment of 100 µM. The only 
significant reduction in viability is seen for the NhTrp peptoids (peptoids 289 and 290, 
reducing viability to approximately 65 %) but these also are cytotoxic to HaCaT with 
ED50 values of 18 µM and 10 µM respectively.  
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To help identify peptoids for further investigation, the viability data obtained for each 
compound was plotted against the ED50 value against HaCaT, as shown by Figure 3.12. 
Ideally, any potential future antiparasitic treatment would significantly reduce cell 
viability of L. mexicana but have low toxicity to mammalian cells.  
Many peptoids display no activity against either the parasites or the mammalian cells (in 
the top right corner) and others show toxicity but little activity against L. mexicana. The 
area highlighted on the graph shows a handful of peptoids that show lower toxicity to 
mammalian cells but have potent activity against the parasites.†† 
 
Figure 3.12. Correlation of L. mexicana amastigote viability when treated with 100 µM 
peptoid (sequences as shown in Table 3.6) against the median effective dose against 
HaCaT. Compounds which reduce parasite viability by at least 50 % with an ED50 
> 40 µM against HaCaT are labelled. 267 (NaeNpfpNspe)4, 268 
[(NGluNpfbNspe)(NLysNpfbNspe)]2, 275 (NGluNspeNspe)(NaeNspeNspe)2 
(NGluNspeNspe), 276 (NaeNspeNspe)(NGluNspeNspe)2(NaeNspeNspe) and 278 
[(NGluNspeNspe)(NaeNspeNspe)]2. 
 
Following the identification of peptoids 267, 276, 278, 268 and 275, ED50 determination 
was undertaken. Other peptoids, such as the arginine-only and mixed lysine- and 
arginine-type peptoids 293–155 and a few extra sequences 298–303 were also tested to 
allow a more rigorous SAR discussion. 
 
                                                     
††
 ED50 HaCaT > 50 µM; ED50 L. mexicana < 50 µM. 
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Some compounds that had been identified as promising in the viability assay, were 
subsequently shown to have ED50 in excess of 100 µM as no activity was seen at 
concentrations less than 100 µM. Therefore an ED50 value could not be calculated; for 
example 267 reduces parasite viability to 42 % at 100 µM, but has an ED50 > 100 µM. 
 
 Sequence ED50 (µM) 
L. mexicana 
amastigotes 
HaCaT 
293 (NhArgNpheNphe)4 > 100 > 100 
294 (NhArgNpheNphe)2 > 100 > 100 
152 (NhArgNspeNspe)4 51 20 
295 (NhArgNspeNspe)3 > 100 > 100 
153 (NhArgNmfbNmfb)4 42 28 
296 (NhArgNmfbNmfb)3 > 100 > 100 
181 (NhArgNhLeuNspe)4 > 100 > 100 
297 (NhArgNhLeuNspe)3 > 100 > 100 
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 30 36 
147 (NLysNspeNspe)2(NhArgNspeNspe)2 37 > 100 
148 (NhArgNspeNspe)2(NLysNspeNspe)2 34 15 
149 (NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2 > 100 33 
150 [(NhArgNspeNspe)(NLysNspeNspe)]2 37 33 
151 [(NnArgNspeNspe)(NaeNspeNspe)]2 > 100 35 
155 (NnArgNspeNspe)4 74 18 
267 (NaeNpfpNspe)4 > 100 52 
268 [(NGluNpfbNspe)(NLysNpfbNspe)]2  62 73 
275 (NGluNspeNspe)(NaeNspeNspe)2(NGluNspeNspe) 33 75 
276 (NaeNspeNspe)(NGluNspeNspe)2(NaeNspeNspe) 41 > 100 
278 [(NGluNspeNspe)(NaeNspeNspe)]2 20 49 
298 (NLysNspeNspeNspe)3 33 44 
299 (NLysNpheNspe)4 > 100 > 100 
300 (NaeNpheNspe)4 > 100 > 100 
301 (NLysNrpeNrpe)4 > 100 75 
302 (NaeNrpeNrpe)4 36 87 
303 (NaeNrpeNrpe)3 > 100 > 100 
Table 3.7. Median effective dose against L. mexicana amastigotes and cytotoxicity data 
against HaCaT for selected peptoids within the third generation library. 
 
To study the effect of the cationic monomer (i.e. arginine- or lysine-type residues), 
peptoids 293–154 (arginine-only) can be compared to the mixed functionality sequences 
147–155 and the lysine-only analogues from sections 3.3.4 and 3.3.5. Overall, sequences 
with the arginine-type residues show more potent activity against L. mexicana 
amastigotes, although there are several exceptions, so this effect is sequence dependent. 
For example, for peptoids with the (NxNspeNspe)4 motif, sequences 152 (NhArg) and 22 
(NLys) have ED50 values of 51 µM and > 100 µM respectively so the arginine-type peptoid 
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has a greater activity. For sequences with Nmfb monomers 153 and 228, again the NhArg 
peptoids show a greater activity than their NLys equivalents (ED50 against amastigotes 
42 µM compared to 69 µM), although neither of the 9 residue peptoids following this 
design (296 and 229) show any activity with either cationic residue. Equally, the 
introduction of the arginine-type monomers doesn’t make inactive sequences active, i.e. 
compare the (NxNpheNphe)4 or (NxNhLeuNspe)4 motifs – peptoids 186/293 or 182/181 
where neither the NLys or NhArg analogues show any activity at 100 µM. 
However, when looking at the shorter lysine- or arginine-type monomers, Nae and 
NnArg, peptoid 156 has an ED50 of 17 µM against L. mexicana amastigotes whereas the 
guanido-functionalised 155 has less potent activity of 74 µM. Therefore, it appears that 
amino lysine-type residues are more potent at the shorter 2-carbon side chain length 
than the arginine-type monomers, however this trend is reversed for the longer NLys or 
NhArg building blocks (4 carbons in length). Other exceptions are also seen (for 
example, peptoids 243 and 154 where the NLys analogue shows the most potent activity) 
so whether the lysine- or arginine-type monomers induce the greatest activity against 
the parasites is a sequence-dependent effect. 
The peptoids containing the NGlu monomers (268–278) show intermediate activity 
against L. mexicana axenic amastigotes, but lower toxicity to HaCaT compared to the 
parent (NaeNspeNspe)4 sequence, peptoid 156 which has ED50 values of 17 µM against 
L. mexicana and 26 µM against HaCaT. In the case of peptoid 278, activity against the 
amastigotes is at 20 µM, similar to peptoid 156 but the toxicity is reduced two-fold to 
49 µM. Therefore, reducing the charge of a sequence with an NGlu monomer may retain 
biological activity but reduce toxicity to mammalian cells, especially when compared to 
reducing the sequence charge by substitution alkyl monomers like Namy.  
 
Figure 3.13. Structures of the NGlu peptoids 268 and 278. 
 
Although AMPs are typically cationic to target cell membranes, it is suggested that these 
NGlu peptoids in particular may be interesting candidates for leishmanicidal activity due 
Ch. 3 Antiparasitic Peptoids 
129 
 
to the unique environment in which Leishmania parasites reside. The parasites are 
typically found in acidic parasitophorous vacuoles which are produced by the parasites 
when inside their host cells, to allow growth whilst protected from host cell defence 
mechanisms. It has previously been shown that basic drugs can accumulate in these low 
pH vacuoles and shift the pH higher, which increases the efficacy of the drug against 
Leishmania.97 Since these peptoids are the sequences with the least positive net charge in 
the library and NGlu residues have basic character, they may also be able to act in a 
similar manner. Therefore, in section 3.3.8 these sequences were tested in a study of 
Leishmania infected macrophages.  
Finally, peptoids 298–303 were synthesised to compare to the simple library in Table 3.4. 
Peptoid 298 (NLysNspeNspeNspe)3 deviates from the typical three monomer repeat unit 
seen in 22 (NLysNspeNspe)4  but is still 12 residues in length overall. By changing the 
periodicity of the sequence, peptoid 298 it is significantly more hydrophobic‡‡ and shows 
improved activity against the parasites but less toxicity; ED50 L. mexicana 33 µM and 
> 100 µM, ED50 HaCaT 44 µM and 20 µM for 298 and 22 respectively.  
Peptoids 299 and 300 were synthesised with both Nspe and Nphe monomers in an 
attempt to reduce the toxicity, however neither sequence showed any activity against the 
parasites. The Nrpe peptoids 301–303 are enantiomers of the Nspe peptoids and as 
expected, show a very similar pattern in activity, although are slightly less potent than 
the Nspe sequences 22, 156 and 218.  
In conclusion, further factors that are necessary for leishmanicidal activity have been 
elucidated. It has been confirmed that the reduction of net charge from the typical + 4 in 
the peptoid 22 (NLysNspeNspe)4 and its analogues can increase the antimicrobial action 
of peptoids; either by replacement of cationic monomers with alkyl residues such as 
Namy or Nbut or the anionic carboxyl moiety NGlu. In the case of replacement by alkyl 
chains, this is often associated by increased toxicity to mammalian cells. However, in 
certain sequences where the compound charge is reduced by the inclusion of NGlu 
monomers, the peptoids show negligible toxicity to HaCaT.  
The introduction of fluorine is often highly advantageous in pharmaceutical compounds. 
As a small atom, substitution of hydrogen atoms with a fluorine only causes a small 
steric change but can modulate lipophilicity, basicity and bioavailability of compounds.98 
Peptoid sequences in this library with fluorinated monomers also display good 
antiparasitic activities. Since our assay is a simple cell based in vitro assay, presumably 
the increased activity of the fluorine-containing monomers is due to the altered 
lipophilicity of these sequences.  
Finally, it was shown that most active compounds had a significant proportion of α-
chiral residues (such as Nspe, Nrpe or Nsfb). As previously reported, the inclusion of 
such residues can help to induce a helical secondary structure and increase antimicrobial 
effect.76,95,99-101  
                                                     
‡‡
 RP-HPLC retention time 20.0 min for peptoid 298 cf 17.6 min for peptoid 22 over a 30 minute gradient. 
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3.3.7 Cyclic peptoids  
Cyclic peptoids 135–144 were synthesised by Alan-Yao Liu in the laboratory of Professor 
Kent Kirshenbaum, New York University, USA. 
 
Cyclisation has been shown to increase the biological activity of peptoids against various 
bacteria and fungi which is attributed to restricted structures and the removal of charged 
termini which can increase membrane permeability.102 Since the smallest, 6 residue 
peptoids in the first and second generation libraries displayed no activity against 
L. mexicana (see section 3.3.4 and 3.3.5), a few cyclic peptoids were synthesised to 
investigate if cyclisation could affect an improved biological activity.  
The synthesis and design of this library has already been discussed in Chapter 2 and the 
structures of all cyclic compounds are shown in Figure 3.14. Peptoids 130 and 131 were 
analogues of linear 6 residue peptoids already tested and peptoids 132–134 contain 
similar monomers but have two-fold periodicity. Compounds 132–134 have a greater net 
charge and literature studies suggest these compounds will organise with all hydrophobic 
and hydrophilic residues on opposing faces of the macrocycle, which may increase 
biological activity.72,73  The laboratory of Professor Kent Kirshenbaum from New York 
State University, USA also provided ten cyclic peptoids (compounds 135–144) to expand 
the study into the anti-leishmanial properties of cyclic peptoids. In these compounds 
larger ring sizes and utilisation of different monomers created different scaffolds to 
peptoids 130–134.  
The results from the biological evaluation of all cyclic peptoids against L. mexicana 
promastigotes and amastigotes can be found in Table 3.8. Peptoids 130–134 
unfortunately showed no activity at the highest 100 µM concentration tested to either life 
stage of the parasite. Peptoids 130  and 131  are cyclic versions of peptoids 188 
(NLysNpheNphe)2  and 227 (NLysNpfbNpfb)2. The linear analogues also show no activity 
against L. mexicana so in this case the cyclisation does not improve biological activity.  
Peptoids 132–134 also showed no activity against L. mexicana despite the increased 
compound charge and potentially more amphipathic structure. All of these cyclic 
compounds also showed no toxicity to the mammalian keratinocytes HaCaT at 100 µM, 
so these compounds are probably not suited to cause parasitic membrane disruption. 
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Figure 3.14. Structures of cyclic compounds synthesised (130–134) and compounds 
synthesised by Alan-Yao Liu in the Kirshenbaum lab (135–144). 
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Compound 
ED50 (µM) 
Promastigotes Amastigotes 
191    Amphotericin B < 2 < 2 
130 > 100 > 100 
131 > 100 > 100 
132 > 100 > 100 
133 > 100 > 100 
134 > 100 > 100 
135 > 100 43 
136 40 > 100 
137 > 100 > 100 
138 46 > 100 
139 17 63 
140 19 > 100 
141 > 100 > 100 
142 > 100 > 100 
143 46 > 100 
144 38 > 100 
Table 3.8. Median effective dose of cyclic peptoid library against L. mexicana 
promastigotes and amastigotes tested in a 1 hour cytotoxicity assay.  
 
For peptoids 135–144, some display good activity against the promastigote stage of the 
parasites. In particular, 139 and 140 show potent activity with ED50 values 17 µM and 
19 µM respectively. These peptoids are both 6 monomers in size, with an alternating 
pattern of hydrophilic (N-(4-aminopropyl) glycine monomers (Nap) and hydrophobic 
residues that have either a biphenyl or diphenyl sidechain (Nbpe or Ndpe). Other 6 
residue cyclic compounds with substituted phenyl groups (136, 143 and 144) and the 10 
monomer peptoid 138 also showed moderate activity against the promastigotes. 
However, activity against the axenic amastigotes is marginal for these compounds, which 
was consistent with results seen for linear peptoids within this molecular weight range. 
Although several sequences show a reduction in parasite viability at concentrations of 
100 µM and 50 µM, only peptoids 135 and 139 have measurable ED50 values and these are 
only moderately active at 43 µM and 63 µM respectively. 
Due to the lack of activity against L. mexicana, the toxicity of these compounds to 
mammalian cells was not assessed. Overall, there is no evidence that cyclic peptoids 
display good antiparasitic activity against L. mexicana. Peptoids 135–144 have been 
previously proven to have potent antibacterial activities, i.e. peptoids 139 and 140 each 
have an MIC of 3.9 µg mL-1 against S. aureus. It is possible that all cyclic peptoids have a 
mechanism of action that is ineffective against protozoa.72,73 
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3.3.8 Validation of peptoids against intracellular L. mexicana  
Screening undertaken in sections 3.3.4 to 3.3.7 all collected data against axenic 
Leishmania mexicana, i.e. extracellular, cultured amastigotes. These in vitro promastigote 
and axenic amastigote assays are often used in anti-leishmanial drug screening. 
However, due to the significant cellular, biochemical and physiological differences 
between these parasites and intracellular amastigotes, more representative assays can be 
useful. In the clinical stage of leishmaniasis, amastigotes reside within macrophages and 
therefore macrophage-amastigote models are considered to be more representative.103,104 
This section describes an assay developed to test peptoids against L. mexicana infected 
macrophages.  
A parasite-rescue and transformation assay system was recently described by Jain et al.105 
for screening compounds against L. donovani infected differentiated THP1 cells (visceral 
leishmaniasis) and was modified to suit L. mexicana.103,105,106 
Briefly, RAW 264.7 murine macrophages were subcultured in 96-well plates and 
incubated with L. mexicana amastigotes for 24 hours. The macrophages were then 
washed to removed non-viable cells that had not adhered to the plates and the 
macrophages are treated with peptoid solutions at varying concentrations for 24 hours, 
before being lysed by SDS solution to release the parasites. Following a further 48 hour 
incubation, the parasite viability was assessed using the alamarBlue® reagent. To assess 
the cytotoxicity of the peptoid sequences against RAW 264.7 only, in addition to the 
assay against L. mexicana infected macrophages, the protocol was carried out 
simultaneously in the absence of parasites.  
Sufficient controls were added to each plate to ensure results were significant; for 
example, RAW 264.7 only, L. mexicana only, medium only and a L. mexicana/RAW 
positive control. At the end point of the assay viable parasites can be seen in wells which 
were treated with non-active compounds. These parasites resemble the infective, 
metacyclic promastigotes and were rescued from the lysed RAW macrophages.§§ In these 
wells, the parasite population appears healthy, with plenty of cell division occurring. In 
wells treated by intermediately active compounds, some viable parasites are seen, but at 
a reduced cell density. In wells treated by amphotericin B or active peptoids, few or no 
parasites are rescued from the assay. 
Triage from the axenic screening of the first and second generation libraries against 
L. mexicana highlighted promising sequences to take forwards into the infected assay. 
Peptoids 180 (NaeNpheNphe)4 and 156 (NaeNpheNphe)4 are from the first generation 
library, with 156 showing low micromolar activity against both the promastigotes and 
axenic amastigotes. 180 is the achiral analogue and shows only mild activity against the 
insect stage of the parasite so was used as a negative control. Peptoids 157 and 244 were 
also chosen to investigate the effect of using the Npfb and Namy building blocks, which 
as discussed in section 3.3.5 were shown to increase efficacy of sequences against both 
                                                     
§§
 The appendix contains a photograph to illustrate the appearance of rescued parasites. 
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life stages of the parasite, where peptoid 157 is [(NLysNpfbNpfb)(NLysNspeNspe)]2 and 
peptoid 244 (NamyNspeNspe)2(NLysNspeNspe)2 with a reduced net charge and greater 
hydrophobicity. 
In a second round of screening, compounds were identified from the third generation 
library that were able to significantly reduce the viability of L. mexicana amastigotes at 
100 µM but had reduced toxicity to the mammalian cell line HaCaT, as highlighted in 
Figure 3.12. These peptoids, 268, 275, 276 and 278 all include the glutamic acid peptoid 
mimic, NGlu, and so have a reduced net charge due to the anionic character of this 
residue. The identification of these sequences was particularly surprising, because the 
action of AMPs is often attributed to their net positive charge. However, given previous 
studies that showed accumulation of Tamoxifen, a basic drug, in parasitophorous 
vacuoles and its ability to raise the pH of the compartment to induce leishmanicidal 
activity97, these compounds were also used in the infected assay to examine the effect of 
pH on the compounds. Peptoid 268 has Npfb residues in combination with Nspe/NLys. 
Peptoids 275, 276 and 278 are based around an NaeNspeNspe motif with certain Nae 
residues replaced with NGlu. 
The results discussed below were obtained in triplicate from at least two independent 
assays to ensure a robust data set was obtained. The reduction in cell populations of 
L. mexicana and the macrophages when treated by the peptoid sequences can be found 
in the Appendix A4. The ED50 values obtained from peptoid action against intracellular 
L. mexicana and RAW 264.7 are shown in Table 3.9. 
From this data, it can be seen that peptoids with activity against axenic amastigotes tend 
to retain activity against the intracellular amastigotes, i.e. peptoid 278 has an ED50 of 
20 µM against axenic amastigotes and ED50 of 12 µM against intracellular amastigotes. 
Overall, the effect of peptoid treatment on the intracellular amastigotes tends to be 
larger than the axenic amastigotes (as demonstrated by lower ED50 values). As expected, 
peptoid 180 shows no activity under all concentrations tested, showing that peptoids 
with little activity against the axenic amastigotes are also likely to show no activity to 
intra-macrophage amastigotes. Peptoids 156 and 157 show some activity against the 
intracellular parasites at 5 µM, the highest concentration measured, reducing viability to 
50 % and 70 % respectively. However, at lower concentrations activity was negligible. 
Peptoid 244 has the lowest ED50 value against the axenic amastigotes (16 µM) and is also 
the most active against the intracellular amastigotes with an ED50 of 1.6 µM. 
A similar story was seen for peptoids 268, 275, 276 and 278. For these compounds, 
screening was undertaken from 0.2 µM to 50 µM and ED50 values were obtained that 
were in all cases lower than the values against axenic amastigotes. For these compounds, 
the best activity was seen in sequence 268 containing the fluorinated Npfb monomer. 
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Table 3.9. Biological data for the intracellular L. mexicana amastigote assay. ED50 values against the intracellular amastigotes (L. mexicana 
M379) and against the murine macrophages (RAW 264.7) are tabulated. Values are also shown for the in vitro assays against promastigotes 
and axenic amastigotes for comparison. 
 
 Sequence ED50 (µM) 
 Promastigotes Axenic 
amastigotes 
Intracelluar 
amastigotes 
RAW 
 
Amphotericin B  < 2 < 2 0.195 > 100 
DMSO   >100 > 100 >100 > 100 
180 (NaeNpheNphe)4 21 > 100 > 5 > 5 
156 (NaeNspeNspe)4 7 17 > 5 3 
157 [(NLysNpfbNpfb)2(NLysNspeNspe)]2 6 21 > 5 5 
244 (NamyNspeNspe)2(NLysNspeNspe)2 11 16 1.6 1.7 
268 [(NGluNpfbNspe)(NLysNpfbNspe)]2  62 10 14 
275 (NGluNspeNspe)(NaeNspeNspe)2(NGluNspeNspe)  33 14 13 
276 (NaeNspeNspe)(NGluNspeNspe)2(NaeNspeNspe)  41 >25 >25 
278 [(NGluNspeNspe)(NaeNspeNspe)]2  20 12 8 
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However, although potent activities were recorded against the intracellular L. mexicana, 
there was also significant toxicity against RAW 264.7. For example, peptoids 156 and 157 
demonstrated greater toxicity against the macrophages than the intracellular, and 
axenic, amastigotes (ED50 > 5 µM for the intracellular parasite compared to ED50 of 3 µM 
and 5 µM against the macrophages respectively). Peptoid 244 is equivalently cytotoxic to 
both host and parasite (ED50 of 1.7 µM and 1.6 µM respectively).  For peptoids 268–278, 
little difference was seen in the activity of the peptoids against both the L. mexicana and 
RAW macrophages. 
This toxicity is consistent with studies from other groups, where peptoids with increased 
antimicrobial activity also demonstrate increased host cell cytotoxicity,71,76,81,107 although 
these groups have not explicitly drawn attention to the hemolytic activity or toxicity to 
mammalian cell lines. It was also highlighted in section 3.3.5 that activity against the 
parasites was accompanied by a certain level of toxicity to the mammalian cell lines 
HaCaT and HepG2. Clearly, overcoming this selectivity issue is a general problem for 
peptoids therefore further investigations into the toxicity of peptoids is examined in 
Chapter 5. 
However, the fact that several peptoids did display low micromolar activity against 
L. mexicana infected macrophages provides a starting point for future studies into the 
antimicrobial and cytotoxic effects of peptoids.  Despite the host cell toxicity, this data 
has helped to elucidate the key characteristics required for anti-leishmanial peptoid 
development and are the first peptoids with potent activity against L. mexicana 
promastigotes and amastigotes that retain activity against the clinically significant 
infected macrophages. 
 
3.4 Further investigations into peptoid action against 
trypanosomatids 
Biological testing in this section was carried out by Dr Marcel Kaiser at the Swiss Tropical 
and Public Health Institute, Basel.   
 
Other important neglected tropical diseases are also caused by protozoa and these 
comprise a significant percentage of the 1 billion people affected by NTD’s worldwide. In 
particular, diseases caused by trypanosomatids, kinetoplastid protozoa with a 
characteristic single flagellum, are particularly significant. Leishmania spp. are counted 
within this class alongside Trypanosoma brucei spp. and Trypanosoma cruzi, the 
causative agents of African sleeping sickness and Chagas disease.  
Peptoids are proposed to disrupt the cell membrane of mammalian, bacterial and 
parasitic species. The major surface molecules of the trypanosomatids are related 
displaying glycosylphosphatidylinositol (GPI)-anchored glycoproteins. However, the 
membranes are significantly different with predominant variant surface glycoproteins 
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seen on T. brucei, surface mucins on T. cruzi with more complex glycophospholipids 
such as the lipophosphoglycans and glycoinositolphospholipids seen in Leishmania 
spp.108 
Given the similarity between the trypanosomatids, both in biology, cell surface 
molecules and genomic sequences, it has been suggested that Chagas disease, sleeping 
sickness and leishmaniasis could be targeted by a drug that can modulate a conserved 
target across all three species. Although a broad spectrum drug to treat infections across 
species has not yet been discovered to date, a promising and selective kinetoplastid 
proteasome inhibitor has recently been identified for all three diseases.14 Due to the 
similarities between these parasite species a selection of our peptoid library were tested 
against other species by the Swiss Tropical and Public Health Institute in Basel. 
Leishmaniasis has already been introduced in section 3.1; over 20 distinct Leishmania 
species can cause visceral, cutaneous or mucocutaneous Leishmaniasis. Of these, the 
visceral form is the most serious, causing fatalities in 95 % of untreated cases. In 
particular, L. donovani causes VL in East Africa and the Indian subcontinent and 
L. infantum is the species responsible for the disease in Europe, North Africa and Latin 
America. AMPs that are active against one species of Leishmania are not always active 
against other species. Therefore, the work into CL was extended and peptoid compounds 
were tested against L. donovani as a representative species for VL.10,16,94 
Human African trypanosomiasis (or sleeping sickness) is transmitted by tsetse flies in 
rural sub-Saharan Africa and is caused by T. brucei species. Fewer than 4,000 cases were 
reported in 2014, but the disease is usually fatal if left untreated. African sleeping 
sickness causes acute and intermittent fever that develops into a second meningo-
encephalitic stage with symptoms including sleep disturbance and the onset of 
psychiatric disorders. Diagnosis relies on laboratory examination of samples; treatment 
requires parenteral administration and can cause serious adverse side-effects.109 
Chagas disease (or American trypanosomiasis) is another life-threatening disease caused 
by T. cruzi. Occurring in Latin America, the disease affects an estimated 7 million people 
and is becoming an emerging problem in previously unaffected areas due to increased 
population mobility. The insect vector is a triatomine bug that spreads disease by faeceal 
contamination of the eyes, mouth or open skin, which includes blood meal sites.  The 
initial acute phase is often asymptomatic but can cause fever and abdominal and chest 
pain. During the chronic phase, complications of the digestive system or destruction of 
the cardiac and nervous systems can lead to sudden death. Although current treatments 
are reasonably effective, alternative drugs are needed as severe adverse reactions can 
develop in up to 40 % of cases and these drugs are not suitable for pregnant women.110  
Due to the limited number of studies where peptoids are tested against protozoa and the 
promising results from our investigations with L. mexicana, a diverse library of peptoids 
was chosen to screen against T. b. rhodesiense, T. cruzi and L. donovani, the 
trypanosomatids that cause some of the world’s most prevalent and significant parasitic 
NTDs.  
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3.4.1 Biological evaluation of peptoid library  
The 54 sequences tested in this study were selected from peptoids that had already been 
evaluated for their leishmanicidal properties against L. mexicana. As so little information 
is available concerning the antiparasitic properties of peptoids, a diverse library of 
compounds were screened which included a large number of monomers to represent as 
many chemical functionalities as possible. 
 Due to the similarity of the trypanosomatid species, the sequences chosen included 
peptoids that had been identified with good activity against L.  mexicana, in particular 
with α-chiral monomers, like N-(S/R-phenylethyl) glycine which induce stable peptoid 
helicies76,95,100 and were previously shown to increase antimicrobial activity in section 3.3. 
The previous investigations against L. mexicana also showed that 12 residue peptoids 
were the most efficacious, so mainly peptoids of 12 residues in length were chosen, with 
some shorter sequences included for comparison. Other factors that contribute towards 
promising biological activity were also identified, such as the inclusion of fluorinated 
monomers so a variety of sequences containing fluorine-containing residues were also 
tested as well as those that are similar to amino acids to further expand our 
understanding of biologically active peptoid monomers. 
To further enhance the chemical space accessed by the library, several design motifs 
were included to investigate the effect of sequence periodicity further (i.e. sequences 
with two, three and four monomer repeat units). As before, the cationic monomers 
utilized were also varied; lysine-type (NLys, Nae), arginine-type (NhArg, NnArg) or 
peptoids containing both functionalities in the same sequence and in some sequences 
the overall charge was reduced by placing an alkyl chain in the third position of the 
motif (i.e. Namy or Nbut).  
Peptoid sequences tested and the IC50 values obtained from biological testing against 
L. donovani, T. b. rhodesiense and T. cruzi are shown in Table 3.10. In all assays, an 
appropriate reference drug (304–307)  was used as a positive control and the relevant 
infective life stage was tested; i.e. for the Trypanosoma species trypomastigotes and for 
L. donovani axenic amastigotes were used. The detailed procedures for these assays can 
be found in the Experimental Chapter 7. 
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Peptoid Sequence 
 
IC50 (µM) 
T. b. rhodesiense T. cruzi L. donovani L-6 
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 304 Melarsoprol 
 
 
0.01    
305 Benznidazole 
 
 
 1.99   
192 Miltefosine 
 
 
  0.27  
306 Podophyllotoxin 
 
 
   0.01 
P
e
p
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186 (NLysNpheNphe)4 10.1 10.5 nd 9.8 
180 (NaeNpheNphe)4 10.6 10.3 15.0 10.8 
299 (NLysNpheNspe)4 3.0 4.1 10.8 3.7 
300 (NaeNpheNspe)4 10.2 8.1 15.7 7.5 
25 (NLysNspeNspe)2 32.3 59.3 nd 76.4 
22 (NLysNspeNspe)4 3.3 5.0 6.8 3.6 
301 (NLysNrpeNrpe)4 3.2 3.8 12.5 3.5 
219 (NaeNspeNspe)2 60.8 60.2 nd 60.9 
156 (NaeNspeNspe)4 8.6 5.4 6.1 4.3 
302 (NaeNrpeNrpe)4 12.1 9.7 10.9 8.6 
235 (NLysNnValNspe)4 23.2 34.8 nd 30.4 
182 (NLysNhLeuNspe)4 2.8 4.0 14.2 3.6 
259 (NLysNspe)6 29.9 26.9 nd 26.6 
260 (NaeNspe)6 31.7 30.3 nd 33.3 
183 (NLysNpfbNspe)4 3.5 3.5 5.8 2.7 
157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 8.4 5.3 5.0 4.0 
256 (NLysNpfbNrpe)4 9.9 5.2 15.7 5.4 
257 (NaeNpfbNrpe)4 11.6 7.5 8.0 7.6 
252 (NaeNpfbNspe)4 11.0 7.7 8.3 5.8 
254 (NLysNpfbNLysNspe)3 28.6 24.4 nd 29.0 
255 (NaeNpfbNaeNspe)3 31.7 29.8 nd 30.9 
261 (NLysNdfbNspe)4 9.0 5.2 11.9 5.7 
262 (NaeNdfbNspe)4 21.7 7.6 8.2 8.1 
263 (NLysNsfbNsfb)4 8.4 6.0 6.9 3.8 
264 (NaeNsfbNsfb)4 19.8 6.2 6.7 5.8 
265 (NLysNsfbNspe)4 8.5 6.6 9.8 7.2 
266 (NaeNtfeNspe)4 26.2 29.4 nd 37.3 
152 (NhArgNspeNspe)4 2.2 4.8 4.0 3.2 
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 2.4 6.7 5.1 5.8 
147 (NLysNspeNspe)2(NhArgNspeNspe)2 3.5 6.5 5.9 7.2 
150 [(NhArgNspeNspe)(NLysNspeNspe)]2 8.8 11.3 10.5 11.0 
151 [(NnArgNspeNspe)(NaeNspeNspe)]2 3.6 3.7 5.3 3.9 
155 (NnArgNspeNspe)4 3.4 6.2 6.2 6.5 
271 (NGluNspeNspe)(NLysNspeNspe)2(NGluNspeNspe) 9.9 13.4 22.2 17.2 
275 (NGluNspeNspe)(NaeNspeNspe)2(NGluNspeNspe) 10.0 10.4 17.4 10.5 
276 (NaeNspeNspe)(NGluNspeNspe)2(NaeNspeNspe) 24.6 15.4 27.9 25.4 
268 [(NGluNpfbNspe)(NLysNpfbNspe)]2  28.0 10.8 22.0 15.8 
243 (NamyNspeNspe)[(NLysNspeNspe)]3 7.4 7.0 5.7 4.4 
244 (NamyNspeNspe)2(NLysNspeNspe)2 6.0 8.5 6.9 9.4 
280 (NLysNbutNspe)4 7.0 14.9 nd 19.4 
281 (NaeNbutNspe)4 9.2 17.7 nd 28.8 
308 (NbutNspeNspe)2(NaeNspeNspe)2 8.8 6.9 7.8 9.0 
284 (NLysNhHisNspe)4 nd 41.7 nd nd 
285 (NaeNhHisNspe)4 nd 43.7 nd nd 
286 [(NLysNspeNspe)(NLysNhHisNspe)]2 31.8 25.0 nd 32.9 
287 [(NaeNspeNspe)(NaeNhHisNspe)]2 30.4 24.8 nd 34.5 
288 (NLysNhTyrNspe)4 10.3 25.0 nd 16.9 
309 (NaeNhTyrNspe)4 10.6 19.4 nd 27.9 
291 [(NLysNspeNspe)(NLysNpyrNspe)]2 10.4 25.4 nd 29.3 
310 [(NaeNspeNspe)(NaeNpyrNspe)]2 10.6 23.0 nd 36.0 
292 (NLysNhCysNspe)4 30.7 30.6 nd 32.4 
311 (NaeNspeNmoeNspe)3 11.8 20.9 nd 31.4 
290 [(NaeNspeNspe)(NaeNhTrpNspe)]2 11.3 7.5 8.4 7.6 
289 [(NLysNspeNspe)(NLysNhTrpNspe)]2 9.9 7.5 12.8 6.9 
Table 3.10. Biological activity of the peptoid library against the causative parasites of the following 
diseases; T. b. rhodesiense STIB 900 trypomastigotes for African sleeping sickness; T. cruzi Tulahuen C4 
strain amastigotes for Chagas disease; L. donovani MHOM-ET-67/L82 amastigotes for visceral 
leishmaniasis. Cytotoxicity was carried out against L6 rat myoblasts (skeletal tissue) and all tests were also 
carried out on multiple occasions using relevant reference drugs for controls. nd indicates that no IC50 
value could be calculated due to negligible activity at the highest concentrations tested. 
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In general, across the trypanosomatids tested, some potent sequences were found against each 
species. For example, against T. b. rhodesiense and T. cruzi a few IC50 values of less than 10 µM 
were recorded; for each parasite the best peptoid was 152 with activity at 2.2 µM and 151 at 
3.7 µM respectively. For L. donovani several compounds had IC50 values less than 10 µM (for 
example, peptoids 22, 156, 183, 157, 264 and peptoid 152 with the lowest IC50 against 
L. donovani of 4.0 µM). 
The peptoids were also tested against L-6 myoblasts (rat skeletal tissue) as a representative 
mammalian cell line in order for a selectivity index (SI) to be calculated for each sequence.*** 
The SI provides a measure to ascertain which sequences are the most selective peptoids and 
several promising sequences for each species of parasite tested are highlighted in Table 3.11. 
 
 
Peptoid Sequence 
IC50 
(µM) 
Selectivity 
Index  
HPLC 
RT 
(min) 
African sleeping 
sickness  
(T. b. rhodesiense) 
    304 Melarsoprol 
 
0.01 2260 
 
25 (NLysNspeNspe)2 32.3 2.4 14.4 
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 2.4 2.4 22.4 
280 (NLysNbutNspe)4 7.1 2.7 16.5 
281 (NaeNbutNspe)4 9.2 3.1 16.9 
309 (NaeNhTyrNspe)4 10.6 2.6 14.8 
291 [(NLysNspeNspe)(NLysNpyrNspe)]2 10.4 2.8 13.4 
310 [(NaeNspeNspe)(NaeNpyrNspe)]2 10.6 3.4 14.1 
311 (NaeNspeNmoeNspe)3 11.8 2.7 16.8 
Chagas disease 
(T. cruzi) 
 
 
  
305 Benznidazole 
 
1.99 193 
 
261 (NLysNdfbNspe)4 5.2 1.1 17.9 
151 [(NnArgNspeNspe)(NaeNspeNspe)]2 3.7 1.1 19 
276 (NaeNspeNspe)(NGluNspeNspe)2(NaeNspeNspe) 15.4 1.7 20.5 
281 (NaeNbutNspe)4 17.7 1.6 16.9 
308 (NbutNspeNspe)2(NaeNspeNspe)2 6.9 1.3 21.9 
290 [(NaeNspeNspe)(NaeNhTrpNspe)]2 7.5 1.0 17.8 
Visceral  
Leishmaniasis 
(L. donovani) 
 
 
  
192 Miltefosine 
 
0.27 499 
 
157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 5.0 0.8 17.6 
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 5.1 1.1 22.4 
244 (NamyNspeNspe)2(NLysNspeNspe)2 6.9 1.4 22.8 
308 (NbutNspeNspe)2(NaeNspeNspe)2 7.8 1.2 21.9 
Table 3.11. Summary of selected peptoids and their biological activities against 
trypanosomatid parasites and SI, which can be compared to reference drugs. Analytical HPLC 
retention times from compounds > 95 % pure and are recorded from the centre of the peak; 
gradient = 0–100% solvent B over 30 minutes, column oven set to 40 ˚C, where A = 95 % H2O, 
5 % acetonitrile, 0.1 % TFA, B = 95 % acetonitrile, 5 % H2O, 0.1 % TFA. 
                                                     
***
 Selectivity index is defined as the toxicity to L6 rat myoblast cells divided by the IC50 against the parasite 
concerned. 
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Although none of the peptoids had better activity than the reference drugs, many of the 
peptoids tested were found to have comparable or improved antiparasitic activity to AMPs 
reported in the literature. For example, the leishmanicidal CA(1-8)M(1-18)62 peptide 
(compound 195) has IC50 values between 1 - 5 µM against L. donovani promastigotes (our assay 
tests against the less vulnerable amastigote life stage) and histatin 5111 (compound 205) is 
reported to have an IC50 of 14.2 µM against L. donovani amastigotes. The most active peptoids 
highlighted in Table 3.11 against L. donovani amastigotes have IC50 values from 5.0–7.8 µM. 
However, it should be noted that the SI for these compounds is not ideal as they are all 
around 1, showing that the peptoids that have shown good activity against L. donovani are not 
very selective and display equal toxicity to the L-6 cells. For T. cruzi, the AMPs cecropin60 
(compound 2) and meucine-2461 have IC50 values of 0.2 µM and 10–20 µM respectively. 
Although our peptoids cannot match the activity of cecropin, most of the peptoids with the 
highest SIs around 2 have low micromolar activity below 10 µM. 
Against T. b. rhodesiense, the SIs were slightly higher, between 2–3, with peptoid 154 showing 
the best activity of 2.4 µM. In two of the most efficacious compounds selected for this parasite, 
peptoids have the Nbut alkyl monomer in the second position of the trimer repeat, so these 
compounds have less aromatic character than other members of the library. These peptoids 
(280 and 281) have IC50 values of 7.0 µM and 9.2 µM. They also display activity against T. cruzi 
(14.9 µM and 17.7 µM) but no activity against L. donovani.  
Most of the compounds selected with the best SIs for L. donovani have alkyl residues in the 
third position of the trimer motif. In these compounds (154, 244, 308), the hydrophobicity of 
the compound is increased, as evidenced by the increased RP-HPLC retention times, and are 
also less charged than other members of the library. Encouragingly, peptoid 244 identified in 
the infected macrophage study (section 3.3.8) has also been highlighted here as a promising 
lead against L. donovani, although the SI is a point for improvement. 
It is not possible to directly compare the ED50 values obtained against L. mexicana in section 
3.3 with the IC50 values against L. donovani, due to drastically different assay procedures; 
against L. donovani peptoids are incubated with amastigotes for 70 hours, however, against 
L. mexicana a quick-kill assay is used with the amastigotes incubated with compound for 
1 hour, then at ten-fold reduced concentration for 24 hours. However, trends in activity can 
still be compared and it can be concluded that the factors identified for activity against 
L. mexicana are also applicable to L. donovani. For example, inclusion of α-chiral monomers or 
those containing fluorine and peptoids designed around the threefold repeating motif tend to 
be the most effective against L. mexicana (CL) and also L. donovani (VL). Reduction in overall 
sequence charge by replacing a cationic moiety with an alkyl group also remains a good 
strategy to increase antiparasitic activity.  
These generalised trends are also applicable to T. cruzi and T. b. rhodesiense. Overall, for the 
best peptoids identified in Table 3.11, Trypanosoma species have slightly lower IC50 values, and 
better SIs compared to L. donovani. Although the selectivity of these sequences is a point for 
future improvement, these peptoids provide a starting point for further enhancements and 
also demonstrate that the peptoids have trypanocidal activity against more than one parasitic 
species. 
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3.5 Targeting malaria: peptoids against Plasmodium falciparum 
Biological testing in this section was carried out by Dr Marcel Kaiser at the Swiss Tropical 
and Public Health Institute, Basel. Hemolysis data was collected by Dr Russel Luo and Dr 
Fionnuala Lundy (Queen’s University, Belfast).  
 
Although malaria is not classified as a NTD by the World Health Organisation and the 
rates of incidence have decreased substantially in recent years, malaria remains the most 
prevalent and debilitating protozoan infection in the world, affecting populations in 
South and Central America, Africa and Asia. Malaria is an infection of red blood cells 
caused by various Plasmodium spp. that are transmitted by the bite of an infected 
Anopheles mosquito. Malaria can cause severe fever, nausea or seizures but when treated 
promptly, uncomplicated infections have a low mortality rate of ~0.1 %. Despite the 
favourable prospects for treatment and deployment of insecticide-treated mosquito nets, 
in 2015, there were 214 million new cases of the disease and it caused an estimated 
438,000 fatalities.6,70,112  
Most cases of malaria are caused by Plasmodium vivax or Plasmodium falciparum, which 
is responsible for approximately 90% of malaria deaths. The Plasmodium spp. are quite 
different to the trypanosomatids discussed above, with a more complex infectious cycle 
and very different cell surface coats.6,70  
The same peptoid library discussed in section 3.4 tested against the causative parasites of 
Chagas disease, leishmaniasis and African sleeping sickness was also evaluated against 
P. falciparum to see if any sequences have the potential to be developed as selective 
antimalarial compounds and to draw comparisons between the activity of peptoids 
against the Trypanosoma and Leishmania parasites. 
 
3.5.1 Results from biological screening 
In the assays against P. falciparum, chloroquinine was used as a positive control in the 
antimalarial assays as it is one of the drugs prescribed for malaria prevention and 
treatment, although widespread resistance of P. falciparum to the drug is now seen in 
endemic areas.113 The IC50 values following screening of the peptoid library against 
P. falciparum are tabulated in Table 3.12. 
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Table 3.12. Biological activity of the peptoid library against P.  falciparum NF54 IEF stage. 
Cytotoxicity was carried out against L-6 rat myoblasts (skeletal tissue) and all tests were 
also carried out on multiple occasions using relevant reference drugs for controls. nd 
indicates that no IC50 value could be calculated due to negligible activity at the highest 
concentrations tested.  
 
 
  
Peptoid Sequence 
 
IC50 (µM) Selectivity 
Index P. falciparum L-6 
D
ru
g
  307 Chloroquine 
 
0.0047  41500 
306 Podophyllotoxin 
 
 0.01 - 
P
e
p
to
id
 
186 (NLysNpheNphe)4 4.05 9.8 2.4 
180 (NaeNpheNphe)4 2.85 10.8 3.8 
299 (NLysNpheNspe)4 1.48 3.7 2.5 
300 (NaeNpheNspe)4 1.51 7.5 5.0 
25 (NLysNspeNspe)2 34.20 76.4 2.2 
22 (NLysNspeNspe)4 0.56 3.6 6.5 
301 (NLysNrpeNrpe)4 0.41 3.5 8.6 
219 (NaeNspeNspe)2 27.55 60.9 2.2 
156 (NaeNspeNspe)4 0.68 4.3 6.3 
302 (NaeNrpeNrpe)4 0.79 8.6 10.9 
235 (NLysNnValNspe)4 nd 30.4 nd 
182 (NLysNhLeuNspe)4 0.85 3.6 4.3 
259 (NLysNspe)6 2.60 26.6 10.2 
260 (NaeNspe)6 0.68 33.3 49.2 
183 (NLysNpfbNspe)4 0.73 2.7 3.6 
157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 1.53 4.0 2.6 
256 (NLysNpfbNrpe)4 1.05 5.4 5.1 
257 (NaeNpfbNrpe)4 1.49 7.6 5.1 
252 (NaeNpfbNspe)4 1.51 5.8 3.8 
254 (NLysNpfbNLysNspe)3 8.50 29.0 3.4 
255 (NaeNpfbNaeNspe)3 2.40 30.9 12.9 
261 (NLysNdfbNspe)4 1.34 5.7 4.3 
262 (NaeNdfbNspe)4 0.99 8.1 8.1 
263 (NLysNsfbNsfb)4 0.69 3.8 5.5 
264 (NaeNsfbNsfb)4 0.72 5.8 8.0 
265 (NLysNsfbNspe)4 1.21 7.2 6.0 
266 (NaeNtfeNspe)4 8.06 37.3 4.6 
152 (NhArgNspeNspe)4 0.22 3.2 14.6 
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 0.05 5.8 124.8 
147 (NLysNspeNspe)2(NhArgNspeNspe)2 0.79 7.2 9.2 
150 [(NhArgNspeNspe)(NLysNspeNspe)]2 1.43 11.0 7.7 
151 [(NnArgNspeNspe)(NaeNspeNspe)]2 0.55 3.9 7.0 
155 (NnArgNspeNspe)4 0.59 6.5 11.1 
271 (NGluNspeNspe)(NLysNspeNspe)2(NGluNspeNspe) 4.83 17.2 3.6 
275 (NGluNspeNspe)(NaeNspeNspe)2(NGluNspeNspe) 3.06 10.5 3.4 
276 (NaeNspeNspe)(NGluNspeNspe)2(NaeNspeNspe) 6.88 25.4 3.7 
268 [(NGluNpfbNspe)(NLysNpfbNspe)]2  4.78 15.8 3.3 
243 (NamyNspeNspe)[(NLysNspeNspe)]3 0.19 4.4 22.4 
244 (NamyNspeNspe)2(NLysNspeNspe)2 0.19 9.4 49.0 
280 (NLysNbutNspe)4 5.66 19.4 3.4 
281 (NaeNbutNspe)4 2.74 28.8 10.5 
308 (NbutNspeNspe)2(NaeNspeNspe)2 0.23 9.0 39.1 
284 (NLysNhHisNspe)4 nd > 50 nd 
285 (NaeNhHisNspe)4 nd > 50 nd 
286 [(NLysNspeNspe)(NLysNhHisNspe)]2 nd 32.9 nd 
287 [(NaeNspeNspe)(NaeNhHisNspe)]2 22.35 34.5 1.5 
288 (NLysNhTyrNspe)4 14.44 16.9 1.2 
309 (NaeNhTyrNspe)4 9.74 27.9 2.9 
291 [(NLysNspeNspe)(NLysNpyrNspe)]2 23.23 29.3 1.3 
310 [(NaeNspeNspe)(NaeNpyrNspe)]2 12.76 36.0 2.8 
292 (NLysNhCysNspe)4 nd 32.4 > 50 
311 (NaeNspeNmoeNspe)3 8.53 31.4 3.7 
290 [(NaeNspeNspe)(NaeNhTrpNspe)]2 1.56 7.6 4.8 
289 [(NLysNspeNspe)(NLysNhTrpNspe)]2 1.63 6.9 4.2 
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Overall, the peptoids tested show greater activity against P. falciparum compared to the 
trypanosomatids T. cruzi, L. donovani and T. b. rhodesiense. Many IC50 values were 
recorded against P. falciparum that were significantly lower than 1 µM, for example 
peptoid 154 at 0.05 µM. Although activity at this level is significantly less than 
chloroquine, when comparing the activity of peptoid sequences to natural AMPs, it can 
be seen that several of the peptoids in Table 3.12 have improved activities. The AMPs 
cecropin57,58 (compound 2) and gomesin64 are reported to have IC50 values of 1.5 µM and 
50 µM respectively against P. falciparum, whereas selected peptoids from the library have 
sub-micromolar activities.  
The selectivity of the library has been determined in a similar manner to section 3.4 by 
calculating a selectivity index††† and a selection of the most promising compounds has 
been highlighted in Table 3.13. From this data, it can be seen that the SIs against 
P. falciparum are much improved compared to those against the trypanosomatids and 
this stems from the more potent activity against Plasmodium.  
 
 
Peptoid Sequence 
IC50 
(µM) 
Selectivity 
Index  
HPLC RT 
(min) 
Malaria 
(P. falciparum) 
    307 Chloroquine 
 
0.0047 41500 
 259 (NLysNspe)6 2.60 10.2 13.7 
260 (NaeNspe)6 0.68 49.2 14.1 
152 (NhArgNspeNspe)4 0.22 14.6 17.8 
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 0.05 124.8 22.4 
147 (NLysNspeNspe)2(NhArgNspeNspe)2 0.79 9.2 16.5 
244 (NamyNspeNspe)2(NLysNspeNspe)2 0.19 49.0 22.8 
308 (NbutNspeNspe)2(NaeNspeNspe)2 0.23 39.1 21.9 
Table 3.13. Summary of selected peptoids and their biological activities against specific 
parasites. Selectivity index is defined as the toxicity to L6 rat myoblast cells divided by 
the IC50 against P. falciparum and can be compared to the selectivity index of the 
reference drugs. Analytical HPLC retention times from compounds > 95 % pure and are 
recorded from the centre of the peak; gradient = 0–100% solvent B over 30 minutes, 
column oven set to 40 ˚C, where A = 95 % H2O, 5 % acetonitrile, 0.1 % TFA, B = 95 % 
acetonitrile, 5 % H2O, 0.1 % TFA. 
 
In particular, compound 154 [NamyNspeNspe)(NhArgNspeNspe)]2 with the very potent 
0.05 µM activity has a selectivity index in excess of 100. Since this sequence has toxicity 
to   L-6 at 5.8 µM and similar activity against T. b. rhodesiense, T. cruzi and L. donovani, 
poor SIs were recorded for these species. However, due to the excellent anti-plasmodial 
activity of 154, it has a large selectivity window against P. falciparum. 
Peptoids 244 and 308 also have good SIs and sub-micromolar activity, although are not 
quite as potent as 154. In these three sequences, cationic residues in the trimer repeat 
motif have been replaced by a monomer with alkyl functionality (for 154 and 244 Namy, 
                                                     
†††
 Selectivity index is defined as the toxicity to L6 rat myoblast cells divided by the IC50 against the parasite 
concerned. 
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for 308 Nbut). Therefore these sequences are more hydrophobic, as seen by the longer 
RP-HPLC retention times in Table 3.13, and are less highly charged than other members 
of the library (i.e. overall +2 charge instead of the standard +4 net charge).  
It is worth noting that the most promising anti-malarial peptoids also mostly contain 
guanido-functionalised NhArg residues instead of the amino analogues (NLys), i.e. 
compare the activity of 152 to peptoid 22, (NLysNspeNspe)4. In this case, the inclusion of 
the arginine-type residues doesn’t change the toxicity to the L-6 mammalian cells (both 
around 3 µM), but does significantly increase the activity against P. falciparum. This is in 
agreement with the only other study of anti-plasmodial peptoids, where peptide-β-
peptoid hybrids‡‡‡ with the amino acid arginine had more potent activity than lysine 
analogues.81 
Interestingly, peptoids 259 and 260 shown in Figure 3.15 were also highlighted amongst 
the peptoids with the best SI. Although the activity against P. falciparum is not as good 
as others in Table 3.13, these sequences display much reduced toxicity to the 
mammalian L-6 cells. The sequences of both peptoids are based upon an alternating 
pattern of cationic (NLys or Nae) and hydrophobic aromatic residues (Nspe), with the 
shorter Nae monomers in compound 260 being the most efficacious. It is interesting to 
note that both 259 and 260 do not have the common three-fold repeat motif, which has 
previously been suggested to impart an amphipathic, helical structure and thus lead to 
increased antimicrobial effects.76,99  
 
 
Figure 3.15. Chemical structures for peptoids 259 (NLysNspe)6 and 260 (NaeNspe)6, that 
both show promising SI against P. falciparum. 
                                                     
‡‡‡
 In these peptide-peptoid hybrids, peptoid monomers were used for the hydrophobic monomers and 
peptide amino acids for the cationic residues of lysine or arginine. 
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3.5.2 Hemolytic activity of selected peptoids 
The compounds identified as the most promising anti-plasmodial peptoids (in Table 
3.13) were also tested for their hemolytic activity to investigate toxicity of peptoids to 
human erythrocytes, in addition to their selectivity index. Briefly human whole blood 
was diluted in PBS to form a clear 8 % erythrocyte suspension and peptoid solutions 
were added and incubated for 1 hour at 37 ˚C before analysis (detailed protocol for the 
standard hemolysis assay can be found in Chapter 7). The hemolytic activities of the 
7 peptoid sequences and chloroquine diphosphate (as a reference drug) are shown in 
Figure 3.16.  
As expected by the variety of residues present in this library, a variety of hemolytic 
activities were recorded. Some of the compounds screened showed significant hemolytic 
activity, such as peptoids 152, 244 and 147 causing approximately 80 % hemolysis at 
12.5 µM. Sequences 154 and 308 had even stronger detrimental activity to the human 
erythrocytes, even at the lowest concentration tested (6.25 µM). However, peptoids 259 
and 260 show little hemolytic activity in the same range as the chloroquine control, even 
at 100 µM. 
 
Figure 3.16. Hemolytic assay of peptoids selected in Table 3.13. Chloroquine 
diphosphate salt was tested as a control. Human erythrocytes treated with compounds 
from 6.25–100 µM. Data collected from three independent experiments, each undertaken 
in triplicate. 
 
These findings highlight the need for multiple assessments of toxicity since peptoid 154 
has a very high selectivity index using the in vitro testing against the mammalian cells, 
but shows over 50 % hemolytic activity even at the lowest concentration tested. As 
already eluded to in section 3.3.8, other groups have also identified peptoid toxicity as an 
issue but few people have attempted to overcome this challenge. In particular, for some 
of the most active peptide-β-peptoid hybrids tested by Olsen et al. against P. falciparum, 
their sequences also showed hemolytic activity at concentrations lower than 10 µM. 
Additionally, human red blood cells were also examined in this study using microscopy 
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and even peptoids that had low hemolytic activity caused severe membrane alterations 
at low concentrations. Therefore, in the future the appearance of the erythrocytes should 
be studied following treatment by peptoids 259 and 260.81  
Peptoids 259 and 260 have only mild toxicity to mammalian cells (around 30 µM 
against  L-6), and show low hemolytic activity but potent activity against P. falciparum. 
Therefore sequences 259 (IC50 2.60 µM and SI of 10.2) and 260 (IC50 0.68 µM and SI of 
49.2) may be interesting candidates for further development. These sequences both 
follow an alternating design of hydrophobic and charged monomers which is different to 
the typical three residue repeat often seen in antimicrobial peptoids. Therefore in the 
future, it would be useful to evaluate the toxicity, hemolytic activity and antiparasitic 
activity of a variety of peptoids with different charge : hydrophobicity ratios and to 
change the hydrophobic monomer (for both 259 and 260, α-chiral Nspe is used). This 
would allow further investigation into whether it is the increased net cationic charge, or 
the increased number of hydrophobic residues that causes the improved antimicrobial 
effect and lower toxicity/hemolytic activities. 
 
3.6 Conclusions 
In conclusion, the work presented in this chapter represents the first comprehensive 
investigation into the use of peptoids as a novel class of antiparasitic agents. Initial work 
focussed on the effect of peptoids against the causative agent of cutaneous leishmaniasis, 
Leishmania mexicana. In this work, the first examples of peptoids were found that were 
active against both insect stage promastigotes and mammalian axenic amastigotes. 
Additionally, this work identified the first peptoids that were active against intracellular 
parasites (in this case inside infected macrophages), with peptoid 244 
(NamyNspeNspe)2(NLysNspeNspe)2 having an ED50 of 1.6 µM. 
A variety of other protozoa responsible for disease were also studied and active 
sequences were identified against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, 
L. donovani and P. falciparum. In particular, peptoids 259 (NLysNspe)6 and 260 
(NaeNspe)6 have been identified that display significant anti-plasmodial activity (IC50 of 
2.68 µM and 0.68 µM respectively), low toxicity to L-6 mammalian cells and negligible 
hemolytic activity. Despite the similarity of the surface GPI-anchored glycoproteins and 
GPI-related complex glycophospholipids of the trypanosomatids, each species does have 
different cell surface molecules, which is the most likely cause of the different 
susceptibility of each species to specific peptoid sequences.  
The peptoids have an increased resistance to proteolysis than peptide-based therapeutics 
and show comparable or improved antimicrobial activity to many common AMPs in the 
literature. Therefore, the increased stability of the peptoids makes them promising 
candidates for further investigation as they overcome the problematic in vivo biostability 
typically displayed by AMPs. Additionally, since the predicted mode of action of peptoids 
is plasma membrane disruption or pore formation, the risk of parasite resistance 
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development is low. This is advantageous compared to the small molecule drugs 
currently in clinical use, to which drug resistance is developing. 
Hydrophobicity has been identified as a very important property that can contribute 
towards antimicrobial activity. Many potent sequences had a large proportion of 
hydrophobic residues, fluorine substitution or a reduced net charge compared to inactive 
compounds. To help rationalise biological activity and correlate this to hydrophobicity of 
sequences, a detailed study of peptoid hydrophobicity was undertaken in Chapter 5. 
The selectivity of peptoids can be problematic as many active sequences presented here 
in Chapter 3 have been shown to be toxic to mammalian cells or to have significant 
hemolytic activity. This is a point for improvement in the future and is discussed further 
in Chapter 5, where the mode of action of antimicrobial peptoids is investigated in more 
detail. However, in applications against cutaneous leishmaniasis, potential treatments 
can be formulated for a topical application, where a certain level of toxicity to host cells 
may be acceptable. Many of the treatments in current clinical use against NTDs also 
show some level of toxicity or severe side effects and this point emphasises the drastic 
need for new therapeutics to be developed against these diseases. 
Finally, this library represents the largest, and most functionally varied, library of 
antiparasitic peptoids reported to date and thus it should help inform and direct future 
research into biologically active peptoids. Given that many studies in the literature have 
found a low hit rate in whole cell parasite screens against the trypanosomatids, peptoids 
are presented as very promising drug candidates. For example, in the GlaxoSmithKline 
Tres Cantos facility, over 1.8 million small molecule compounds were screened to find 
around 200 potent hits against each of L. donovani, T. cruzi or T. brucei.114 In the case of 
the peptoid library presented as part of this project, around 200 compounds were 
screened to find many sequences with potent activity, particularly against P. falciparum. 
The study should also benefit the scientific field as it provides the largest toxicity 
screening of peptoids to date and it is anticipated that the data may aid the design of 
bioactive peptoids in the future. 
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Chapter 4 
Antibacterial and Antifungal Peptoids 
 
Since the discovery of penicillin in 1928, a large range of antibiotics have been 
successfully developed to combat a wide variety of infections. However, as discussed 
earlier for the neglected tropical diseases, antimicrobial resistance is an extreme threat to 
global public health. Statements from organisations like the World Health Organisation 
highlight the real possibility of entering a new era with a lack of suitable antibiotics. 
Recent initiatives such as the 10 x 20 Initiative in 2010 and the 2015 Global Antimicrobial 
Resistance Research Innovation Fund encourage investment and a commitment to the 
development of new antibacterial drugs.1 
Antibiotic resistance is reported frequently in the media, with a high proportion of 
hospital acquired infections caused by multi-drug resistant bacteria. Resistance to these 
antibiotics is increasing at a remarkable rate and is a significant problem. Clinically 
noteworthy antibiotic resistance has developed against every single antibiotic in use and 
as illustrated by Figure 4.1, the first observations of drug resistant bacteria often occurs 
very soon after the first clinical use of the drugs. For example, in the case of daptomycin 
(discovered in 2004), resistance was seen only one year later in 2005. Despite this, the 
development of new classes of antibiotics has stalled even though the need for such 
drugs has increased dramatically.2-9 
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Figure 4.1. Timeline to show the deployment of key antibiotics in the clinic and the first 
reported occurrence of antibiotic resistance to these drugs. 
 
The problem of antibiotic resistance will only escalate in the future, therefore there is a 
desperate need to design, make and test new antibiotic compounds. AMPs have been 
extensively studied as new antibiotic compounds with different modes of action to 
traditional small molecule drugs that may decrease the chance of resistance developing. 
As discussed in Chapter 1, peptoids have also been shown as very promising new 
antibiotic compounds with a greater resistance to proteolysis than peptide counterparts. 
Therefore, the peptoid sequences designed for antiparasitic activity were also tested as 
novel antibiotics in this project.  
Bacteria can be classified as either Gram positive or Gram negative, dependent on their 
membrane structure. Gram positive bacteria have a thick, multi-layered peptidoglycan 
membrane that protects a single cytoplasmic membrane. The Gram negative bacteria 
have a single peptidoglycan layer but an extra outer membrane made of glycolipids 
(especially lipopolysaccharides), which can provide protection against toxins and makes 
the Gram negative bacteria less susceptible to antibiotics. In addition to these layers, 
bacterial cell membranes are decorated with other molecules and proteins, as shown in 
Figure 4.2.6,10  
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Figure 4.2. A comparison of the membrane structures of Gram positive and Gram 
negative bacteria. 
 
Clinically relevant microorganisms often exist naturally in complex biofilms that are 
substantially different in phenotype to planktonic bacteria. A biofilm is an aggregate of 
microorganisms that can comprise a mixture of bacterial or fungal species. In the 
biofilm, cells typically adhere to each other, or to a surface, and are frequently embedded 
in a self-produced matrix of extracellular polymeric substances (EPS) (see Figure 4.3). 
Biofilms are not easily washed from any surfaces they adhere to as the EPS matrix, 
typically made of polysaccharides, protects the biofilm.11-13  
 
 
Figure 4.3. The lifecycle of a biofilm; bacteria populate and attach to a surface, bacteria 
produce EPS, aggregate and grow in the biofilm community then after maturation, single 
cells are released to start new colonies. 
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Biofilms are responsible for many device related infections in a hospital setting, i.e. on 
catheters or surgical implants, and also cause tissue infections including dental plaques 
or chronic wound infections. Conventional antibiotics that work well against planktonic 
bacteria are often inadequate for the treatment of biofilms. The extracellular matrix 
provides some protection for the biofilm as any drug may fail to penetrate beyond the 
surface layer of the biofilm. Additionally, biofilms are often not as metabolically active as 
planktonic species so therefore might not respond so well to antibiotics that target 
metabolic processes. Multiple species can exist within a biofilm, so any antibiotic would 
have to target multiple bacterial or fungal strains and certain genes may be up- or down-
regulated in the biofilms.14  
Consequently any investigation into new antibiotics should ideally target both 
planktonic and biofilm bacterial phenotypes, and across both Gram negative and Gram 
positive strains. Therefore, peptoids were evaluated as novel antibiotic compounds in 
tests against bacteria in both their planktonic (section 4.1) and biofilm form (section 4.2). 
It is suspected that peptoids disrupt the cell membrane and since Gram negative and 
Gram positive bacteria have significantly different membrane structures, a selection of 
bacterial strains were tested that represented both classes of bacterial cell envelope. The 
action of peptoids against biofilms was then investigated in both single and multispecies 
biofilms. Following these investigations into the antibacterial and fungicidal properties 
of the peptoid library, a method to potentially improve the selectivity index of peptoids 
was explored in section 4.3, via conjugation of peptoid sequences to the lantibiotic nisin.  
 
4.1 Bacterial minimum inhibitory concentration determination 
Antibacterial screening was undertaken in collaboration with Dr Gary Sharples in the 
Biosciences Department at Durham University, and contributions to the collection of 
bacterial MIC data were made by Dr Gabriela Eggimann (postdoctoral research assistant, 
Cobb group), Mark Laws (undergraduate project student, Cobb group) and Sophia 
Schwartz (Erasmus student, Cobb group). 
 
To assess the antibacterial properties of a selection of peptoids, minimum inhibitory 
concentrations (MICs) were determined for the peptoids against Staphylococcus aureus 
and Staphylococcus epidermidis (Gram positive), Escherichia coli and Pseudomonas 
aeruginosa (Gram negative). Certain strains of E. coli and S. aureus are responsible for 
food poisoning and S. aureus can also cause respiratory disease or skin infections. 
S. epidermis is part of the normal skin flora, however in patients with compromised 
immune systems, infections can develop especially within biofilms on surgical implants 
or catheters. P. aeruginosa is another opportunistic pathogen that can colonise medical 
devices and is also associated with serious illnesses. It typically infects the respiratory 
tract, urinary tract or open wounds, particularly in patients with a weakened immune 
system, and can lead to sepsis.15 
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The MIC is defined as the lowest concentration of peptoid that completely inhibits 
bacterial growth after incubation at 38 ˚C for 16 hours, using the procedure by Andrews 
et al.16 Ampicillin (101) was used as a comparative as it is a commonly used antibiotic and 
results were quantified via absorbance values. 
Peptoids assessed in this study were chosen from the library already tested against 
L. mexicana to gain a broader understanding of the factors that lead to effective and 
selective antimicrobial peptoids. Since the mode of action of peptoids against bacteria is 
assumed to be membrane disruption, the sequences selected contained a wide variety of 
side chain functionalisation to help elucidate the factors necessary for activity. As before, 
sequences 6, 9 and 12 residues in length were included and the library included residues 
with alkyl character, substituted aromatic monomers and different cationic functionality; 
such as the mixed lysine- and arginine- type peptoids. All sequences were designed 
around the trimer motif previously described and reported to promote amphipathic 
structures, where the third monomer was typically a cationic monomer (since the 
peptoid helix turn is reported to be every three residues in a polyproline type I helix).17-19 
In addition to the MIC data, as a measure of toxicity against mammalian cells the 
peptoid library was also tested against the epithelial HaCaT and HepG2 cell lines 
introduced in Chapter 3. From these ED50 values obtained a selectivity index
* was 
calculated for the action of the peptoids against each pathogen. The results from the 
biological evaluation of the peptoid library are shown in Table 4.1. To the best of our 
knowledge this library is the single largest library of linear antibacterial peptoids to date 
and many of the sequence motifs and monomers included have not yet been reported in 
antibacterial peptoids. 
                                                     
*
 Selectivity index is defined as toxicity/activity and represented as an average of the selectivity to HaCaT and 
HepG2. 
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Table 4.1. The minimum inhibitory concentrations for the peptoid library against S. aureus 
and S. epidermidis (Gram positive), E. coli and P. aeruginosa (Gram negative). Toxicity against 
two mammalian cell lines (HaCaT and HepG2) is also shown to calculate selectivity values. 
The selectivity index is represented as an average of the selectivity to HaCaT and HepG2. MIC 
values recorded at 100 µM have true MIC values > 100 µM. 
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210 (NahNpheNphe)4 100 100 13 100 2 6 8 1 50 17 
211 (NahNpheNphe)3 100 100 50 100 6 3 2 1 17 33 
212 (NahNpheNphe)2 100 100 100 100 100 100 1 1 1 1 
186 (NLysNpheNphe)4 36 100 13 50 3 2 6 2 23 34 
187 (NLysNpheNphe)3 100 100 50 100 25 6 2 1 4 17 
188 (NLysNpheNphe)2 100 100 100 100 100 100 1 1 1 1 
180 (NaeNpheNphe)4 100 100 13 50 2 6 8 2 50 17 
213 (NaeNpheNphe)3 100 100 100 100 13 100 1 1 8 1 
214 (NaeNpheNphe)2 100 100 100 100 100 100 1 1 1 1 
215 (NahNspeNspe)4 23 41 25 50 2 2 2 1 16 17 
216 (NahNspeNspe)3 100 100 25 100 3 2 4 1 33 50 
217 (NahNspeNspe)2 100 100 100 100 100 25 1 1 1 4 
22 (NLysNspeNspe)4 20 29 25 50 2 1 1 1 13 25 
26 (NLysNspeNspe)3 100 100 13 100 2 2 8 1 50 50 
25 (NLysNspeNspe)2 100 100 100 100 100 25 1 1 1 4 
156 (NaeNspeNspe)4 26 41 100 50 2 2 0 1 17 17 
218 (NaeNspeNspe)3 100 100 25 100 2 13 4 1 50 8 
219 (NaeNspeNspe)2 100 100 100 100 100 100 1 1 1 1 
220 (NLysNpmbNpmb)4 41 100 100 100 3 2 1 1 24 36 
184 (NLysNpcbNpcb)4 18 22 100 100 25 6 0 0 1 4 
223 (NLysNpcbNpcb)3 22 23 50 25 3 2 0 1 8 12 
225 (NLysNpfbNpfb)4 46 30 13 25 2 1 3 2 19 38 
226 (NLysNpfbNpfb)3 100 45 13 25 3 3 6 3 24 24 
228 (NLysNmfbNmfb)4 25 17 25 25 6 3 1 1 4 7 
229 (NLysNmfbNmfb)3 64 43 13 25 6 2 4 3 9 27 
183 (NLysNpfbNspe)4 20 26 13 13 2 2 2 2 12 12 
231 (NLysNpfbNspe)3 52 36 25 25 3 2 2 2 15 22 
157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 100 55 6 50 2 1 13 2 39 78 
233 (NLysNspeNspe)(NLysNpfbNpfb)(NLysNspeNspe) 65 43 13 25 3 2 4 3 21 28 
243 (NamyNspeNspe)[(NLysNspeNspe)]3 12 15 50 50 2 2 0 0 7 7 
244 (NamyNspeNspe)2(NLysNspeNspe)2 20 18 100 100 2 1 0 0 10 19 
245 (NLysNspeNspe)2(NamyNspeNspe)(NLysNspeNspe) 20 22 100 100 6 2 0 0 4 11 
293 (NhArgNpheNphe)4 100  
6 25 
 
2 17 4 
 
50 
152 (NhArgNspeNspe)4 20 12 6 13 1 1 3 2 16 16 
295 (NhArgNspeNspe)3   
6 50 2 2     
153 (NhArgNmfbNmfb)4 28 21 13 13 2 2 2 2 12 12 
296 (NhArgNmfbNmfb)3   
6 25 2 1     
181 (NhArgNhLeuNspe)4   
13 25 1 2     
297 (NhArgNhLeuNspe)3    
100 3 2     
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 31 24 100 100 3 6 0 0 9 5 
147 (NLysNspeNspe)2(NhArgNspeNspe)2 100  
17 34 17 
 
6 3 6 
 
148 (NhArgNspeNspe)2(NLysNspeNspe)2 15  
17 17 17 
 
1 1 1 
 
149 (NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2 33  
17 17 17 
 
2 2 2 
 
150 [(NhArgNspeNspe)(NLysNspeNspe)]2 33  
17 67 17 
 
2 0 2 
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As seen from the data summarised in Table 4.1, many peptoids within the library have low 
MIC values against both Gram negative and Gram positive bacteria, ranging from the most 
active at less than 1 µM to inactive peptoids with no activity even at 100 µM. Some of the MIC 
values obtained are within the same range of selected natural antimicrobial peptides described 
in the literature. For example, the AMP cecropin A† (compound 2) was shown to kill 90 % of 
E. coli at 2 µM and peptoids 293, 152, 295 and 296 all have an MIC against E. coli of 6 µM.20 
Magainin 2‡ (compound 1), an amphibian derived AMP, was reported to have MIC values 
against E. coli, S. epidermidis and S. aureus of 5 µg mL-1 (20 µM), 10 µg mL-1 (4 µM) and 
50 µg mL-1 (2 µM) respectively and many of the peptoids in Table 4.1 exhibit even better 
antibacterial activities than this (see Figure 4.4).21,22 
 
Figure 4.4. Structures of peptoids 152, 293, 296 with NhArg functionalisation. 
Unsurprisingly, the activity of most peptoids is significantly greater against the Gram positive 
species (S. aureus and S. epidermidis) than Gram negative species (E. coli or P. aeruginosa). 
This differential activity is most probably due to the presence of the lipopolysaccharide-rich 
outer membrane of Gram negative bacteria, which presents a significant permeability barrier 
to many hydrophobic molecules. Certain compounds within the library displayed selectivity 
for certain bacterial species, however no Gram negative specific peptoids were identified. Any 
sequences that can selectively target Gram negative bacteria are highly sought after due to 
rising concerns about antibiotic resistance.2,9,23-26 
                                                     
†
 2 cecropin A sequence: KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK-NH2  
‡
 1 magainin 2 sequence: GIGKFLHSAKKFGKAFVGEIMNS-NH2  
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4.1.1 Structure activity relationships in antibacterial peptoids 
First generation peptoid library – effect of sequence length and chirality 
As a starting point, the first generation peptoid library (compounds 210–219), previously 
tested for activity against L. mexicana27 was also examined. In the work against the 
parasites, it was determined that factors such as overall sequence length and inclusion of 
chiral monomers could enhance the antimicrobial effect of the peptoid. It was also 
shown that the length of cationic side chain was important, with the shortest Nae 
monomer imparting better activity than NLys and the longest Nah residue having the 
least potent antiparasitic activity. 
These trends are also replicated in the activity of the peptoid library against the bacteria 
in Table 4.1. The longest 12 residue peptoids (210, 186, 180, 215, 22 and 156) were always 
more active than their 9 residue analogues, which were themselves more active than the 
6 residue peptoid sequences.  Hexapeptoids 212, 188, 214, 217, 25 and 219 showed 
generally limited antibacterial activity against the bacteria tested with MICs of 100 µM, 
although it is interesting to note that S. epidermidis did show some sensitivity to 
peptoids 25 and 219. 
Interestingly, the effect of monomer chirality was less important to achieve antibacterial 
activity than with L. mexicana; in many cases, sequences comprised exclusively from 
achiral monomers had comparable or better activity than analogues containing the chiral 
Nspe building block (see Table 4.1). For example, comparing peptoid 186 to 22 
(structures in Figure 4.5) which are achiral and chiral analogues of the same sequence, 
similar MIC values are observed against P. aeruginosa (50 µM for both) and S. aureus 
(MIC 3 µM and 2 µM). However, against E. coli, the achiral peptoid 186 has an MIC of 
12 µM compared to 25 µM for the chiral equivalent 22. A similar pattern is apparent with 
peptoids 180 and 156 (sequences with the shorter Nae monomer and either Nphe or Nspe 
respectively), with the peptoids having similar activity against both P. aeruginosa and 
S. aureus but the achiral sequence 180 shows better activity against E. coli (MIC 13 µM 
and > 100 µM respectively). 
 
 
Figure 4.5. Structures of the achiral peptoid 186 (where R = H) and chiral peptoid 22 
(where R = CH3). 
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When comparing sequences containing the different amino-functionalised cationic 
monomers, Nae, NLys and Nah, it is not possible to draw a simple conclusion about the 
optimum length of side chain for the best antibacterial activity as promising activity is 
seen for all three cationic residues (monomer structures given in Figure 4.6). Peptoids 
based upon the (NxNpheNphe)4 motif 210 (Nx = Nah), 186 (Nx = NLys) and 180 (Nx = 
Nae) all have an MIC of 13 µM against E. coli and good activity against both 
Staphylococcus species. However, when comparing the chiral analogues of the same 
motif (NxNspeNspe)4, the sequences with Nah and NLys (215 and 22) have an MIC of 
25 µM against E. coli but peptoid 156 with the shortest Nae residue has negligible activity. 
For these peptoids 215, 22 and 156, the activity against P. aeruginosa, S. aureus and 
S. epidermidis is similar regardless of the choice of cationic monomer (see Table 4.1). 
 
Figure 4.6. Cationic monomers used in sequences 210–219 with 2, 4 and 6 carbons in the 
side chain. 
 
Effects of substitution to aromatic monomers 
The effect of additional substituents to the aromatic groups on peptoid sequences within 
the library was examined in a similar way to those described in Chapter 3.28 Monomer 
substitutions included a methoxy group in the para position of the benzyl group (Npmb), 
chlorine in the para position (Npcb) or fluorine in either the para or meta position (Npfb 
or Nmfb). Against L. mexicana, it was shown that halogenated monomers (in particular 
fluorinated ones) improve the efficacy of the sequence against amastigotes.  
Based upon these observations, the screening of peptoids against bacteria focused on the 
halogenated sequences so only the longest 12 residue methoxy substituted peptoid was 
tested, compound 220 in Table 4.1. Addition of the –OMe group to the ring had a 
negligible effect to the Gram negative bacteria and no improvement in action was seen 
against the Gram positive bacteria compared to the unsubstituted analogue, peptoid 186. 
Addition of chlorine in the para position of the benzyl ring was shown to increase 
toxicity to the mammalian cell lines but improved activity against axenic amastigotes. 
However, a similar increase in activity was not seen against the bacteria. For example, 
compound 184 has an MIC of > 100 µM against E. coli, whereas the unsubstituted 
analogue 186 shows potent activity at 13 µM (see Table 4.1). 
The fluorinated peptoid sequences were more successful at targeting the various 
bacterial species. Peptoids containing the achiral Nmfb or Npfb (225–229) show 
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marginally improved antibacterial activities compared to the unsubstituted peptoids 
(186–188). There is no significant difference on antibacterial activity for monomers 
substituted in the para or meta position and interestingly, the 9 residue peptoids 226 and 
229 have a similar level of broad spectrum antibacterial activity as the longer 12 residue 
peptoids, 225 and 228, but have a reduced toxicity to the mammalian cells. In this case, it 
appears that the shorter 9 residue sequences may be better antibacterial candidates with 
a larger therapeutic window. 
The peptoids containing the chiral Nspe monomer in combination with the fluorinated 
monomer Npfb (183–233, Table 4.1) show slightly more potent activity against the 
bacterial species than the achiral fluorinated peptoids 225–229, however also tend to be 
more toxic to the mammalian cells. In particular the 12 residue peptoid 157 is promising, 
where the Nspe and Npfb are designed in a coblock manner. 
[(NLysNpfbNpfb)(NLysNspeNspe)]2 has good activity towards E. coli (MIC 6 µM), 
S. aureus and S. epidermidis (MIC 2 µM and < 1 µM) but shows a reduced toxicity towards 
HaCaT and HepG2 compared to the sequences made of Nspe or Npfb exclusively. 
 
Peptoids with alkyl substitution  
To probe the relationship between net charge and hydrophobicity of a peptoid and its 
biological activity, analogues of peptoid 22 (NLysNspeNspe)4 were synthesised where the 
alkyl monomer Namy was substituted in the place of the cationic NLys monomers. In 
these analogues (peptoids 243–245, Table 4.1), the charge is replaced either at the N 
terminal end of the sequence or in two positions within the sequence (see Figure 4.7 for 
an example structure).  
The parent sequence 22 shows moderate activity against E. coli and P. aeruginosa (MIC 
25 µM and 50 µM respectively) and potent micromolar activity against the Gram positive 
bacteria. Substitution of the cationic NLys monomer with Namy retains activity against 
both Gram positive bacteria, but leads to a reduction of overall activity against Gram 
negative bacteria. To illustrate this, peptoids 243–245 have MIC values of 50 µM or 
> 100 µM against E. coli and similar reductions in activity are seen for P. aeuriginosa.  
 
 
Figure 4.7. Example structure for peptoid 244 where charged NLys residue is replaced by 
Namy. 
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The effect of lysine- or arginine-type monomers on antibacterial activity 
Arginine containing peptoids have been shown to increase membrane permeability and 
antibacterial activity in the literature29-31 so sequences containing arginine peptoid 
monomers were included in the library. This allowed the comparison of differently 
functionalised cationic residues on the peptoid sequences (i.e. the amino NLys peptoids 
or the guanidine groups of NhArg). It has also been suggested that arginine in peptide 
sequences can increase antibacterial potency but also will have an associated rise in 
toxicity.29,32 In an attempt to modulate the biological properties of the peptoid library, for 
the first time, peptoids with both lysine and arginine in the same sequence have been 
evaluated against bacterial targets using the new methodology developed in this 
project.33 
This sub-library of peptoids can be split between sequences exclusively containing 
arginine residues (Table 4.1, peptoids 293–154) and those that contain a mixture of both 
lysine and arginine-type side chains (Table 4.1, peptoids 147–150). In these compounds 
NhArg has been introduced, which is the equivalent side chain to the NLys residue, with 
4 carbons in the backbone and the terminal guanidine moiety. An example structure for 
peptoid 150 is shown in Figure 4.8.  
 
Figure 4.8. Structure of peptoid 150 [(NhArgNspeNspe)(NLysNspeNspe)]2, that contains 
both amino-functionalised lysine-type monomers and the arginine-mimetic residues. 
 
In contrast to peptoids that contain amino-functionalised NLys residues, the sequences 
with NhArg exclusively tend to have an increased toxicity to the mammalian cell lines 
tested but do display improved activity against the bacteria tested (see Table 4.1). For 
example, when comparing the fluorinated peptoids 153 and 296 to their lysine-
equivalents (228 and 229 respectively) we see an approximate 2-fold increase in 
antibacterial activity for all species tested; for the longest 12 residue sequence 
(NxNmfbNmfb)4 activity against E. coli is 13 μM in 153 (where Nx is NhArg) compared to 
25 μM in 228 (where Nx is NLys). Against S. aureus the arginine-type peptoid has an MIC 
of 2 μM contrasting with 6 μM for the lysine equivalent. However, in sequences that 
were inactive with lysine residues, replacement by NhArg does not make the sequence 
active (see peptoid 154, where the sequence is not active against Gram negative bacteria 
at any concentration), but in these cases the inclusion of the guanidine group does 
increase the toxicity. 
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As predicted, sequences with a combination of lysine and arginine-type residues show a 
balance between toxicity to mammalian cells and antibacterial activity compared to 
sequences with the NLys or NhArg residues only. For example, in related peptoids 
containing all arginine residues (152), all lysine residues (22) and both lysine/arginine 
monomers within the same sequence (peptoids 148-150), we see toxicity to the HaCaT 
keratinocytes at 11 μM, 20μM and 15–33 μM respectively.  The general antibacterial 
activity follows a similar trend for example against E. coli, the lysine-only peptoid 22 has 
the lowest activity at 25 µM, the arginine-only peptoid 152 has the most potent activity 
with an MIC of 6 µM and the mixed sequences 148–150 have intermediate activity at 
17 µM.  
The observation that guanidine-only peptoids display the most potent biological 
activities is in agreement with previous studies into arginine-rich peptides, which are 
able to bind membrane-bound lipids more readily than their amino-functionalised lysine 
equivalents. In this case it was proposed that the arginine-type side chains can form 
bidentate hydrogen bonds with the phospholipid head groups. This has also been 
concluded in studies with antimicrobial peptide-peptoid hybrids containing both lysine 
and arginine.29,34 
 
4.1.2 Conclusions from antibacterial MIC determination 
In summary, the peptoids within this library that have antiparasitic activity are also 
successful antibacterial compounds. In general, all peptoids were far more active towards 
the Gram positive species tested than to the Gram negative bacteria, in keeping with 
their differing envelope structures. Hence the peptoid library has much better selectivity 
indices against S. aureus and S. epidermidis.  
The best activity against E. coli reported was 6 µM for peptoids 293 (NhArgNpheNphe)4, 
152 (NhArgNspeNspe)4 and 295 (NhArgNspeNspe)3 and 17 µM against P. aeruginosa for 
peptoids 148 (NhArgNspeNspe)2(NLysNspeNspe)2 and 149 (NLysNspeNspe)-
(NhArgNspeNspe)(NLysNspeNspe)2. Many peptoids also showed micromolar activities 
against S. aureus and S. epidermidis with both species showing a similar pattern of 
sensitivity; although S. aureus did show a tendency to be more resistant than 
S. epidermidis possibly due to minor differences in cell surface charge and 
hydrophobicity.35,36 In many cases, P. aeruginosa also proved more peptoid-resistant than 
E. coli. This may reflect differences in the lipid composition of each species or the ability 
of P. aeruginosa to form biofilms, which has been observed previously with AMPs such as 
LL-37 (compound 179).37 
Factors contributing to enhanced antimicrobial activity include the overall length of 
sequence, with longer 12 residue peptoids typically displaying the best activity, although 
in many cases the 9 residue peptoids also display broad spectrum activity against 
bacteria. As seen in Chapter 3, substitution of fluorine in peptoid monomers also 
enhances activity.  
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In many cases, achiral sequences displayed potent activity, especially against the Gram 
positive bacteria. For example, peptoid 153 (NhArgNmfbNmfb)4 contains achiral N-(3-
fluorophenylmethyl) glycine residues and has MIC values of 13 µM against E. coli and 2 
µM against S. aureus. Interestingly, from our library most compounds that are active 
against the bacteria but exhibit no/low toxicity to mammalian cells contain achiral 
monomers, or at least a reduced frequency of chiral monomers within the sequence 
compared to the standard NxNspeNspe motif. Whether through the presumed increase 
in hydrophobicity, or through other effects, the addition of chiral Nspe residues in a 
sequence often has a detrimental effect on overall toxicity. Since many of the achiral 
sequences show potent antibacterial activity and these peptoids are not expected to form 
fully folded peptoid helicies, secondary structure is perhaps not as important as 
predicted. However, it should be noted that this is not replicated in activity against 
protozoa, where chirality has been shown to be far more important. Therefore, a larger 
potential therapeutic window may exist for antibacterial peptoids compared to 
antiparasitic peptoids. 
Additionally, in Chapter 3, some of the best sequences were identified when a cationic 
monomer was replaced with an alkyl chain, resulting in a reduced net charge and 
increased overall hydrophobicity, as measured by RP-HPLC. No effect is seen for this 
substitution against Gram positive bacteria. However, such substitutions by the Namy 
residue are detrimental to the activity of the library against E. coli and P. aeruginosa. 
Peptoid 22 (NLysNspeNspe)4 has MIC values of 25 µM and 50 µM against E. coli and 
P. aeruginosa respectively, however peptoid 244 (NamyNspeNspe)2(NLysNspeNspe)2.is 
inactive against both species at 100 µM. 
This peptoid library was designed to mimic natural antimicrobial peptides, which are 
proposed to act on cell membranes, among other targets. For certain compounds, 
particularly the more hydrophobic sequences that are both active against bacteria but 
toxic to mammalian cells, this may be the case. However, other compounds exhibited 
negligible toxicity to mammalian cells but good activity against bacteria and this may 
indicate that cell membrane disruption is not the only mechanism at work. Selectivity of 
the peptoids has also proved slightly problematic, with some of the best antibacterial 
compounds also having equipotent toxicity to mammalian cells, resulting in poor 
selectivity indices. Overall, there is more work to be done to elucidate the mode of action 
of antimicrobial peptoids and this is explored in further detail in Chapter 5.  
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4.2 Peptoid activity against bacterial and fungal biofilms  
Biofilm testing was carried out at Queens University, Belfast by Dr Yu Luo (postdoctoral 
research assistant), under the supervision of Dr Fionnuala Lundy.  
 
The preliminary data presented in section 4.1 shows that many peptoid sequences have 
excellent MIC values against planktonic bacteria, as determined in broth culture. 
However as discussed in the introduction, the majority of infections in vivo involve 
biofilms which may be comprised of multiple bacterial and/or fungal species. Microbes 
growing in their biofilm form differ significantly from their planktonic equivalent; such 
as the production of EPS matrix that can protect the biofilm and often have slower 
growth rates. Biofilms also tend to display high mutation rates, so resistance to 
conventional antibiotics is a significant problem. Therefore, the MIC value may not 
always be an accurate predictor for activity against more complicated biofilms and it is 
important that anti-biofilm properties are also studied.11,14,38 
Chapter 1 reviews the previous studies into the antibacterial and antifungal properties of 
peptoids and they have been shown to be efficacious against a range of planktonic 
micro-organisms19,39,40 and bacterial biofilms.41 However, to date, the activity of peptoids 
against fungal biofilms, and in particular, polymicrobial bacterial and bacterial-fungal 
biofilms has yet to be determined. 
In addition to the bacteria studied in MIC determination (S. aureus and E. coli), the 
fungal species Candida albicans was incorporated into anti-biofilm activity assays to 
represent the natural complexity of a biofilm. Although C. albicans is common in the 
gastrointestinal and genitourinary flora of a large proportion of the human population, it 
is an opportunistic pathogen that can cause candidiasis ranging from superficial to life-
threatening systemic infection, particularly in immunocompromised patients. Biofilms 
containing C. albicans are responsible for a large number of clinical infections on both 
biological and abiotic surfaces; for example the cornea or endotracheal tubes.42-44  
In polymicrobial infections in vivo, species have been shown to influence each other, 
through sensing and signalling or the formation of the biofilm architecture.45,46 
C. albicans has been shown to dramatically affect the physical environment of any 
biofilm it is present in and can influence interspecies protein expression.47,48 
Additionally, as with most fungal pathogens, C. albicans is becoming increasingly 
resistant to antibiotics so new treatments for cross-kingdom biofilms are desperately 
needed.49,50 
Traditionally, the efficacy of a compound against a biofilm can be determined using a 
crystal violet assay or based upon the metabolic activity of the biofilm. The crystal violet 
assay uses a triarylmethane dye (see compound 312, Figure 4.9) that when solubilised 
adheres to proteins and DNA and can quantify the total biofilm mass present. The 
biomass counted typically includes the EPS matrix, extracellular or dead cells, as well as 
the live biofilm so can lead to an overestimation of the biomass present. The metabolic 
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assay is similar to the alamarBlue® assay described in Chapter 3. For biofilms, a 
tetrazolium-based dye is used (commonly XTT, 313) which is reduced in the 
mitochondria to the formazan product and can reflect the number of viable cells present 
colourimetrically. This assay only measures living microorganisms, but different strains 
of the same pathogen may have very different metabolic activities which can make 
comparisons between discrete assays difficult.51 In addition, neither of these assays are 
useful for application to mixed species biofilms as they cannot distinguish between 
species, for example, if the treatment has killed one species selectively. 
 
 
Figure 4.9. Dyes used in the crystal violet assay, metabolic assay and in PMA-qPCR 
(discussed below). 
 
Recently, the Lundy group at Queen’s University Belfast has adapted a quantitative 
polymerase chain reaction (qPCR) based assay to aid in the quantification of mixed 
species biofilms. Briefly, PCR is a technique used to amplify DNA. Through several steps 
DNA is denatured to a single stranded form that complementary primers can bind to. 
Following the primer annealing step, DNA polymerase is used to produce a 
complimentary copy of the target DNA strand. In qPCR, the reaction is followed using a 
fluorescent reporter to measure DNA generation in real-time.52 
This qPCR approach used by the Lundy group is also modified by the use of propidium 
monoazide (314, PMA in Figure 4.9), a photoreactive dye that is able to intercalate DNA 
with high affinity upon exposure to intense visible light. PMA can only bind to 
extracellular DNA or in cells with compromised membranes and forms irreversible 
covalent linkages to the DNA. This means the PMA-qPCR only amplifies DNA from 
viable cells so results are potentially more accurate than those obtained from a crystal 
violet assay or metabolic assay.51,53  
Additionally, since PCR uses primers specific to each bacteria or fungi, viable organism 
numbers for each species within the polymicrobial biofilm can be quantified. It also 
allows quantification of viable, but non-culturable microorganisms (VBNC), which 
biofilms are very likely to contain. Microorganisms have been reported to enter a VBNC 
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state when exposed to antibiotic treatment so the use of a non-cultivation based assay in 
this case is very appealing.53,54 
Initially, the efficacy of the peptoid library was determined against monospecies biofilms 
containing C. albicans, S. aureus or E. coli using a crystal violet assay for preliminary 
screening purposes. The anti-biofilm properties of selected peptoids were then 
determined against polymicrobial bacterial-fungal biofilms using the PCR 
approach.Peptoid action against single species biofilms 
For initial screening of the entire peptoid library, a crystal violet assay was used to 
quantify the change in biofilm mass following peptoid treatment. Peptoids were added at 
a concentration of 100 µM to established single species biofilms of C. albicans, S. aureus 
and E. coli. It was assumed that if a peptoid could reduce viable biofilm mass, it would 
also be useful to prevent biofilms.  
The peptoids used in this study are shown in Table 4.2 and are all sequences initially 
synthesised for testing against Leishmania. As before, the peptoids were typically 
designed with a repeat of three residues where the third residue has cationic 
functionality to induce an amphipathic structure with bulky Nphe and Nspe residues to 
encourage formation of a helical structure which may improve the antimicrobial effect.  
 
Table 4.2. Peptoid library tested for efficacy against single species fungal and bacterial 
biofilms. Anti-biofilm activity of peptoids in the first column can be found in Figure 4.11; 
those in the second column are illustrated in Figure 4.12. 
 
 
Sequence 
 
 Sequence 
 
186 (NLysNpheNphe)4  228 (NLysNmfbNmfb)4 
187 (NLysNpheNphe)3  182 (NLysNhLeuNspe)4 
188 (NLysNpheNphe)2  245 [(NamyNspeNspe)(NLysNspeNspe)]2 
22 (NLysNspeNspe)4  293 (NhArgNpheNphe)4 
26 (NLysNspeNspe)3  152 (NhArgNspeNspe)4 
25 (NLysNspeNspe)2  153 (NhArgNmfbNmfb)4 
180 (NaeNpheNphe)4  181 (NhArgNhLeuNspe)4 
213 (NaeNpheNphe)3  154 [(NamyNspeNspe)(NhArgNspeNspe)]2 
214 (NaeNpheNphe)2  147 (NLysNspeNspe)2(NhArgNspeNspe)2 
156 (NaeNspeNspe)4  148 (NhArgNspeNspe)2(NLysNspeNspe)2 
218 (NaeNspeNspe)3  149 (NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2 
219 (NaeNspeNspe)2  150 [(NhArgNspeNspe)(NLysNspeNspe)]2 
210 (NahNpheNphe)4  132 Cyclo (NLysNphe)3 
211 (NahNpheNphe)3  133 Cyclo (NhArgNphe)3 
212 (NahNpheNphe)2  134 Cyclo (NLysNpheNhArgNpheNLysNphe) 
215 (NahNspeNspe)4    
216 (NahNspeNspe)3    
217 (NahNspeNspe)2    
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The library contains 18 peptoids (186–217) to examine the effect of overall sequence 
length, cationic monomer functionality and chirality on the biofilm growth to be 
investigated. Additionally, selected peptoids from the second generation library were 
tested using a crystal violet assay to compare the effect of lysine-type monomers with the 
arginine-type monomers (peptoids 228–150). Three cyclic peptoids, 132–134 were also 
considered. A planktonic culture of microorganism was prepared in 96 well plates and 
incubated for 4 hours at 37 ˚C to allow initial biofilm formation. After washing to remove 
planktonic cells, 100 µM of compound were added to the plate wells and incubated for a 
further 24 hours to allow biofilm maturation. The peptoids show variable antifungal and 
antibacterial activities when screened for inhibitory activity against monospecies 
biofilms of C. albicans, S. aureus and E. coli. 
Many sequences show good efficacy with a large percentage reduction in overall biofilm 
mass, as shown in Figure 4.11 and Figure 4.12. In particular, peptoids 26, 180, 156, 218, 
210 and 245 show over 75 % reductions in biofilm mass across the different species. 
Figure 4.12 also shows a comparison to a synthetic peptide with repeating lysine-
leucine-alanine residues (KLA peptide 315 in Figure 4.10) with potent anticancer 
properties.55 315 has only mild activity against the E. coli biofilm and no activity against 
S. aureus or C. albicans.  
Figure 4.10. Structure of the KLA AMP, 315. 
 
Sequence length effects 
To examine the effect of sequence length, the peptoids in Figure 4.11 were compared. In 
agreement with the antiparasitic testing undertaken in Chapter 3, the longest peptoids 
tend to show the greatest activities; the longest 12 residue peptoids are more efficacious 
than the 9 residue peptoids that have an intermediate activity and the shortest 6 residue 
peptoids are mostly inactive. For example, against C. albicans peptoids based upon the 
NaeNpheNphe motif show the most activity for the longest sequence 180 and the least 
potent compound is the 6 reside peptoid 214.  Against S. aureus, the longer peptoids had 
good activity and no activity for the shortest peptoids, but interestingly it was the 
comparable shorter 9 residue analogues that caused the greatest reduction in biofilm 
mass (see peptoids 213 and 180 or 218 and 156). For E. coli, the trends are split where the 
longest peptoids are the most active with Nae or NLys residues, however with the Nah 
monomer the intermediate 9 residue peptoids are the most active (i.e. compare peptoids 
210 and 216). 
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Figure 4.11. Efficacy of peptoids 186–217 against A; C. albicans B; S. aureus C; E. coli 
monospecies biofilms determined by crystal violet assay. Biofilms were treated with peptoids 
at 100 µM and compared with untreated, control biofilms. The results (average of 3 
independent experiments) were plotted as percent biomass of controls. Statistical analysis was 
determined by one-way ANOVA followed by Tukey’s post hoc correction for multiple 
comparisons (ns: p > 0.05; *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001). 
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Figure 4.12. Efficacy of peptoids 228 to 134 and the AMP 315 against A; C. albicans B; S. aureus 
C; E. coli monospecies biofilms determined by crystal violet assay. The peptoid treated 
biofilms were compared with untreated, control biofilms, the AMP KLA and the results 
(average of 3 independent experiments) were plotted as percent biomass of controls. 
Statistical analysis was determined by one-way ANOVA followed by Tukey’s post hoc 
correction for multiple comparisons (ns: p > 0.05; *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p 
< 0.0001). 
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Chirality 
The peptoid library in Figure 4.11 was also designed to include sequences containing 
either the chiral Nspe or the achiral Nphe monomer to determine the effect of sequence 
chirality on the anti-biofilm activities of the compounds. Overall, sequences containing 
Nspe were more efficacious than their achiral analogues across all three biofilm species 
tested (e.g. compare achiral peptoid 186 and chiral peptoid 22). However, for peptoids 
containing the Nae monomer, there was little difference in activity between the chiral 
and achiral peptoids against S. aureus or C. albicans (i.e. compare peptoid families 156–
219 and 180–214 respectively). The differences in activity for chiral and achiral members 
of the entire peptoid library were even less pronounced against E. coli. 
 
Effect of cationic monomers 
The success of many AMPs is attributed to their overall cationic charge that allows them 
to target the membranes of prokaryotes over mammalian cells.48 Within the library, the 
effect of different cationic monomers was investigated when comparing the amino-
functionalised Nae, NLys and Nah residues (2, 4 and 6 carbons in length respectively) to 
the NhArg monomers with guanidine moieties – see Figure 4.13. Results for sequences 
decorated with these cationic monomers are shown in both Figure 4.11 and Figure 4.12. 
 
Figure 4.13. Monomers used to examine the effect of different cationic residues on the 
anti-biofilm activity of sequences. 
 
When comparing peptoid sequences of the same overall length (i.e. 12 residues), 
peptoids containing the shortest Nae monomer tended to be more active than the longer 
NLys monomer for all species (e.g. compare peptoid 186 and peptoid 180). On the whole, 
peptoids containing the Nah monomer were less active than those containing either Nae 
or NLys, as shown by the greater reduction in biofilm mass for Nae or NLys sequences in 
Figure 4.11. However, peptoid 216 (NahNspeNspe)3 is an exception as it can be seen that 
216 reduced E. coli biofilm by around 95 % or a S. aureus biofilm by approximately 75 %. 
The Nah peptoids are also less effective in our anti-leishmanial testing and potentially 
the reduced activity of the NahNyNy motif could stem from the greater flexibility of the 
longer aminohexane chain.  
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To examine the effect of cationic functionalisation, peptoid sequences containing NLys 
and NhArg can be compared. For example, peptoids containing the achiral Nphe or Nspe 
residues with either NLys or NhArg cationic residues (186/228 and 293/153 respectively) 
the lysine-type peptoids 186/293 show greater anti-biofilm activities compared to the 
arginine-type analogues across all species. This is an interesting conclusion, since against 
planktonic bacteria it was shown that the arginine peptoids often displayed the most 
potent activity. The achiral sequences containing the fluorinated monomer Nmfb show 
little activity with either type of cationic residue. As can be seen from Figure 4.12, for 
sequences with both lysine- and arginine-type residues (i.e. 147, 148, 150, 149) 
intermediate activity is seen for both S. aureus and E. coli, greater than the guanido-only 
peptoids (152) but less than the amino-only peptoid (22). 
Finally, the charge of certain sequences was reduced through substitution of the Namy 
monomer (i.e. 245 and 154) as this had shown to be a useful strategy for developing anti-
leishmanicidal peptoids. It can be seen from Figure 4.12 that peptoid 245 has potent 
activity at 100 µM against C. albicans and S. aureus, reducing the biofilm mass more than 
22 (the analogous sequence where Namy residues are substituted for NLys). However 245 
shows no activity against E. coli monospecies biofilms whereas peptoid 22 reduces 
biofilm mass by approximately 95% at the same concentraion. In sequence 154 
containing Namy and NhArg residues, a similar trend is seen (no activity for E. coli but 
substantial activity against C. albicans and S. aureus compared to the all NhArg peptoid 
152). Overall, as seen with the other peptoids where lysine- and arginine-type residues 
are compared, the amino-functionalised 245 causes a greater reduction in biofilm mass 
than the NhArg peptoid. 
 
Cyclisation 
Cyclisation is often used as a strategy to increase antimicrobial activity, but as mirrored 
by the antibacterial MIC and antiparasitic ED50 values already determined in Chapters 3 
and 4, cyclic peptoids were inactive even at the 100 µM concentrations in the biofilm 
activity assays. The cyclic peptoids 132–134 were all 6 residues in length, and similar to 
their linear analogues showed no significant activity against any of the monospecies 
biofilms, as shown by Figure 4.12. 
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4.2.1 Mixed species biofilm assay using PMA-modified qPCR 
All results discussed above were obtained from the crystal violet assay described. 
Although routinely used by the scientific community for biofilm quantification, this 
approach detects both live and dead organisms alongside matrix components. Therefore, 
PMA modified qPCR was developed to selectively and quantitatively determine the 
antimicrobial activity of selected peptoids against single- and multi-species biofilms. The 
activity of the peptoids against polymicrobial biofilms is particularly interesting, as these 
systems are more representative of clinically relevant biofilms. First the PMA-qPCR was 
validated against monospecies biofilms and then used in the multi-species biofilm 
assays. 
Three sequences were chosen for further study, which represented some of the most 
active peptoids in the single species crystal violet assays discussed in section 4.2; 
peptoids 26 (NLysNspeNspe)3, 180 (NaeNpheNphe)4, and 216 (NahNspeNspe)3 (results as 
in Figure 4.11 and Figure 4.12, structures in Figure 4.14). One peptoid was chosen from 
each class of cationic residue and two chiral and one achiral peptoids were used. These 
compounds also displayed negligible toxicity of > 100 µM to mammalian cell lines, 
HaCaT and HepG2.§ 
 
Figure 4.14. Structures of the peptoids 26, 180, 216 chosen for evaluation in mixed 
species biofilms. 
                                                     
§
 Description of the toxicity evaluation can be found in Chapter 3. 
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As predicted from the significant activity seen in the crystal violet assay, the 
monospecies biofilms treated with peptoid all showed significant reduction in cell 
numbers. This indicates strong antibacterial and fungicidal activity of peptoids 26, 180 
and 216 and the data is shown in Figure 4.15.  
Treatment by peptoid had a potent effect against C. albicans, with peptoids 26 and 180 
reducing the cell number by over 4 orders of magnitude. In agreement with the crystal 
violet assay results, the Nah containing peptoid 216 did not perform quite as well against 
C. albicans, although it still caused a significant reduction in the fungal biofilm. All three 
peptoids also considerably reduced the cell counts of the S. aureus and E. coli biofilms, 
but cell counts were reduced to a smaller extent than with the fungal biofilm. For 
S. aureus, all peptoids had a similar effect but in the E. coli monospecies biofilms, 
peptoid 216 was the most effective. This leads to the interesting conclusion that peptoid 
216 may be more specific to the fungal biofilm over E. coli and S. aureus and would be 
very useful given increasing bacterial resistance. 
 
 
Figure 4.15. PMA-qPCR quantification of cell number following peptoid treatment of 
monospecies biofilms. Cell numbers of A; C. albicans B; S. aureus C; E. coli treated with 
100 µM peptoid 26, 180 and 216 (****: p < 0.0001.). 
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Peptoids 26, 180 and 216 were also tested against mixed species biofilms containing 
C. albicans and either S. aureus or E. coli, with results from testing at 100 µM shown in 
Figure 4.16. In the mixed species biofilm containing C. albicans and S. aureus (Figure 
4.16A and B), cell numbers were reduced more for the bacteria than fungi. Peptoid 26 
was better able to reduce the cell count of S. aureus than the other peptoids and peptoid 
180 showed the greatest reduction in C. albicans cell numbers. In the polymicrobial 
biofilm with C. albicans and E. coli (Figure 4.16C and D), the biofilm cell numbers were 
reduced more for C. albicans than E. coli with treatment by all three peptoids. In this 
polymicrobial biofilm, the Nah sequence 216 was the most active against both species, 
followed by peptoid 180 and then 26.  
 
 
Figure 4.16. PMA-qPCR quantification of cell numbers following 100 µM peptoid 
treatment of polymicrobial biofilms made of C. albicans and either S. aureus or E. coli. 
Cell numbers of A; C. albicans and B; S. aureus within the same polymicrobial biofilm, 
following treatment with peptoids. Cell numbers of C; C. albicans and D; E. coli within 
the same polymicrobial biofilm, following treatment with peptoids (**: p < 0.01; ****: p < 
0.0001.). 
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When present in a biofilm with S. aureus, C. albicans appeared to be less susceptible to 
treatment with 100 µM peptoid 216 than in a single species biofilm (section 4.2) or in a 
polymicrobial biofilm with E. coli.  Since there has been very limited work on peptoid 
efficacy in polymicrobial biofilms it remains to be determined if this is a unique 
phenomenon.  
Finally, when cross-kingdom biofilms were treated with peptoids 26, 180 and 216 at 
concentrations lower than 100 µM a dose dependent effect was seen. In the mixed 
species biofilms, all three peptoids significantly reduced the cell numbers of S. aureus by 
approximately 100%, even when treated at 10 µM. Reduction in cell viability for 
C. albicans or E. coli were negligible at 10 µM, but considerable reduction in cell numbers 
were seen at 25 µM and 50 µM respectively. For all three species present in the cross-
kingdom biofilms, achiral peptoid 216 showed the greatest reduction in cell number. 
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Figure 4.17. PMA-qPCR quantification of cell numbers following peptoid treatment of polymicrobial biofilms following treatment with peptoids 
26, 180 and 216 at concentrations of 10, 25, 50 and 100 µM. Within C. albicans and S. aureus biofilms; cell numbers (percentage of untreated 
control) for A C. albicans and B S. aureus. Within C. albicans and E. coli biofilms cell numbers (percentage of untreated control) for C C. albicans 
and D E. coli (*: p < 0.05; **: p < 0.01; ****: p < 0.0001. One-way ANOVA followed by Tukey’s post hoc correction for multiple comparisons, N=3 
independent experiments, 3 replicates in each. Statistical analysis was performed independently for each peptoid). 
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4.2.2 Permeablisation of cell membranes by peptoids 
A large proportion of antimicrobial peptides have been shown to disrupt cell membranes 
which, at least in part, may cause their antimicrobial effects. Several proposed 
mechanisms of action for AMPs on cell membranes have already been described in 
Chapter 1. It is thought that the mode, or modes, of action of antimicrobial peptoids are 
mechanistically very similar to AMPs and therefore may also involve membrane 
disruption, although currently there are only a few studies to support this.23,56-59 
To help elucidate the mode of action of peptoids, a membrane permeabilisation assay 
was performed with peptoids from the library against C. albicans, S. aureus and E. coli. 
The assay is designed to show whether the peptoids are capable of causing cell lysis and 
if the cell membranes of these pathogens are a target.  
 
Figure 4.18. SYTOX® Green, the nucleic acid stain and unsymmetrical cyanine dye used 
to assess the integrity of cell membranes. 
The dye SYTOX® Green (316) is able to bind nucleic acids but is impermeable to living 
eukaryotic and prokaryotic cells. Therefore, this dye is routinely used to assess the 
integrity of plasma membranes and used as an indicator of dead cells. If a microbial cell 
membrane has been compromised, for example by treatment with a compound, SYTOX® 
Green can bind the cellular nucleic acids. This association event increases the 
fluorescence of the dye and renders cells with compromised membranes as brightly 
green fluorescent. After binding, the fluorescence emission of the dye can be enhanced 
by as much as one thousand fold and is proportional to the fraction of permeabilised 
cells in the population.60,61 
For the three peptoids used in the qPCR study in section 4.2.1, the propensity to 
permeabilise the cell membranes was assessed using SYTOX® Green, as shown in Figure 
4.19 (peptoids 26, 180 and 216, with structures shown in Figure 4.14). Sufficient controls 
were undertaken and other measurements to determine the background levels of 
fluorescence, for example untreated cells permeabilised by heat treatment as a positive 
control, the Mueller Hinton Broth (MHB) growth medium alone and also each peptoid 
in the uninoculated broth. All peptoid treatments were at 100 µM, the screening 
concentration used in the anti-biofilm evaluations described in section 4.2 
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Figure 4.19. Propensity for peptoids 26, 180 and 216 to permeabilise the microbial 
membranes of; A C. albicans; B E. coli; C S. aureus, as determine by the SYTOX® Green 
assay. The efficacy of membrane permeabilisation by peptoids was compared with 
untreated controls and the results (average of 3 independent experiments) were analysed 
by ANOVA followed by Tukey’s post hoc correction for multiple comparisons (****: p < 
0.0001). Cells permeabilised by heat treatment were used as positive controls. 
 
In all cases, a significant increase in fluorescence was seen following treatment with 
100 µM peptoid for the bacteria and fungi, suggesting that the peptoids cause significant 
membrane permeabilisation in C. albicans, E. coli and S. aureus. This test also validates 
use of the PMA-qPCR (since the PMA can only bind to DNA within cells that have 
compromised membranes). The results show that the peptoids that have the greatest 
antimicrobial effect against single species biofilms (Figure 4.15) also cause the greatest 
membrane permeabilisation via the SYTOX® Green assay (Figure 4.19). For example, 
against C. albicans peptoid 26 causes the greatest reduction in cell number and causes 
the greatest increase in fluorescence. 
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An additional five peptoids from Table 4.2 (186, 182, 293, 181, 149) were also tested using 
the SYTOX® Green assay, with structures shown in Figure 4.20. Although in all cases, an 
enhancement of fluorescence was seen following peptoid treatment, the data show that 
there were some differences in the ability of specific peptoids to permeablise bacterial 
and fungal cell membranes. When C. albicans was incubated in the presence of SYTOX® 
Green and each of the five peptoids, a substantial enhancement of fluorescence was seen 
in all cases, demonstrating that the peptoids are all able to significantly permeablise the 
cell membrane of the fungal species (see Figure 4.21A).  
Results for Gram positive S. aureus are shown in Figure 4.18B and Gram negative E. coli 
in Figure 4.18C. For both bacteria, the peptoids also caused considerable membrane 
disruption, but a smaller increase in fluorescence intensity was seen compared to 
C. albicans, suggesting a smaller extent of membrane permeabilisation. Although still 
statistically significant, peptoids 293, 181, 149 were less efficacious against S. aureus and 
E. coli than 186 and 182. 
Figure 4.20. Structures of peptoids 186, 182, 293, 181 and 149 studied in the SYTOX® 
Green assay. 
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Figure 4.21. Membrane permeabilization activities of selected peptoids at 100 µM against 
planktonic cultures of A; C. albicans B; S. aureus C; E. coli. One-way ANOVA followed by 
Tukey’s post hoc correction for multiple comparisons from three independent 
experiments, where: *p< 0.5; **p<0.05, ***p< 0.001; **** p< 0.0001. 
 
A small number of peptoids were tested so detailed conclusions regarding SARs cannot 
be drawn, however peptoid 182 (NLysNhLeuNspe)4 appears to cause the largest increase 
in fluorescence across the second SYTOX® Green assay. For the analogous peptoid 181 
with NhArg residue instead of NLys, a similar increase in fluorescence is seen when 
C. albicans is treated with both peptoids. However, 181 is less able to disrupt the cell 
membranes of S. aureus and E. coli than 182. Peptoids 186 and 293, also differing only by 
the cationic monomers (NLys and NhArg respectively) and show a similar pattern where 
the amino-functionalised sequence causes a greater increase in fluorescence than the 
guanido-functionalised sequence for both bacteria, but little difference against 
C. albicans.  
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From this data, it appears that sequences with lysine-type monomers may cause more 
disruption to the cell membranes of S. aureus and E. coli than those with arginine-type 
monomers. This is an interesting conclusion since several studies investigating the 
potential application of peptoids as molecular transporters have suggested that the 
guanidinium group of arginine can enhance cellular uptake.31,62 
From the biofilm inhibition data obtained from Crystal Violet assays (section 4.2), it can 
be seen that all peptoids have a greater effect against C. albicans than the bacterial 
biofilms. This agrees with the SYTOX® Green assay, where the enhancement of 
fluorescence seen is much greater for the fungi than S. aureus or E. coli. The propensity 
of these peptoids to disrupt cell membranes via SYTOX® Green assay also correlates to 
their anti-biofilm activity. As shown in Table 4.3 peptoid 182 causes the greatest 
membrane disruption and the best antibacterial and fungicidal activity of the five 
studied. Sequence 293, shows the smallest increase in fluorescence and also the least 
significant reductions in biomass, with no effect seen against S. aureus and E.coli. 
 
 
Table 4.3. Peptoids studied in SYTOX® Green assay and their approximate anti-biofilm 
activity against fungal and bacterial biofilm, as determined by Crystal Violet assay. 
 
In conclusion, the SYTOX® Green assay has identified that the plasma membranes of 
C. albicans, S. aureus and E. coli are a target for antimicrobial peptoids. The results 
strongly support that the microbial action of peptoids 5, 7 and 17 is due to membrane 
disruption, but additional action via a secondary intracellular target cannot be 
completely ruled out. The data obtained helps to rationalise some of the anti-biofilm 
activities recorded, with the best antimicrobials showing the largest membrane 
disruption, as expected. Further work to elucidate the mechanism of action of these 
peptoids is described in Chapter 5, which extends this work using fluorescent 
microscopy experiments to further pinpoint cellular targets of peptoids. 
 Sequence Approximate reduction in 
biomass (%) 
C. albicans S. aureus E. coli 
186 (NLysNpheNphe)4 25 20 45 
182 (NLysNhLeuNspe)4 10 25 25 
293 (NhArgNpheNphe)4 10 ns ns 
181 (NhArgNhLeuNspe)4 10 25 40 
149 (NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2 10 40 40 
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4.2.3 Conclusions from biofilm activity screening 
For the first time, peptoids have shown to be efficacious against fungal biofilms and also 
against polymicrobial biofilms. The peptoid library tested displays excellent bactericidal 
and fungicidal activities in vitro against C. albicans, S. aureus and E. coli biofilms using 
both a traditional crystal violet assay and novel PMA-modified qPCR. On the whole, the 
peptoid library showed similar activity patterns across the three species tested, i.e. 
peptoids that were active at some level against one species also tended to be active 
against the others. In general, the peptoids studied in multispecies assays cause the 
greatest reduction in biomass against S. aureus, followed by C. albicans, with E. coli 
showing the least effect following peptoid treatment. This trend is in agreement with 
other studies in the literature that conclude planktonic E. coli is more difficult to target 
with peptoids than Gram positive bacteria or fungi and is due to the extra outer 
membrane leaflet in Gram positive bacteria.63,64 Peptoid 216 (NahNspeNspe)3 was 
identified with significant activity against S. aureus in a mixed biofilm with C. albicans at 
10 µM and also shows good activity against both species within the C. albicans and E. coli 
cross-kingdom biofilm when treated at higher concentrations. 
The sequences with arginine-type monomers are typically less efficacious against the 
biofilms than peptoids containing lysine-type monomers. This is supported by the 
SYTOX® Green assay, which shows that sequences with lysine-type monomers are able to 
cause a greater extent of membrane disruption. This is a potential point for further 
investigation, since against planktonic bacteria in section 4.1.1, this trend is reversed and 
peptoids containing arginine-type monomers have lower MIC values (therefore more 
potent activity). 
Another important conclusion from this study is the identification of peptoids such as 
216 (NahNspeNspe)3, 150 [(NhArgNspeNspe)(NLysNspeNspe)]2 and 147 
(NLysNspeNspe)2(NhArgNspeNspe)2 that are effective against C. albicans but have a less 
significant effect against either S. aureus or E. coli. These compounds could be useful as 
probes to determine if inhibition of C. albicans alone can perturb polymicrobial biofilm 
formation. Given the recent suggestions that C. albicans has a significant influence on 
local biofilm environment this may be a noteworthy direction of research.47,48 More 
discussion about these compounds and potential future studies can be found in the 
Future Work section in Chapter 6.  
Initially, this study aimed to determine whether MIC is predictive of anti-biofilm activity. 
From the data gathered, it has confirmed that MIC determination is unsuitable to 
predict which peptoids may display potent activity against biofilms. To choose one 
example, peptoids 215 (NahNspeNspe)4 and 216 (NahNspeNspe)3 both have an MIC of 
25 µM against planktonic E. coli but very different activity against the E. coli biofilm, as 
determined from the crystal violet assay.  
An improved knowledge of the treatment of clinically relevant polymicrobial biofilms in 
vitro should ultimately translate to better treatment of infections in vivo and provides 
further support for investigating peptoids as future antimicrobial agents. 
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4.3 Peptoids with a dual mode of action: nisin-peptoid conjugates 
4.3.1 The lantibiotic nisin 
Nisin is a polycyclic peptide produced by several strains of the Gram positive bacterium 
Lactococcus lactis and is an antimicrobial against other Gram positive bacteria with 
nanomolar potency. Nisin (compound 9) is frequently used as a food preservative (E234) 
due to its high antibacterial activity and negligible toxicity to humans and provides a 
potential scaffold for the development of novel antibacterial agents. However, due to its 
susceptibility to proteolytic degradation use as a general antibiotic has been hindered.65 
 
Figure 4.22. The lantibiotic nisin (9), where Dhb = dehydrobutyrine, Dha = 
dehydroalanine and Abu = aminobutyric acid. 
 
Nisin (9) shares similar characteristics to typical antimicrobial peptides, such as overall 
positive charge and amphipathic structure. Classified as a lantibiotic due to the presence 
of unusual lanthionine rings in its structure, nisin also contains unsaturated amino acids 
introduced by posttranslational modifications, such as dehydroalanine and 2-
aminobutyric acid. In total, nisin has five lanthione rings (labelled A – E in Figure 4.22) 
and these rings impart a conformation that is key to nisin’s ability to act as a potent 
antimicrobial. The A/B ring system at the N terminus has been shown to bind to lipid II, 
which is a crucial membrane component used in bacterial cell wall synthesis. Following 
lipid II binding, the nisin can insert into the bacterial membrane and create pores that 
leads to cell death.65-68  
Nisin provides an excellent starting point for the design new antibiotics, however, due to 
its peptide-based structure, several problems arise in the application of the full length 
sequence. These include immunogenicity issues, the susceptibility of nisin to proteolytic 
degradation in vivo and consequent poor pharmacokinetics. Some groups have sought to 
overcome these by the total chemical synthesis of nisin analogues with improved 
properties.69,70 
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It has been shown that C-terminally truncated peptides containing the A/B ring system 
can still display significant activity, as it is the A/B ring system that is essential for lipid II 
binding.71 A vast library of truncated nisin peptides have now been biologically 
evaluated, including very promising semi-synthetic lipopeptides. These peptides contain 
the crucial N terminal nisinA/B fragment that is reported to be stable to further enzymatic 
degradation and have lipid-type groups coupled to the C terminus. Example structures 
are shown in Figure 4.23 and these products show potent inhibition of bacterial growth, 
including against clinical isolates, comparable to nisin itself.68  
 
Figure 4.23. Structures of two example semi-synthetic lipopeptides, 317 and 318, based 
upon the nisinA/B rings.68  
 
In this project, we wished to exploit the antibacterial activity of nisin by the addition of 
peptoid sequences to the N terminal A/B ring (residues 1-12). By linking a peptoid with 
the truncated nisin ring fragment, it was hoped that the antibacterial action could be 
amplified. The combination of the lipid II targeting ring system of nisinA/B with peptoids, 
known to disrupt cell membranes non-specifically, may produce a potent antibiotic with 
a dual mode of action, similar to that seen in the full nisin sequence.  As for peptoids in 
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general, these hybrids would have a different mode of action from current antibiotics 
and as they would target the bacterial cell envelope, the potential for drug resistance 
would be low. 
The protocol for the synthesis of lipopeptides derived from nisin provides an efficient 
synthetic route to the nisin-peptoid conjugates. NisinA/B is obtained from the 
chemoenzymatic degradation of the full length nisin and this fragment can then be 
modified at the C terminus.68  In particular, an azide functionality can be installed that 
provides a convenient handle for ligation to alkynes via a copper catalysed click 
cycloaddition. The peptoid sequences are stable by their nature, since the nisinA/B ring is 
itself formed as a product of digestion and compounds like 317 and 318 have been shown 
to have improved stability in serum relative to nisin, the whole conjugate should be 
stable to proteolysis.  These peptide-peptoid hybrids could therefore potentially form a 
new class of potent antibiotic compounds to help combat emerging antimicrobial 
resistance. 
 
4.3.2 Azide-alkyne click-reactions 
The azide-alkyne cycloaddition is an example of a simple ‘click’ reaction and is used to 
form 1,2,3 triazoles. A thermally activated Huisgen 1,3-dipolar cycloaddition between an 
azide and terminal alkyne (Scheme 4.1a) often forms a mixture of two regioisomers 
when using asymmetric alkynes. However, when the reaction is catalysed, either by 
copper(I) or ruthenium, the reaction follows a different mechanism and allows 
regioselective products to be obtained. As shown in Scheme 4.1b and Scheme 4.1c, the 
copper catalysed conditions form a 1,4-disubstituted triazole and the ruthenium 
catalysed reaction preferentially creates the 1,5- triazole.72-74  
 
 
Scheme 4.1. Azide-alkyne cycloadditions a) thermal; b) copper(I) catalysed click 
reaction to form 1,4-triazole; c) ruthenium catalysed click reaction yielding 1,5-triazole. 
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This click reaction between an azide and a terminal alkyne is compatible with a range of 
conditions, tolerates a broad range of chemical functionalities and provides a robust 
strategy for chemical ligations. As an isostere of the amide bond (see Figure 4.24), the 
triazole formed by click reactions is not just a passive connector, but provides a 
biocompatible linker that readily associates with biological targets through hydrogen 
bonding and dipole interactions. Additionally, the copper(I) catalysed click reaction can 
be performed under aqueous conditions at room temperature, so is well suited for use 
with peptide-based reagents. For these reasons, the copper catalysed click reaction is 
ideal for the ligation of nisin with peptoid sequences.75  
 
Figure 4.24. The similarity between an amide bond and the 1,2,4 triazole formed in a 
copper catalysed click reaction.  
 
4.3.3 Synthesis of nisin-peptoid conjugates 
This synthetic work was carried out by HLB in collaboration with the group of Dr 
Nathaniel Martin and assisted by Laurens Kleijn (Utrecht University).  
 
Nisin was digested using a protocol developed in the Martin lab with trypsin and the 
fragment containing the A/B ring system isolated by preparative HPLC. The nisinA/B was 
then coupled to azidopropylamine and a second RP-HPLC purification undertaken to 
yield nisin with an azide linker (compound 321, as in Scheme 4.2). This azide linker 
provides a handle to allow further functionalisation, in this case the addition of a peptoid 
sequence to nisinA/B.68 
Peptoid sequences were prepared using the submonomer procedure for the solid phase 
synthesis of peptoids and an alkyne tail added to the sequence using propargylamine 
under standard coupling conditions. Peptoids were then cleaved from the resin and 
purified by RP-HPLC prior to the click reaction. Ligation of nisinA/B-azide and the alkyne 
tagged peptoids were assisted by microwave irradiation using a copper(I) catalysed ‘click’ 
cycloaddition. The active Cu(I) catalyst is generated from the Cu(II) salt using sodium 
ascorbate as a reducing agent and with Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA) as a ligand to cleanly afford the expected product. The general reaction is shown 
in Scheme 4.2 and forms a 1,2,3-triazole linker.  
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Scheme 4.2. Click reaction of nisinA/B-azide and an alkyne-tagged peptoid sequence. 
Two peptoid sequences were chosen to click with nisinA/B which had previously shown 
promising antibacterial activities. The two peptoids used in the click reaction were  
compound 319 NprpNspeNspe(NaeNspeNspe)4 derived from 156 (MIC 2 µM against 
S. aureus) and peptoid 320 NprpNspeNspe[(NLysNpfbNpfb)(NLysNspeNspe)]2 from 157 
(MIC 2 µM against S. aureus and 5 µM against E. coli). Both 319 and 320 were 15 
monomers in length; the 12 residue parent sequence followed by an extra two Nspe 
monomers to lengthen the chain between the last cationic residue and an N terminal 
Nprp monomer with alkyne functionality.  
The click reaction between the nisinA/B-azide (321) and either peptoid 319 or 320 was 
catalysed by Cu(I) and therefore the 1,4 regioisomer is the expected product of the 
reaction, with the two resulting peptide-peptoid conjugates, 322 and 323. No 
optimisation of the reaction was needed, with completion seen via LC-MS after 20 
minutes reaction at 80 ˚C. Following a final RP-HPLC purification, the expected 
conjugates were obtained in >99% purity for biological testing, as shown by Figure 4.25. 
Full experimental details can be found in Chapter 7. 
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Figure 4.25. Analytical HPLC traces for the two click linked nisinA/B-peptoid conjugates, 322 and 323. Products are expected to be the 1,4 
regioisomer and were obtained as a homogeneous sample via RP-HPLC; 60 minute gradient; 0–100 % solvent B, where  A = 100 % H20, 0.1 % 
TFA; B = 100 % acetonitrile, 0.1 % TFA. 
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4.3.4 Antibacterial and toxicity testing 
Bacterial MIC determination was carried out by Laurens Kleijn (Utrecht University, Martin 
group) and cytotoxicity assays were carried out by HLB at Durham University.  
 
The antibacterial activity of the nisin-peptoid conjugates was determined against 
methicillin-resistant S. aureus (USA 300); the predominant strain associated with 
community-acquired MRSA infection in the United States of America.76 The minimum 
inhibitory concentrations were calculated and compared to the peptide antibiotic 
vancomycin (compound 324) and nisin (compound 9), as shown by Table 4.4. 
Table 4.4. Biological evaluation of peptide-peptoid conjugates and other fragments for 
comparison. Antibacterial activity against methicillin-resistant S. aureus and toxicity 
against HaCaT and HepG2 cell lines are also recorded. 
 
The parent peptoids without the alkyne linker show excellent activity against the 
methicillin resistant S. aureus, with 156 and 157 displaying MICs of 2 µM and 2–4 µM 
respectively, which are better than the 5 µM MIC of nisin itself. Functionalising these 
sequences with the alkyne linker reduces the activity by approximately half for both 319 
(4 µM) and 320 (4–7 µM), although these compounds compare favourably to the nisin-
azide 321 which has an MIC of 26 µM. 
Unfortunately, the nisin-peptoid hybrids 322 and 323 show additional diminished activity 
and are overall less active than the unconjugated peptoids. When comparing 322 to 156, 
the nisin-peptoid conjugate is approximately five-fold less active than the parent peptoid 
(i.e. MIC 5–10 µM compared to 2 µM) and this reduction in activity is similar for the 
second peptoid sequence with fluorinated monomers, 323 and 157 (MIC 9–18 µM vs 2–
4 µM).  Potentially, the peptoid tail may interfere with lipid II binding of the nisinA/B 
rings and could explain the reduced activity.  
However, despite the reduction in activity compared to the peptoids alone, the MIC 
values are still in the low micromolar range and promising against a resistant bacterium. 
Interestingly 321, the nisin[1-12]-azide, exhibits a reduced biological activity when 
 Sequence MIC (µM) ED50 (µM) 
S. aureus 
(USA300) 
HaCaT  HepG2  
324 Vancomycin 1   
9 Nisin 5   
321 Nisin[1–12]-azide 26   
156 (NaeNspeNspe)4 2 26 15 
157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 2-4 53 18 
319 NprpNspeNspe(NaeNspeNspe)4 4 20 12 
320 NprpNspeNspe[(NLysNpfbNpfb)(NLysNspeNspe)]2 4–7 15 17 
322 Nisin[1–12]-NspeNspe(NaeNspeNspe)4 5–10 24 15 
323 Nisin[1–12]-NspeNspe [(NLysNpfbNpfb)(NLysNspeNspe)]2 9–18 22 23 
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compared to nisin itself, potentially  due to interference in the lipid II binding by the 
azide. For 322, the MIC is similar to nisin (compound 9) at approximately 5 µM. 
However, none of the compounds display as potent activity as vancomycin (compound 
324) with an MIC of < 1 µM. 
The toxicity of the peptoid library has been discussed throughout Chapters 3 and 4, and 
as discussed is often overlooked in other literature regarding antimicrobial peptoids. 
From our initial investigations, it has become apparent that the toxicity of peptoids is 
something that needs to be carefully considered alongside their biological activity. 
Despite the somewhat disappointing antibacterial activity of nisin-peptoid hybrids, it 
was proposed that conjugation to nisin may be a potential strategy to manipulate the 
cytotoxicity of the peptoid sequences to mammalian cells and increase their selectivity. 
In order to ascertain whether the decreased activity displayed by the nisin-peptoid 
conjugates (when compared to their parent peptoid sequences) was accompanied by a 
beneficial reduction in toxicity, cytotoxicity assays were performed against HaCaT 
keratinocytes and epithelial HepG2 cells. These assays were all undertaken in triplicate 
on a minimum of three occasions to ensure a robust data set was obtained and the ED50 
values are presented as the average over the multiple assays in Table 4.4. 
The peptoid sequences 319 and 320 with the N terminal alkyne were the most cytotoxic 
to both mammalian cell lines tested (ED50 values of < 20 µM). Regrettably, the nisin-
conjugated peptoid sequences 322 and 323 were also moderately cytotoxic to both 
mammalian cell lines tested around 20 µM. The ED50 values obtained show that the 
nisin-peptoids have a similar level of toxicity to the peptoid sequences 156 and 157. Given 
that nisin is known to show negligible toxicity and no observable adverse activity in 
in vivo studies, this was a disappointing result. In an attempt to rationalise the 
unexpected toxicity and the reduced antibacterial activity compared to the parent 
peptoids, enzymatic stability assays were undertaken.77 
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4.3.5 Stability of peptide-peptoid conjugates to enzymatic degradation 
The stability of the nisinA/B-peptoid conjugates 322 and 323 was assessed using a trypsin 
degradation assay. This assay was based upon the same conditions used to obtain the 
nisinA/B ring from chemoenzymatic degradation of the full nisin sequence.68 Compounds 
322 and 323 were incubated with TPCK** trypsin for 24 hours at 37 ˚C in tris-HCl buffer 
(50 mM at pH 7.8, with 5 mmol CalCl2
††). The peptoid sequences 156 and 157 were also 
subjected to the same digestion procedure for comparison. 
The digestion was monitored using a combination of analytical RP-HPLC and MALDI 
mass spectrometry. For analysis using mass spectrometry, a 10 µL aliquot was removed 
from incubation and analysed spotted to the MALDI target immediately (as a mixture 
with α-cyano-4-hydroxycinnamic acid matrix). After 24 hour incubation with the 
enzyme, no significant change is seen in the MALDI spectra of 156 or 157.  
However, for the nisin-peptoid conjugates 322 and 323, ions are seen that were not 
present in initial MALDI spectra before digestion and these appear at lower m/z values 
than the molecular ion, suggesting that the initial conjugates are being digested into 
lower molecular weight fragments (see Figure 4.26 and Figure 4.27). 
 
 
Figure 4.26. MALDI mass spectrum showing products following 24 hour trypsin 
degradation of peptoid 322 with ions labelled. The spectrum has been expanded to show 
the weak molecular ion peak at m/z 3379.5. Suppression of ions at m/z < 1000.  
                                                     
**
 TPCK trypsin: N-tosyl-L-phenylalanyl chloromethyl ketone treated to inhibit any chymotrypsin activity 
which may be present. 
††
 CaCl2 added to reduce trypsin autolysis. 
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Figure 4.27. MALDI mass spectrum showing products following 24 hour trypsin 
degradation of peptoid 323 with ions labelled. The spectrum has been expanded to show 
the weak molecular ion peak at m/z 3379.5. Suppression of ions at m/z < 1000.  
 
As shown by both MALDI spectra, the peaks corresponding to molecular ion after 
trypsin degradation are significantly decreased and can only be seen fully using an 
expanded view‡‡. In the spectra for 322 and 323, peaks appear at m/z 2225.4 and 2353.5, 
which correspond to peptoid fragments produced by the cleavage of the Lys12 residue 
attached to the nisinA/B ring (325 and 326 in Scheme 4.3). A peak at m/z 1150 
corresponding to the nisinA/B fragment 327 can be seen in the MALDI spectrum following 
digestion of 322 in Figure 4.26.§§ 
                                                     
‡‡
 Although the smaller peak intensity cannot be correlated to the amount of sample present. 
§§
 The peak at m/z 1150 cannot be seen in the MALDI following digestion of 323, possibly due to the 
suppression of low molecular weight ions. 
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Scheme 4.3. Proposed cleavage of the Lys12 residue on nisin
AB ring into peptoid and 
peptide fragments (325 and 326 are seen via MALDI).  
 
MS/MS experiments are commonly used to aid in the sequencing of peptides or 
peptoids78-80 and commonly lead to fragmentation at the amide bond of the backbone 
resulting in a series of product ions. These ions either appear to extend from the N-
terminus (termed ‘b ions’, containing the carbonyl part of the CO-NH bond) or the C-
terminus (‘y ions’, with the nitrogen atom of the amide bond). To confirm the identity of 
the peaks at m/z 2225.4 and 2353.5, MALDI LIFT-ToF/ToF MS/MS was used. This LIFT 
technique allows the detection of product ions resulting from fragmentation of a 
specified ion, as a result of elevated laser power.81 
The product ions seen from fragmentation of m/z 2225.4 and 2353.5 are summarised in 
Figure 4.28a and Figure 4.28b respectively and the annotated MALDI LIFT spectra 
obtained for both can be found in the Appendix. Since some fragmentations are 
preferred over others, certain ions are absent and the abundance of observed peaks 
varies. Overall, the fragmentation observed in both cases is consistent with the proposed 
compounds 325 or 326 formed by cleavage at the Lys12 residue, as shown in Scheme 4.3. 
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Figure 4.28. Summary of ions observed via MALDI LIFT-ToF/ToF, where ions resulting 
from amide cleavage are observed as b ions or y ions; A following fragmentation of ion at 
m/z 2225.4 in sample obtained following digestion of 322; B following fragmentation of 
ion at m/z 2353.5 in sample obtained following digestion of 323. 
 
The digestion of 322 and 323 can also be monitored using analytical RP-HPLC to 
investigate the relative amounts of cleaved versus intact compound in greater detail. In 
control peptoids 156 and 157, no significant change is seen in the RP-HPLC 
chromatogram after 24 hour incubation with the enzyme (see Figure 4.29a and Figure 
4.29c).  
However, for the nisin-peptoid conjugates 322 and 323, significant differences are seen in 
the appearance of RP-HPLC chromatograms before degradation (t = 0 h) and afterwards 
(t = 24 h). As shown in Figure 4.29b and Figure 4.29d, the chromatograms for both 
nisin-peptoid conjugates show several peaks following incubation with trypsin which 
suggests that substantial digestion is occurring under these conditions. For example, for 
both conjugates (322 and 323) the single peak seen at t = 0 h (at retention time ~ 20 min) 
is significantly decreased at t = 24 h and extra peaks appear on the chromatogram at 
reduced retention times; ~ 15 min from the nisinA/B rings (compound 327) and at ~ 18 min 
is also seen, which is attributed to the peptoid fragments 325 or 326. 
To study the rate of digestion, at several time points an aliquot was removed (100 µL), 
10 µL TFA added to quench enzyme activity and a 10 µL injection made to the HPLC 
instrument. Further conditions are described in Chapter 7 and the chromatograms 
obtained for digestion of conjugate 322 are plotted in Figure 4.30 (a similar time point 
plot for 323 can be found in the Appendix). The data obtained suggest that the half-life of 
the nisin-peptoid conjugates is between 2-3 hours, based upon integration of the RP-
HPLC chromatograms, with the majority of the conjugate cleaved into peptide and 
peptoid fragments after 6 hours.  
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Figure 4.29. RP-HPLC chromatograms for the digestion of nisin-peptoid conjugates by trypsin over a 24 hour time period in tris-HCl buffer 
(50 mM at pH 7.8, with 5 mmol CalCl2) A peptoid 156; B peptoid 157; C nisin-peptoid conjugate 322; D nisin-peptoid conjugate 323 where black 
chromatogram shows the trace at t = 0 h (i.e. with no digestion) and coloured traces at t = 24 h. 
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Figure 4.30. RP-HPLC chromatograms for the digestion of 322 by trypsin in tris-HCl 
buffer (50 mM at pH 7.8, with 5 mmol CalCl2) over a 24 hour time period. Intense peak at 
retention time = 2 min corresponds to the TFA added to quench enzyme activity. The 
initial nisin-peptoid conjugate 322 is labelled with a star in each chromatogram to show 
its digestion to fragments 325 and 327 at reduced retention times. 
 
Therefore, it is evident that under the conditions used, the nisinA/B-peptoid conjugates 
are not stable to enzymatic degradation by trypsin. This is perhaps unsurprising due to 
the C-terminal lysine residues on the nisinA/B ring system, however previously 
biologically active semi-synthetic lipopeptides have been prepared using the same 
methodology and also contain the Lys12 amide bond (see examples 317 and 318 in Figure 
4.23).68 Both 317 and 318 were tested for their stability and were shown to be stable for 
over 10 hours in serum and also showed potent antimicrobial activity. It would be 
interesting to perform the same trypsin degradation on these compounds to determine 
their enzymatic stability.   
The poor stability seen for the nisinA/B-peptoid conjugates 322 and 323 is a possible 
explanation for their unexpectedly high toxicity and poor antibacterial activity, since 
these compounds may also be unstable in the biological assays they were applied in or in 
serum (although this remains to be determined). If the Lys12 residue is cleaved the 
peptide 327 and peptoid fragments 325 or 326 would be formed.  
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Cleavage into these fragments could explain why the antibacterial activity of both 322 
and 323 is reduced compared to the peptoids 156 (NaeNspeNspe)4 and 157 
[(NLysNpfbNpfb)(NLysNspeNspe)]2 alone, as the peptoid fragments 325 and 326 have an 
N-terminal triazole group. The activity of the Nprp compounds with N-terminal alkynes 
(319 and 320 MIC 4 and 4–7 µM respectively) are two-fold less potent than 156 or 157 
(MIC 2 and 2–4 µM) and this may also be the case for 325/326. Cleavage into the peptoid 
fragments would also explain why the ED50 values against HepG2 and HaCaT are similar 
for 156 and the conjugate 322 or 157 and the conjugate 323, as the peptoid sequences are 
not conjugated to the nisinA/B rings in either case. Additionally, the peptoid chain may 
interfere with the ability of the A/B ring fragment of nisin to bind to lipid II, which could 
explain the reduced activity of the conjugates. Lipid II binding assays should be 
completed to test this hypothesis in the future. 
In conclusion, conjugation of a peptoid sequence to a peptide (in this case, nisin[1-12]-
azide) is simple using copper catalysed click methodology and the peptide-peptoid 
hybrids 322 and 323 were obtained in good yield and purity. However, for the sequences 
illustrated here, there is no advantage to conjugating the peptoids to nisinA/B; the 
peptoid sequences themselves would be better antibacterial candidates and both the 
peptoid sequences and the peptide-peptoid hybrids display similar levels of toxicity to 
mammalian cells.  
The nisinA/B-peptoid hybrids are not stable to tryptic degradation and it has been shown 
that enzymatic cleavage occurs at the Lys12 residue. The poor stability of the peptide-
peptoid conjugates is the likely explanation for their poor antibacterial activity and the 
unexpected toxicity to mammalian cells. Cleavage at Lys12 during the course of the assay 
forms the nisinA/B rings which are not themselves active and a peptoid fragment similar 
to 319 or 320 which have poorer activity than the parent peptoids 156 and 157. 
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4.4 Conclusions 
In conclusion, the peptoids presented in this chapter have been shown to display potent 
antibacterial activity against planktonic bacteria, and also against bacteria and fungi in 
their biofilm form. This is the first time that peptoids have been shown to be efficacious 
against fungal biofilms and also against cross-kingdom, polymicrobial biofilms.  
Certain members of this library provide promising starting points for the development of 
lead compounds and confirm that peptoids may be a promising new class of antibiotics 
that could potentially help to combat the increasing problem of antibiotic resistance. For 
example, peptoid 153 (NhArgNmfbNmfb)4 has MIC values against planktonic E. coli and 
P. aeruginosa of 13 µM; for both S. aureus and S. epidermidis the MIC is 2 µM. Against 
bacteria or fungi in their biofilm form, peptoid 216 (NahNspeNspe)3 was identified with 
significant activity against S. aureus, E. coli and C. albicans in mixed species biofilms. 
Factors that enhance antibacterial activity against Gram positive and Gram negative 
bacteria, and those within biofilms, have been highlighted in the appropriate sections. It 
has also been demonstrated that MIC determination is generally unsuitable to predict 
which sequences may display potent activity against biofilms. 
The peptoid library tested was designed to mimic helical and cationic antimicrobial 
peptides, found in nature as part of the innate immune response of many organisms. 
Many of the AMPs are proposed to cause membrane disruption, among other possible 
mechanisms of action, and it is thought that peptoids also behave in a similar manner. It 
has been shown that the cell membranes of bacteria and fungi in biofilms are indeed 
disrupted following treatment by selected peptoids from the library, using the SYTOX® 
Green assay. The peptoids which cause the largest plasma membrane permeabilisation 
also tend to display the largest antimicrobial activities, such as peptoid 182 
(NLysNhLeuNspe)4, which causes the greatest increase in fluorescence in the SYTOX® 
Green assay against S. aureus, E. coli and C. albicans (> 3,000 fold increase in 
fluorescence for all three species). Treatment by peptoid 182 also causes significant 
reductions in biomass within single species biofilms by 25 % for S. aureus, 25 % for E. coli 
and 10 % for C. albicans, as measured by the Crystal Violet assay. Further work to 
elucidate the mechanism of action of these peptoids is described in Chapter 5, and aims 
to further clarify the cellular targets of these antimicrobial peptoid sequences. 
Finally, the peptoid community is clearly able to design and synthesise potent 
antimicrobial peptoids. Sequences designed as part of this project and those already in 
the literature display very good activities against a wide range of bacterial and fungal 
pathogens. However, many of these peptoids are also toxic towards host and mammalian 
cells. Chapter 5 examines the selectivity of antimicrobial peptoid sequences in more 
detail, in an attempt to overcome this challenge. 
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Chapter 5 
Investigations into Peptoid Mode of Action 
 
Within Chapters 3 and 4 a large number of peptoid sequences were evaluated as 
antimicrobial compounds and structure activity data was analysed. Particularly against 
parasitic targets, there was little data already available in the literature to aid in the 
design of antiparasitic peptoids. From the work carried out in Chapters 3 and 4, several 
factors important for activity were elucidated but it was also shown that biophysical 
characteristics of the peptoids, such as hydrophobicity, have a large impact upon their 
biological activity and little information is available to help rationalise this activity.  
Peptoids are thought to cause membrane disruption as their primary mechanism of 
action, although this has not been conclusively determined or confirmed as the only 
mode of action.  Previously, cyclic peptoids have been shown to disrupt S. aureus 
membranes using scanning electron microscopy. Cells treated with sub-MIC, MIC or 
supra-MIC concentrations of selected peptoids showing cell surface damage and/or pore 
formation, which is consistent with the proposed mode of action against the 
membrane.1,2  
A lysine-peptoid hybrid, 328 shown in Figure 5.1, has been shown to inhibit DNA 
replication and induce the SOS response in S. aureus* leading to inhibition of cell 
growth.3 In a separate study with S. aureus, peptides substituted with NLys monomers 
have been shown to cause a much weaker membrane depolarisation compared to parent 
peptides that cause significant depolarisation of the cell membrane at their MIC. This 
suggests that the antibacterial action of these peptide-peptoid hybrids is probably not 
due to disruption of the bacterial cytoplasmic membrane, but perhaps inhibition of 
intracellular components.4,5 
Short fluorescently-tagged cell penetrating peptoids (329 and 330 in Figure 5.1 are 
examples) have also been shown specifically target cellular organelles such as 
mitochondria, nuclei or endosomes.6 Although the cell penetrating peptoids are much 
shorter than the typical antimicrobial sequences and the hybrid compounds have greater 
                                                     
*
 The SOS response is triggered following DNA damage to a cell. As part of the response the cell cycle is 
arrested and DNA repair and mutagenesis processes are activated.
3 
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peptide character, it is therefore probable that peptoids could be directed towards an 
intracellular target, in addition to the cell membrane.  
 
Figure 5.1. Chemical structure of the lysine-peptoid hybrid, 328 and two fluorescently-
tagged cell-penetrating peptoids, 329 and 330, that target mitochondria and endosomes 
respectively.4-6 
 
This chapter describes several investigations into peptoid mode of action and an attempt 
to develop methods that may assist in the rational design of antimicrobial peptoids. 
With the data set obtained from the antibacterial MIC determination, a correlation 
between activity, toxicity and hydrophobicity was undertaken in section 5.1 to examine 
how these parameters affect the selectivity of peptoids and in an attempt to address the 
challenge of host-cell toxicity. Following on from issues highlighted, a detailed study into 
the hydrophobicity of peptoid sequences via partitioning experiments is described in 
section 5.2. Finally, given the inconclusive evidence in the literature, fluorescent 
microscopy is used in section 5.3 to probe the biological mode of action of the particular 
peptoid sequences synthesised as part of this project. 
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5.1 Further exploration of peptoid antimicrobial activity and toxicity 
In Chapters 3 and 4, an antimicrobial peptoid library was screened to explore the 
structure-activity relationships against protozoa, bacteria and fungi. The selectivity 
indices of the peptoids were also determined to help to evaluate the true potential of 
peptoids as novel anti-infective compounds. However, it was shown that many potent 
sequences also displayed significant host-cell toxicity or hemolytic activity (Chapter 3). 
In order to progress the clinical development of peptoids, a more detailed understanding 
of their toxicity must be established. 
From the data in section 4.1 (antibacterial MIC determination), many promising peptoids 
were identified that showed little or no toxicity to either of the mammalian cell lines 
tested. For example, compounds such as 180 (NaeNpheNphe)4, 226 (NLysNpfbNpfb)3 and 
157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 display negligible toxicity to HaCaT or HepG2 at 
the highest concentrations tested and are also broad spectrum antibacterial agents. 
However, many sequences did display significant toxicity to mammalian cells, and in 
general these compounds were similarly toxic to both HaCaT and HepG2. On the whole, 
as the antimicrobial action of a compound increases, the associated toxicity is also 
increased. This is a problem found in other recent studies that focus on the biological 
applications of peptoids, however often attention is not directed towards the issue of 
toxicity.7-9  
Many assessments of peptoid toxicity currently reported in the literature have been 
evaluated by hemolytic activity, however these assays cannot necessarily be accurately 
used to predict toxicity more generally against mammalian cells. For example, many 
peptoids in the literature are based upon peptoid 22 (NLysNspeNspe)4 which exhibits 
excellent antimicrobial properties, with a reported selectivity ratio of > 6 and acceptable 
50 % hemolytic dose (HD50 of 100 µM).
10 However, in toxicity screening undertaken as 
part of this project, peptoid 22 was found to have ED50 of 20 µM and 29 µM against 
HaCaT and HepG2 respectively.11 More recently, other research groups have carried out 
in vitro mammalian assays and seen toxicity of peptoid 22 at 5.1 µM against NIH-3T3 
murine fibroblast cells.9 Therefore, there is a clear need to scrutinise the relationship 
between peptoid antimicrobial activity and toxicity towards mammalian cells in greater 
detail. 
 
5.1.1 Correlations between antibacterial activity, toxicity and 
hydrophobicity 
The selectivity of sequences was highlighted as a particular challenge for the design of 
antimicrobial peptoids in Chapters 3 and 4. To explore the relationship between activity, 
and toxicity a comparison was made between the MIC values gathered in Chapter 4.1 
against each bacterial species against the average toxicity of each peptoid to HaCaT and 
HepG2 (shown in Figure 5.2). 
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Figure 5.2. Correlations antibacterial activity of compounds with the average toxicity to mammalian cell lines (averaged for HaCaT and HepG2) 
where; A E. coli; B P. aeruginosa; C S. aureus; D S. epidermidis. Multiple compounds had MIC > 100 µM and ED50 > 100 µM. Compounds indicated 
in green show activity against prokaryotes or less toxicity to eukaryotes, those in red show increased toxicity to mammalian cells and/or weaker 
activity against the bacteria. 
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The data in Figure 5.2 shows that a handful of peptoids have been identified that show 
respectable antibacterial activity and also display low toxicity to mammalian cells (i.e. 
compounds indicated in green on the bottom right hand quadrant of each graph in 
Figure 5.2). These compounds have the potential to be future selective antibiotic 
compounds. However, a large proportion of the peptoids within this library do display 
significant toxicity (those indicated in red to the left hand side of each graph). There are 
also many sequences that are toxic to the mammalian cells, but show little activity 
against Gram negative bacteria. It is likely that the external lipopolysaccharide layer on 
the outer cell membranes of E. coli and P. aeruginosa (absent in Gram positive bacteria) 
prevents these peptoids from reaching the cell membrane. To investigate a possible 
explanation for this observation, the hydrophobicity of the compounds was considered. 
In Chapters 3 and 4, hydrophobicity was shown to be an important characteristic of 
peptoids, so to examine the relationship between hydrophobicity and the activity or 
toxicity of peptoids, retention times of the library were assessed using analytical reverse-
phase HPLC. Although this approach can only provide a relatively crude measure of 
hydrophobicity and will not translate into predictions about how a compound will 
interact with the cell membranes of biological systems, certain interesting trends were 
evident. 
The correlation of peptoid antibacterial activity against the HPLC retention times is 
shown in Figure 5.3. Since the activity of peptoids is much greater against Gram positive 
bacteria than Gram negative bacteria, the graphs are predominantly populated by 
peptoids for E. coli and P. aeruginosa due to their higher MIC values. There appears to be 
a linear relationship between activity and retention time for the Gram positive bacteria, 
where the peptoids at longer retention times (therefore more hydrophobic) have the 
lowest MIC values against S. aureus or S. epidermidis.  
However, for the Gram negative bacteria, there is no clear correlation between 
hydrophobicity and activity of the peptoid library.  Some compounds with the longest 
retention times (presumably the most hydrophobic) are inactive against these bacteria, 
whereas others with shorter retention times display good activity. It has previously been 
suggested that highly hydrophobic sequences may have lower activities due to self-
association that prevents full contact with the cell membrane.7 However, this may be an 
overly simplistic explanation as the same is not seen against Gram positive bacteria, 
where the same hydrophobic peptoid sequences result in low MIC values. 
The conclusion that peptoids with high hydrophobicity do not always appear as the most 
potent hits against E. coli and P. aeruginosa, but against S. aureus a linear relationship is 
seen between hydrophobicity and activity, has been corroborated by one recent report in 
the literature.7 
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Figure 5.3. Antibacterial activity of compounds plotted against the HPLC retention times where; A E. coli; B P. aeruginosa; C S. aureus; D for 
S. epidermidis. HPLC gradient from 0–100 % B over 30 minutes, column oven at 40 ˚C, where solvent A =  95% H2O, 5% MeCN, 0.1% TFA; solvent 
B = 95% MeCN, 5% H2O, 0.1% TFA. Peptoids shown in green show antibacterial activity, those in black have negligible activity.
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When comparing the toxicity of the peptoid library (via mammalian ED50 values) to the 
HPLC derived retention times, there is a linear relationship between toxicity and 
hydrophobicity (see Figure 5.4). A similar profile of toxicity is seen for both HaCaT and 
HepG2 cell lines and the least hydrophobic compounds tend to be the least toxic, with 
those at highest retention times showing the lowest ED50 values. 
 
Figure 5.4. Average peptoid toxicity (values for HaCaT and HepG2 averaged) plotted 
against their retention time, obtained via analytical RP-HPLC; HPLC gradient from 0–
100 % B over 30 minutes, column oven at 40 ˚C, where solvent A =  95 % H2O, 5 % 
MeCN, 0.1 % TFA; solvent B = 95 % MeCN, 5 % H2O, 0.1 % TFA. Compounds indicated 
by green show negligible toxicity, those in red show toxicity to the mammalian cells. 
 
In the literature, HPLC retention times are used to rationalise antimicrobial activity7,10,12 
and also in in silico predictions of activity.9 From the data presented, it is suggested that 
HPLC retention time alone cannot estimate or rationalise activity. For Gram negative 
bacteria, HPLC retention time is not predictive of activity and although peptoids with 
longer retention times may have an increased efficacy against Gram positive bacteria, 
these compounds may also have a concomitant and undesirable increased toxicity. 
This emphasises the need for the community to develop extra tools to predict and 
understand peptoid activities. Other parameters to evaluate the activity of antimicrobial 
peptiods and guide the design of bioactive peptoids need to be considered. In an attempt 
to rationalise the activity of the library a detailed investigation into the hydrophobicity 
of the peptoids using partitioning experiements was undertaken and this is described in 
section 5.2.1. 
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5.1.2 In vivo peptoid toxicity using a Galleria mellonella model 
Testing was carried out at Queens University, Belfast by Dr Yu Luo (postdoctoral research 
assistant), under the supervision of Dr Fionnuala Lundy.  
 
Once a compound has shown to be effective in in vitro models, such as those described 
in Chapters 3 and 4, its efficacy is typically evaluated in an animal model. However, there 
are significant ethical considerations before mammalian models can be used and these 
are often expensive and time consuming. Therefore, ethically more acceptable 
invertebrate models are being used increasingly. Insects have a complex innate immune 
system similar to mammals, for example many species produce small antibacterial 
peptides and such insect models have provided useful tools for investigation into the 
pathogenesis of a wide range of microbial infections. One such model uses the larvae of 
the greater wax moth, Galleria mellonella which provides a reliable investigation into 
compound toxicity and efficacy in vivo and is an inexpensive and rapid alternative to the 
use of animal models.13,14  
A small selection of peptoids were tested against G. mellonella via a direct injection of 
100 µM peptoid solution through the cuticle and the number of larvae alive after 
72 hours treatment time were counted to assess the toxicity of peptoids in vivo. 
Photographs showing larvae following treatment by peptoids and positive and negative 
controls are shown in Figure 5.5. The results obtained for other compounds are recorded 
in Table 5.1 and show that none of the peptoid sequences were toxic in the Galleria 
model; all larvae treated are still alive after 72 hours treatment.  
 
 
Figure 5.5. Investigation of in vivo peptoid toxicity using a Galleria mellonella model. A 
positive control, G. mellonella injected with 20 µL E. coli (108 colony forming units mL-1) 
causing death of 5/5; B negative control, G. mellonella injected with 20 µL PBS, 5/5 alive; 
C G. mellonella treated with 20 µL of 100 µM peptoid 186, 5/5 alive after 72 hours 
treatment. 
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Treatment  Toxicity to 
G. mellonella  
(no larvae alive/5) 
ED50 
HaCaT 
(µM) 
 
E. coli 0 nd 
PBS 5 > 100 
186 
(NLysNpheNphe)4 
5 36 
182 
(NLysNhLeuNspe)4 
5 > 100 
293 
(NhArgNpheNphe)4 
5 > 100 
181 
(NhArgNhLeuNphe)4 
5 28 
149 
(NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2 
5 33 
Table 5.1. Effect of 72 h peptoid treatment (20 µL, 100 µM sample) on G. mellonella. 5 
moth larvae were treated for each sample and for all peptoids 5/5 larvae were alive 
following 72 h treatment. The ED50 against HaCaT is shown for comparison.  
 
Through this simple G. mellonella model, it has been shown that peptoids have low in 
vivo toxicity to the larvae. Interestingly, although none of the peptoids caused death to 
the moth larvae, several of the peptoids showed moderate toxicity to HaCaT 
keratinocytes at concentrations much lower than the 100 µM treatment used in the 
G. mellonella assay (see Table 5.1). This work is, to the best knowledge, one of the first 
studies carried out to evaluate the in vivo toxicity of peptoids and shows that toxicity 
considerations are a complex issue and the need for system specific evaluation.  
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5.2 Investigation of peptoid secondary structure  
This work was carried out in collaboration with Dr Beth Bromley and students (Durham 
University, Physics Department). All compounds were designed, synthesised, and purified 
by HLB and their biophysical properties investigated by Charlotte Williams (MPhys 
student) and Dr Lara Small (Postdoctoral Research Assistant). 
 
5.2.1 Hydrophobicity as a predictive tool in the rational design of bioactive 
peptoids 
In nature, systems that have efficient and specific functions are often accompanied by 
well-defined structures that support their applications. Within the field of biochemistry, 
proteins are a perfect example. The knowledge of how a sequence determines its fully 
folded structure is key to the de novo design of such molecules and the ability to 
synthesise stable folded compounds is key for a wide variety of applications from drug 
discovery to the development of new materials.  
Natural proteins and peptides explore a variety of conformational states from fully 
stabilised to unfolded global structures; peptoids are no different. Peptoids have already 
been shown to adopt stable and well defined folds in solution, such as the peptoid 
helix10,15-17 or peptoid nanosheets18-20, as in Chapter 2. Unlike peptides where regular 
backbone hydrogen bonding helps to stabilise the secondary structures adopted, 
peptoids typically rely upon the local steric17,21 or electronic effects22-24 of side chains to 
help stabilise any secondary structures formed. The positioning of the side chains on the 
nitrogen of the amide (as opposed to the α-carbon) also renders the backbones of 
peptoid sequences achiral and the tertiary amides are more easily isomerised between cis 
and trans conformations than the secondary amides of a peptide. As discussed in 
Chapter 2, this means that the secondary structures adopted by peptoids are influenced 
heavily by the choice of side-chains. Peptoids that contain chiral monomers (e.g. Nspe) 
often have helical structures, with a range of different circular dichroism (CD) spectra that 
are dependent on the side chains used. The chemistry of such structures is well 
established and these helical states show excellent stability to chemical and thermal 
denaturation. As shown in previous chapters, this has enabled chemists to design helical 
peptoids with specific functions as it is possible to predict which sequences will form 
stable helices in solution, for example the antimicrobial peptide mimics in the literature 
and Chapters 3 and 4.7,10-12,25 
Additionally, classification of the hydrophobicity of a compound is often extremely 
useful in the prediction of drug efficacy in small molecule drug development. Knowledge 
of such physiochemical properties at an early stage of compound development can help 
in assessment of how well a potential drug can cross biological membranes to reach its 
target in vivo. Often values such as log P or log D values (the partition coefficient for the 
compound between octanol and water or buffer respectively) are determined for small 
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molecules, or predicted using a variety of software tools. However log P is not a simple 
additive property and these predictive programmes can be overly simplistic; other effects 
such as hydrogen bonding or specific electronic properties all play a part. For larger 
molecules, including peptoids, where folding is possible, the situation is far more 
complicated.26,27 
To date, there have been few studies that link the secondary structure of peptoids with 
their biophysical properties such as intrinsic hydrophobicity.28 Knowledge of such 
parameters would provide very useful tools to rationalise, and potentially predict, the 
behaviour and/or biological properties of peptoids. Typically, researchers have referred 
to the reverse-phase HPLC retention times of compounds as a crude measure of average 
hydrophobicity and it has been suggested that the hydrophobicity of a given peptoid 
sequence has a large effect on both toxicity and antimicrobial activity.7,8,10  
However, in sequences where a peptoids global structure is dependent on environment, 
the hydrophobicity of the folded molecule, may be very different; analogous to the 
exposed hydrophobic area in a folded protein being very different to that seen in the 
unfolded state. With few exceptions, using HPLC to predict log P or log D is mostly 
unsuitable, since properties responsible for retention in chromatography are different to 
those responsible for partitioning – in particular the contribution from hydrogen 
bonding. Additionally, our HPLC system has 0.1 % added TFA so retention times are 
based at pH 2.2 (very different to typical biological systems), whereas the partitioning is 
carried out in PBS at approximately pH 7.4. Although these pH values are different, basic 
amino-functionalised side chains typically included in antimicrobial peptoids will be 
protonated in both cases. However, in other peptoids with acidic side chains or those 
with a lower pKa, the discrepancy between HPLC pH conditions and partitioning may 
become more important. We believe that the partitioning experiments will be very useful 
in these cases, as the hydrophobicity measured from log D values may be more 
representative of biological conditions.  
Therefore, partitioning experiments were carried out on a small peptoid library to 
compare the hydrophobicity determined from partitioning to their HPLC-derived 
hydrophobicity and investigate peptoid conformation in solution by CD spectroscopy.  
The partitioning experiments were carried out to calculate log D values and to provide a 
measure of the ‘folded hydrophobicity’. 
The peptoids tested in this study were based upon the simple three-fold repeat motif 
NxNyNy, previously synthesised for biological testing (see Table 5.2); where Nx is a 
hydrophilic monomer with primary amine functionality, either NLys or Nae; Ny is a 
hydrophobic residue comprising either Nspe or Nphe. 6, 9 and 12 residue peptoids based 
on this motif were synthesised to examine the effects of sequence length, chirality and 
cationic side chain length. 
 
 
Ch. 5 Investigations into Peptoid Mode of Action 
216 
 
Nx Ny Peptoid Sequence 
 
 
186 (NLysNpheNphe)4 
187 (NLysNpheNphe)3 
188 (NLysNpheNphe)2 
 
22 (NLysNspeNspe)4 
26 (NLysNspeNspe)3 
25 (NLysNspeNspe)2 
  
180 (NaeNpheNphe)4 
213 (NaeNpheNphe)3 
214 (NaeNpheNphe)2 
 
156 (NaeNspeNspe)4 
218 (NaeNspeNspe)3 
219 (NaeNspeNspe)2 
Table 5.2. The peptoids tested in partitioning experiments of differing lengths, 
containing either chiral (Nspe) or achiral (Nphe) residues and containing either shorter 
(Nae) or longer (NLys) positive side chains. All sequences have a C-terminal amide group 
and N-terminal free amine. 
 
A peptoid solution (between 10 and 100 µM) in PBS was added to octanol and the system 
allowed to equilibrate under gentle agitation for 150 hours. At this point it is assumed 
that the peptoid has partitioned between these two phases, such as to minimise its free 
energy. A combination of UV spectrometry and dynamic light scattering were used to 
determine that no aggregation was taking place in either phase (data shown in the 
Appendix). The peptoid concentrations of both phases were then determined using UV-
Vis spectroscopy and the logarithm of the ratio of concentration in PBS over 
concentration in octanol (log D) was calculated. 
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Figure 5.6. Illustration of peptoid partitioning between aqueous (PBS) and organic 
(octanol). When ΔG˚ < 0, the partitioning is spontaneous with a PBS to octanol 
transition being favoured. The more negative ΔG˚, the more hydrophobic peptoid; when 
ΔG˚ > 0, the reaction is not spontaneous and the reverse reaction (octanol to PBS) is 
favoured and peptoids largely remain in the PBS phase. 
 
It has already been highlighted that reverse phase HPLC retention times of compounds 
are used as a crude measure of average hydrophobicity to rationalise behaviour (for 
example, antibacterial properties).7,9,10 The HPLC retention times for the compounds 
tested in Figure 5.7A indicate that the peptoids become more hydrophobic as the chain 
is increased in length. There is also an increase in hydrophobicity caused by switching 
from the achiral Nphe monomer to the chiral Nspe monomer, e.g. compare 186 
(NLysNpheNphe)4 and 22 (NLysNspeNspe)4. It has previously been suggested that this 
change may be due to the extra α-CH3 group present in Nspe monomer. However, it may 
be that this is a too simplistic an explanation given that there is a decrease in the 
hydrophobicity when the Nae monomer is replaced in a sequence by the longer NLys, 
e.g. peptoids 186 (NLysNpheNphe)4 and 180 (NaeNpheNphe)4 respectively.  
The trends in hydrophobicity observed from analysis of the HPLC retention times are 
not reproduced in the folded hydrophobicity data collected from the partitioning data. 
In Figure 5.7B it can be seen that the partition coefficients are similar for all peptoids 
except for the 9 and 12 residue peptoids with the combination of both Nae and Nspe (156 
and 218). Peptoids 156 (NaeNspeNspe)4 and 218 (NaeNspeNspe)3 are the only peptoids in 
the library to show significant movement into the hydrophobic phase (e.g. they have 
negative log D values). It can also be seen from comparison of 156 and 218 that, 
increasing the sequence length gives rise to an increase in partitioning to the 
hydrophobic phase (i.e. 156 partitions into the octanol layer more than 218).  
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The dramatic differences in the two descriptions of hydrophobicity suggest that the 
folding of peptoids in both the aqueous and hydrophobic phases is important to their 
biophysical properties. In particular it is clear that the difference in energy between the 
folded state adopted in PBS and the folded state adopted in octanol is greater when the 
peptoid is longer, there are chiral residues present, and the positive side chains are 
shorter (i.e. Nae perfered over NLys).  
The conformation of the chiral peptoids in both phases was investigated by circular 
dichroism (CD). All of the peptoids gave a significant CD signal and hence were found to 
be adopting helical folded conformations in both PBS and octanol (see Figure 5.7 C/D), 
however, the shapes of the curves suggest different solution conformations. The peptoids 
in PBS show a change in the shape of the CD spectra as the length increases, perhaps 
indicating that the lowest energy conformation changes as the peptoid becomes longer. 
The CD spectra of the peptoids in octanol show a different shape to those in PBS and 
again exhibits a variation with peptoid length. Again this indicates a difference in the 
details of the helical structure being adopted.  
For the two longest chiral peptoids, 22 [(NLysNspeNspe)4] and 156 [(NaeNspeNspe)4] 
there is no difference in the CD spectrum in either PBS or octanol as function of cationic 
side chain length. The large difference in folded hydrophobicity between these two 
peptoids must therefore stem from a difference in energy of the same folded state with 
short (Nae) or long (NLys) cationic side chains. It cannot be determined from these data 
whether the long side chain stabilises the aqueous folded state or destabilised the 
hydrophobic folded state or if both are occurring. A likely reason for this difference is 
that the folded conformation may enable increased shielding of the positive charge from 
the solvent in the short chained case that would be energetically unfavourable in PBS 
and energetically favourable in octanol.  
This difference in energy of the folded state is highly likely to be implicated in difference 
in the antimicrobial efficacy between these two peptoids. To consider how log D could 
be used to help rationalise and predict the antimicrobial properties of peptoids, 
22 (NLysNspeNspe)4 and 156 (NaeNspeNspe)4 were selected as they have the same overall 
net charge (+4) but very different log D values (+1.21 and -1.85). As shown in Table 5.3, 
the HPLC retention time can indeed be potentially predictive of biological activity, for 
example in the case of the L. mexicana amastigotes, where peptoid 156 has a longer 
HPLC retention time than 22 and greater biological activity (ED50 17 compared to >100 
µM).  
However, when screening against other microbes which have different membrane 
compositions, the hydrophobicity as predicted by log D may prove to be more significant 
in determining the activity. The activity of the peptoids against E. coli illustrates this, 
where Peptoid 156 with the longer retention time is inactive, but 22 has an MIC of 25 µM. 
These differences in activity cannot be rationalised in terms of HPLC retention time, but 
the clear difference in the log D values does offer a route by which to probe the link 
between physical properties and biological activity in more detail. 
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Figure 5.7. A comparison of HPLC and partitioning-derived hydrophobicity for peptoids 186–219; A reverse phase HPLC retention times; B log D 
values as calculated from partition experiments. Also, a comparison of CD spectra for all of the chiral peptoids; C in PBS; D in octanol.
Ch. 5 Investigations into Peptoid Mode of Action 
220 
Table 5.3. A comparison of the biological activity of the peptoids 22 and 156 with the 
analytical HPLC retention times and log D values at pH 7.4. Gradient: 0–100 % solvent B 
over 30 min at 220 nm, column oven at 40 ˚C (where solvent A = 95 % H2O, 5 % MeCN 
0.1  % TFA; solvent B = 95 % MeCN, 5 % H2O, 0.1 % TFA). All biological screening in 
triplicate on a minimum of two separate occasions to ensure a robust data set was 
collected 
 
In conclusion, in this study the hydrophobicity of peptoids that mimic antimicrobial 
peptides have been measured via partition experiments for the first time. This method 
produces a measure of the hydrophobicity of the folded state of the peptoids via log D 
values. Analysis shows that the folding of peptoids can have a significant impact on their 
biophysical characteristics; in particular their folded hydrophobicity can be significantly 
different to that measured by HPLC retention time. The partitioning experiments are 
therefore an important addition to the toolbox for drug efficacy prediction alongside the 
measures normally used, including measures of average hydrophobicity such as HPLC 
retention time. The influence of folding on the efficacy of a peptoid as a drug could be 
profound and here it has been shown that the log D values could be an important 
additional predictor to use in the rational design of biologically active peptoid sequences 
in the future.  
More work is now being carried out to optimise these partitioning experiments, through 
use of a NanoDrop spectrophotometer to reduce the volumes necessary and hence 
amount of peptoid sample needed. This will allow more repeats can be carried out, a 
reduced equilibration time and the possibility to examine a greater number of 
compounds in a high throughput process. Using this modified protocol, the Bromley 
group is now investigating a larger subset of the peptoid library to further probe the 
potential applications of log D values as a predictive tool to assist with rational design of 
biologically active peptoids in the future. 
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Sequence 
ED50 
(µM) 
MIC 
(µM) 
HPLC 
RT 
(min) 
 
log D 
(pH 7.4) 
  
L. mex 
promastigotes 
L. mex 
amastigotes 
E.coli S. aureus 
22 (NLysNspeNspe)4 8 >100 25 2 14.9 1.21 
156 (NaeNspeNspe)4 7 17 >100 2 16.7 - 1.85 
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5.3 Mode of action studies using confocal fluorescence microscopy 
Peptides 342 and 343 synthesised with assistance from Sophia Schwartz (Erasmus student) 
and microscopy experiments in collaboration with Dr Robek Pal (Durham University, 
Chemistry department). 
 
Fluorescently labelled molecules are highly useful compounds and can be used, among 
many other applications, to help determine the mechanism of action of a compound. 
Using confocal fluorescence microscopy, these fluorescent compounds can be visualised 
in live cells and organelle specificity examined using one of many commercially available 
stains in co-localisation experiments.  
A number of studies have already performed detailed spectroscopic characterisation of 
fluorescently labelled peptoids and studied these in cell based microscopy, such as 
peptoids 329 and 330 (see Figure 5.1 for structures).6,29-32 In particular, the Bräse and 
Schepers groups have used confocal microscopy to investigate the cell penetrating 
properties of peptoid sequences. In this work it was shown that highly charged peptoids 
enter the cells by endocytosis and are subsequently released back into the cytoplasm. For 
peptoids with a higher proportion of hydrophobic residues, localisation is seen in the 
mitochondria. Amino-functionalised peptoids tend to accumulate in the cytosol, 
whereas arginine-mimetic peptoids with guanidinium groups collect preferentially in the 
nucleus.6,30  
However, the sequences studied in the literature to date tend to be shorter than the 
most active compounds in our library and our sequences display very different charge to 
hydrophilic ratio and patterns. As the typical sequences found in our library are both 
highly charged and have many lipophilic monomers, a series of fluorescence microscopy 
experiments were planned to determine if our compounds are also transported to 
specific organelles, which would be a very powerful tool for targeted drug delivery. 
Determination of where these peptoids localise, whether at the cell membrane or inside 
specific organelles within the cell, should also enable more detailed information to be 
gathered about their mechanism of action. 
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5.3.1 Synthesis of fluorescent compounds 
There are thousands of commercially available dyes available to add to compounds. The 
existing library is vast, covering wide emission wavelengths with dyes of diverse 
structures, chemical functionality and provide a range of photophysical properties. Some 
of the most commonly used fluorophores are those structurally related to fluorescein, i.e. 
compounds 331–333 Figure 5.8. 
 
 
Figure 5.8. Chemical structure of two fluorescein fluorophores and rhodamine B, with 
corresponding photophysical properties. 
 
A small selection of peptoids were tagged with fluorescein (see Table 5.5 for a list of the 
sequences), including those that were biologically active and those with no activity in 
order to gather mechanistic information. Two peptides sequences from the temporin 
family of AMPs, were also synthesised and tagged for comparison. Both peptides and 
peptoids were synthesised on Rink Amide resin and a glycine spacer was added between 
the sequence and the fluorophore using manual SPPS. Fluorescein was chosen as a dye 
due to its biocompatibility, low cost and chemical stability under a variety of conditions.  
The addition of fluorescein to the peptide/peptoid sequences is straightforward as 
commercially available fluorescein exists with a free carboxy group, so a simple amide 
bond formation reaction is sufficient to add the dye to a sequence. For peptoids, 
standard fluorescein (331) dye was used, for the peptides, 5(6)-carboxyfluorescein was 
used (332) due to availability in the lab at this stage of synthesis. Both fluorescein dyes 
are very similar, with comparable wavelengths for excitation and emission, as shown in 
Figure 5.8, therefore comparisons should be able to be drawn between these 
compounds. 
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Scheme 5.1. Synthesis of fluorescein-tagged peptoid sequences for microscopy; i. 
Addition of glycine spacer using standard SPPS; ii. fluorescein coupling using activating 
agents to form fluorescent sequence. A similar pathway follows for the peptides but with 
5(6)-carboxyfluorscein and different activating agents, as explained below. 
 
All fluorescein additions were made manually. For peptoids, PyBOP was used as an 
activating agent in combination with DIPEA. For the temporin peptides, a few different 
conditions were trialled since those used to add fluorescein to the peptoids failed. These 
conditions are summarised in Table 5.4 and for the peptides, the only successful 
coupling conditions where the target mass was seen from a test cleave was condition 4, 
using DIC/HOBt activation. It is suggested that aggregation of the temporin peptides on 
resin caused these difficulties and that use of the sterically less bulky activating agent 
DIC was able to overcome the problematic aggregation.33 
 
Table 5.4. Summary of conditions used for the manual coupling of fluorescein to peptoid 
and peptide sequences. 
Conditions Dye Activator Conditions Target m/z 
by LC-MS 
Peptoids 1 Fluorescein 4 eq PyBOP 
4 eq DIPEA 
1 hour, RT 
 
 
 
 
 
Peptides 
1 5(6)-carboxyfluorescein 4 eq PyBOP 
4 eq DIPEA 
1 hour, RT 
 
2 5(6)-carboxyfluorescein 4 eq PyBOP 
4 eq DIPEA 
1 hour, RT 
Double coupling 
 
3 5(6)-carboxyfluorescein 1.1 eq HATU 
1.1. eq DIPEA 
1 hour, RT 
 
4 5(6)-carboxyfluorescein 1.1 eq DIC 
1.1 eq HOBt 
1 hour, RT 
 
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Table 5.5 shows the sequences that were successfully fluorescently labelled. Following 
the addition of dye to the peptides and peptoids, compounds were cleaved from the resin 
and purified by RP-HPLC to > 95 % purity for use in the microscopy experiments (see 
Figure 5.9). 
 
 Sequence 
334 Fluorescein-G-(NLysNspeNspe)2 
335 Fluorescein-G-(NLysNspeNspe)4 
336 Fluorescein-G-(NaeNspeNspe)4 
337 Fluorescein-G-(NLysNpheNphe)4 
338 Fluorescein-G-(NLysNhLeuNspe)4 
339 Fluorescein-G-(NLysNnValNspe)4 
340 Fluorescein-G-[(NamyNspeNspe)(NLysNspeNspe)]2 
341 Fluorescein-G-[(NLysNpfbNpfb)(NLysNspeNspe)]2 
342 5(6)-carboxyfluorescein-FLPLIGRVLSGIL-NH2  (Temporin A) 
343 5(6)-carboxyfluorescein-GLLPIVGNLLKSLL-NH2  (Temporin B) 
 
Table 5.5. The fluorescent peptoid and peptides synthesised for microscopy.  
 
 
 
Figure 5.9. Analytical RP-HPLC chromatograms for selected fluorescently labelled 
peptoids; a) 335; b) 341; c) 339; d) 338. Gradient 0–100 % solvent B (solvent A = 95 % H2O, 
5 % MeCN, 0.1 % TFA; solvent B = 95 % MeCN, 5 % H2O, 0.1 % TFA); column oven at 
40 ˚C; λ = 220 nm. 
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5.3.2 Confocal fluorescent microscopy and co-localisation experiments 
In a series of preliminary experiments, the interactions between fluorescently labelled 
peptoid sequences 334 and 335 and mammalian cells were investigated using confocal 
fluorescent microscopy.† The two fluorescein-tagged peptide sequences, 342 and 343, 
were also studied to provide a comparison with known AMPs. 
Two cell lines were chosen for live imaging; NIH-3T3 murine fibroblasts and PC3 human 
prostate cancer cells derived from bone metastases. Different incubation conditions were 
used and the addition of commercially available cell stains addressed several questions 
relating to the mode of action of these compounds. For example, the concentration and 
time dependence of uptake into the cell, whether compounds were taken up via an active 
or passive transport process and the site(s) of compound localisation within the cell (see 
Figure 5.10 for a diagram of the cell and possible organelles in which compounds may 
accumulate).  
 
Figure 5.10. A diagram of the complex mammalian cell, to show the different organelles 
in which a compound may accumulate. For organelles studied in this work, the 
particular cellular probe used has been labelled.‡ 
                                                     
†
 All microscopy images can be found in supplementary information accompanying this report. 
‡
 Image reproduced from Dr. Duncan Casey, Liverpool John Moores University from 
http://widnesscibar.blogspot.co.uk/2016/04/single-cell-experiments.html [accessed 21/10/16] 
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Since the peptide and peptoid sequences were tagged with fluorescein, a green 
fluorescent dye, orthogonal cell stains from Invitrogen were used. MitoTracker® Red 
(MTR) is a far red-fluorescent dye and accumulates in the mitochondria of live cells, 
dependent on membrane potential, ER-Tracker™ Green (ERTG) is a highly selective stain 
for the endoplasmic reticulum (ER) and LysoTracker® Red (LTR) has very high selectivity 
for acidic organelles so tends to accumulate in lysosomes.34-36 Lastly, propidium iodide 
(PI) was used, which is a red-fluorescent and membrane impermeable dye that is able to 
stain dead cells by binding to DNA or RNA in non-viable cells.37 
The conditions used in microscopy experiments with NIH-3T3 cells and the peptoids, 334 
and 335, are summarised in Table 5.6. Both peptoids are both based upon compound 22, 
the (NLysNspeNspe)x motif; where 334 is 6 residues in length and 335 is 12 residues long 
(i.e. x = 2 and 4 respectively). 
 
Compound Condition Time  
(min) 
Concentration 
(µM) 
 
334 
1 15 40  
2 30 40  
3 60 40  
4 120 40  
5 60 4  
335 
2 30 40  
3 60 40  
6 30 2  
7 30 2 MTR 
8 30 20 4˚C, PI 
9 30 20 MTR 
Table 5.6. Time and concentration of peptoids 334 and 335 incubated with NIH-3T3 cells. 
All incubations were at 37 ˚C, unless stated. MitoTracker® Red (MTR) and propidium 
iodide (PI) were also added in conditions 7 and 8.  
 
Concentration and time dependent uptake of peptoids 334 and 335 
To determine the effect of peptoid concentration or incubation time on cellular uptake 
and the optimum conditions for imaging, conditions 1–5 were trialled. After addition of 
40 µM peptoid solution (made in cell media), the cells were incubated between 15 and 
120 minutes. For the shorter 6 monomer sequence 334, after 30 minutes peptoid gathered 
around the cell membrane but was only detected inside the cells after incubation in 
excess of 60 minutes. Due to large fluorescence outside the cells the 334 solution was 
reduced to 4 µM (condition 5) and under these conditions, a low amount of green-
fluorescence of the peptoid was seen inside the cell, presumably entering via membrane 
permeabilisation. Microscopy images for these conditions can be found in the Appendix. 
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The same conditions 1–4 were also applied to 335, the longer 12 residue peptoid of the 
same sequence. Compared to 334, peptoid 335 was able to translocate into the NIH-3T3 
cells at a much faster rate. As seen in Figure 5.11, a 30 minute incubation was sufficient 
to see a large amount of green fluorescence from within the cell (condition 2). 
Compound 335 was also significantly more toxic towards the mammalian cells, so a lower 
concentration (2 µM) was used in conditions 6–9. Condition 6 was determined to be 
optimal for imaging (2 µM, 30 minute incubation time) and was used to inform the 
further experiments outlined below. 
Figure 5.11. Peptoid 335 fluorescein-Gly-(NLysNspeNspe)4 enters cell following 30 minute 
incubation of 40 µM 335 with NIH-3T3 cells at 37 ˚C. Showing optical cell images (top 
left), cell autofluorescence under UV (top right), 335 fluorescence (bottom left), merge 
(bottom right). Scale bar 20 µm.  
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Cellular compartmentalisation of peptoid 335 
Using the MTR probe (condition 7), it was shown that peptoid 335 interacted with and 
localised in the cellular mitochondria as there is a very good overlay between the peptoid 
green fluorescence and the MTR detection (see Figure 5.12C). Peptoid 335 was shown to 
diffuse through the outer mitochondrial membrane and then sits in the intermembrane 
space, with the uptake dependent on an intact mitochondrial membrane potential.38  
 
Figure 5.12. Peptoid localisation in mitochondria. Images from incubation of 2 µM 
peptoid 335 fluorescein-Gly-(NLysNspeNspe)4 with NIH-3T3 cells and MTR at 37 ˚C for 30 
minutes. Scale bar 10 µm. A peptoid 335 fluorescence; B MTR fluorescence; C merge.  
 
Peptoid 335 enters cells via a passive transport mechanism 
In the aforementioned experiments, peptoid 335 was shown to cross the cell membrane 
and enter cells efficiently. In order to determine whether 335 entered the cell via an 
active or a passive transport mechanism, peptoids were incubated with NIH-3T3 cells at 
4 ˚C; a lower temperature that should prevent active transport. 
As shown in Figure 5.13B, peptoid 335 is detected inside cells even with an incubation 
temperature of 4 ˚C (condition 8) so a passive transport mechanism across the cell is 
suspected. PI was also added to differentiate between healthy and non-viable cells. Any 
cell with red fluorescence from PI is assumed to be dead, with a compromised cell 
membrane. Although in Figure 5.13C PI is seen inside the cells after 4 ˚C incubation, this 
occurs during transport of cells from the incubator to the microscope, so cannot infer 
anything about the mechanism of cell death at this stage. 
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Figure 5.13. Peptoid enters the cell during incubation of 20 µM peptoid 335 fluorescein-
Gly-(NLysNspeNspe)4 with NIH-3T3 cells at 4 ˚C for 30 minutes. PI added immediately 
before imaging. Scale bar 20 µm. A optical image of cells; B peptoid 335 fluorescence can 
be seen inside the cell; C propidium iodide fluorescence; D merge.  
 
Mode of toxicity for peptoid 335 – apoptotic or necrotic? 
Finally, a comparison of the cell morphologies shows that the majority of cells that died 
during treatment by peptoid 335 under condition 9 were killed via an apoptotic 
mechanism. Apoptosis is a regulated process of programmed cell death, whereas necrosis 
occurs due to accidental cell damage and the two modes of cell death have distinct 
morphological features. In apoptosis, often membrane blebbing occurs or the formation 
of membrane bound vesicles without a loss of membrane integrity, a shrinking 
cytoplasm or condensed cell nucleus and the mitochondria typically become ‘leaky’.39,40 
This can be seen in Figure 5.14 where apoptotic and necrotic cells are compared 
(necrotic cells A-D, apoptotic cells E-G).  
Only a few cells from those studied were found to be necrotic, where a loss of membrane 
integrity is seen and typically organelles are seen to swell and ends in total cell lysis.39,40 
This total cell lysis can be seen in image A, where cell efflux is occurring. 
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Figure 5.14. Comparison of necrotic and apoptotic cells following incubation of 20 µM peptoid 335 fluorescein-Gly-(NLysNspeNspe)4 with NIH-
3T3 cells and MTR at 37 ˚C for 30 minutes. Scale bar 20 µm. Necrotic cells can be seen in images A-D, apoptotic cells in images E-G. A image of 
cells; B/E peptoid 335 fluorescence; C/F MTR fluorescence; D/G merge. 
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Similar confocal fluorescence microscopy experiments were undertaken with peptides 
342 and 343 and the cell incubation conditions are shown in Table 5.7. 
 
Compound Experiment Time  
(min) 
Concentration 
(µM) 
 Cell  
342 
1 30 20 PI NIH-3T3 
2 30 20 LTR NIH-3T3 
3 120 20 LTR NIH-3T3 
4 24 h 20 LTR NIH-3T3 
5 30 20 4 ˚C NIH-3T3 
6 30 20 LTR PC3 
7 4 h 20 ERTR PC3 
8 30 20 ERTR PC3 
343 
1 30 20 PI NIH-3T3 
2 30 20 LTR NIH-3T3 
3 120 20 LTR NIH-3T3 
4 24 h 20 LTR NIH-3T3 
5 30 20 4 ˚C NIH-3T3 
6 30 20 LTR PC3 
7 4 h 20 ERTR PC3 
8 30 20 ERTR PC3 
Table 5.7. Incubation conditions for peptides 342 and 343 with NIH-3T3 or PC3 cells. All 
incubations were at 37 ˚C, unless stated. Stains added: ER-Tracker™ Red (ERTR), 
LysoTracker® Red (LTR), propidium iodide (PI). 
 
Membrane permeability of temporin peptides 342 and 343 
To examine the membrane permeability of the temporin peptides, NIH-3T3 cells were 
first incubated at 37 ˚C with a 20 µM solution of either 342 or 343 (condition 1 in Table 
5.7). Fluorescently labelled temporin A (342) was seen around the outer membrane of 
the cells, and also in lipid droplets indicating surface activity. The peptide fluorescence 
around the outside of the cell membrane can be seen in Figure 5.15B. Exposure of 
temporin B (343) also showed green fluorescence around the cell membrane, with a 
higher concentration of peptide detected inside the cells (i.e. higher fluorescence 
intensity). Both 342 and 343 are surface active, causing cell death to a number of cells 
with the relative proportion of compound found inside the cell correlating with the 
number of dead cells seen; for temporin A (342) approximately 20 % of cells are dead 
whereas for temporin B (343), around 50 % have undergone cell death.§ 
When PI was added immediately before imaging (condition 1), PI fluorescence signal was 
only detected inside a minority of cells showing that the peptides 342 and 343 are not 
toxic to the mammalian cells under these conditions, unlike the peptoids 334 and 335.  
                                                     
§
 Cell death estimated by counting cells within a defined field of view. 
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Figure 5.15.Temporin A, 342 can be seen to localise around the surface of NIH-3T3 cells 
following incubation at 37 ˚C with a 20 µM peptide solution and PI for 30 minutes. Scale 
bar 20 µM. A cell image; B peptoid fluorescence in green; C PI fluorescence in red to 
show the cell nuclei; D merge. 
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Peptides 342 and 343 enter cells via an active transport mechanism 
As with the peptoid sequences, incubation of NIT-3T3 cells with the fluorescently 
labelled 342 and 343 was undertaken at 4 ˚C (condition 5). Since no fluorescence was 
seen after a 30 minute incubation** it is suggested that unlike peptoids 342 and 343, both 
peptide 342 and 343 enter the cells via an active transport mechanism. (See Appendix for 
the image obtained – showing mitochondrial autofluorescence only) 
 
Cellular compartmentalisation of temporin peptides 342 and 343 
Since the formation of lipid droplets occurred, LTR was used to determine whether the 
peptides localised in lysosymes of the NIH-3T3 cells. It is well known that lipid droplets 
interact with many other structures within the cell to maintain cellular homeostasis so it 
is possible that the peptides within the droplets interact with other cellular machinery. 
For example, lipid droplets have been shown to form associations with organelles such as 
the mitochondria, vacuoles or lysosomes and the endoplasmic reticulum.41 Therefore 
LTR and ERTG were deployed to examine possible cellular localisation of 342 and 343. 
The LTR is a probe for the acidic lysosomes, which are key for the degradation and 
recycling of macromolecules in the cell. ERTG is a common tracker for the endoplasmic 
reticulum, a continuous membrane system made of various domains that perform 
different functions for the cell such as translocation, folding or modification of 
proteins.42,43 
Using condition 2 with the LTR probe showed no overlay of peptide green fluorescence 
and the red LTR signal, showing that the peptides do not localise in the lysosymes after a 
short 30 minute incubation. At longer incubation times (i.e. 120 minutes in condition 3), 
larger lipid droplets were seen and as before, higher concentrations of peptide 343 could 
be detected inside the cell compared to 342 At the longest incubation time of 24 hours 
(condition 4) an overlay of MTR is seen with the peptide fluorescence. Images to 
illustrate this are shown in Figure 5.16 for peptide 343.  
After 24 hour incubation, intracellular 342 fluorescence has an approximate an 
approximate 40% overlay with LTR and for 343 this overlay increases to around 60 %, 
suggesting localisation of the compounds in the lysosomes. Imperfect alignment is due 
to cellular homeostatic movement during the slow scanning of the microscope during 
image acquisition. In the cells incubated with 342 or 343 for 24 hours, cell death occurred 
via an apoptotic mechanism, since cell membranes remain intact. 
                                                     
**
 A small amount of peptide fluorescence is seen inside the cell when incubated at 37 ˚C for 30 minutes. 
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Figure 5.16.Images to show the overlay of peptide 343 fluorescence with LTR after 24 h 
incubation at 37 ˚C with a 20 µM solution of 343, LTR and NIH-3T3 cells. Scale bar 
20 µm. A peptoid fluorescence shown in green; B cell image; C LTR fluorescence shown 
in red; D mitochondrial autofluorescence shown in pink; E merge of A, B, C and D; F 
merge of A, C and D. 
 
To corroborate results in a second cell line, the PC3 cells were used. Again, a partial 
overlay of LTR and peptide fluorescence is seen for both 342/343 after a 30 minute 
incubation (condition 6) with the PC3 cells. The partial overlay of F9 and LTR can be 
seen in Figure 5.17.  
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Since the overlay with LTR was not adequate to conclusively confirm that peptides were 
localising in the acidic lysosymes, ERTG was also used in conditions 7 and 8. Again, 
partial overlap was seen with the tracker and 342/343. These images are shown in the 
Appendix. The formation of lipid droplets within the cells may increase the fluorescently 
labelled peptide signals in this case, therefore future investigations into the exact 
compartmentalisation of the peptides is necessary. 
 
Figure 5.17. Image shows partial overlay of 20 µM peptide 342 solution with LTR. 342 
fluorescence (green), LTR fluorescence (red), mitochondrial autofluorescence (pink) 
following 30 min incubation with PC3 cells at 37 ˚C. Scale bar 20 µm.  
 
5.3.3 Conclusions from confocal fluorescence microscopy 
In conclusion, fundamental differences between the antimicrobial peptoids (334 and 335) 
and the temporin peptides (342 and 343) have been revealed using confocal fluorescence 
microscopy and fluorescein labelled sequences. Whilst the peptides show surface activity 
and gather around the cell membrane before entering mammalian cells, the peptoids 
permeate through the cell membrane much more efficiently and at a faster rate. The 
behaviour of peptoid 335 agrees with the work of Olsen et al, who showed that 
fluorescently labelled α-peptide β-peptoids localised inside HeLa cells, with little surface 
activity.44 When examining the surface activity of the peptides, temporin A (342) shows 
an increased surface activity cf temporin B (343), which is found at higher concentrations 
inside the cell via its higher fluorescence intensity. The rapid transport of peptoid 335 
inside the cell is very interesting; many studies suggest that antimicrobial peptoids act 
on the cell membrane in order to affect their biological effect. However, the fact that 335 
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localises inside the cells efficiently may suggest that this is not the only mode of action 
for this peptoid sequence. 
Peptoid 335 was more cytotoxic to the cells studied in the microscopy experiments†† than 
the peptides (342 and 343). However when cell death occurred, an apoptotic 
mechanism‡‡ was responsible for the majority of cells treated by both the peptoids and 
peptides. Again, the lack of necrosis seen in cells treated by peptoid 335, suggests that 
this antimicrobial sequence does not disrupt cell membranes as severely as other 
peptoids in the literature. For example, cyclic peptoids synthesised by the Kirshenbaum 
group were shown to significantly damage S. aureus cell membranes via pore formation, 
visualised using SEM in Chapter 1.2  
The use of several organelle-specific trackers showed that peptoid 335 is transported into 
the mitochondria, whereas for the peptides localisation in the lysosomes or the ER are 
suspected (although the overlay between peptide fluorescence and the tracker was not 
perfect, so this needs to be investigated further in the future). The peptides 342 and 343 
are not taken up into cells at 4 ˚C, however peptoid 335 is able to translocate into the 
NIT-3T3 cells at 4 ˚C, suggesting active and passive mechanisms respectively. 
In the study by the Bräse and Schepers groups, peptoids with a critical level of 
lipophilicity were also shown to localise in the mitochondria, although their highly 
charged sequences (with 3 or more NLys monomers) were taken into the cell by 
endocytosis (an active transport mechanism) and accumulated in endosomes.6 In this 
study, peptoid 335 is both highly charged with 4 NLys monomers (net charge +4) and 
also fairly lipophilic with a large number of Nspe monomers, so has both of these 
properties. In the Bräse study, peptoid sequences were only four monomers in length so 
it is only to be expected that our compounds may behave differently and therefore it is 
necessary to undertake more work in this direction for longer antimicrobial peptoid 
sequences. 
Although only four sequences were studied, this preliminary work has laid the 
groundwork for future microscopy studies which will allow these conclusions to be 
compared a larger peptoid library and in order to rationalise biological activity and 
toxicity. Compounds 336–341 (Table 5.5) are currently being applied in similar 
microscopy experiments to study their cell permeability and where the sequences 
localise in mammalian cells. Study of less lipophilic sequences such as 338 and 339, or the 
less charged peptoid 340 (net charge +2) will allow further comparisons to the Bräse and 
Schepers work with longer sequences. In this work, more controls need to be undertaken 
to ensure that the fluorescein dye is not altering the properties of the peptoid 
compounds, such as their membrane permeability or cytotoxicity. The direction of this 
research is discussed in greater detail in Chapter 6: Conclusions and Future Work.  
 
                                                     
††
 Additionally, peptoid 335 has an ED50 of 20 µM for HaCaT and 29 µM for HepG2 (both mammalian cell 
lines). 
‡‡
 In apoptosis the cell membrane remains largely intact. 
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Finally, it is hoped that the information gathered from this study may allow more 
rational and an improved design of antimicrobial peptoids in the future; for example, 
knowledge of the organelles in which the compounds localise can allow us to target 
specific cellular processes or to alter the compound’s structure to decrease toxicity. 
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Chapter 6 
Conclusions and Future Work 
 
In conclusion, the library synthesised as part of this project represents one of the largest 
and most functionally varied library of antimicrobial peptoids reported to date. In 
addition to the library synthesis, novel chemical methodology has been developed. In 
particular, the efficient synthesis of peptoids with both lysine- and arginine-type 
monomers within the same sequence was described in Chapter 2 and the ligation of 
peptide and peptoid fragments via a copper catalysed click reaction in Chapter 5.  
From work undertaken in Chapter 3, certain peptoid sequences were shown to have 
potent micromolar potencies against clinically relevant protozoa, including those 
responsible for the neglected tropical diseases of cutaneous and visceral leishmaniasis, 
African sleeping sickness and Chagas disease. Additionally some selective peptoids were 
identified with sub-micromolar against P. falciparum, one of the species responsible for 
fatal malaria infection. This work has provided the first examples of peptoids with 
activity against trypanosomatid protozoa (i.e. Leishmania and Trypanosoma species). 
In Chapter 4, peptoids have also been successfully applied against planktonic bacteria 
and cross kingdom biofilms containing multiple bacterial and fungal species. Peptoids 
have been shown to be active, and significantly species specific, for the treatment of 
cross kingdom, mixed species biofilms. Detailed SAR discussions regarding peptoid 
action against protozoa and bacteria or fungi can be found in the conclusions for 
Chapters 3 and 4 respectively.  
The analysis in Chapter 5 provides a large correlation of antimicrobial and toxicity 
screening, thus it should help inform and direct future research into biologically active 
peptoids. Chapter 5 also describes further investigation into the biophysical properties of 
our sequences and it was shown for the first time that HPLC-derived retention times are 
not the best measure of peptoid hydrophobicity as a means to rationalise compound 
activity; instead the fundamental log D parameter is suggested to be more appropriate. 
Additionally, the confocal fluorescence microscopy experiments described in Chapter 5 
show that the peptoid sequence tested entered mammalian cells via a passive 
mechanism and localised in the mitochondria.  
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Peptoids have been presented as a class of antimicrobial compounds which are less likely 
to develop resistance than traditional small molecule drugs, due to their proposed mode 
of action against cell membranes and the significant advantages that peptoids have over 
peptide analogues due to their reduced susceptibility to proteolysis and resulting higher 
stability in vivo. However, there are still many aspects of peptoids that need to be 
investigated before they can be applied as pharmaceutical compounds, for example, few 
studies have looked into the immunogenicity of peptoid sequences and as highlighted in 
Chapter 1, pharmacokinetic properties still have yet to be optimised; the oral availability 
of peptoids will need to be improved for applications with enteral administration and the 
fast excretion rates currently recorded would have to be addressed.1,2  
One particular challenge highlighted in Chapter 5 is the design of peptoid sequences 
with high therapeutic indices. The results presented as part of this project show that 
selectivity has often been problematic since many active sequences have either had some 
level of toxicity to mammalian cells, or have shown hemolytic activity. In certain 
circumstances some level of toxicity may be acceptable; for example, in topical 
applications for cutaneous leishmaniasis, or where current treatments already have 
significant toxicity and side effects. However, in preliminary studies using a G. mellonella 
model as an in vivo measure of toxicity, treatment using high concentrations of peptoid 
does not lead to larvae death. Overall, in order to enable the further development of 
peptoids as a new class of antimicrobial compounds, the gaps in our knowledge around 
the toxicity and in vivo efficacy of peptoids need to be addressed and it is clear new 
models are needed to evaluate toxicity. 
A large amount of SAR data was collected from peptoids that covered a large area of the 
chemical space available and analysis of this has identified several further immediate 
directions of research in section 6.1. Collection of extra biological activity data is 
suggested in sections 6.2 and 6.3 outlines possible directions of research to further 
elucidate the mode of action of antimicrobial peptoids. 
Finally, there is an increasing trend in the field of peptide chemistry for N-methylation 
and removal of hydrogen bonding sites, particularly for medicinal applications. Such 
changes to peptides are inspired by naturally occurring N-methylated peptides such as 
the cyclic immunosuppressant drug cyclosporine.3 N-methylation is reported to increase 
the biostability of a peptide, prevent aggregation and to assist with membrane 
permeability due to the removal of hydrogen bonding sites.4-8 Peptoids by their design 
already have groups attached to the amide nitrogen and therefore lack hydrogen 
bonding sites on the backbone, so may provide an alternative platform in the future. 
Whether peptoids are used as therapeutics themselves or as additions to current 
bioactive molecules, for example as a targeting moiety or to assist with transit across 
membranes, peptoids will no doubt begin to feature in an increasing number of lead 
molecules in the future. 
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6.1 Improving peptoid selectivity - suggested peptoid syntheses 
One of the aims of this project was to synthesise a library that covered a large sector of 
the chemical space available to peptoids and this was achieved with a great range of 
varied monomers included across several different design motifs. However, there are 
some structures, not yet investigated, that may help with the design of selective and 
biologically active peptoids. 
In the antiparasitic screening undertaken, it was shown that chirality was important to 
overall activity against Leishmania mexicana with the N-(S-phenylethyl) glycine 
monomers (Nspe) showing more potent activity than the N-benzyl glycine analogues 
(Nphe). Although chirality was not quite so important in the antibacterial evaluation of 
the same compounds, chiral sequences were often the most active. It is suggested that 
the success of the chiral sequences comes from the induced helical secondary structure, 
rather than the associated increase in hydrophobicity from inclusion of an extra methyl 
group.*   
So far in the library, the chiral residues necessary to induce helical structure have 
included aromatic residues (Nspe, Nsfb or Nrpe) and it would be advantageous to reduce 
the proportion of such α-chiral aromatic residues included in the sequence as they have 
the potential to be hemolytic, more toxic to human cells and also have a poor atom 
efficiency due the their relatively high molecular weight. It is suggested that inclusion of 
α-chiral monomers with alkyl character may be a simple approach to balance the toxicity 
of peptoid sequences with good antimicrobial activity.  
A large range of chiral amines are cheap and commercially available, due to their wide 
use in asymmetric catalysis. Of these many have alkyl functionality, such as those shown 
in Figure 6.1. Inclusion of the sec-butyl  type monomers have already been shown via CD 
spectroscopy to induce a helical structure in a peptoid sequence.9 Adding these residues 
to a peptoid may allow the fraction of α-chiral aromatic residues to be reduced, or 
removed entirely, in order to reduce toxicity and hemolytic activity, whilst still retaining 
the necessary helical structure for antimicrobial activity.  
 
 
 
Figure 6.1. Commercially available amines that could be introduced into the 
submonomer method of peptoid synthesis to achieve peptoids with α-chiral alkyl 
monomers that would induce a helical structure. 
 
                                                     
*
 See partitioning experiments in Chapter 5. 
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Additionally in Chapter 2 it was shown that there is a lack of data concerning peptoid 
conformation in the literature; certain CD spectra published by other groups suggest 
that related peptoid sequences can form a range of stable helical conformations, however 
these have yet to be elucidated and characterised in detail. If peptoid secondary 
structures were clarified, it would allow the diversity of peptoid libraries to be improved. 
It is known that α-chiral substituents can induce helicity, but the requirement for 
approximately half of side chains to be bulky α-chiral monomers9-11 places certain 
restrictions on the synthesis of diverse peptoid libraries. Future studies should focus 
upon the development of novel peptoid monomers or side chains that do not rely upon 
this steric control to stabilise peptoid folding to allow a more through exploration of 
chemical space and potentially improve the selectivity of peptoids. 
 
6.2 Advancing peptoids as antimicrobial compounds 
6.2.1 Future screening 
In Chapter 2, the synthesis of 20 lipopeptoids (compounds 158–177) was described. 
Lipopeptides are synthesised nonribosomally in bacteria and fungi and can be highly 
active against multidrug resistant species of bacteria, with the lipid tail facilitating 
insertion into lipid bilayers of prokaryotic cell membranes.12 Due to time constraints, 
these compounds have not yet been biologically evaluated so in the future these could be 
tested against a variety of bacteria or fungi to determine their activity and toxicity. 
Additional testing could also include further investigation into the anti-biofilm activity 
of the peptoid library. In the initial crystal violet assay, all the biofilms were treated with 
peptoid solutions at 100 µM which is a very high concentration. Three peptoids (180, 216 
and 26) were identified at this stage and taken forward into the qPCR study against 
mixed biofilms. However, the activity of these sequences at concentrations less than 
100 µM were less promising. Therefore, in the future it would be useful to determine if 
activity is retained at lower concentrations using the crystal violet assay, before 
utilisation of the more expensive qPCR method. This may allow the identification of the 
most active sequences at an earlier stage. 
In Chapter 3, peptoids 259 (NLysNspe)6 and 260 (NaeNspe)6 were identified that had 
only mild toxicity to mammalian cells and negligible hemolytic activity but potent 
activity against P. falciparum, (IC50 2.60 µM and 4 µM; TI of 10.2 and 49.2 respectively). 
Therefore these sequences may be interesting candidates for further development. The 
sequences of peptoids 259 and 260 both follow an alternating design of hydrophobic and 
charged monomers which is different to the typical three residue repeat often seen in 
antimicrobial peptoids. In the future, it would be useful to evaluate the toxicity, 
hemolytic activity and antiparasitic activity of a variety of peptoids with different charge 
: hydrophobicity ratios and to change the hydrophobic monomer (for both 259 and 260, 
α-chiral Nspe is used). This would allow further investigation into whether it is the 
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increased net cationic charge, the increased number of hydrophobic residues, a 
structural difference or combination of the above factors that causes the improved 
antimicrobial effect and lower toxicity/hemolytic activities. 
In addition, it may be of merit to investigate a potential synergism between routinely 
prescribed antibiotic or antiparasitic drugs and the peptoid sequences. Synergy between 
AMPs and commercially available drugs13-15 or between peptoids and AMPs16 has proven 
successful in previous studies. It would be simple to repeat the assays already performed 
and treat relevant pathogens with a mixture of some of the most potent peptoid 
sequences and a relevant drug to see if the membrane permeabilisation properties of the 
peptoids cause an enhancement in activity of the known drug. This strategy could 
potentially be useful against multi-drug resistant bacteria, parasites or fungi since the 
peptoids may disrupt the cell membrane and allow the small molecule therapeutic to 
target the appropriate mechanism in a compromised cell.  
Finally, the large amount of biological data collected as part of this project has been 
analysed qualitatively in SAR studies, however it may benefit from a further 
bioinformatics approach to correlate activity with specific features of active sequences. 
Tests such as the Pearson correlation could be applied to the entire data set to 
statistically determine if positive or negative correlations exist between activity and 
characteristics such as hydrophobicity, chirality, net charge or specific monomers within 
the sequence. These tests should be applied to data obtained from assays against each 
bacteria or parasite to draw out the trends for these different species. 
 
6.2.2 Investigation into the role of C. albicans in polymicrobial biofilms 
Biofilms containing Candida albicans are responsible for a large number of infections in 
the clinic, including those associated with medical devices.17-19 Recently it has been 
suggested that the presence of C. albicans can significantly modify the physical 
environment and structure of a biofilm.20 Additionally, the presence of fungi can affect 
the action of antibiotics and bacteria can influence antifungal activity.21  
In the biofilm testing carried out as part of Chapter 4, several peptoids were identified 
that were active against C. albicans but had no significant effect upon S. aureus or E. coli, 
such as sequences 152 (NhArgNspeNspe)4, 153 (NhArgNmfbNmfb)4 and 181 
(NhArgNhLeuNspe)4. Use of such compounds could provide a starting point for further 
investigation into the role of C. albicans in cross-kingdom biofilms. It is anticipated that 
these molecules could act as probes to determine if inhibition of C. albicans alone could 
perturb or prevent polymicrobial biofilms. With increasing bacterial resistance observed 
against many conventional antibiotics in polymirobial biofilms containing C. albicans, 
these experiments would be very useful and may provide a starting point for new anti-
biofilm treatments.22  
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6.3 Further investigations into peptoid mode of action 
6.3.1 The nature of the peptoid helix: further investigations using circular 
dichroism 
This section describes ongoing collaboration with Dr Beth Bromley (Physics Department, 
Durham University). 
 
Following from Chapter 3, where peptoids 259 (NLysNspe)6 and 260 (NaeNspe)6 were 
identified with potent activity and therapeutic indices greater than 10, a further 
investigation into the nature of the peptoid helix is suggested. These sequences have an 
alternating pattern of hydrophobic and cationic monomers which differs from the typical 
trimer repeat motif (NxNyNy)n that the majority of the library is based upon. It is 
proposed that the differential activity profile could be due to different secondary 
structures of these two design patterns. It has already been shown that there is a lack of 
information regarding the peptoid helix, with CD spectra published by other groups 
suggesting that related peptoid sequences can form a range of stable helical 
conformations.  
In order to address this issue, a group of peptoids were synthesised with the same side 
chains, but different repeat motifs as shown in Table 6.1 and Figure 6.2. In these 
sequences a cationic monomer (Nae or NLys) is used with the hydrophobic monomer 
Nspe, with the cationic monomer placed in an alternating manner (259, 260), in the 
typical trimer repeat (156, 22) or in the 4 residue repeat motif (344 and 345). 
 
 
 Sequence Motif 
260 (NaeNspe)6 
2 repeat 
259 (NLysNspe)6 
156 (NaeNspeNspe)4 
3 repeat 
22 (NLysNspeNspe)4 
344 (NaeNspeNspeNspe)3 
4 repeat 
345 (NLysNspeNspeNspe)3 
 
 
Table 6.1. Sequences synthesised for 
investigation of the peptoid helix via CD. 
 Figure 6.2. Repeat motifs used in the 12 
residue peptoids shown in Table 6.1. 
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The peptoids absorb the circularly polarised light according to their conformation in 
space. In the typical CD spectrum of a helical peptoid, two absorption bands are seen 
around 200 nm and 220 nm, attributed to the π → π* and n → π* transitions of the 
amide backbone respectively.23,24 The appearance of the CD spectra for helical peptoids is 
often very different to that obtained from a typical α-helical peptide. In particular, the 
minima of the 200 nm and 220 nm transitions are often dissimilar, whereas with α-
helical peptides they are mostly even at a similar MRE value. This suggests very different 
conformations are present, potentially with different helix pitches or different molecular 
interactions, for example π-π stacking of the aromatic residues. The literature also 
reports peptoid CD spectra with uneven minima and a suggestion is made that these 
different shapes are due to different side chains.9-11,25-27 However, in Chapter 5, the CD 
spectra of peptoids with the same side chains showed different minima (either biased 
towards the 200 nm or 220 nm transition), so this cannot be the case and the different 
characteristic CD signals must mean different conformations are being adopted.  
As a starting point to try and elucidate the different conformations present in the 
peptoids, the partitioning behaviour of the peptoids in Table 6.1 and their CD spectra in 
PBS (aqueous) and octanol (hydrophobic solvent) are currently being collected. In 
addition molecular dynamics is being used by the group of Dr Beth Bromley in an 
ambitious project to help identify the lowest energy conformations to populate a 
Ramachandran plot to help identify the allowed regions for the backbone dihedral angles 
for these peptoids and to predict the energetically accessible helical conformations in 
different solvents. Molecular dynamics and combined molecular dynamics-quantum 
mechanical simulations have been used previously to evaluate accessible peptoid 
backbone conformations, but these have never been used to study the conformations of 
helical peptoids or to link structures obtained from modelling to the CD data.28-31 
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6.3.2 Peptoid action against model membranes 
This section describes ongoing collaboration with Dr Beth Bromley and Dr Kislon 
Voitchovsky (Physics Department, Durham University). 
 
It is clear that certain peptoid sequences can interact with and pass through the cell 
membranes of both eukaryotic and bacterial cell membranes from the microscopy work 
(Chapter 5) and from the membrane permeabilisation assay using SYTOX® Green 
(Chapter 4). Continuing collaborations are investigating how peptoids act upon different 
model membranes. Firstly, neutral 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) 
and anionic 1,2-dioleoyl-sn-glycero-3-phospho-l-serine (DOPS) vesicles are being 
studied, as well as some lipids doped with cholesterol to provide a representative chiral 
membrane surface. These DOPC and DOPS vesicles are a model for cell membranes and 
the vesicles are labelled with rhodamine and fluorescein dye is trapped inside. Following 
treatment by peptoid, the dye leakage and appearance of the micelles can be studied.  
Additionally, atomic force microscopy (AFM) is being used to examine the interactions 
between a peptoid sequence and a model bilayer. Two peptoids, based upon sequence 22 
are currently being investigated (see Figure 6.3). Both peptoid 346 and reteropeptoid 347 
have one N terminal cysteine residue and an aminohexanoic acid linker to allow the 
sequences to be added to a gold coated AFM probe via sulphur-gold affinity. 
 
Figure 6.3. Peptoid 346 and reteropeptoid 347 synthesised for attachment to AFM probe. 
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6.3.3 Confocal fluorescence microscopy 
The microscopy experiments described in Chapter 5 provide preliminary investigations 
into the behaviour of peptoids inside living cells. Currently, compounds 336–341 (see 
fluorescent peptoid library in Chapter 5.3 .1, as yet unstudied) are being used in further 
microscopy experiments to ascertain the mechanism of entry into mammalian cells and 
where these compounds accumulate in mammalian cells. These sequences include 
peptoids that are less lipophilic than those already studied and also with a lower net 
charge and should allow more information to be obtained regarding the chemical 
structures needed to target peptoids to specific organelles. This may help to rationalise 
the biological activity and toxicity of the sequences in the future. In this work, the 
cytotoxicity of the labelled compounds should also be obtained, to gauge the effect of the 
fluorescein dye on the overall compound toxicity. Additionally, it is planned to treat 
bacteria with the fluorescently labelled peptoids library to further investigate the mode 
of action of these compounds against prokaryotes.  
Biological testing as part of Chapters 3 and 4 highlighted some interesting trends when 
comparing the activity of lysine- and arginine-type peptoids. Against planktonic bacteria, 
sequences comprised exclusively of the arginine peptoid monomers were consistently 
more active than the lysine-only derivative peptoids. However, the arginine-type 
peptoids were typically less efficacious against the biofilms and this was supported by 
the SYTOX® Green assay, which shows that lysine sequences are able to cause a greater 
extent of membrane disruption to the species within the biofilm. This could be a point of 
further investigation utilising fluorescent microscopy, to examine the localisation of 
fluorescently labelled lysine-only, arginine-only and mixed peptoids in planktonic 
bacteria or within a biofilm in an attempt to explain this phenomenon. 
Finally, the effect of cyclic peptoids against biological targets has been studied in 
traditional assays and also using SEM to image the cell membrane of S. aureus32, however 
as yet, cyclic peptoids have not been studied using fluorescent microscopy. None of the 
cyclic peptoids synthesised as part of this project (130–134) showed any activity against 
protozoa or bacteria. Although the peptoids obtained from the Kirshenbaum lab (135–
144) showed no anti-protozoan activity they have been reported as potent antibacterial 
compounds.32,33  
It is suggested that differences in activity could be investigated in more detail if a 
selection of the cyclic library was resynthesised with fluorescent tags, to compare their 
mode of action. The method developed for the synthesis of mixed arginine- and lysine-
type peptoids using Dde-protection could also be adapted to make these fluorescently 
tagged cyclic peptoids. 
 
 
 
Ch 6. Conclusions 
248 
A proposed synthetic route to the synthesis of an example compound (348) is suggested 
in Scheme 6.1. This involves the solid-phase synthesis of linear peptoid precursor on 2-
chlorotrityl chloride resin, Dde deprotection using 2% hydrazine DMF and on-resin 
fluorescein addition using standard coupling conditions. Following cleavage from the 
resin using HFIP, which leaves Boc protection on side chains untouched, the peptoid can 
be cyclised as before and then a final treatment with TFA used to deprotect the Boc 
groups. It is anticipated that efficient macrocyclisation will occur, even with the bulky 
fluorescein attached to one sidechain. 
 
 
 
Scheme 6.1. The proposed synthetic route to synthesise fluorescently tagged, cyclic 
peptoid 348 using the submonomer method of peptoid synthesis on 2-chlorotrityl 
chloride resin, using orthogonal Boc and Dde protection of sidechains. 
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Chapter 7 
Experimental  
 
7.1 Materials and reagents 
All reagents used in this project were purchased from commercial sources and used 
without further purification unless otherwise specified. In particular, peptide synthesis 
grade DMF was obtained from AGTC Bioproducts (Hessle, UK), PyBOP from Apollo 
Scientific (Stockport, UK) and NMR solvents which were purchased from Cambridge 
Isotopes Inc., supplied by Goss Scientific (Crewe, UK). All resins and amino acids were 
purchased from Novabiochem by Merck (Darmstadt, Germany). Amines used in 
submonomer peptoid synthesis were obtained either from Sigma Aldrich (Gillingham, 
UK) or TCI Europe (Zwijndrecht, Belgium). These chemicals were used without further 
purification and stored under appropriate conditions, as detailed in the manufacturer’s 
instructions. Bond Elut solid phase extraction cartridges (20 mL, polypropylene with two 
polypropylene frits) were purchased from Crawford Scientific and used as reaction 
vessels for solid phase  synthesis. 
Solvents were removed under reduced pressure using a Büchi Rotavapor R11. The 
following centrifuges were used: an Eppendorf centrifuge 5415D (for 1.5 mL tubes) or a 
Beckman-Coulter Allegra X-22R (for 15mL or 50 mL tubes). A Radleys Discovery 
Technology shaker was also used to mix solutions where indicated and aqueous 
solutions were lyophilised using a Christ Alpha 1-2 LD Plus freeze-drier. 
Abbreviations for common reagents and protecting groups are as follows: tert-
butoxycarbonyl (Boc); 9-fluorenylmethoxylcarbonyl (Fmoc); triphenylmethyl or trityl 
(Trt); N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde); trifluoroacetic acid 
(TFA); triisopropylsilyl (TIPS); N,N-dimethylformamide (DMF); N,N-
diisopropylcarbodiimide (DIC); dimethylsulphoxide (DMSO); dichloromethane (DCM).
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7.2 Characterisation  
7.2.1 Liquid chromatography electrospray ionisation mass spectrometry   
Analytical LC-MS data were obtained using a triple quadrupole mass spectrometer 
equipped with an Acquity UPLC (Waters Ltd, UK) and a photodiode array detector. 
Samples were injected onto the Acquity UPLC BEH C18 column (1.7 μm, 2.1 mm × 
50 mm) with a flow rate of 0.6 mL min-1 and a linear gradient of 5–95 % of solvent B over 
3.8 min (A = 0.1 % formic acid in H2O, B = 0.1 % formic acid in acetonitrile). The flow was 
introduced into the electrospray ion source of the Aquity TQD mass spectrometer. 
 
7.2.2 Quadrupole time-of-flight mass spectrometry  
Measurements were performed using a QToF Premier mass spectrometer with an 
Acquity ultra-performance liquid chromatography system (Waters Ltd, UK). Samples 
were injected to the Acquity UPLC BEH C18 column (1.7 µm, 2.1 mm x 100 mm) with a 
flow rate of 0.6 mL min-1 and a linear gradient of 0–99 % of solvent B over 6 min 
(A = 0.1 % formic acid in H2O, B = 0.1 % formic acid in acetonitrile). The solvent flow 
from the UPLC was injected into a 0.2 mL/min flow of acetonitrile which was introduced 
into the electrospray ion source. 
 
7.2.3 Matrix-assisted laser desorption/ionisation mass spectrometry 
MALDI-ToF analysis was obtained using an Autoflex II ToF/ToF mass spectrometer 
(Bruker Daltonik GmBH) equipped with a 337 nm nitrogen laser. The sample solution 
(ideally at 1 mg mL-1) was mixed with matrix solution, typically α-cyano-4-
hydroxycinnamic acid (~ 50 mg mL-1) in the ratio 9:1 matrix to sample. 1 µL of the 
matrix/sample solution was spotted to the MALDI target and allowed to evaporate prior 
to analysis, where the metal target is placed into the MALDI ion source. The samples 
were analysed in positive detection mode with reflectron enhanced mass resolution for 
m/z between 500 and 5000. Internal mass calibration with known standards was used to 
established the mass accuracy. Variable laser intensities were used to ensure the most 
representative mass spectra for samples were produced. 
MALDI MS/MS was performed using LIFT technology (MALDI LIFT-ToF-ToF) which 
enables detection of product ions that result from elevated laser power. 
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7.2.4 Nuclear magnetic resonance spectroscopy  
1H, 13C, 19F NMR spectra were obtained on the following machines; Varian Mercury-400 
MHz, Varian VNMRS-600 MHz and Bruker Avance-400 MHz spectrometers.  
Chemical shifts are reported in parts per million (δ ppm) and relative to residual solvent 
peaks. J couplings are reported in megahertz (MHz). Multiplicities: s = singlet, d = 
doublet, t = triplet. 
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Chemical Synthesis and Solid Phase Synthesis 
Methods 
7.3 Linear peptoid synthesis 
7.3.1 Manual synthesis at room temperature 
Rink Amide resin: 
Modified protocol following the submonomer synthesis of peptoids.1 Fmoc-protected 
Rink Amide resin (normally 100–300 mg, 0.1–0.3 mmol, typical loading between 0.6–
0.8 mmol g-1) was swollen in DMF (at least 1 hour, overnight preferred, at room 
temperature) in a 20 mL polypropylene syringe fitted with two polyethylene frits. The 
resin was deprotected with piperidine (20 % in DMF v/v, 2 x 20 min) and washed with 
DMF (3 x 2 mL). The resin was treated with haloacetic acid (either bromo- or 
chloroacetic acid dependent on monomer to be installed, 1 mL, 0.6 M in DMF) and DIC 
(0.20 mL, 50 % v/v in DMF) for 20 minutes at room temperature at 400 rpm. The resin 
was washed with DMF (3 x 2 mL), before the desired amine sub-monomer was added 
(1 mL, 0.8–2.0 M in DMF) and allowed to react for 60 minutes at room temperature on 
the shaker. The resin was again washed with DMF (3 x 2 mL) and the bromoacetylation 
and amine displacement steps were repeated until the final submonomer had been 
added and the desired peptoid sequence had been obtained. The resin was shrunk in 
diethyl ether to remove DMF in preparation for cleavage, as in section 7.12.1. The 
products on resin were stored at -18 ˚C and purified using RP-HPLC (section 7.13.1). 
 
2-chlorotrityl chloride resin: 
2-chlorotrityl chloride resin (normally 100–250 mg, 0.1–0.2 mmol, typical loading 
1.22 mmol g-1) was swollen in dry DCM (45 minutes at room temperature) in a 20 mL 
polypropylene syringe fitted with two polyethylene frits. The resin was washed with dry 
DCM (3 x 2 mL) and loaded with bromoacetic acid (1 mL, 0.6 M in DMF) and neat DIPEA 
(16 eq. with respect to the resin) for 30 minutes at RT on a shaker at 400 rpm. The resin 
was washed with DMF (3 x 2 mL), before the desired amine sub-monomer was added 
(1 mL, 1.5 M in DMF) and allowed to react for 60 minutes at RT on the shaker. The resin 
was again washed with DMF (3 x 2 mL) and the resin was treated with bromoacetic acid 
(1 mL, 0.6 M in DMF) and DIC (0.2 mL, 50 % v/v in DMF) for 20 minutes at RT on the 
shaker. The resin was washed again with DMF (3 x 2 mL) and amine displacement and 
bromoacetylation steps repeated until the final sub-monomer had been added and the 
desired linear peptoid precursor had been obtained. The resin was shrunk in diethyl 
ether to remove DMF in preparation for cleavage (section 7.12.2). If required, the 
products on resin were stored at -18 ˚C 
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7.3.2 Automated synthesis at room temperature 
Automated peptoid synthesis using an Aapptec Apex 396 synthesiser. Fmoc-protected 
Rink Amide resin (0.1 mmol, loading typically 0.54 mmol g-1) was swollen in DMF (2 mL, 
2 min, 475 rpm at RT) and deprotected with 4-methylpiperidine (20 % in DMF v/v, 1 mL 
for 1 min, 475 rpm at RT; then 2 mL for 12 min, 475 rpm at RT). The resin was treated 
with haloacetic acid solution (either bromo- or chloroacetic acid, 1 mL, 0.6 M in DMF) 
and DIC (0.18 mL, 50 % v/v in DMF) for 20 min at 475 rpm, RT. The resin was washed 
with DMF (2 mL DMF for 1 min at 475 rpm, x 5) before the desired amine sub-monomer 
was added (1 mL, 1.5M in DMF) and shaken for 60 minutes at 475 rpm (90 min if 
chloroacetic acid was used as the acetylating agent). The resin was washed again with 
DMF (2 mL DMF for 1 min at 475 rpm, x 5) and the acetylation and amine displacement 
steps were repeated until the desired sequence was achieved. The resin was shrunk in 
diethyl ether in preparation for resin cleavage, as in section 7.12.1. The products on resin 
were stored at -18 ˚C and purified using RP-HPLC (section 7.13.1). 
 
7.4 Addition of glycine-glycine spacer to N terminus of peptoids 
The linear peptoid was synthesised via manual SPPS, as in section 7.3 and the glycine 
spacer added as follows. Peptoids on resin were swollen in DMF in a polypropylene 
syringe fitted with a polyethylene frit (at least 1 hour, overnight preferred, at RT). PyBOP 
(4 eq. with respect to the resin), Fmoc-Gly-OH (4 eq.) and DIPEA (4 eq.) were dissolved 
in the minimum volume of DMF and left to preactivate for several minutes, before being 
added to the resin and placed on the shaker at 400 rpm at room temperature for 1 hour. 
The resin was washed with DMF (3 x 2 mL) and the resin deprotected using piperidine 
(20 % in DMF v/v, 2 x 20 min). The resin was washed with DMF (3 x 2 mL) and the 
second glycine residue added as above, followed by a second deprotection step. The resin 
was shrunk in diethyl ether to remove DMF and if necessary, the products on resin were 
stored at -18 ˚C prior to cleavage, as in section 7.12. 
 
7.5 Addition of Ahx to peptoid sequence  
The linear peptoid was synthesised via manual or automated SPPS on Rink Amide, as in 
section 7.3. Peptoids on resin were swollen in DMF in a polypropylene syringe fitted with 
a polyethylene frit (at least 1 hour, overnight preferred, at RT). PyBOP (4 eq. with respect 
to the resin), Fmoc-Ahx-OH (4 eq.) and DIPEA (4 eq.) were dissolved in the minimum 
DMF and left to preactivate for several minutes, before being added to the resin and 
placed on the shaker at 400 rpm at room temperature for 1 hour. Fmoc-Ahx-OH coupling 
repeated. The resin was then washed with DMF (3 x 2 mL) and deprotected using 
piperidine (20 % in DMF v/v, 2 x 20 min) and washed as before. PyBOP (4 eq. with 
respect to the resin), Fmoc-Cys(Trt)-OH (4 eq.) and DIPEA (4 eq.) were dissolved in the 
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minimum volume of DMF and left to react for several minutes, before being added to the 
resin and placed on the shaker at 400 rpm at room temperature for 1 hour. Fmoc-
Cys(Trt)-OH coupling repeated. The resin was washed with DMF (3 x 2 mL) then the 
Fmoc-group deprotected immediately prior to final cleavage using piperidine (20 % in 
DMF v/v, 2 x 4 mL, 2 x 20 mins). The resin was washed with DMF (3 x 2 mL) and resin 
cleavage (section 7.12.1), deprotection and RP-HPLC purification (section 7.13.1) was 
undertaken as before to afford the desired Cys-Ahx tagged peptoid.  
 
7.6 Addition of fluorescein to peptoid sequence  
The linear peptoid was synthesised via manual or automated SPPS, as in section 7.3 on 
Rink Amide resin and a glycine spacer added prior to the fluorescent dye: peptoids on 
resin were swollen in DMF in a polypropylene syringe fitted with a polyethylene frit (at 
least 1 hour, overnight preferred, at RT). PyBOP (4 eq. with respect to the resin), Fmoc-
Gly-OH (4 eq.) and DIPEA (4 eq.) were dissolved in the minimum volume of DMF and 
left to preactivate for several minutes, before being added to the resin and placed on the 
shaker at 400 rpm at room temperature for 1 hour. The resin was then washed with DMF 
(3 x 2 mL) and the resin deprotected using piperidine (20 % in DMF v/v, 2 x 20 min) and 
washed as before. PyBOP (4 eq. with respect to the resin), fluorescein (4 eq.) and DIPEA 
(4 eq.) were dissolved in the minimum DMF and left to react for several minutes, before 
being added to the resin and placed on the shaker at 400 rpm at room temperature for 
1 hour. The fluorescein coupling was repeated and then the resin was washed with DMF 
(6 x 2 mL) and finally DCM (3 x 2 mL). Resin cleavage (see protocol 7.12.1) and RP-HPLC 
purification (section 7.13.1) was undertaken to afford the desired fluorescently tagged 
peptoid. Peptoids on resin and the cleaved product should be stored in the dark.  
 
7.7 Addition of lipid tail groups to peptoid N terminus 
The linear peptoid sequence was synthesised via manual or automated SPPS on Rink 
Amide, see protocol 7.3. The lipid tail was added under standard conditions for the 
peptoid submonomer method using a variety of lipoamines: acylation of the peptoid 
sequence using bromoacetic acid solution (1 mL, 0.6 M in DMF) and DIC (0.2 mL, 
50 % v/v in DMF) for 20 min at 400 rpm at RT. The resin was washed with DMF (3 x 
2 mL) before the desired amine submonomer was added (1 mL, between 0.5–2M in DMF, 
DCM or NMP depending upon amine solubility) and shaken for 60 min at 400 rpm. The 
resin was washed with DMF (3 x 2 mL) and resin cleavage and deprotection (section 
7.12.1) and RP-HPLC purification (section 7.13.1) was undertaken as before to afford the 
desired peptoid with lipid tail.  
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7.8 Addition of lipid head groups to peptoid C terminus 
The linear peptoid sequence was synthesised via manual or automated SPPS on 2-
chlorotrityl chloride resin, as in section 7.3. The peptoid was cleaved from the resin 
(whilst still protected) using HFIP/DCM cleavage cocktail protocol (section 7.12.2) to 
afford a lyophilised protected peptoid. The lipohead group was added in a solution phase 
coupling: the peptoid sequence (1 eq., typically 20 µmol), PyBOP (4 eq. with respect to 
the peptoid) and DIPEA (4 eq.) were dissolved in the minimum volume of DMF and left 
to preactivate for several minutes. The required amine was then added (4 eq. with 
respect to the peptoid in in DMF, DCM or NMP, depending upon solubility) and stirred 
for 90 minutes at RT. The solvent was removed in vacuo in a fumehood, the remaining 
peptoid residue washed with HCl (0.1 M, ~20 mL) and then the peptoid extracted into 
DCM. The organic layers were combined, dried over MgSO4, filtered then the DCM was 
removed in vacuo. The peptoid was then deprotected in TFA/DCM (50 % v/v) for 
30 minutes at room temperature. The TFA solution was removed in vacuo and the 
residue remaining was dissolved in 1 : 1 H2O : MeCN (~5 mL), frozen and lyophilised. RP-
HPLC purification was undertaken as in section 7.13.1 to afford the desired peptoid with 
lipid head group. 
 
7.9 Cyclic peptoids 
7.9.1 Synthesis of linear precursors 
2-chlorotrityl chloride resin (normally 100–250 mg, 0.1–0.2 mmol, typical loading 
1.22 mmol g-1) was swollen in dry DCM (45 minutes at RT) in a 20 mL polypropylene 
syringe fitted with two polyethylene frits. The resin was washed with dry DCM (3 x 2 mL) 
and loaded with bromoacetic acid (1 mL, 0.6 M in DMF) and neat DIPEA (16 eq. with 
respect to the resin) for 30 minutes at RT on a shaker at 400 rpm. The resin was washed 
with DMF (3 x 2 mL), before the desired amine sub-monomer was added (1 mL, 1.5 M in 
DMF) and allowed to react for 60 minutes at RT on the shaker. The resin was again 
washed with DMF (3 x 2 mL) and the resin was treated with bromoacetic acid (1 mL, 
0.6 M in DMF) and DIC (0.2 mL, 50 % v/v in DMF) for 20 minutes at RT on the shaker. 
The resin was washed again with DMF (3 x 2 mL) and amine displacement and 
bromoacetylation steps repeated until the final sub-monomer had been added and the 
desired linear peptoid precursor had been obtained. The resin was shrunk in diethyl 
ether to remove DMF in preparation for cleavage (7.12.2). If required, the products on 
resin were stored at -18 ˚C. 
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7.9.2 Off-resin cyclisation  
The linear peptoid precursors were made as above and cleaved from 2-chlorotrityl 
chloride resin (as in 7.12.2) to yield the protected linear peptoid. Crude peptoids were 
used without further purification. Typically the linear peptoid (100 µmol) was dissolved 
in dry, deoxygenated DMF (10 mL) and added dropwise to a solution of PyBOP (4 eq. 
with respect to the crude linear peptoid) and DIPEA (4 eq.) in the minimum amount of 
DMF over 5 hours. The reaction was allowed to proceed for a further hour at room 
temperature under an inert atmosphere. The solvent was removed in vacuo and diluted 
with DCM (20 mL) and HCl (0.2M, 20 mL). The crude peptoids were extracted using 
DCM (2 x 20 mL). The organic phases were combined, washed with water and dried over 
MgSO4 before filtration and solvent removal in vacuo. The resulting residue was 
dissolved in 50 % MeCN in H2O and lyophilised. The protected peptoids were then 
dissolved in 50 % MeCN in H2O and purified by preparative RP-HPLC; flow rate = 
2 mL min-1; injection made at 50 % B and a linear gradient elution 50–100 % solvent B 
over 60 minutes (solvent A = 0.1 % TFA in 95 % H2O, 5 % MeCN, solvent B = 0.1 % TFA in 
5 % H2O, 95 % MeCN). Relevant fractions were collected, lyophilised and analysed by 
LC-MS. The crude products were deprotected using 50 % TFA in DCM for 30 minutes 
and the cleavage cocktail then evaporated using a stream of N2. The crude products were 
dissolved in ~1.5 mL (95 % H2O, 5 % MeCN, 0.1 % TFA) and purified by preparative RP-
HPLC flow rate = 2 mL min-1; linear gradient elution 0–50 % solvent B over 60 minutes, 
then 50–100 % B over 15 minutes. Relevant fractions were collected, lyophilised and 
analysed by LC-MS. 
 
7.10 Arginine-type peptoids 
7.10.1 Synthesis of polyarginine peptoids 
For the synthesis of polyarginine peptoids (where all lysine residues are transformed to 
the guanidine group of arginine residues), the peptoids were made, as in 7.3.1 via manual 
SPPS, using NLys or Nae submonomers, cleaved from the resin and purified using RP-
HPLC (section 7.13.1) to afford the unprotected, linear amino-functionalised peptoid. 
Guanidinylation of the free primary amine chains was undertaken using pyrazole-1-
carboxamidine hydrochloride (4 eq. per free amine, with respect to the crude peptoid) 
and DIPEA (4 eq. per amine), which were dissolved in the minimum amount of DMF and 
added to the peptoid. The reaction was stirred at room temperature for 6 hours. A 
mixture of TFA : H2O 10 : 90 was added to quench the reaction until a neutral pH was 
achieved. The solvent was removed in vacuo, the residue dissolved in acidified H2O 
(0.1 % TFA) and lyophilised before purification using protocol 7.13.1.  
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7.10.2 On-resin synthesis of mixed NLys and NArg type peptoids 
To introduce arginine-type residues during the submonomer procedure, the appropriate 
unprotected diamine was added under normal submonomer coupling conditions (1.5 M 
amine in DMF, 60 minutes, RT) in place of the mono-N-Boc diamine and the resin 
washed with DMF (3 x 2 mL). Dde-OH (10 eq. wrt resin in the minimum volume of DMF) 
was added to the resin and placed on the shaker at RT for 60 minutes and the resin 
washed well with DMF (3 x 2 mL). Subsequent peptoid couplings were made as normal 
until the desired sequence was achieved, including any extra Dde-protected residues. 
After synthesis of the linear peptoid sequence, on resin deprotection of the Dde group 
was undertaken using 2 % hydrazine in DMF (4 x 4 mL x 3 mins) and the resin washed 
with DMF (3 x 2 mL). Guanidinylation of the free amines was achieved using pyrazole-1-
carboxamidine (6 eq. per free amine, in the minimum amount of DMF) and DIPEA (6 eq. 
per free amine) on the shaker at 400 rpm, RT for 60 minutes. The resin was washed with 
DCM (3 x 2 mL) and shrunk in ether prior to cleavage from the resin (section 7.12) 
 
7.10.3 Synthesis of cyclic mixed NLys and NArg type peptoids 
2-chlorotrityl chloride resin (0.1 mmol, typical loading 1.22 mmol g-1) was swollen in dry 
DCM (45 minutes, at RT) in a 20 mL polypropylene syringe fitted with two polyethylene 
frits. The resin was washed with dry DCM (3 x 2 mL) and loaded with bromoacetic acid 
(1 mL, 0.6 M in DMF) and neat DIPEA (16 eq. with respect to the resin) for 30 minutes at 
RT on a shaker at 400 rpm. The resin was washed with DMF (3 x 2 mL), before the 
desired amine sub-monomer was added (1 mL, 1.5 M in DMF) and allowed to react for 
60 minutes at RT on the shaker. The resin was again washed with DMF (3 x 2 mL) and 
the resin was treated with bromoacetic acid (1 mL, 0.6 M in DMF) and DIC (0.2 mL, 50 % 
v/v in DMF) for 20 minutes at RT on the shaker. The resin was washed again with DMF 
(3 x 2 mL) and amine displacement and bromoacetylation steps repeated until the final 
sub-monomer had been added and the desired linear peptoid precursor had been 
obtained.  The resin was shrunk in ether prior to cleavage. Final cleavage from resin was 
achieved using HFIP (4 mL, 20 % v/v in DCM) for 30 minutes. The resin was removed by 
filtration and the cleavage cocktail sparged off using a fine stream of N2. The crude 
product was precipitated in diethyl ether (15 mL) and the precipitate retrieved by 
centrifuge for 15 min at 5,000 rpm. The ether phase was decanted, the crude, protected 
product dissolved in a mixture of acidified H2O (0.1 % TFA) and MeCN then lyophilised.  
Crude peptoids were cyclised in solution without further purification. Typically, the 
linear peptoid (100 µmol) was dissolved in dry DMF (10 mL) and added dropwise to a 
solution of PyBOP and DIPEA (both 6 eq. with respect to the crude linear peptoid, in 
10 mL DMF) over 8 hours. The reaction was allowed to proceed for a further 60 minutes 
at room temperature following the last addition. The DMF solvent was removed in vacuo 
and the crude peptoids were extracted using DCM (2 x 20 mL). The organic phases were 
combined, washed with water and dried over MgSO4 before filtration and solvent 
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removal in vacuo. The resulting residue was dissolved in 50 % MeCN in H2O and 
lyophilised.  
The protected peptoids were then dissolved in 50 % MeCN in H2O and purified by 
preparative RP-HPLC; flow rate = 2 mL min-1; injection made at 50 % B and a linear 
gradient elution 50–100 % solvent B over 60 minutes (solvent A = 0.1 % TFA in 95 % H2O, 
5 % MeCN, solvent B = 0.1 % TFA in 5 % H2O, 95 % MeCN). Relevant fractions were 
collected, lyophilised and analysed by LC-MS.  
At this stage, any Dde-groups were removed using 2 % hydrazine in DMF (4 x 4 mL x 
3 mins) and then the resin washed with DMF (3 x 2 mL). Guanidinylation of the free 
amines was undertaken using pyrazole-1-carboxamidinee (6 eq. per free amine, in the 
minimum amount of DMF) and DIPEA (6 eq. per free amine) on the shaker at 400 rpm, 
RT for 60 minutes. The cyclic peptoids were then deprotected using 95 : 2.5 : 2.5 TFA : 
H2O : TIPS (4 mL) for 1.5 hours. The cleavage cocktail was removed in vacuo, the crude 
product precipitated in diethyl ether (45 mL) and the precipitate retrieved by centrifuge 
for 15 min at 5,000 rpm. The ether phase was decanted, the crude product dissolved in a 
mixture of acidified H2O (0.1 % TFA) and MeCN and lyophilised prior to final 
purification by RP-HPLC (section 7.13.1). 
 
7.11 Peptide synthesis 
Fmoc SPPS procedures are detailed in the following sections. Resin swelling was 
undertaken in a fritted polypropylene reaction vessel (Crawford Scientific) in DMF for a 
minimum of 1 h (overnight preferred), followed by washing with DMF. Amino acid side 
chain functionality was protected as follows: FmocArg(Pbf)OH, FmocAsn(Trt)OH, 
FmocAsp(tBu)OH, FmocCys(Trt)OH, FmocGln(Trt)OH, FmocGlu(tBu)OH, 
FmocHis(Trt)OH, FmocLys(Boc)OH, FmocSer(tBu)OH, FmocThr(tBu)OH, 
FmocTrp(Boc)OH and FmocTyr(tBu)OH. Fmoc deprotections were carried out using a 
20 % (v/v) solution of piperidine in DMF.  
 
7.11.1 Automated peptide synthesis 
Automated SPPS was carried out on a CEM Liberty 1 single channel microwave peptide 
synthesizer equipped with a Discover microwave unit. All reactions were carried out 
using the 30 mL PTFE reaction vessel, with microwave heating and agitation by bubbling 
N2. Couplings were carried out using Fmoc protected amino acid (5 eq.), DIC (10 eq., 
0.8 M solution of DIC in DMSO), HOBt (20 eq., 0.5 M solution of HOBt in DMF). For 
double couplings the reaction vessel was drained after each cycle and fresh reagents were 
added. Microwave couplings at 0.10 mmol scale were carried out for 10 min at 75 ˚C and 
25 W power unless otherwise stated. Cys and His residues were coupled at low 
temperature: 10 min at room temperature followed by 10 min at 50 ˚C (25 W). Arg 
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residues were double coupled, with the first coupling carried out for 45 min at RT 
followed by 5 min at 75 ˚C (25 W), and the second using the standard microwave 
conditions given. Room temperature reactions were carried out using 2 x 1 h couplings 
(3 x 1 h for Arg residues). The Fmoc group was removed by two successive treatments 
with piperidine solution (5 min then 10 min). Automated SPPS was continued until the 
sequence was complete. 
 
7.11.2 Manual peptide synthesis 
Manual peptide synthesis was only used for additions of several amino acids to a peptide 
or peptoid sequence. The linear peptoid was synthesised via manual or automated SPPS 
as previously described. The sequence on resin was swollen in DMF in a polypropylene 
syringe fitted with a polyethylene frit (at least 1 hour, overnight preferred, at room 
temperature). PyBOP (4 eq. with respect to the resin), the Fmoc-protected amino acid 
(4 eq.) and DIPEA (4 eq.) were dissolved in the minimum DMF and left to preactivate for 
several minutes, before being added to the resin and placed on the shaker at 400 rpm at 
room temperature for 1 hour. The resin was then washed with DMF (3 x 2 mL) and 
deprotected using piperidine (20 % in DMF v/v, 2 x 20 min) and washed as before. 
Further amino acid couplings and Fmoc-deprotection steps were made as necessary.  The 
resin was washed with DMF (3 x 2 mL) and resin cleavage (section 7.12.1) and RP-HPLC 
purification (section 7.13.1) was undertaken as before.  
 
7.12 Cleavage protocols from acid-labile resins 
7.12.1 Rink Amide resin 
Final cleavage from resin was achieved using TFA (95 %), H2O (2.5 %) and TIPS (2.5 %). 
For test cleaves approximately 1 mL of the cleavage cocktail was used and for cleavage 
from 100 mg resin, approximately 4 mL of the cleavage cocktail was added. The resin was 
then placed on the shaker at 400 rpm for 1.5 hours* and the resin removed by filtration. 
The cleavage cocktail was removed in vacuo, the crude product precipitated in diethyl 
ether (45 mL) and the precipitate retrieved by centrifuge for 15 min at 5,000 rpm. The 
ether phase was decanted, the crude product dissolved in a mixture of acidified H2O and 
MeCN and lyophilised. 
 
                                                     
*
 Cleavage times depended on the particular sequence. For peptoids with only Boc protection cleavage of 45 
minutes was adequate. For peptide sequences containing Arg(Pbf) cleavage times of around 6 hours were 
necessary. 
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7.12.2 2-Chlorotrityl chloride resin 
Final cleavage from resin was achieved using hexafluoroisopropanol in DCM (20 % v/v). 
For test cleaves approximately 1 mL of the cleavage cocktail was used and for cleavage 
from 100 mg resin, approximately 4 mL of the cleavage cocktail was added. The resin was 
then placed on the shaker at 400 rpm for 30 minutes and the resin removed by filtration. 
The cleavage cocktail was evaporated using a stream of N2, the crude product dissolved 
in a mixture of H2O and MeCN and lyophilised. 
 
7.13 Purification protocols  
7.13.1 Preparative high performance liquid chromatography  
Crude peptoids were dissolved into ~1.5 mL (95 % H2O, 5 % MeCN, 0.1 % TFA) and 
purified by preparative RP-HPLC using a Perkin Elmer 200 Series LC pump with a 
Perkin-Elmer 785A UV-vis detector (λ = 250 nm or 220 nm) on a SB Analytical column 
(ODS-H Optimal), 250 x 10 mm, 5 µm; flow rate = 2 mL min-1; typical linear gradient 
elution 0–50 % solvent B over 60 minutes, then 50–100 % B over 15 minutes (solvent A = 
0.1 % TFA in 95 % H2O, 5 % MeCN, solvent B = 0.1 % TFA in 5 % H2O, 95 % MeCN). The 
gradients chosen were informed by the analytical HPLC retention times of crude 
products. Relevant fractions were collected, lyophilised and analysed by LC-MS. 
 
7.13.2 Analytical high performance liquid chromatography  
Samples were dissolved in 100 µL acidified water and the purity of products was 
estimated by an injection of 10 µL to analytical RP-HPLC using a Perkin Elmer 200 Series 
LC pump with a Perkin-Elmer 785A UV-vis detector on an SB Analytical column (ODS-H 
Optimal), 4.6 x 100mm , 3.5 µm; flow rate = 1 mL min-1; loop size = 20 µL; λ = 220 nm; 
gradient: 0–100 % solvent B over 30 min (solvent A: 95 % H2O, 5 % MeCN, 0.05 % TFA; 
solvent B: 95 % MeCN, 5 % H2O, 0.03 % TFA). 
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7.14 Preparation of amines for peptoid synthesis 
Most amines were commercially available in a useable form (see appendix for table of 
amine submonomers). Amines that needed treatment or protection before use are 
described below.  
 
7.14.1 Freebasing of tBu-β-alanine (127) NGlu(tBu) 
Commercially available tBu β-alanine HCl (5.04 g, 27.7 mmol) was 
dissolved in DCM (15 mL) and neutralised using NaOH (1M, 
approximately 100 mL). The organic phase was separated and dried 
over Na2SO4, filtered and the solvent removed from the filtrate in 
vacuo to yield tBu β-alanine as a clear oil (2.7 g, 67 %). The product was used without 
further characterisation or purification. 
 
7.14.2 Trityl protection of thioethylamine (128) NCys(Trt) 
 Protocol followed as in the literature2 and product also 
commercially available. Thioethylamine HCl (3.00 g, 264 mmol) 
was dissolved in TFA (50 mL) and cooled to 0 ˚C. 
Triphenylmethanol (7.72 g, 264 mmol) was added and the 
reaction stirred for 3 hours. The TFA was diluted in water (100 
mL) and neutralised using solid NaHCO3 (1 M). DCM was added 
(100 mL) and the organic phase was separated, dried over 
MgSO4, filtered and the chloroform removed from the filtrate in 
vacuo. The 2-(tritylsulfanyl)ethanamine was found as a white powder and used without 
further purification (3.01 g, 36 %); 1H NMR (400 MHz, CDCl3) δ 2.47 (4H, s, CH2), 7.22–
7.45 (15H, m, Ar-H); 13C NMR (400 MHz, CDCl3) δ 33.17, 39.84, 66.93, 126.88, 128.04, 
129.49, 144.49; IR (cm-1) 3018 (N-H), 1676, 1142, 753, 699; LCMS (ESI-TQD) m/z: [M+H]+ 
mass calculated: 319.1, [2M+H]+ mass observed: 639.2.  
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7.14.3 Synthesis of N-Boc-1,4-diaminobutane (129) NLys(Boc) 
 1,4-diaminobutane (17.60 g, 200 mmol) was dissolved in 
chloroform (100 mL) and cooled to 0 ˚C. Di-tert-butyl 
dicarbonate (4.40 g, 20 mmol) was dissolved in chloroform 
(200 mL) and added to the 1,4-diaminobutane solution at 
0 ˚C dropwise over 6 hours. The mixture was then stirred at 
room temperature for a further 18 hours and washed with deionised water (8 x 200 mL) 
until the organic phase became clear. The organic phase was separated and dried over 
MgSO4, filtered and the chloroform removed from the filtrate in vacuo to yield N-Boc 1,4-
diaminobutane as a  clear, yellow oil (2.10 g, 76 %); 1H NMR (400 MHz, D2O) δ 1.43–1.48 
(9H + 4H, m, CH3 + CH2), 2.60 (2H, t, J 8.0, NH2CH2CH2-), 3.06 (2H, t, J 8.0, -
CH2CH2NHBoc); 
13C NMR (400 MHz, D2O) δ 26.5, 27.8 (CH3), 29.1, 39.9, 40.3, 80.6 
(C(CH3)3), 158.2 (C=O); IR (neat, cm
-1) 3345 (N-H), 2960, 2915, 2850, 1700 (C=O), 1560, 
1545, 1525, 1475, 1270, 860; LCMS (ESI-TQD) m/z: [M+H]+ mass calculated: 188.3, mass 
observed: 188.7.  
 
7.14.4 Attempted Synthesis of N-Dde-1,4-diaminobutane (145) NLys(Dde) 
 1,4 diaminobutane (2.42 g, 27.44 mmol) was dissolved in 
chloroform or DCM (100 mL) and cooled to 0 ˚C. 2-
acetyldimedone (0.50 g, 2.74 mmol) was dissolved in 
chloroform or DCM (100 mL) and added to the amine 
solution at 0 ˚C dropwise over 1, 6 or 10 hours. The mixture 
was then stirred at room temperature for a further 18 hours 
and washed with deionised water until the organic phase 
became clear. The organic phase was separated and dried over MgSO4, filtered and the 
chloroform removed from the filtrate in vacuo. The resulting mixture of mono and di-
protected 1,4-diaminobutane was separated using silica column chromatography in 
DCM/MeOH. The mono product 145 was not isolated, only diprotected N-N-Dde-,4-
diaminobutane 146 as a white powder (0.88 g, 77 %); 1H NMR (400 MHz, CDCl3) δ 0.98 
(12H, s, CH3), 1.79 (4H, m, NHCHCH2CH2CHNH), 2.31 (8H, s, CH2), 2.51 (6H, s, CH3), 3.42 
(4H, NHCH2CH2CH2CH2NH), 13.51 (2H, br s, NHCH2CH2CH2CH2NH); 
13C NMR (400 
MHz, CDCl3) δ 17.85, 26.45, 28.23, 30.04, 42.78, 52.82, 107.90, 173.53, 197.88; LCMS (ESI-
TQD) m/z: [M+H]+ mass calculated: 418.6, mass observed: 418.9. 
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7.15 Nisin-tagged Peptoids 
Click reactions to tag peptoid sequences with nisinA/B ring fragments were undertaken at 
the University of Utrecht with Professor Nathaniel Martin and assisted by Laurens Kleijn. 
 
7.15.1  Digestion of nisin to nisinA/B ring fragments 
Nisin (600 mg, 0.18 mmol) was dissolved in 250 mL Tris buffer (25 mmol, NaOAc, 
5 mmol Tris acetate, 5 mmol CaCl2, pH 7.0) and the solution cooled on ice for 15 minutes. 
Trypsin (50 mg) was added and stirred at room temperature for 15 minutes. The mixture 
was then heated to 30 °C for 16 hours, then another 50 mg of trypsin was added and after 
an additional 24 hours the reaction was complete by HPLC. The reaction was acidified 
with HCl (1 M) to pH 4.0 and solvents removed in vacuo. The nisin fragment was isolated 
by preparative HPLC and product fractions lyophilised to obtain a white powder (80 mg, 
39 %).3  
 
7.15.2  Amide-coupled azide-nisinA/B 
NisinA/B was dissolved in DMF (240 µL). BOP (2 eq.), DIPEA (4 eq.) and 
azidopropylamine (50 eq.) were added. The reaction was stirred for 20 minutes then 
quenched in the appropriate buffer (95 % H2O, 5 % MeCN, 0.1 % TFA, 4 mL). The 
solution was centrifuged for 5 min at 5,000 rpm to remove any insoluble material and the 
supernatant was purified by RP-HPLC. Relevant fractions were collected and analysed to 
yield the pure NisinA/B-azide.3 
 
7.15.3  Click protocol of alkyne-peptoids with nisinA/B-azide 
10x stock solutions of CuSO4 (16.2 µmol, 2.59 mg in 1 mL H2O), 10x sodium ascorbate 
(32.4 µmol, 6.42 mg in 1 mL H2O) and 10x TBTA (4.1 µmol, 2.18 mg in 1 mL DMF) were 
freshly prepared. NisinA/B-azide (1 eq., 8.1 µmol, 10 mg) was dissolved in 200 µL DMF and 
added to the peptoid in the microwave reaction vessel (1 eq., 8.1 µmol). 100 µL of the 
CuSO4 solution (0.2 eq., 1.62 µmol), 100 µL of sodium ascorbate stock (0.4 eq., 3.24 µmol) 
and 100 µL of the TBTA solution (0.05 eq., 0.41 µmol) were added. The vessel was sealed 
and heated under microwave power for 20 minutes at 80 °C. The reaction mixture was 
diluted in the appropriate buffer (95 % H2O, 5 % MeCN, 0.1 % TFA, 4mL) and purified by 
RP-HPLC on a Reprospher 100 C8- or C18- Aqua column (10 µm x 250 x 20 mm) at a flow 
rate of 6 mL min-1; λ = 214 nm; linear gradient elution 20–80 % solvent B over 120 minutes 
(where A = 95 % H2O, 5 % MeCN, 0.1 % TFA; B = 95 % MeCN, 5 % H2O, 0.1 % TFA). 
Relevant fractions were combined and lyophilised from 1 : 1 H2O : 
tBuOH mixture to yield 
purified peptoid-peptide conjugates as a white powder. 
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Products 
 
A table to illustrate the monomers used in this library, their abbreviation code and the 
amine submonomer they are derived from can be found in Table A1 in the appendix. 
These monomers are also listed on www.pep-calc.com/peptoid, which is a useful tool for 
the calculation of peptoid molecular weights or molecular formulae. Yields are expressed 
as an overall yield calculated from the initial scale of resin used and final amount of pure 
peptoid obtained. If the whole crude peptoid was not purified, yields are calculated in 
the same way, but taking account of the proportion of crude product that was purified.  
 
7.15.4 Linear peptoid sequences 
Peptoids were synthesised using the submonomer method of peptoid synthesis on Rink 
Amide resin (typical loading 0.79–0.82 mmol g-1, 0.1 mmol scale) as outlined by the 
protocol section 7.3 (or section 7.10 for those sequences containing NnArg, NArg or 
NhArg) and cleaved from the resin using protocol 7.12.1 to afford the crude deprotected 
sequence. The crude sample, or a portion of, was purified by procedure 7.13.1 and pure 
fractions combined to yield the peptoid as a powder. Characterisation data is shown in 
Table 7.1 for these sequences. 
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# Sequence Analytical HPLC Accurate Mass Spectrometry Yield†  
Retention 
time‡ (min) 
Approx. 
purity (%) 
Mass calculated Mass observed (%) (mg) 
210 (NahNpheNphe)4 15.8 > 50 [M+2H]
2+ 910.0473 910.0468 15 15 
211 (NahNpheNphe)3 15.2 > 75 [M+2H]
2+ 684.9157 684.9141 17 13 
212 (NahNpheNphe)2 14.2 > 50 [M+H]
+ 918.5605 918.5634 26 13 
186 (NLysNpheNphe)4 16.6 > 99 [M+2H]
2+ 853.9847 853.9835 24 25 
187 (NLysNpheNphe)3 15.4 > 85 [M+2H]
2+ 642.8688 642.8666 29 22 
188 (NLysNpheNphe)2 14.1 > 85 [M+2H]
2+ 431.7529 431.7513 58 30 
180 (NaeNpheNphe)4 15.3 > 99 [M+2H]
2+ 797.9221 797.9189 22 21 
213 (NaeNpheNphe)3 15.8 > 80 [M+2H]
2+ 600.8218 600.8185 49 35 
214 (NaeNpheNphe)2 14.4 > 80 [M+H]
+ 806.4354 806.4370 45 22 
215 (NahNspeNspe)4 17.7 > 95 [M+2H]
2+ 966.6115 966.6127 14 15 
216 (NahNspeNspe)3 16.8 > 95 [M+2H]
2+ 726.9627 726.9601 16 12 
217 (NahNspeNspe)2 15.2 > 75 [M+2H]
2+ 974.6232 974.6246 23 12 
185 (NLysNspeNspe)6 19.2 > 95 [M+2H]
2+ 1360.8119 1360.8058 14 57 
22 (NLysNspeNspe)4 17.6 > 99 [M+2H]
2+ 910.0473 910.0483 38 15 
26 (NLysNspeNspe)3 17.0 > 95 [M+2H]
2+ 684.9157 684.9142 34 28 
25 (NLysNspeNspe)2 14.4 > 99 [M+2H]
2+ 459.7842 459.7801 36 20 
156 (NaeNspeNspe)4 16.0 > 95 [M+2H]
2+ 853.9847 853.9841 18 13 
218 (NaeNspeNspe)3 17.0 > 95 [M+2H]
2+ 642.8688 642.8660 37 11 
219 (NaeNspeNspe)2 14.1 > 95 [M+2H]
2+ 862.4980 862.4994 48 25 
220 (NLysNpmbNpmb)4 16.5 > 99 [M+2H]
2+ 974.0269 974.0264 7 13 
221 (NLysNpmbNpmb)3 15.9 > 90 [M+2H]
2+ 1464.7931 1464.7937 6 8 
222 (NLysNpmbNpmb)2 14.4 > 75 [M+2H]
2+ 982.5402 982.5395 52 51 
184 (NLysNpcbNpcb)4 20.6 > 99 [M+2H]
2+ 989.8288 989.8279 22 43 
223 (NLysNpcbNpcb)3 19.5 > 99 [M+H]
+ 1490.4945 1490.4976 21 31 
224 (NLysNpcbNpcb)2 17.9 > 95 [M+H]
+ 998.3420 998.3422 28 28 
225 (NLysNpfbNpfb)4 17.5 > 95 [M+2H]
2+ 1850.8861 1850.8865 18 33 
                                                     
†
 Yield is expressed as an overall yield calculated from the final mass recovered following RP-HPLC purification and expressed as a percentage of the original scale of resin used. 
‡
 Gradient, solvents and conditions for analytical HPLC as described in section 7.13.2. 
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226 (NLysNpfbNpfb)3 16.7 > 95 [M+H]
+ 1392.6732 1392.6732 11 15 
227 (NLysNpfbNpfb)2 15.0 > 95 [M+2H]
+ 934.4603 934.4601 14 13 
228 (NLysNmfbNmfb)4 17.0 > 95 [M+2H]
2+ 925.9470 925.9431 34 63 
229 (NLysNmfbNmfb)3 16.4 > 95 [M+H]
+ 1392.6732 1392.6746 47 66 
230 (NLysNmfbNmfb)2 15.1 > 95 [M+H]
+ 934.4603 934.4610 32 30 
183 (NLysNpfbNspe)4 17.6 > 95 [M+2H]
2+ 917.9971 917.9981 14 15 
231 (NLysNpfbNspe)3 16.6 > 95 [M+H]
+ 1380.7484 1380.7505 21 29 
232 (NLysNpfbNspe)2 15.1 > 95 [M+2H]
2+ 926.5104 926.5111 26 24 
157 [(NLysNpfbNpfb)(NLysNspeNspe)]2 18.4 > 95 [M+2H]
2+ 917.9971 917.9983 27 50 
233 (NLysNspeNspe)(NLysNpfbNpfb)(NLysNspeNspe)  16.5 > 80 [M+H]+ 1376.7736 1376.7734 23 32 
234 (NLysNpfbNpfb)(NLysNspeNspe) 15.7 > 80 [M+H]+ 926.5104 926.5096 28 26 
235 (NLysNnValNspe)4 14.8 > 50 [M+H]
+ 1571.0242 1571.0286 41 64 
236 (NLysNnValNspe)3 14.0 > 95 [M+H]
+ 1182.7767 1182.7771 45 53 
237 (NLysNnValNspe)2 12.7 > 95 [M+H]
+ 794.5992 794.5280 33 26 
238 (NLysNLeuNspe)4 16.1 > 99 [M+H]
+ 1627.0868 1627.0897 44 71 
239 (NLysNLeuNspe)3 15.4 > 99 [M+H]
+ 1224.8236 1224.8247 20 24 
240 (NLysNLeuNspe)2 14.0 > 99 [M+H]
+ 822.5605 822.5604 35 29 
182 (NLysNhLeuNspe)4 17.7 > 99 [M+2H]
2+ 842.0786 842.0757 18 12 
241 (NLysNhLeuNspe)3 17.2 > 90 [M+2H]
2+ 1266.8706 1266.8696 18 22 
242 (NLysNhLeuNspe)2 15.4 > 95 [M+H]
+ 850.5919 850.5925 21 18 
243 (NamyNspeNspe)[(NLysNspeNspe)]3 19.4 > 99 [M+2H]
2+ 909.5497 909.5507 18 20 
244 (NamyNspeNspe)2(NLysNspeNspe)2 22.7 > 95 [M+2H]
2+ 909.0521 909.0528 8 9 
245 [(NamyNspeNspe)(NLysNspeNspe)]2 22.8 > 95 [M+2H]
2+ 909.5536 909.5457 8 9 
246 (NLysNspeNspe)2(NamyNspeNspe)(NLysNspeNspe) 20.0 > 90 [M+2H]
2+ 909.5497 909.5483 11 12 
293 (NhArgNpheNphe)4 16.7 > 99 [M+2H]
2+ 938.0283 938.0276 32 12 
294 (NhArgNpheNphe)2 14.6 > 95 [M+H]
+ 946.5416 946.5424 23 30 
152 (NhArgNspeNspe)4 17.9 > 99 [M+2H]
2+ 994.0909 994.0880 46 34 
295 (NhArgNspeNspe)3 17.3 > 95 [M+2H]
2+ 1494.8890 1484.8894 43 19 
153 (NhArgNmfbNmfb)4 17.3 > 99 [M+2H]
2+ 1009.9906 1009.9874 41 23 
296 (NhArgNmfbNmfb)3 16.7 > 95 [M+H]
+ 1518.7386 1518.7372 60 26 
181 (NhArgNhLeuNspe)4 18.3 > 95 [M+2H]
2+ 926.1222 926.1262 82 30 
297 (NhArgNhLeuNspe)3 17.2 > 90 [M+H]
+ 1392.9360 1392.9371 36 27 
154 [(NamyNspeNspe)(NhArgNspeNspe)]2 22.4 > 99 [M+2H]
2+ 951.0739 951.0692 22 40 
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147 (NLysNspeNspe)2(NhArgNspeNspe)2 16.6 > 95 [M+2H]
2+ 952.0691 952.0682 5 6 
148 (NhArgNspeNspe)2(NLysNspeNspe)2 16.9 > 99 [M+2H]
2+ 952.0691 952.0693 7 13 
149 (NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2 17.8 > 99 [M+2H]
2+ 931.0582 931.0579 3 8 
150 [(NhArgNspeNspe) (NLysNspeNspe)]2 16.6 > 99 [M+2H]
2+ 952.0691 952.0730 4 8 
151 [(NnArgNspeNspe)(NaeNspeNspe)]2 18.9 > 99 [M+2H]
2+ 896.0038 896.0026 19 41 
155 (NnArgNspeNspe)4 19.1 > 99 [M+2H]
2+ 938.0283 938.0297 13 30 
247 (NaeNspeNdfea)(NaeNpheNdfea)3 14.4 > 99 [M+2H]
2+ 752.8609 752.8582 25 17 
248 (NaeNspeNea)(NaeNpheNea)3 13.6 > 99 [M+2H]
2+ 680.8986 680.8969 19 25 
249 (NaeNspeNea)4 14.5 > 99 [M+2H]
2+ 701.9221 701.9249 28 16 
250 (NaeNpheNea)2(NaeNspeNea)(NaeNpheNea) 13.4 > 99 [M+H]+ 1360.7894 1360.7881 41 18 
251 (NaeNpheNdfea)2(NaeNspeNdfea)(NaeNpheNdfea) 14.3 > 99 [M+H]+ 1504.7140 1504.7124 36 38 
252 (NaeNpfbNspe)4 17.8 > 99 [M+H]
+ 1722.8643 1722.8632 25 9 
253 [(NaeNpfbNpfb)(NaeNspeNspe)]2 18.0 > 99 [M+2H]
2+ 861.9345 861.9322 18 5 
254 (NLysNpfbNLysNspe)3 13.4 > 99 [M+H]
+ 1765.0333 1765.0327 14 9 
255 (NaeNpfbNaeNspe)3 13.7 > 95 [M+H]
+ 1596.8456 1596.8475 32 18 
256 (NLysNpfbNrpe)4 17.6 > 99 [M+2H]
2+ 917.9971 917.9981 16 13 
257 (NaeNpfbNrpe)4 18.0 > 99 [M+2H]
2+ 861.9345 861.9346 14 8 
258 [(NaeNpfbNspe)(NLysNpfbNspe)]2 17.9 > 99 [M+2H]
2+ 899.9658 899.9665 32 14 
259 (NLysNspe)6 13.7 > 99 [M+2H]
2+ 877.0582 877.0576 31 14 
260 (NaeNspe)6 14.1 > 99 [M+2H]
2+ 792.9643 792.9655 48 21 
261 (NLysNdfbNspe)4 17.9 > 99 [M+H]
+ 1906.9487 1906.9468 17 6 
262 (NaeNdfbNspe)4 18.7 > 95 [M+2H]
2+ 897.9157 897.9141 53 16 
263 (NLysNsfbNsfb)4 18.7 > 99 [M+H]
+ 1963.0114 1963.0105 23 7 
264 (NaeNsfbNsfb)4 19.5 > 99 [M+2H]
2+ 925.9470 925.9482 43 16 
265 (NLysNsfbNspe)4 18.7 > 99 [M+2H]
2+ 1892.0521 1892.0444 41 13 
266 (NaeNtfeNspe)4 16.2 > 99 [M+2H]
2+ 809.8632 809.8655 22 18 
267 (NaeNpfpNspe)4 18.4 > 99 [M+2H]
2+ 909.8592 909.8594 26 18 
268 [(NGluNpfbNspe)(NLysNpfbNspe)]2  19.8 > 99 [M+2H]
2+ 918.9406 918.9448 19 21 
269 (NGluNpfbNspe)(NLysNpfbNspe)3 18.5 > 99 [M+2H]
2+ 918.9725 918.9694 18 20 
270 (NGluNspeNspe)(NLysNspeNspe)3 18.3 > 99 [M+2H]
2+ 910.5211 910.5221 19 21 
271 (NGluNspeNspe)(NLysNspeNspe)2(NGluNspeNspe) 20.4 > 99 [M+2H]
2+ 910.9949 910.9929 18 9 
272 (NLysNspeNspe)(NGluNspeNspe)2(NLysNspeNspe) 20.0 > 90 [M+2H]
2+ 910.9949 910.9950 35 16 
273 (NGluNspeNspe)2(NLysNspeNspe)2 19.8 > 99 [M+2H]
2+ 910.9949 910.9943 36 17 
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274 (NGluNspeNspe)2(NaeNspeNspe)2 20.5 > 90 [M+H]
+ 1764.9194 1764.9165 15 16 
275 (NGluNspeNspe)(NaeNspeNspe)2(NGluNspeNspe) 20.8 > 90 [M+2H]
2+ 882.9636 882.9627 20 21 
276 (NaeNspeNspe)(NGluNspeNspe)2(NaeNspeNspe) 20.5 > 95 [M+H]
+ 1764.9196 1764.9194 38 15 
277 (NGluNspeNspe)(NaeNspeNspe)3 19.5 > 95 [M+H]
+ 1735.9404 1735.9377 39 20 
278 [(NGluNspeNspe)(NaeNspeNspe)]2 20.1 > 99 [M+2H]
2+ 882.9636 882.9604 25 16 
279 [(NGluNspeNspe)(NLysNspeNspe)]2 20.0 > 99 [M+2H]
2+ 910.9949 910.9956 29 24 
280 (NLysNbutNspe)4 15.3 > 95 [M+2H]
2+ 814.0439 814.0473 13 13 
281 (NaeNbutNspe)4 16.9 > 99 [M+H]
+ 1514.9615 1514.9597 26 3 
282 (NbutNspeNspe)2(NLysNspeNspe)2 21.8 > 99 [M+2H]
2+ 895.0364 895.0354 15 17 
283 [(NbutNspeNspe)(NLysNspeNspe)]2 22.0 > 95 [M+2H]
2+ 895.5380 895.5336 46 11 
308 (NbutNspeNspe)2(NaeNspeNspe)2 21.9 > 95 [M+2H]
2+ 867.0051 867.0031 49 11 
349 [(NbutNspeNspe)(NaeNspeNspe)]2 21.5 > 95 [M+2H]
2+ 867.0051 867.0063 25 26 
284 (NLysNhHisNspe)4 10.8 > 90 [M+2H]
2+ 890.0326 890.0314 32 11 
285 (NaeNhHisNspe)4 11.2 > 85 [M+2H]
2+ 833.9657 833.9641 15 15 
286 [(NLysNspeNspe)(NLysNhHisNspe)]2 13.4 > 99 [M+2H]
2+ 1799.0677 1799.0692 14 5 
287 [(NaeNspeNspe)(NaeNhHisNspe)]2 14.6 > 95 [M+2H]
2+ 843.9752 843.9747 14 11 
288 (NLysNhTyrNspe)4 14.0 > 99 [M+2H]
2+ 942.0371 942.0366 6 4 
309 (NaeNhTyrNspe)4 14.8 > 95 [M+2H]
2+ 885.9745 885.9759 13 8 
289 [(NLysNspeNspe)(NLysNhTrpNspe)]2 17.0 > 95 [M+H]
+ 1897.1085 1897.1005 30 6 
290 [(NaeNspeNspe)(NaeNhTrpNspe)]2 17.8 > 99 [M+2H]
2+ 892.9938 892.9956 12 6 
291 [(NLysNspeNspe)(NLysNpyrNspe)]2 13.4 > 99 [M+H]
+ 1793.0459 1793.0468 30 13 
310 [(NaeNspeNspe)(NaeNpyrNspe)]2 17.8 > 99 [M+2H]
2+ 840.9636 840.9643 17 7 
292 (NLysNhCysNspe)4 14.5 > 99 [M+2H]
2+ 821.9288 821.9265 13 11 
298 (NLysNspeNspeNspe)3 20.0 > 95 [M+2H]
2+ 926.5418 926.5414 26 12 
344 (NaeNspeNspeNspe)3 20.8 > 95 [M+2H]
2+ 884.4949 884.4952 25 14 
345 (NaeNmeoNspeNspe)3  17.4 > 95 [M+2H]
2+ 815.4638 815.4620 27 27 
311 (NaeNspeNmoeNspe)3 17.3 > 95 [M+2H]
2+ 815.4638 815.4659 23 22 
299 (NLysNpheNspe)4 16.6 > 99 [M+2H]
2+ 882.0160 882.0151 25 27 
300 (NaeNpheNspe)4 17.2 > 95 [M+2H]
2+ 825.9534 825.9551 14 14 
301 (NLysNrpeNrpe)4 17.6 > 99 [M+2H]
2+ 910.0473 910.0439 16 17 
302 (NaeNrpeNrpe)4 18.0 > 95 [M+2H]
2+ 853.9847 853.9850 34 26 
303 (NaeNrpeNrpe)3 17.1 > 90 [M+2H]
2+ 642.8688 642.8653 31 40 
Table 7.1. Accurate mass spectrometry data, reverse phase analytical HPLC retention times and approximate purity for the linear peptoid library. 
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7.15.5 Cyclic peptoids 
The cyclic peptoids shown in Figure 7.1 and Figure 7.2 were synthesised using the 
submonomer method of peptoid synthesis using 2-chlorotrityl chloride resin (loading 
1.22 mmol g-1, typically 0.1 mmol scale) and cleaved from the resin using as outlined by 
protocols in section 7.9.1, to afford the protected linear precursor. Peptoids were cyclised 
in solution to afford the head to tail cyclic product and the crude sample, or a portion of, 
was purified (as in section 7.9.2). All peptoids were obtained as white powders with 
characterisation data shown in Table 7.2. 
 
Figure 7.1. Cyclic compounds synthesised, with characterisation data provided in Table 
7.2. 
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Figure 7.2. Cyclic peptoids synthesised and provided by the Kirshenbaum Group (New 
York State University, USA). 
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# Sequence Analytical HPLC Accurate Mass Spectrometry Yield§  
Retention time** 
(min) 
Approx. purity (%) 
Mass calculated Mass observed (%) mg 
130 cyclo (NLysNpheNphe)2 13.9 > 95 [M+H]
+ 863.4820 863.4823 28 24 
131 cyclo (NLysNpfbNpfb)2 15.5 ~ 70 [M+H]
+ 917.4337 917.4358 32 32 
132 cyclo(NLysNphe)3 13.3 > 95 [M+H]
+ 826.4980 826.4959 17 14 
133 cyclo (NhArgNphe)3 13.8 > 99 [M+H]
+ 952.5634 952.5636 20 3 
134 cyclo (NLysNpheNhArgNpheNLysNphe) 13.4 > 95 [M+H]+ 868.5198 868.5201 18 2 
Table 7.2. Accurate mass spectrometry data, reverse phase analytical HPLC retention times and approximate purity for the cyclic peptoid library.  
                                                     
§
 Yield is expressed as an overall yield calculated from the final mass recovered following RP-HPLC purification and expressed as a percentage of the original scale of resin used. 
**
 Gradient, solvents and conditions for analytical HPLC as described in section 7.13.2. 
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7.15.6 Lipopeptoids 
Peptoids with a lipid tail (at the N terminus) were synthesised using the submonomer 
method of peptoid synthesis on Rink Amide resin (typical loading 0.79–0.82 mmol g-1, 0.1 
mmol scale) as outlined by the protocol section 7.3 and 7.7, with the N terminal residue 
being the appropriate lipoamine submonomer. Peptoids were cleaved from the resin 
using protocol 7.12.1 to afford the crude deprotected sequence and the crude sample, or a 
portion of, was purified by procedure 7.13.1 and pure fractions combined to yield the 
peptoid as a powder. Characterisation data is shown in Table 7.3. 
Peptoids with a lipid head group (at the C terminus) were synthesised using the 
submonomer method of peptoid synthesis on 2-chlorotrityl chloride resin (loading 1.22 
mmol g-1, 0.1 mmol scale) as outlined by the protocol section 7.8. Peptoids were cleaved 
from the resin using protocol 7.12.1 to afford the crude deprotected sequence and the 
lipid head group was added in a solution phase coupling with the appropriate lipoamine 
and coupling agent, as described in procedure 7.8. The crude sample was purified by 
procedure 7.13.1 and pure fractions combined to yield the peptoid as a powder. 
Characterisation data is shown in Table 7.4. 
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# Sequence Analytical HPLC Accurate Mass Spectrometry Yield†† 
Retention time‡‡ 
(min) 
Approx. purity 
(%) 
Mass calculated Mass observed (%) (mg) 
158 NC7(NaeNspeNspe)4 20.1 > 99 [M+2H]
2+ 931.5502 931.5508 30 15 
159 NC12(NaeNspeNspe)4 22.8 > 95 [M+2H]
2+ 966.5893 966.5894 58 25 
160 NC16(NaeNspeNspe)4 25.2 > 99 [M+2H]
2+ 994.6206 994.6207 25 10 
161 NcycloC7(NaeNspeNspe)4 19.3 > 99 [M+H]
+ 1860.0769 1860.0771 39 16 
162 Nte(NaeNspeNspe)4 18.5 > 99 [M+2H]
2+ 955.5425 955.5422 18 12 
163 NC7[(NLysNpfbNpfb)(NLysNspeNspe)]2 18.9 > 99 [M+2H]
2+ 995.5605 995.5626 25 13 
164 NC12[(NLysNpfbNpfb)(NLysNspeNspe)]2 21.6 > 99 [M+2H]
2+ 1030.6018 1030.6014 31 13 
165 NC16[(NLysNpfbNpfb)(NLysNspeNspe)]2 23.7 > 99 [M+2H]
2+ 1058.6331 1058.6310 23 11 
166 NcycloC7[(NLysNpfbNpfb)(NLysNspeNspe)]2 18.3 > 99 [M+2H]
2+ 994.5548 994.5518 34 19 
167 Nte[(NLysNpfbNpfb)(NLysNspeNspe)]2 17.6 > 99 [M+2H]
2+ 1019.5550 1019.5535 36 19 
Table 7.3. Accurate mass spectrometry data, RP-HPLC retention times and approximate purity for the linear peptoid library with lipid tail groups. 
 
# Sequence Analytical HPLC Accurate Mass Spectrometry Yield†† 
Retention time‡‡ 
(min) 
Approx. purity 
(%) 
Mass calculated Mass observed (%) (mg) 
168 (NaeNspeNspe)4-C7H15 21.2 > 99 [M+2H]
2+ 903.0394 903.0374 9 4 
169 (NaeNspeNspe)4-C12H25 24.6 > 95 [M+2H]
2+ 938.0786 938.0784 14 6 
170 (NaeNspeNspe)4-C16H33 27.1 > 99 [M+2H]
2+ 966.1099 966.1111 7 3 
171 (NaeNspeNspe)4-cycloC7H15 20.8 > 95 [M+2H]
2+ 902.0316 902.0325 21 9 
172 (NaeNspeNspe)4-te 18.9 > 95 [M+2H]
2+ 927.0318 927.0311 18 8 
173 [(NLysNpfbNpfb)(NLysNspeNspe)]2-C7H15 20.2 > 95 [M+2H]
2+ 967.0519 967.0496 10 4 
174 [(NLysNpfbNpfb)(NLysNspeNspe)]2-C12H25 23.7 > 95 [M+2H]
2+ 1002.0911 1002.0896 9 4 
175 [(NLysNpfbNpfb)(NLysNspeNspe)]2-C16H33 26.0 > 90 [M+2H]
2+ 1030.1223 1030.1222 22 10 
176 [(NLysNpfbNpfb)(NLysNspeNspe)]2-cycloC7H15 19.5 > 95 [M+2H]
2+ 966.0441 966.0430 10 4 
177 [(NLysNpfbNpfb)(NLysNspeNspe)]2-te 18.4 > 95 [M+2H]
2+ 991.0443 991.0417 32 14 
Table 7.4. Accurate mass spectrometry data, RP-HPLC retention times and purity for the linear peptoid library with lipid head groups.  
                                                     
††
 Yield is expressed as an overall yield calculated from the final mass recovered following RP-HPLC purification and expressed as a percentage of the original scale of resin used. 
‡‡
 Gradient, solvents and conditions for analytical HPLC as described in section 7.13.2. 
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7.15.7 Fluorescently labelled compounds 
Peptoids were synthesised using the submonomer method of peptoid synthesis outlined 
by protocols in section 7.9 and peptides were synthesised using standard SPPS, as in 
section 7.11. A glycine spacer was added for all peptoids (section 7.4) and the fluorescent 
dye added to the peptide or peptoid sequence as in section 7.6. Compounds were then 
cleaved from the resin and purified using protocols 7.12.1 and 7.13.1 respectively, to yield 
the fluorescently labelled products as yellow powders (fluorescein dye). Characterisation 
data is shown in Table 7.5. 
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# Sequence Analytical HPLC Accurate Mass Spectrometry Yield§§  
Retention 
time*** (min) 
Approx. 
purity (%) 
Mass calculated Mass observed (%) (mg) 
334 Fluorescein-G-(NLysNspeNspe)2 18.9 > 95 [M+H]
+ 1289.6399 1289.6406 20 13 
335 Fluorescein-G-(NLysNspeNspe)4 19.7 > 99 [M+2H]
2+ 1095.5870 1095.5784 8 5 
336 Fluorescein-G-(NaeNspeNspe)4 20.1 > 99 [M+2H]
2+ 1039.5244 1039.5181 9 7 
337 Fluorescein-G-(NLysNpheNphe)4 18.1 > 95 [M+2H]
2+ 1039.5422 1039.5159 18 2 
338 Fluorescein-G-(NLysNhLeuNspe)4 19.7 > 99 [M+2H]
2+ 1027.6183 1027.6104 11 7 
339 Fluorescein-G-(NLysNnValNspe)4 16.6 > 95 [M+H]
+ 1942.1035 1942.1025 24 2 
340 Fluorescein-G-[(NamyNspeNspe)(NLysNspeNspe)]2 24.9 > 90 [M+2H]
2+ 1094.5917 1094.5865 18 <1 
341 Fluorescein-G-[(NLysNpfbNpfb)(NLysNspeNspe)]2 19.6 > 99 [M+2H]
2+ 1103.5368 1103.5300 9 6 
342 5(6)-carboxyfluorescein-FLPLIGRVLSGIL-NH2  
(Temporin A) 
24.2 > 80 [M+2H]2+ 877.9800 877.9785 9 1 
343 5(6)-carboxyfluorescein-GLLPIVGNLLKSLL-NH2  
(Temporin B) 
25.7 > 80 [M+2H]2+ 904.0062 904.0040 15 2 
Table 7.5. Accurate mass spectrometry data, reverse phase analytical HPLC retention times and approximate purity for the linear peptoid library. 
 
                                                     
§§
 Yield is expressed as an overall yield calculated from the final mass recovered following RP-HPLC purification and expressed as a percentage of the original scale of resin used. 
***
 Gradient, solvents and conditions for analytical HPLC as described in section 7.13.2. 
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7.15.8 NisinA/B-peptoid conjugates 
NprpNspeNspe(NaeNspeNspe)4 (319) 
Synthesis on Rink Amide resin (0.82 mmol g-1 loading, 0.1 mmol scale) via manual solid 
phase peptoid synthesis as outlined by procedure 7.3.1, with propargylamine coupled as 
the N terminal peptoid submonomer. The global deprotection and resin cleavage was 
carried out following protocol 7.12.1 and half of the sample was purified as in section 7.13 
and pure fractions combined to afford the peptoid as a white powder (33.6 mg, 32 %); 
RP-analytical HPLC††† RT 20.0 min; approximate purity 99 %; accurate QToF MS mass 
calculated [M+2H]2+ 1062.5873, mass observed [M+2H] 2+ 1062.5857. 
 
NprpNspeNspe[(NLysNpfbNpfb)(NLysNpfbNpfb)]2 (320) 
Synthesis on Rink Amide resin (0.82 mmol g-1 loading, 0.1 mmol scale) via manual solid 
phase peptoid synthesis as outlined by procedure 7.3.1, with propargylamine coupled as 
the N terminal peptoid submonomer. The global deprotection and resin cleavage was 
carried out following protocol 7.12.1 and half of the crude sample was purified as in 
section 7.13 and pure fractions combined to afford the peptoid as a white powder 
(42.92 mg, 38 %); RP-analytical HPLC††† RT 19.0 min; approximate purity > 95 %; 
accurate QToF MS mass calculated [M+2H]2+ 1126.5997, mass observed [M+2H]2+ 
1126.6017. 
 
NisinA/B-NspeNspe(NaeNspeNspe)4 (322) 
NisinA/B-azide (8.1 µmol, 10.32 mg in 200 µL DMF) and NprpNspeNspe(NaeNspeNspe)4 
(8.1 µmol, 13.89 mg) were conjugated following click protocol 7.15.3 to yield the peptide-
peptoid conjugate as a white powder (9.16 mg, 34 %); RP-analytical HPLC‡‡‡ RT 33.3 min; 
approximate purity > 99 %; accurate QToF MS mass calculated [M+2H]2+ 1678.4032, mass 
observed [M+2H] 2+ 1678.3981. 
 
NisinA/B-NspeNspe[(NLysNpfbNpfb)(NLysNpfbNpfb)]2 (323) 
NisinA/B-azide (8.1 µmol, 10.10 mg in 200 µL DMF) and NprpNspeNspe(NaeNspeNspe)4 
(8.1 µmol, 18.34 mg) were conjugated following click protocol 7.15.3 to yield the peptide-
peptoid conjugate as a white powder (13.86 mg, 49 %); RP-analytical HPLC‡‡‡ RT 31.8 
min; approximate purity >99%; accurate QToF MS mass calculated [M+2H]2+ 1742.4156, 
mass observed [M+2H] 2+ 1742.4037. 
                                                     
†††
 Conditions for analytical HPLC as described in section 7.13.2; λ = 220 nm; gradient: 0–100 % solvent B over 
30 mins (solvent A: 95 % H2O, 5 % MeCN, 0.05 % TFA; Solvent B: 95 % MeCN, 5 % H2O, 0.03 % TFA). 
‡‡‡
 Conditions for analytical HPLC as described in section 7.13.2; λ = 220 nm; gradient: 0–100 % solvent B 
over 60 mins (solvent A: 95 % H2O, 5 % MeCN, 0.1 % TFA; Solvent B: 95 % MeCN, 5 % H2O, 0.1 % TFA). 
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Biophysical Characterisation 
7.16 Circular dichroism spectroscopy (CD) 
Circular dichroism experiments were undertaken by the author of this report, Charlotte 
Williams (MPhys student) and Dr Lara Small (Postdoctoral research assistant) supervised 
by Dr Beth Bromley, in the Physics Department at Durham University. 
 
Circular dichroism spectroscopy was conducted on sequences with a chiral reporter 
monomer present using a Jasco J-810 spectropolarimeter, with a 0.1 cm path length and 
500 µL quartz cuvette. Samples were made to 5 mM in distilled water, then diluted to 
50 µM in a phosphate buffered solution (PBS, 1 M). 300 µL of this solution was 
transferred to a cuvette for the measurements. All data collection was taken at room 
temperature and data was collected as an accumulation of 10 measurements, adjusted by 
the background spectrum of the PBS buffer. Scans were conducted at 50 nm min-1 
between 260–190 nm, 1 nm data pitch, 5 mdeg sensitivity and a 2 s response. 
Mean residue molar ellipticity [θ] was obtained using the equation: 
[θ] =  
100 × θobs  × M
n × l × c
 
where θobs is measured ellipticity (˚), M is the molecular weight (g mol
-1), n is the number 
of residues, l is path length (cm), and c is the concentration of peptoid (mg mL-1).  
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7.17 Partitioning experiments 
Partitioning experiments and dynamic light scattering was undertaken by Charlotte 
Williams (MPhys student), supervised by Dr Beth Bromley, in the Physics Department at 
Durham University. 
 
Peptoids were dissolved at concentrations between 10 and 300 µM in either Phosphate 
Buffered Saline (PBS) or 1-octanol. Exact concentrations were measure using UV 
spectrometry (Shimadzu UV-3600) using the phenylalanine-like peak centred at 258 nm 
and a molar extinction coefficient of 195 M-1 cm-1 per residue. It was necessary to subtract 
baselines and the influence of the peptoid backbone absorption at lower wavelengths in 
order to get accurate concentration data. 
Partition experiments were carried out by putting 450 µL of octanol in contact with 
450 µL of PBS, which contained between 10 and 100 µL of peptoid. Each peptoid was 
measured in triplicate. The samples were allowed to equilibrate under gentle agitation 
for ~150 hours (as 48 hours was not found to be sufficient for the system to reach 
equilibrium). After this point samples were taken from the PBS half and the octanol half 
and diluted to produce sufficient volume for spectroscopy. The concentration of peptoid 
remaining in the PBS and the octanol was measured individually using the phenylalanine 
peak as before. From these concentrations the ratio Kv of concentration in PBS to 
concentration in octanol was calculated along with the free energy of insertion into 
octanol ∆𝐺 = 𝑅𝑇 ln 𝐾𝑣. All PBS solutions were checked for aggregation both by 
inspection of the UV spectra to look for scattering effects and by measuring particle size 
using dynamic light scattering. 
 
7.18 Dynamic light scattering 
All of the peptoids tested in partitioning experiments (7.17) were checked at high 
concentration (~500 µM) in PBS for indicators of aggregation using dynamic light 
scattering (Malvern Zetasizer Nano). Due to the increase in intensity of scattering with 
size, the presence of a signal at small hydrodynamic diameters indicates the 
overwhelming majority of the sample in all cases is present in the smallest peak. 
Peptoids that substantially partitioned into the octanol during the partitioning 
experiments were checked at high concentration (~500 µM) in octanol for indicators of 
aggregation using dynamic light scattering. Due to the increase in intensity of scattering 
with size, the presence of a signal at small hydrodynamic diameters indicates the 
overwhelming majority of the sample is present in the smallest peak. 
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7.19 Peptoid stability assays 
The HPLC based chymotrypsin stability assay was undertaken by Emily Corlett (MSc 
project student, Durham University). 
 
7.19.1 Chymotrypsin activity assay 
1 mL samples were made up 500 µl of 50 mM ammonium bicarbonate buffer (pH 7.8), 
467 µL of 1.18 mM BTEE in MeOH/H2O and 33 µL of chymotrypsin solution, made up at 
0.1 mg mL-1 in 1 mM HCl solution. The negative control contained 33 µL of 1 mM HCl 
solution in place of the chymotrypsin solution.  Samples were analysed for 1 minute at 
256 nm with a spectrophotometer. The chymotrypsin was added to the cuvette in the 
spectrophotometer so that analysis could begin as soon as the sample had been mixed. 
Three samples were run for each assay at 22 ˚C and one negative control. All assays were 
carried out in triplicate.  
 
7.19.2 Chymotrypsin stability assay 
Chymotrypsin was incubated at the digestion temperature of 22 ˚C in buffer (stock 
solution containing 5 mL of 50 mM ammonium bicarbonate buffer and 0.33 mL of 
chymotrypsin solution, made up at 0.1 mg mL-1 in 1 mM HCl solution). These volumes 
were chosen to correspond directly to those used in the chymotrypsin activity assay 
(section 7.19.1). This stock solution was kept at 22 ˚C and used to run the chymotrypsin 
activity assay at 0 h, 8 h and 24 h. Negative controls were made up separately to the same 
protocol as used in the activity assay. 
 
7.19.3 Chymotrypsin automated digestion protocol 
A sample was made up of 187.5 μL of 50 mM ammonium bicarbonate buffer (pH 7.8), 
containing 2 mM CaCl2 to activate the chymotrypsin, 37.5 μL substrate solution, made 
up at 5 mg mL-1 in DMSO, and 25 μL chymotrypsin solutions, at 0.5 ng μL-1. The negative 
control contained 25 μL extra buffer in the place of chymotrypsin solution. 10 μL of the 
sample was pipetted by an auto-sampler at given time points and immediately analysed 
HPLC with the DAD focused at 215 nm.  
 
 
Ch. 7 Experimental 
282 
7.19.4  Trypsin digestion  
Substrate stocks of peptoid or control were prepared in tris-HCl buffer (6 mg mL-1 in tris-
HCl 50 mM at pH 7.8, with 5 mmol CalCl2
§§§). N-tosyl-L-phenylalanyl chloromethyl 
ketone treated**** bovine trypsin solution was freshly made (1 mg in 5 mL tris-HCl, 
0.2 mg mL-1). Solutions were preincubated at 37 ˚C†††† for 20 minutes. 120 µL substrate 
stock and 80 µL trypsin solution were mixed in 600 µL tris-HCl buffer and incubated at 
37 ˚C on a heated shaker platform. After 0 hours (for verification prior to tryptic 
digestion) or after treatment with trypsin (at several time points) the reaction mixtures 
were analysed.  
For analysis using analytical RP-HPLC, an aliquot of 100 µL was removed from 
incubation 37 ˚C and acidified by addition of 50 % TFA in acetonitrile (20 µL) to stop 
further enzyme activity. Samples were analysed following a 10 µL injection to the HPLC 
instrument, with the DAD focussed at 220 nm. 
For analysis using mass spectrometry, a 10 µL aliquot was removed from incubation and 
analysed using MALDI immediately. The matrix solution was prepared (α-cyano-4-
hydroxycinnamic acid in 400 µL MeCN, 800 µL water (+0.1% TFA) as a saturated 
solution). A solution containing the digestion sample to be analysed was prepared (9 : 1 
matrix to sample) and 1 µL of this was spotted to the MALDI target. The plate was dried 
and then each spot washed carefully with 5 µL of water (+0.1 % TFA) to wash away excess 
salt. MALDI-TOF MS or MALDI LIFT MS was performed, as outlined in section 7.2.3.  
                                                     
§§§
 CaCl2 added to reduce trypsin autolysis. 
****
 Trypsin treated with TPCK to inhibit any chymotrypsin activity which may be present. 
††††
 The optimum temperature for trypsin activity. 
Ch. 7 Experimental 
283 
7.20 Confocal Fluorescence Microscopy 
Fluorescent microscopy experiments were undertaken in collaboration with Dr Robek Pal 
(Durham University, Chemistry Department) and assisted by Sophia Schwartz (Erasmus 
student). Methods and procedure provided by Dr Robek Pal. 
 
Mammalian cells (either NIH-3T3 or PC3) were subcultured onto sterile, tissue culture 
treated slides from Ibidi (Thistle Scientific Ltd). Cells were incubated with fluorescent 
compound alone, or with a variety of trackers prior to imaging (Fisher Scientific). 
Visualisation of the peptoids and cell images were obtained using a Leica SP5 II 
microscope, as previously described.4 A HeNe laser was used to visualize fluorescein-
peptoid/peptide fluorescence and either a He/Ne or Ar ion laser was used to corroborate 
cellular localisation in combination with commercially available organelle-specific stains 
(e.g. LysoTrackerRed© or MitoTrackerRed©). All tracker stains were used under 
conditions and concentrations recommended by the manufacturer(s).  
The microscope was equipped with a triple channel imaging detector, comprising two 
conventional PMT systems and a HyD hybrid avalanche photodiode detector. The latter 
part of the detection system, when operated in the BrightRed mode, is capable of 
improving imaging sensitivity above 550 nm by 25 %, reducing signal-to-noise by a factor 
of 5. The pinhole was always determined by the Airy disc size, calculated from the 
objective in use (HCX PL APO 63x/1.40 NA LbdBlue), using the lowest excitation 
wavelength (488 nm). Scanning speed was adjusted to 100 Hz in a bidirectional mode, to 
ensure both sufficient light exposure and enough time to collect the emitted light from 
the fluorescent compounds with no field averaging (view area 98 µm x 98 µm, 1024 × 
1024 pixel array, a pixel size of 45 × 45 nm at a depth of 380 nm).4  
The three-dimensional reconstructions wwere achieved using a novel saturation 
elimination algorithm update of the existing ImageJ 1.46r 3D plug-in using LSCM images 
recorded on the above detailed Leica SP5 II microscope. In these z-stack images, a 
deliberate 20% overlap in the applied axial resolution was introduced, determined by the 
applied optics and experimental parameters detailed above.4 
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Biological Assays 
7.21 Antibacterial testing 
Antibacterial testing was carried out at Durham University by Dr Gabriela Eggimann 
(post-doctoral research assistant) and assisted by Mark Laws (MChem Project student) 
and Sophia Schwartz (Erasmus student).  
 
7.21.1 Bacterial culture preparation  
Escherichia coli K-12 wild-type strain (W3110 / ATCC27325, F-, λ-, rpoS(Am), rph-1, 
Inv(rrnD-rrnE)), Pseudomonas aeruginosa PA01 (ATCC 15692) Staphylococcus aureus 
(3R7089 strain Oxford / ATCC9144) and Staphylococcus epidermidis (laboratory strain 
from clinical isolate) were selected for bacteriological studies as representative Gram-
negative (E. coli and P. aeruginosa) and Gram-positive (S. aureus and S. epidermidis) 
species. Bacterial cultures were prepared by streaking bacterial strains onto LB agar 
plates with an inoculation loop and incubated overnight at 37 °C. A single colony was 
selected and placed in 5 mL of Iso-sensitest broth (Oxoid, ThermoScientific) and 
incubated with shaking for 16–18 h at 37 °C to provide liquid cultures for testing.  
 
7.21.2 Antibacterial minimum inhibitory concentration determination  
MIC values were obtained according to the previously described protocol5 and were 
conducted in 96-well plates (Sarsted, Fisher Scientific). Bacteria were grown from 
overnight cultures in  Iso-sensitest broth to an A650nm of 0.07 equivalent to a 0.5 
MacFarland standard (240 μM BaCl2 in 0.18 M H2SO4). This culture was diluted ten-fold 
with Iso-sensitest broth before use. Peptoids were initially dissolved in DMSO (5 mM) 
and diluted further in Iso-sensitest broth to achieve a concentration range of 4–200 µM 
using 2-fold serial dilutions. 50 μL of inoculum and 50 μL of peptoid solution were added 
to each test well (final concentration range of 2–100 µM). Experiments were performed in 
triplicate. A positive control for bacterial growth contained only the inoculum and Iso-
sensitest broth. Other controls contained the inoculum and serial dilutions of ampicillin 
(from 250 µg/mL to 2 µg/mL), serial dilutions of DMSO and the inoculum to confirm no 
inhibitory effect on bacterial growth, and Iso-sensitest broth alone as a sterile control. 
The MIC was defined as the lowest concentration which completely inhibited bacterial 
growth after incubation at 37 °C for 16 h with shaking. Quantitative data was attained 
from absorbance values using a Biotek Synergy H4 plate reader. 
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7.22 Anti-leishmanial assays  
Initial anti-leishmanial testing was carried out at Durham University by Dr Gabriela 
Eggimann (post-doctoral research assistant). Subsequent testing was carried out by the 
author of this thesis. 
 
7.22.1  Cell Culture of Leishmania mexicana M379 promastigotes and 
amastigotes 
Leishmania mexicana (M379) promastigote parasites were maintained at 26 °C in 
Schneider's Insect medium (Sigma-Aldrich) supplemented with heat-inactivated foetal 
bovine sera (FBS, 15 %; Biosera Ltd). Cells were counted using a Neubauer Improved 
Hemocytometer. Promastigotes were transformed into axenic amastigotes by a pH and 
temperature shift as previously described.6 A culture of recently transformed (three days) 
promastigotes in the late log phase was transferred into Schneider's Insect medium 
supplemented with 20 % heat-inactivated FBS (pH 5.5) at 5 x 105 parasites/mL. After 
6 days, the parasites were in the metacyclic stage and used for transformation to 
amastigote-like forms by transfer in the same medium at 32 °C at 5 x 105 parasites/mL. 
After additional 5–7 days, the parasites should be in the amastigote stage and be ready 
for cytotoxicity studies and infections. 
 
7.22.2  Cytotoxicity Assays with L. mexicana M379 promastigotes and 
amastigotes 
Cytotoxicity analyses were performed in 96-well plates (Costar, Fisher Scientific) using 
alamarBlue® (Invitrogen) for cell viability detection as previously described.7 
Promastigote and amastigote L. mexicana were pre-incubated with the compounds in 
triplicate (5  mM stock solutions in DMSO; amphotericin B was used as a positive 
control; untreated parasites with DMSO as a negative control) in 50 µL of the 
corresponding media at 4 x 106 mL-1 for 1 hour. Afterwards, 40 µL were removed from 
each well before the addition of 90 µL of the corresponding media, followed by 
incubation for 24 hours at 4 x 105 mL-1. Then, 10 µL alamarBlue® solution (Invitrogen) was 
added to each well for an incubation of 4 hours prior to assessing cell viability using a 
fluorescent plate reader (Biotek; λex 560 nm, λem 600 nm). To investigate the effects of 
serum on the efficacy of the peptoids, the assay described above was modified using 
serum-free medium for the pre-incubation time. For these assays, the parasites were 
washed three times in serum-free medium before adding them to the compound 
solutions. All of the experiments described above were carried out in triplicate on a 
minimum of two separate occasions to ensure a robust data set was collected. 
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7.22.3  Cytotoxicity assays with L. mexicana intracellular amastigotes 
Cytotoxicity analyses were performed in 96-well plates (flat bottom, Costar, Fisher 
Scientific) using alamarBlue® (Invitrogen) for cell viability detection using a modified 
protocol as previously described.4 For the macrophages, RAW 264.7 cells were grown in 
at 37 °C, 5 % CO2 in DMEM high glucose supplemented with heat-inactivated foetal 
bovine sera (FBS, 10 %; Biosera Ltd) and penicillin/streptomycin (P/S, 1 %). The cells 
were treated with the compounds in quadruplet (5 mM stock solutions in DMSO; 
amphotericin B was used as a positive control; untreated parasites with DMSO as a 
negative control).  
On day 1, the RAW cells were seeded at 2.5 x 105 cells mL-1 (200 µL/well) in DMEM10 (10% 
FBS, 1% P/S) followed by an incubation for 24 hours at 37 °C, 5 % CO2. On day 2, the 
RAW cells were washed carefully once with DMEM2 (2 % FBS, 1 % P/S). Addition of 
L. mexicana amastigotes at 2.5 x 106 cells mL-1 (200 µL/well) in DMEM2 (2 % FBS, 1 % P/S) 
followed by an incubation for 24 hours at 37 °C, 5 % CO2. On day 3, the infected RAW 
cells were washed carefully 5 times with DMEM2 (2 % FBS, 1 % P/S) before adding 
100 µL/well of fresh DMEM2 (2 % FBS, 1 % P/S) to each well. Peptoids and control 
solutions were prepared in DMEM2 (2 % FBS, 1 % P/S) and added to the corresponding 
wells (100 µL/well) for an incubation of 24 hours at 37 °C, 5 % CO2. On day 4, infected 
RAW cells were washed carefully 3 times with Schneider's Insect medium (pH 7.0, 
serum-free) and then lysed with 20 µL/well of SDS (0.05 %, v/v) for 30 seconds before 
addition of 180 µL/well of Schneider's Insect medium (pH 7.0, 15 % FBS). Plates were 
wrapped with parafilm and incubated for 48 hours at 26 °C. On day 6, 10 µL of 
alamarBlue® (Invitrogen) was added to each well before a 4 hour incubation at 26 °C 
prior to assessing cell viability using a fluorescent plate reader (Biotek; λex 560 nm, λem 
600 nm). All of the experiments described above were carried out on a minimum of two 
separate occasions in quadruplet to ensure a robust data set was collected. 
 
7.22.4  Statistical analysis 
All ED50 data for parasitic assays represent an average of at least 2 independent 
experiments, undertaken in triplicate. Error bars are plotted to show the variation of data 
between individual wells as a standard deviation. The Z-factor (Z’) was calculated for 
each assay using the mean (µ) and standard deviation (σ) of both positive (p) and 
negative (n) controls. Data were only used for assays with Z’ between 0.5 and 1.0 to 
ensure the assay was of high quality.8 
 
𝑍′ = 1 −  
3 (𝜎𝑝 + 𝜎𝑛)
|𝜇𝑝 −  𝜇𝑛|
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7.23 Cytotoxicity assays against mammalian cells 
7.23.1 Cytotoxicity assays with RAW 264.7 macrophages 
Cytotoxicity analyses were performed in 96-well plates (flat bottom, Costar, Fisher 
Scientific) using alamarBlue® (Invitrogen) for cell viability detection using a modified 
protocol as described above for the intracellular amastigote cytotoxicity assay. The RAW 
264.7 cells were grown in at 37 °C, 5 % CO2 in DMEM10 high glucose supplemented with 
heat-inactivated foetal bovine sera (FBS, 10 %; Biosera Ltd) and penicillin/streptomycin 
(P/S, 1 %). The cells were treated with the compounds in quadruplet (5 mM stock 
solutions in DMSO; amphotericin B was used as a positive control; untreated parasites 
with DMSO as a negative control). On day 1, the RAW cells were seeded at 2.5 x 105 
cells mL-1 (200 µL/well) in DMEM10 (10 % FBS, 1 % P/S) followed by an incubation for 
24 hours at 37 °C, 5 % CO2. On day 2, the RAW cells were washed carefully once with 
DMEM2 (2 % FBS, 1 % P/S). Addition of 200 µL/well of DMEM2 (2 % FBS, 1 % P/S) 
followed by an incubation for 24 hours at 37 °C, 5 % CO2. On day 3, the RAW cells were 
washed carefully 5 times with DMEM (2 % FBS, 1 % P/S) before adding 100 µL/well of 
fresh DMEM2 (2 % FBS, 1 % P/S) to each well. Peptoids and control solutions were 
prepared in DMEM2 (2 % FBS, 1 % P/S) and added to the corresponding wells 
(100 µL/well) for an incubation of 24 hours at 37 °C, 5 % CO2. On day 4, 200 µL/well of 
fresh DMEM10 (10 % FBS, 1 % P/S) was added to each well. Then, 10 µL of alamarBlue® 
(Invitrogen) was added to each well before a 2 hour incubation at 37 °C, 5 % CO2 prior to 
assessing cell viability using a fluorescent plate reader (Biotek; λex 560 nm, λem 600 nm). 
All of the experiments described above were carried out on a minimum of two separate 
occasions in quadruplet to ensure a robust data set was collected. 
 
7.23.2 Cytotoxicity assays with HepG2 epithelial cells 
Cytotoxicity analyses were performed in 96-well plates (Costar, Fisher Scientific) using 
alamarBlue® (Invitrogen) for cell viability detection using a modified protocol as 
previously described.9 The HepG2 cells were grown at 37 °C, 5 % CO2 in DMEM10 high 
glucose supplemented with heat-inactivated foetal bovine sera (FBS, 10 %; Biosera Ltd) 
and penicillin/streptomycin (P/S, 1 %). Cells were counted using a Neubauer Improved 
Hemocytometer. HepG2 cells were seeded 1 day prior to treatment in 96 well plates at a 
concentration of 2 x 105 cells mL-1 in 100 µL of medium (2 x 104 cells/well). After 24 hours, 
cells were incubated with the compounds in a dilution series in triplicate from 2–100 µM 
(5 mM stock solutions in DMSO; untreated cells with DMSO as a negative control) in 
50 µL of the media for 1 hour. Afterwards, 40 µL of medium was removed from each well 
before the addition of 90 µL of the media, followed by incubation for 24 hours at 37 °C, 
5 % CO2. Then, 10 µL of alamarBlue® (Invitrogen) was added to each well before a 2 hour 
incubation prior to assessing cell viability using a fluorescent plate reader (Biotek; λex 560 
nm, λem 600 nm). 
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7.23.3 Cytotoxicity assay with HaCaT keratinocytes 
Cytotoxicity analyses were performed in 96-well plates (Costar, Fisher Scientific) using 
alamarBlue® (Invitrogen) for cell viability detection. HaCaT cells were subcultured at 
37 °C, 5 % CO2 in DMEM10 high glucose supplemented with heat-inactivated foetal 
bovine sera (FBS, 10 %; Biosera Ltd) and penicillin/streptomycin (P/S, 1 %). Cells were 
counted using a Neubauer Improved Hemocytometer. HaCaT cells were seeded in the 
plates 24 hours prior to treatment in 96 well plates at a concentration of 2 x 105 cells mL-1 
in 100 µL of medium (2 x 104 cells/well). Empty wells were filled with 100 µL PBS. After 
24 hours, cells were incubated with the compounds in a dilution series in triplicate from 
2–100 µM (5 mM stock solutions in DMSO; and untreated cells with DMSO as a negative 
control) in 50 µL of the media for 1 hour. Afterwards, 50 µL was removed from each well 
and cells washed with 100 µL PBS. 100 µL of medium was added to each well and the cells 
incubated for 24 hours at 37 °C, 5 % CO2. 10 µL of alamarBlue® (Invitrogen) was added to 
each well before incubation for 1 hour. Cell viability was determined using a fluorescent 
plate reader (Synergy H4; λex 560 nm, λem 600 nm). 
 
7.23.4  Hemolysis assay  
This assay was undertaken at Queens University, Belfast by Dr Russell Luo (postdoctoral 
research assistant), under the supervision of Dr Fionnuala Lundy. 
 
Briefly, PBS was added to 2 mL of whole blood to a final volume of 25 mL in a 50 mL 
centrifuge tube and centrifuged for 5 min at 930 x g. The supernatant was discarded and 
PBS was added again to reach a final volume of 25 mL. This washing procedure was 
repeated until the supernatant was clear to obtain an 8 % erythrocyte suspension. A total 
volume of 50 µL of this suspension was pipetted into sterile microtubes. 50 µL of peptoid 
solution at final concentration of 100 µM, 50 µM, 25 µM, 12.5 µM and 6.25 µM were added 
to the microtubes and inverted to allowing mixing. 50 µL of 2.5 % Triton-X 100 and 50 µL 
of PBS were used as positive and negative controls respectively. The hemolytic activity of 
each peptoid was analysed in triplicate. The microtubes were incubated at 37 ˚C for 
1 hour and then centrifuged for 5 minutes at 930 x g. 80 µL of supernatant from each 
microtube was pipetted into a flat bottomed, clear 96-well plate. The absorbance at 
570 nm in a microtitre plate reader and the percentage hemolysis was calculated using 
the following formula:  
 
% Hemolysis = (A–AO)/(AX–AO) × 100% 
where A is the OD of the peptoid-treated erythrocytes, AO is OD of the negative 
control, and AX is OD of the positive control. 
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7.24 Antiparasitic IC50 determination 
The antiparasitic testing outlined below was carried out at the Swiss Tropical and Public 
Health Institute by Dr Marcel Kaiser. Procedures also provided by Dr Marcel Kaiser. 
 
7.24.1 Activity against Trypanosoma brucei rhodesiense  
This stock was isolated in 1982 from a human patient in Tanzania and after several 
mouse passages cloned and adapted to axenic culture conditions.10 Minimum Essential 
Medium (50 µL) supplemented with 25 mM HEPES, 1g L-1 additional glucose, 1 % MEM 
non-essential amino acids (100x), 0.2 mM 2-mercaptoethanol, 1mM sodium pyruvate and 
15 % heat inactivated horse serum was added to each well of a 96-well microtiter plate. 
Serial drug dilutions of eleven 3-fold dilution steps covering a range from 100 to 
0.002 μg mL-1 were prepared. Then 4 x 103 bloodstream forms of T. b. rhodesiense STIB 
900 in 50 µL was added to each well and the plate incubated at 37 °C under a 5 % CO2 
atmosphere for 70 hours. 10 µL alamarBlue®  (resazurin, 12.5 mg in 100 mL double-
distilled water) was then added to each well and incubation continued for a further 2–4 
hours.11 The plates were read with a Spectramax Gemini XS microplate fluorometer 
(Molecular Devices Cooperation, Sunnyvale, CA, USA; λex 536 nm, λem 588 nm) The IC50 
values were calculated by linear regression12 from the sigmoidal dose inhibition curves 
using SoftmaxPro software (Molecular Devices Cooperation, Sunnyvale, CA, USA). 
Melarsoprol (Arsobal Sanofi-Aventis, received from WHO) is used as control. 
 
7.24.2 Activity against Trypanosoma cruzi  
Rat skeletal myoblasts (L-6 cells) were seeded in 96-well microtitre plates at 
2000 cells/well in 100 μL RPMI 1640 medium with 10 % FBS and 2 mM L-glutamine. After 
24 hours the medium was removed and replaced by 100 μL per well containing 5 x 103 
trypomastigote forms of T. cruzi Tulahuen strain C2C4 containing the β-galactosidase 
(Lac Z) gene.13 After 48 hours the medium was removed from the wells and replaced by 
100 mL fresh medium with or without a serial drug dilution of eleven 3-fold dilution 
steps covering a range from 100– 0.002 μg mL-1. After 96 hours of incubation the plates 
were inspected under an inverted microscope to assure growth of the controls and 
sterility. Then the substrate CPRG/Nonidet (50 μL) was added to all wells. A colour 
reaction developed within 2–6 hours and could be read photometrically at 540 nm. Data 
were analysed with the graphic programme Softmax Pro (Molecular Devices), which 
calculated IC50 values by linear regression from the sigmoidal dose inhibition curves. 
Benznidazole is used as control (IC50 0.5 ± 0.2 g mL
-1). 
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7.24.3 Activity against Leishmania donovani axenic amastigotes 
Amastigotes of L. donovani strain MHOM/ET/67/L82 were grown in axenic culture at 
37 °C in SM medium14 at pH 5.4 supplemented with 10% heat-inactivated foetal bovine 
serum under an atmosphere of 5 % CO2 in air. 100 µL of culture medium with 1 x 10
5 
amastigotes from axenic culture with or without a serial drug dilution were seeded in 96-
well microtitre plates. Serial drug dilutions of eleven 3-fold dilution steps covering a 
range from 90– 0.002 μg mL-1 were prepared. After 70 hours of incubation the plates 
were inspected under an inverted microscope to assure growth of the controls and sterile 
conditions. 10 μL of alamarBlue® (12.5 mg resazurin dissolved in 100 mL distilled water)15 
were then added to each well and the plates incubated for another 2 hours. Then the 
plates were read with a Spectramax Gemini XS microplate fluorometer (Molecular 
Devices Cooperation, Sunnyvale, CA, USA; λex 536 nm, λem 588 nm). Data were analysed 
using the software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA). 
Decrease of fluorescence (= inhibition) was expressed as percentage of the fluorescence 
of control cultures and plotted against the drug concentrations. From the sigmoidal 
inhibition curves the IC50 values were calculated. 
 
7.24.4 Activity against Plasmodium falciparum  
In vitro activity against erythrocytic stages of P. falciparum was determined using a 3H-
hypoxanthine incorporation assay16,17 using the drug sensitive NF54 strain (Schipol 
airport18) or the chloroquine and pyrimethamine resistant K1 strain that originate from 
Thailand19 and the standard drug chloroquine (Sigma C6628). Compounds were 
dissolved in DMSO at 10 mg/mL and added to parasite cultures incubated in RPMI 1640 
medium without hypoxanthine, supplemented with HEPES (5.94 g L-1), NaHCO3 (2.1 g L-
1), neomycin (100 µg mL-1), AlbumaxR (5 g L-1) and washed human red cells A+ at 2.5 % 
haematocrit (0.3 % parasitaemia). Serial drug dilutions of eleven 3-fold dilution steps 
covering a range from 100–0.002 μg mL-1 were prepared. The 96-well plates were 
incubated in a humidified atmosphere at 37 °C; 4 % CO2, 3 % O2, 93 % N2. After 48 hours 
50 μL of 3H-hypoxanthine (= 0.5 μCi) was added to each well of the plate. The plates 
were incubated for a further 24 hours under the same conditions. The plates were then 
harvested with a Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and the red 
blood cells transferred onto a glass fibre filter then washed with distilled water. The 
dried filters were inserted into a plastic foil with 10 mL of scintillation fluid, and counted 
in a Betaplate™ liquid scintillation counter (Wallac, Zurich, Switzerland). IC50 values 
were calculated from sigmoidal inhibition curves by linear regression using Microsoft 
Excel. Chloroquine and artemisinin are used as control. 
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7.24.5 In vitro cytotoxicity with L-6 cells 
Assays were performed in 96-well microtiter plates, each well containing 100 L of RPMI 
1640 medium supplemented with 1 % L-glutamine (200 mM) and 10 % foetal bovine 
serum, and 4 x 103 L-6 cells (a primary cell line derived from rat skeletal myoblasts).20,21 
Serial drug dilutions of eleven 3-fold dilution steps covering a range from 100–
0.002 μg mL-1 were prepared. After 70 hours of incubation the plates were inspected 
under an inverted microscope to assure growth of the controls and sterile conditions. 
10 L of alamarBlue® was then added to each well and the plates incubated for another 
2 hours. Then the plates were read with a Spectramax Gemini XS microplate fluorometer 
(Molecular Devices Cooperation, Sunnyvale, CA, USA; λex 536 nm, λem 588 nm). The IC50 
values were calculated by linear regression (Huber 1993) from the sigmoidal dose 
inhibition curves using SoftmaxPro software (Molecular Devices Cooperation, Sunnyvale, 
CA, USA). Podophyllotoxin (Sigma P4405) is used as control. 
 
7.25 Biofilm prevention and disruption assays 
Biofilm testing was carried out at Queens University, Belfast by Dr Yu Luo (postdoctoral 
research assistant), under the supervision of Dr Fionnuala Lundy. Methods and procedures 
supplied by Dr Fionnuala Lundy. 
 
7.25.1 Micro-organism strains and growth conditions 
C. albicans (NCTC 3179) was subcultured aerobically on Sabouraud agar plates and 
propagated in yeast peptone dextrose broth. E. coli (ATCC 29522) and S. aureus (NCTC 
6571) were grown on blood agar plates and propagated in brain heart infusion (BHI) 
broth. 
 
7.25.2 Preparation and treatment of single species biofilms 
Overnight cultures of C. albicans were washed and resuspended in a modified RPMI-1640 
(Sigma-Aldrich, St Louis, USA) medium to yield an inoculum of 1.0 × 106 cells mL-1.22 
Overnight cultures of S. aureus or E. coli were washed and resuspended in BHI broth 
(Oxoid, Basingstoke, UK) to yield an inoculum of 5.0 × 106 cells mL-1. A total volume of 
100 µL of each inoculum was added to microtitre plate wells (Thermo Fisher Scientific, 
Roskilde, Denmark). An initial biofilm was allowed to form for 4 hours. Wells were 
washed three times with 200 µL PBS to facilitate removal of planktonic cells and the 
biofilms were then treated with 100 µM of peptoids solution in the appropriate broth. 
Plates were incubated for a further 24 hours to allow biofilm maturation. After removal 
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of planktonic cells by washing, biofilms were quantified by the crystal violet assay or by 
PMA-qPCR.  
 
7.25.3 Preparation and treatment of polymicrobial biofilms 
Overnight cultures of C. albicans were prepared in microtitre plates as outlined above 
and allowed to adhere for 4 hours to facilitate initial biofilm formation. Planktonic 
C. albicans cells were then removed as outlined above before the addition of 100 µL of 
S. aureus or E. coli (5.0 × 106 cells mL-1). Bacteria were allowed to adhere to the 
C. albicans biofilms for 4 hours to facilitate polymicrobial biofilm formation. Following a 
washing step, the biofilms were then treated with peptoids (100 µM), and incubated for a 
further 24 hours to allow biofilm maturation. Wells were washed as previously outlined 
and the polymicrobial biofilms were quantified by PMA-modified qPCR. 
 
7.25.4 Biofilm quantification by crystal violet assay 
Washed biofilms were fixed with 100 µL methanol for 10 minutes. Following removal of 
methanol, the wells were air dried and stained with crystal violet solution (Clin-Tech 
Ltd, Guildford, UK) for 20 minutes at room temperature. Excess stain was removed by 
washing, the plate was then air dried and bound crystal violet was re-solubilised in 
160 μL 33 % acetic acid prior to reading at 570 nm in a microtitre plate reader (Tecan 
GENios, Zürich, Switzerland).  
 
7.25.5 Biofilm quantification by PMA-modified qPCR 
To determine the bactericidal and fungicidal activity of peptoids against both single 
species and polymicrobial biofilms, the biofilms were detached from the microtitre plate 
wells prior to quantification. Wells were washed as previously described before 100 μL of 
BHI broth was added and the plate was sealed. Biofilm detachment was achieved by 
sonication for 5 mins in an ultrasonic bath (Dawe, Middlesex, UK). The remaining cells 
were then collected in 80 μL BHI. Twenty microlitres of PMA (Biotium Inc., California, 
USA) (2 mM in broth23) was added to the biofilm suspensions (180 μL) and incubated at 
37 °C (5 min) prior to photoactivation with a broad-spectrum LED floodlight placed at 
15 cm from the tubes, (which were mixed by inversion during the 20 min photoactivation 
step). DNA was extracted using the microLYSIS®-Plus kit (Microzone, Haywards Heath, 
UK) as per the manufacturer’s instructions and qPCR was performed in a Mx3005P qPCR 
System (Agilent Technologies, California USA).  
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Table 7.6. Reaction formulation for C. albicans:24 
 
 
Table 7.7. Reaction formulation for S. aureus:25 
 
 
 
 
 
Component of reaction mix Volume for 10 reactions 
(µL) 
Final 
Concentration 
FastStart Universal SYBR Green Master 
(2X) (Roche) 
 
50 1X 
Forward primer (60 µM):  
CCTGTTTGAGCGTCRTTT 
 
0.25 150 nM 
Reverse primer (200 µM): 
TCCTCCGCTTATTGATAT 
 
0.25 500 nM 
Template 
 
10  
Nuclease free water 
 
39.5  
Component of reaction mix Volume for 10 reactions 
(µL) 
Final 
Concentration 
Platinum® qPCR Supermix-UDG 
 
60 1X 
Forward primer (200 µM): 
CAAAGCATCCTAAAAAAGGTGTAGAGA 
 
0.24 400 nM 
Reverse primer (200 µM): 
TTCAATTTTCTTTGCATTTTCTACCA 
 
0.24 400 nM 
Probe (100 µM): 6FAM-
TTTTCGTAAATGCACTTGCTTCAGGACC
A-BHQ1 
 
0.24 200 nM 
MgCl2 (50 mM) 
 
2.4  
Template 
 
30  
Nuclease free water 
 
26.88  
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Table 7.8. Reaction formulation for E. coli:26 
 
 
Table 7.9. qPCR conditions for C. albicans and E. coli (instructions provided with 
FastSart kit, Roche): 
 
 
Table 7.10. qPCR Conditions for S. aureus (adapted from instructions provided with 
Platinum® Quantitative PCR SuperMix-UDG): 
Cycles Target temperature 
(˚C) 
Hold time Analysis Mode 
1 50 15 min None 
1 95 5 min None 
45 95 10 s None 
60 60 s Single fluorescence 
acquisition 
Cooling 
1 40 10 s None 
Component of reaction mix Volume for 10 reactions 
(µL) 
Final Concentration 
FastStart Universal SYBR Green Master 
(2X) (Roche) 
 
50 1X 
Forward primer (200 µM):  
AGAAGCTTGCTCTTTGCTGA 
 
0.25 500nM 
Reverse primer (200 µM): 
CTTTGGTCTTGCGACGTTAT 
 
0.25 500nM 
Template 
 
10  
Nuclease free water 
 
39.5  
Cycles Target temperature 
(˚C) 
Hold time Analysis Mode 
1 50 15 min None 
1 95 10 min None 
45 95 15 s None 
60 60 s Single fluorescence 
acquisition 
Melting analysis 
1 95 30 s None 
1 35 60 s None 
1 98 30 s Continuous fluorescence 
acquisition 
Cooling    
1 40 10 s None 
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7.25.6 Statistical analysis 
The susceptibility of C. albicans, S.aureus and E.coli in both single species and 
polymicrobial biofilms to novel peptoids was determined by biofilm inhibition assays. All 
data represent an average of 3 independent experiments and were subject to statistical 
analysis by One-way ANOVA followed by Tukey’s post hoc correction for multiple 
comparisons, where ns: p>0.5; * p< 0.5; **p<0.05, ***p< 0.001; **** p< 0.0001.  
 
7.25.7  SYTOX® Green assay 
Briefly, mid log phase microorganism cultures were adjusted to the appropriate 
concentration (OD 0.7 at 600nm for S. aureus and E. coli, OD 2.0 at 600nm for 
C. albicans). A 50 µL of microorganism suspension in Mueller Hinton broth (MHB) was 
added to each well of a 96 well black flat bottomed plate. 50 µL of each peptoid to be 
tested at final concentration of 100 µM were added to the wells. SYTOX® Green was 
added to each well to a final concentration of 5 µM. The plate was covered, protected 
from light and incubated for 2 hours at 37 ˚C. Microorganisms which had been heat 
treated at 99 ˚C for 10 minutes to permeabilise their membranes served as positive 
controls. Bacteria without any form of peptoid treatment acted as negative controls. 
Additional control wells containing SYTOX® Green only were included to ensure there 
was no background fluorescence. Wells containing SYTOX® Green and peptoid only were 
included to ensure there were no interactions between the SYTOX® Green and peptoids 
that could lead to non-specific fluorescence measurements. The plate was read on a 
fluorimeter (SpectraMax Gemini X fluorimeter; λex 480 nm, λem 530 nm). 
 
7.25.8  Generation of standard curves for PMA-qPCR 
To allow quantification of the numbers of C. albicans, S. aureus and E. coli within both 
single species and polymicrobial biofilms, DNA standards were prepared by extraction of 
DNA from planktonic organisms using the microLYSIS®-Plus kit and purified using the 
DNeasy kit (Qiagen, Manchester, UK). DNA standards corresponding to cell numbers 
from 10–1 x 106 were used in PMA-qPCR assays to generate standard curves from which 
the numbers of living organisms within the biofilms could be determined. 
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Appendices 
 
A1. Supplementary information 
Electronic supplementary information accompanies this thesis, containing 
characterisation data for all the compounds described in Chapter 7, data from biological 
testing discussed in Chapters 3–5 and digital copies of the microscopy images discussed 
in Chapter 5. 
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A2. Peptoid nomenclature 
In an effort to implement a consistent nomenclature across peptoid building blocks in 
this project, given the ambiguity in the current literature, peptoid monomers described 
in this thesis have been tabulated below in Table A1. 
Extra nomenclature and monomers are also listed on www.pep-calc.com/peptoid in 
collaboration with Sam Lear (which also includes residues not used in this project, but 
commonly found in the literature).  
Monomer Chemical Structure Amine Sub-monomer 
NLys 
N-(4-aminobutyl) glycine 
 
 
N-Boc-1,4-diaminobutane 
Nah 
N-(6-aminohexyl) glycine 
 
 
N-Boc-1,6-diaminohexane 
Nap 
N-(3-aminopropyl) glycine 
 
 
N-Boc-1,3-diaminopropyl 
Nae 
N-(2-aminoethyl) glycine 
 
N-Boc-1,4-diaminoethane 
Namy 
N-(pentyl) glycine 
 
 
amylamine 
Nphe 
N-(benzyl) glycine 
 
benzylamine 
Nspe 
N-(S)-(1-phenylethyl) glycine 
 
 
Nrpe 
N-(R)-(1-phenylethyl) glycine 
 
 
 
 
(S)-(−)-α-methylbenzylamine 
 
 
 
 
(R)-(+)-α-methylbenzylamine 
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Npmb 
N-(4-methoxyphenylmethyl) 
glycine 
 
4-methoxybenzylamine 
 
 
 
Npfb 
N-(4-fluorophenylmethyl) glycine 
 
4-fluorobenzylamine 
Nmfb 
N-(3-fluorophenylmethyl) glycine 
 
3-fluorobenzylamine 
Ndfb 
N-(3,5-difluorophenylmethyl) 
glycine 
 
3,5-difluorobenzylamine 
Nsfb 
N(S-4-fluorophenylethyl) glycine 
 
 
 (S)-4-fluoro-α-
methylbenzylamine 
Npcb 
N-(4-chlorophenylmethyl) glycine 
 
4-chlorobenzylamine 
NnVal 
N-(propyl) glycine 
 
propylamine 
NhLeu 
N-(isopentyl) glycine 
 
isopentylamine 
NLeu 
N-(isobutyl) glycine 
 
isobutylamine 
Nbut 
N-(butyl) glycine 
 
butylamine 
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NhArg 
N-(4-guanidinobutyl) glycine 
 
n/a 
 
NArg 
N-(3-guanidinopropyl) glycine 
 
n/a 
NnArg 
N-(2-guanidinoethyl) glycine 
 
n/a 
NGlu 
N-(2-hydroxyethyl) glycine 
 
β-Alanine 
t
Bu ester HCl 
 
NhTrp 
N-(2-indole ethyl) glycine 
 
 
tryptamine 
NhTyr 
N-(4-methoxy phenylethyl) glycine 
 
 
tyramine 
Npyr 
N-(pyridyl) glycine 
 
 
4-(aminomethyl)pyridine 
NhHis 
N-(2-imidazole ethyl) glycine 
 
 
histamine 
Ntfe 
N-(2,2,2-trifluoroethyl) glycine 
 
 
2,2,2 trifluoroethylamine 
Npfp 
N-(2,2,3,3,3-pentafluoropropyl) 
glycine 
 
2,2,3,3,3, pentafluoropropylamine 
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Ndfea 
N-(2,2-difluoroethyl) glycine 
 
2,2 difluroethylamine 
NhCys 
N-(2-thioethyl) glycine 
 
trityl-thioethylamine 
Nea 
N-(ethyl) glycine 
 
ethylamine 
Nte 
N-(2-2(2-methoxyethoxy)ethoxy 
ethyl) glycine 
 
2-2(2-methoxyethoxy)ethoxy 
ethylamine 
Nhept 
N-(heptyl) glycine 
 
heptylamine 
Nchept 
N-(cycloheptyl) glycine 
 
cycloheptylamine 
Ndodec 
N-(dodecyl) glycine 
 
dodecylamine 
Nhexdec 
N-(hexadecyl) glycine 
 
hexadecylamine 
Nprp 
N-(3-propargyl) glycine 
 
propargylamine 
Nsch 
N-(S)-(1-cyclohexylethyl) glycine 
 
 
(S)-(-)-1-cyclohexylethylamine 
Nsna 
N-(S)-(1-napthylethyl) glycine 
 
 
(S)-(-)-1-(2-napthyl)ethylamine 
Ncpa 
N-(cyclopentyl) glycine 
 
cyclopentylamine 
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Table A1. Peptoid monomers used in the synthesis of the peptoid library and the 
corresponding amines that the submonomers are derived from. 
Nbsa 
N-(2-4-aminosulphonamide ethyl) 
glycine 
 
4-(2 aminoethyl) 
benzenesulphonamide 
Ndpe 
N-(2,2-diphenylethyl) glycine 
 
 
2-2-diphenylethylamine 
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A3. Synthesis of mixed lysine- and arginine-type peptoids 
The following data gives an illustration of the Dde-protection and deprotection steps to 
synthesise peptoids with both lysine and arginine monomers in the same sequence, as 
described in Chapter 2. 
The synthesis of the peptoids was monitored via LC-MS, using test cleaves on the resin at 
important steps in the procedure. These spectra are shown below to illustrate the 
synthesis of linear peptoids with both amino and guanido functionalized monomers. The 
synthesis of the cyclic peptoid, as monitored by LC-MS, is also shown. 
 
Linear peptoid 
 
Figure A1. Mass spectra and UV chromatograms following the synthesis of a linear 
mixed Lys/Arg peptoid; 151 [(NnArgNspeNspe)(NaeNspeNspe)]2. 
a) After Dde protection step on free amine, m/z = 1026 [From test cleave, Boc protection 
removed by conditions of cleavage but would remain protected on the full resin] 
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b) After chain elongation and second Dde protection, m/z = 2036, see [M+2H]2+ at 1017 
[From test cleave, Boc protection removed by conditions of cleavage but would remain 
protected on the full resin] 
 
c) Following on-resin Dde-deprotection, m/z = 1707 [From test cleave, Boc protection 
removed by conditions of cleavage but would remain protected on the full resin] 
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d) Crude peptoid after guanidinylation reaction, m/z = 1791 [From test cleave, Boc 
protection removed by conditions of cleavage but would remain protected on the full resin] 
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Cyclic peptoid 
 
Figure A2. Mass spectra and UV chromatograms following the synthesis of a mixed 
Lys/Arg cyclic peptoid; cyclo 134 (NhArgNpheNLysNpheNLysNphe). 
 
a) Crude protected linear precursor, m/z = 1209  
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b) Crude cyclised compound, prior to HPLC, m/z = 1190 
 
 
c) Following HPLC, then hydrazine deprotection of Dde group, m/z = 1026
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d) Following guanidinylation, m/z = 1069 
e) Crude product after final Boc deprotection, m/z = 868
 
        
XIII 
A4. Supplementary information for L. mexicana assays 
Comparison of peptoid activity against promastigotes and amastigotes in assays with and without serum  
 
Figure A3. Comparison of serum and serum-free conditions in L. mexicana promastigotes; ■   12 residue, ▲   9 residue and ● 6 residue peptoids 
(compounds 210–219). 
  
XIV 
 
Figure A4. Comparison of serum and serum-free conditions in L. mexicana amastigotes; ■   12 residue, ▲   9 residue and ● 6 residue peptoids 
(compounds 210–219).   
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Parasite viability graphs for the L. mexicana infection assays 
 
 
Figure A5. The viability of RAW 264.7 murine macrophages (top) and intracellular 
L. mexicana (bottom) following treatment by peptoids. 
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Figure A6. The viability of RAW 264.7 murine macrophages (top) and intracellular 
L. mexicana (bottom) following treatment by peptoids. 
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Figure A7. Photograph to show parasites rescued from the infected macrophage assay 
(in this case from L. mexicana infected RAW cells treated with DMSO only). Lysed RAW 
cell debris is seen as the spherical cells. L. mexicana parasites appear similar to the 
infective, metacyclic promastigote form. Cells appear motile and healthy, with cell 
splitting and cell bundles seen, as indicated by the highlighted region on the 
photograph. The pink colour of the culture is due to the alamarBlue® added at the end 
point of the assay and indicates viable cells. 
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A5. Nisin stability data 
HPLC data from digestion of 322 and 323 
Digestion of 322 and 323 was monitored using analytical RP-HPLC. The starting nisin-
peptoid conjugate is labelled with a star in Figure A8 (322) and Figure A9 (323). At the 
relevant time point, the digestion was sampled (100 µL), 10 µL TFA added to quench 
enzyme activity and a 10 µL injection made to the HPLC instrument. Further conditions 
are described in Chapter 7. 
 
 
Figure A8. RP-HPLC chromatograms for the digestion of 322 by trypsin in tris-HCl 
buffer (50 mM at pH 7.8, with 5 mmol CalCl2) over a 24 hour time period. The starting 
nisin-peptoid conjugate is labelled with a star and cleavage to peptide and peptoid 
fragments can be seen. Intense peak at approximately 1 minute corresponds to TFA 
added to quench enzyme activity. 
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Figure A9. RP-HPLC chromatograms for the digestion of 323 by trypsin in tris-HCl 
buffer (50 mM at pH 7.8, with 5 mmol CalCl2) over a 24 hour time period. The starting 
nisin-peptoid conjugate is labelled with a star and cleavage to peptide and peptoid 
fragments can be seen. Intense peak at approximately 1 minute corresponds to TFA 
added to quench enzyme activity. 
 
MALDI spectra following 24 hour digestion 
 
MALDI spectra of the nisin-peptoid conjugates and peptoid sequences were recorded 
before and after sample incubation with trypsin (at t = 0 and t = 24 h). The spectra 
recorded after 24 hours tryptic degradation are shown in Figure A10 and Figure A11 for 
nisin-peptoid conjugate A (322) and nisin-peptoid conjugate B (323) respectively. 
Significant peaks are seen at m/z 2225 (fragment 325) and m/z 2353 (fragment 326) 
corresponding to cleavage at the nisinAB lysine 12 residue. 
MS/MS was also undertaken on the major product ion following degradation 
experiments using MALDI LIFT to confirm the fragments produced (i.e. cleavage at 
nisinAB lysine 12). MALDI LIFT spectra on ions at m/z 2225 (fragment 325) and m/z 2353 
(326) are shown in Figure A12 and Figure A13 respectively. 
 
 XX 
Figure A10. MALDI mass spectrum showing ions following 24 hour trypsin degradation of peptoid 322 with ions labelled. The spectrum has been 
expanded to show the weak molecular ion peak at m/z 3379.5. Suppression of ions at m/z < 1000. 
 XXI 
Figure A11. MALDI mass spectrum showing ions following 24 hour trypsin degradation of peptoid 323 with ions labelled. The spectrum has been 
expanded to show the weak molecular ion peak at m/z at 3485.2. Suppression of ions at m/z < 1000. 
 XXII 
Figure A12. MALDI LIFT TOF/TOF mass spectrum showing fragmentation of ions at m/z 2224 following trypsin degradation of peptoid 322, with 
ions labelled. Fragmentation of ions at m/z 2224 is consistent with peptoid fragment 325 obtained from cleavage of nisinAB lysine 12 residue in 322. 
 XXIII 
Figure A13. MALDI LIFT TOF/TOF mass spectrum showing fragmentation of ions at m/z 2352 following trypsin degradation of peptoid 323, with 
ions labelled. Fragmentation of ions at m/z 2352 is consistent with peptoid fragment 326 obtained from cleavage of nisinAB lysine 12 residue in 323. 
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A6. Partitioning experiments 
Dynamic light scattering  
All of the peptoids used in the hydrophobicity study in Chapter 5 were checked at high 
concentration (~500 µM) in PBS for indicators of aggregation using dynamic light 
scattering (Figure A15).  
Peptoids that partitioned into the octanol substantially during the partitioning 
experiment were also checked at high concentration (~500 µM) in octanol for indicators 
of aggregation using dynamic light scattering (Figure A14).  
Due to the increase in intensity of scattering with size, the presence of a signal at small 
hydrodynamic diameters indicates the overwhelming majority of the sample is present in 
the smallest peak. 
 
 
Figure A14. DLS traces for selected peptoids at 500 µM in octanol. 
         
 
XXV 
 
Figure A15. DLS traces for all peptoids tested in partitioning experiments at 500 µM in PBS. 
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A7. Additional confocal fluorescence microscopy images 
The following section contains additional microscopy images, referred to in Chapter 5. 
 
Figure A16. Incubation of 40 µM peptoid 334 fluorescein-Gly-(NLysNspeNspe)2 with 
NIH-3T3 cells at 37 ˚C. Showing cell images and the green fluorescence seen around the 
cell, rather than inside the cell. Scale bar 20 µm. A incubation time: 15 min; B incubation 
time: 30 min. 
 
 
Figure A17. Incubation of 40 µM temporin A peptide 342 with NIH-3T3 cells at 4 ˚C for 
30 min. Cells washed prior to imaging. The lack of peptide fluorescence suggests an 
active transport mechanism. A cell image; B mitochondrial autofluorescence (pink); C 
channel where peptide fluorescence is expected.  
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Figure A18. Partial overlap of temporin A peptide 342 and ERTG during incubation of 
20 µM 342 with PC3 cells and ERTG at 37 ˚C for 4 h. A cell image; B fluorescence of 342 
(green); C fluorescence of ERTG (red); D autofluorescence of mitochondria (pink); E 
merge.  
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Figure A19. Partial overlap of temporin B peptide 343 and ERTG during incubation of 
20 µM 343 with PC3 cells and ERTG at 37 ˚C for 4 h. A cell image; B fluorescence of 343 
(green); C fluorescence of ERTG (red); D autofluorescence of mitochondria (pink); E 
merge. 
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A8. Selected additional publications 
 
The following publication describes work using Leishmania mexicana mutants, Δlpg1 and 
Δlpg2, with differing cell membrane compositions (see Figure A20) to rationalise the 
differential activities of the Temporin family of antimicrobial peptides against the amastigote 
and promastigote forms of the parasite. It is shown that the although the lipophosphoglycan 
layer (LPG) has little effect, the presence of proteophosphoglycan (PPG) on the parasitic cell 
membrane is at least partly responsible for the increased susceptibility of promastigotes to the 
peptides, in comparison to the more resistant amastigotes. 
 
 
Figure A20. Plasma cell membrane of a typical Leishmania mexicana promastigote. The Δlpg1 
parasite is designed to lack LPG, the Δlpg2 is designed to lack both LPG and PPG. 
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Abstract: Natural product antimicrobial peptides (AMPs) have been proposed as 
promising agents against the Leishmania species, insect vector borne protozoan parasites 
causing the neglected tropical disease leishmaniasis. However, recent studies have shown 
that the mammalian pathogenic amastigote form of L. mexicana, a causative agent of 
cutaneous leishmaniasis, is resistant to the amphibian-derived temporin family of AMPs 
when compared to the insect stage promastigote form. The mode of resistance is unknown, 
however the insect and mammalian stages of Leishmania possess radically different cell 
surface coats, with amastigotes displaying low (or zero) quantities of lipophosphoglycan 
(LPG) and proteophosphoglycan (PPG), macromolecules which form thick a glycocalyx in 
promastigotes. It has been predicted that negatively charged LPG and PPG influence the 
sensitivity/resistance of promastigote forms to cationic temporins. Using LPG and PPG 
mutant L. mexicana, and an extended range of temporins, in this study we demonstrated 
that whilst LPG has little role, PPG is a major factor in promastigote sensitivity to the 
temporin family of AMPs, possibly due to the conferred anionic charge. Therefore, the 
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lack of PPG seen on the surface of pathogenic amastigote L. mexicana may be implicated 
in their resistance to these peptides. 
Keywords: Leishmania mexicana; cutaneous leishmaniasis; drug therapy;  
antimicrobial peptide 
 
1. Introduction 
Leishmaniasis is a neglected tropical disease that is endemic in over 80 countries worldwide. It is 
caused by Leishmania species, insect vector borne protozoan parasites, and affects an estimated  
12 million people a year with a further 350 million people living at risk of infection [1]. At the present 
time a vaccine to prevent leishmaniasis is not available and treatment currently relies entirely on a 
limited arsenal of chemotherapeutics. For example, treatment of cutaneous leishmaniasis (CL) largely 
relies on the pentavalent antimonials such as sodium stibogluconate (Pentostam) and meglumine 
antimoniate (Glucantime) [2,3]. Both Pentostam and Glucantime have been in clinical use for over 70 years 
despite their associated problems, which include severe side-effects such as cardiotoxicity [4] and the 
fact that they require parenteral administration [5]. In addition, the use of pentavalent antimonials in 
the treatment of leishmaniasis is under threat from the emergence of drug resistance [6]. To date 
resistance has not been widespread in the field but Leishmania spp. resistance to Pentostam and 
Glucantime can be easily induced in the laboratory [7]. Amphotericin B (Fungizone) [8] and diamidine 
Pentamidine [9] are employed as second-line drugs in the treatment of CL. Like the antimonials, they 
induce severe side-effects and parasite resistance, although not yet conclusively confirmed in the field, 
has been observed under laboratory conditions [10]. Given the aforementioned issues with both the 
current first- and second-line drugs used to treat CL there is clearly a need to develop new and 
effective therapies for this disease. 
In recent years natural product antimicrobial peptides (AMPs) have been investigated as a potential 
new source of novel antileishmanials [11,12], in part this has been catalysed by the fact that they have 
displayed promising activity against other cutaneous infectious diseases [13]. The activity of AMPs 
against Leishmania species that give rise to CL has recently been reported. However, despite having 
promising activity against insect-stage promastigotes, the amphibian-derived temporin family of AMPs 
has shown limited efficacy against mammalian-stage amastigotes [14]. The predominant surface 
component of promastigote Leishmania is lipophosphoglycan (LPG), a large glycoconjugate which 
together with cell surface associated proteophosphogycan (PPG) forms a dense glycocalyx protecting 
the parasite from the mammalian innate immune response on inoculation from the sand fly vector [15]. 
Subsequently, following infection of macrophage cells and differentiation into the pathogenic 
amastigote form, expression of cell surface LPG and PPG is massively down-regulated [15,16]. Whilst 
it has previously been predicted that this thick, negatively charged layer protects the promastigote 
parasite from cationic AMPs by capturing them and preventing interaction with the cell surface [17], 
the relative resistance of amastigotes to temporin AMPs suggests the opposite. Herein, we report an 
extended study of the antileishmanial properties of temporins and the examination of the protective or 
sensitizing effects of LPG and PPG in L. mexicana, a causative agent of CL. 
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2. Results and Discussion 
2.1. The Antileishmanial Properties of Temporin Antimicrobial Peptides 
Temporins A, B, 1Sa, F and L were synthesized and analyzed as described in the Experimental 
Section. The sequences, formulae and accurate mass data are summarized in Table 1. As previously 
reported [14] temporin A displayed significant activity against L. mexicana promastigotes with an 
ED50 of 8 µM. Whilst temporin B demonstrated low potency with an ED50 of 38 µM (Figure 1A;  
Table 2). However, in contrast to the previous study [14] temporin 1Sa demonstrated good activity 
against these insect stage forms, an ED50 of 4 µM (Figure 1). The reasons for this divergence are not 
clear, however the previously synthesized 1Sa [14] demonstrated similar activity on reanalysis to that 
shown in Figure 1, indicating that the assay is likely to be the source of this discrepancy. Notably, 
serum is observed to mask the efficacy of the temporin peptides [14]. Therefore, it is likely that the 
serum was inadequately removed before assay in the previous study, thereby leading to the 
underestimation of 1Sa efficacy. To expand this work further temporins F and L were synthesized and 
purified as described, and then screened against L. mexicana promastigotes. Both AMPs showed good 
activity, F with an ED50 of 14 µM and L with an ED50 of 5 µM (Figure 1A; Table 2). 
Table 1. Tabulated sequences for the peptides tested including accurate mass data. The 
doubly charged ion was used for accurate mass measurements, i.e., [M+2H]2+. All peptides 
are amidated at the C terminus. Lysine (K) and arginine (R) are positively charged  
side chains. 
 
Peptide Sequence 
Empirical 
Formula 
Mass Calculated 
[M+2H]2+ 
Accurate Mass Found 
[M+2H]2+ 
Temporin A FLPLIGRVLSGIL-NH2 C68H117N17O14 698.9561 698.9548 
Temporin B LLPIVGNLLKSLL-NH2 C67H122N16O15 696.4716 696.4735 
Temporin 1Sa FLSGIVGMLGKLF-NH2 C67H109N15O14S 690.9078 690.9075 
Temporin F FLPLIGKVLSGIL-NH2 C68H117N15O14 684.9531 684.9504 
Temporin L FVQWFSKFLGRIL-NH2 C83H122N20O15 820.9792 820.9792 
Table 2. ED50 for temporins against wild type and mutant L. mexicana promastigotes and 
amastigotes. Mean ED50 (and range) shown for the values from at least 3 independent 
experiments performed in triplicate. 
Peptide 
ED50 (µM) 
L. mexicana 
Promastiogte 
L. mexicana 
Amastigote 
L. mexicana 
∆lpg1 
L. mexicana 
∆lpg2 
Temporin A 8 (6–14)  ~100 11 (8–16)  26 (21–39)  
Temporin B 38 (24–64)  >100 39 (28–70)  41 (40–41)  
Temporin 1Sa 4 (3–13) 42 (35–44) 6 (3–18)  31 (28–35)  
Temporin F 14 (10–27) >100 17 (13–29)  23 (16–49)  
Temporin L 5 (5–6) 83 (46–93)  4 (3–6) 9 (8–12) 
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Figure 1. Activity of the temporin peptides against wild type promastigote and amastigote 
L. mexicana. Using the alamarBlue® assay system, L. mexicana promastigote (A) and 
amastigote (B) viability in the presence of various concentrations (2–100 µM) of the 
temporin peptides was determined with respect to a DMSO control. Amphotericin B  
(2–100 µM) was utilized as a positive control. Data points represent the mean of  
3 independent experiments performed in triplicate. Standard deviation indicated. Cell 
viability <50% indicated by red bars. 
However, as previously noted [14], temporin A demonstrated drastically reduced activity against 
the clinically relevant amastigote form of L. mexicana (ED50 of approximately 100 µM), whilst 
temporin B was inactive at the maximal concentration tested, 100 µM. Similarly, temporin F was 
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inactive at 100 µM, whilst 1Sa and L had very low levels of activity against amastigote compared to 
promastigote forms (ED50 42 and 83 µM respectively; Figure 1B; Table 2). 
Temporins A, B and 1Sa have all demonstrated significant activity against axenic amastigotes forms 
of other Leishmania species, A and B against L. pifanoi [18] and 1Sa against L. infantum [19].  
L. infantum is an Old World species and a member of the L. donovani complex, causing visceral 
disease in the Mediterranean basin, which has subsequently spread to Latin America where it is 
sometimes known as L. chagasi [20]. Like L. mexicana, L. pifanoi is a New World species, however it 
is part of the subgenus Viannia whereas L. mexicana is part of the subgenus Leishmania which actually 
makes it more closely related to L. infantum [21]. The considerable evolutionary distance between 
these different species and subgenra may account for the differing levels of temporin activity observed 
against amastigotes. The distance is reflected in diversity in the predominant surface glycoconjugates 
LPG, PPG and glycoinositolphospholipids (GIPLs), macromolecules which play significant roles in 
the parasite’s interface with its insect and mammalian hosts [22]. However, whilst L. pifanoi and  
L. infantum have not been extensively analyzed, the levels of LPG and PPG in amastigotes from both 
Old and New World species are low or zero [15,16] indicating that other factors confer temperin 
susceptibility. GIPLs are maintained in both lifecycle stages and although L. pifanoi and L. infantum 
remain relatively unstudied, significant inter-species variations in GIPL structure have been elucidated. 
L. Viannia panamenensis decorates the conserved galactose-mannose, glycophosphoinositol core with 
galactose motifs, whereas L. donovani GIPLs are highly mannosylated when compared to the simpler 
L. mexicana structures [22]. It is possible that these significant variations account for the differential 
activity of some temporin AMPs against axenic amastigotes reported in the literature. 
2.2. The Role of Phosphoglycans in the Susceptibility of L. Mexiciana to the Temporin Family of 
Antimicrobial Peptides 
Previously it has been postulated that LPG, which forms a thick negatively charged layer, protects 
the promatigote parasite from cationic AMPs by capturing them and preventing interaction with the 
cell surface [17]. However, the fact that amastigote L. mexicana possess little or no LPG at their 
surface [16], and yet are considerably more resistant to the temporin AMPs, argues against this 
hypothesis. Rather it suggests that LPG is a susceptibility factor, with the negatively charged 
macromolecule perhaps facilitating the concentration of these cationic peptides at the plasma 
membrane. To test this hypothesis the five temporins were assayed for their activity against L. mexicana 
promastigotes engineered to lack LPG, ∆lpg1 [23]. Targeted deletion of the β-galactofuranosyl 
transferase lpg1 in L. mexicana specifically blocked LPG expression, leaving the other 
phosphoglycans unaffected [23]. The results obtained were perhaps surprising, with the temporins 
showing little or no difference in efficacy against the ∆lpg1 mutant when compared with the wild type 
L. mexicana promastigotes (Figures 1A and 2A; Table 2). However, it is notable the that efficacy of 
temporins A and B have previously been reported to be unchanged against a similar, although less 
defined, L. donovani LPG mutant [18,24]. 
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Figure 2. Activity of the temporin peptides against ∆lpg1 and ∆lpg2 promastigote  
L. mexicana. Using the alamarBlue® assay system, L. mexicana ∆lpg1 (A) and ∆lpg2 (B) 
mutant promastigote viability in the presence of various concentrations (2–100 µM) of the 
temporin peptides was determined with respect to a DMSO control. Amphotericin B  
(2–100 µM) was utilized as a positive control. Data points represent the mean of  
3 independent experiments performed in triplicate. Standard deviation indicated. Cell 
viability <50% indicated by red bars. 
Proteophosphogylcans (PPGs) are a large range of secreted and cell surface associated parasite 
glycoconjugates which, like LPG, carry a negative charge [25]. Both axenic and intramacrophage  
L. mexicana amastigotes lack cell surface associated PPG, although the intracellular parasites do 
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secrete a form of PPG known as aPPG [26,27]. Targeted deletion of lpg2, a Golgi GDP-Man 
transporter, to create ∆lpg2 [25] prevented the formation of the phosphoglycan repeats that make up 
the backbone of LPG and PPG leaving the promastigote surface devoid of these negatively charged 
macromolecules. In contrast to the ∆lpg1 mutant, the ∆lpg2 promastigotes appeared less sensitive to all 
the temporins assayed, with the exception temporin B which was the least active of the AMPs against 
wild type promastigote forms. Temporins A, 1Sa and L showed the greatest difference in efficacy 
between wild type and ∆lpg2 promastigotes (temporin A: ED50 8 µM in wild type vs. ED50 26 µM in 
∆lpg2; 1Sa: 4 vs. 31; L: 5 vs. 9), with the activity of 1Sa against the mutant close to that of the 
generically resistant amastigote form (ED50 42 µM in amastigotes vs. ED50 31 µM in ∆lpg2). This 
indicated that PPG plays a role in promastigote sensitivity to the temporins (Figures 1 and 2B; Table 2) 
perhaps due to its negative charge attracting the cationic AMPs to the plasma membrane. However, it 
is notable that the clinical antileishmanial amphotericin B (used as a control in these experiments) is 
also less effective against ∆lpg2 L. mexicana (Figure 2B) indicating that the lack of PPG is leading to a 
generic increase in resistance to disruptors of the parasite cell surface. Like the temporins, 
amphotericin B is a pore forming compound [28]. 
3. Experimental Section 
3.1. Materials and Reagents 
Abbreviations for reagents are as follows: tert-butoxycarbonyl (Boc); 9-fluorenylmethoxylcarbonyl 
(Fmoc); trifluoroacetic acid (TFA); triisopropylsilyl (TIPS); N,N-dimethylformamide (DMF); dimethyl 
sulfoxide (DMSO). Solvents and reagents were purchased from commercial sources and used without 
further purification unless otherwise noted. Rink amide resin (typical loading level 0.6–0.8 mmol/g) 
was purchased from Merck4Biosciences (Darmstadt, Germany). DMF was purchased from AGTC 
Bioproducts (National Diagnostics, Hessle, UK). Piperidine and DIPEA were purchased from Sigma 
Aldrich (Gillingham, UK), PyBOP from Apollo Scientific (Stockport, UK) and Fmoc-protected amino 
acids from Novabiochem (Merck, Nottingham, UK). Preparative RP-HPLC was performed with a 
semi-preparative Perkin Elmer (Waltham, MA, USA) Series 200 lc pump fitted with a 785A UV/Vis 
detector using a SB-Analytical ODH-S optimal column (250 × 10 mm, 5 µm, Waters Ltd, Elstree, UK); 
flow rate 2 mL/min. Peptides were characterised by accurate LC-MS (QToF mass spectrometer and an 
Acquity UPLC from Waters Ltd using an Acquity UPLC BEH C8 1.7 µm (2.1 mm × 50 mm) column 
(Waters Ltd) with a flow rate of 0.6 mL/min and a linear gradient of 5%–95% of solvent B over  
3.8 min (A = 0.1% formic acid in H2O, B = 0.1% formic acid in MeCN). Peptide identities were also 
confirmed by MALDI-TOF mass spectra analysis (Autoflex II ToF/ToF mass spectrometer Bruker 
Daltonik GmBH, (Coventry, UK) operating in positive ion mode using an α-cyano-4-hydroxycinnamic 
acid (CHCA) matrix. Data processing was done with MestReNova Version 8.1. 
3.2. Peptide Synthesis 
Rink Amide AM resin (200–400 mesh, 0.79 mmol/g loading) and all Fmoc-protected amino acids 
used were purchased from Novabiochem, Merck. PyBOP™ was purchased from CEM (Buckingham, 
UK). HPLC grade solvents were obtained from Fisher Scientific (Loughborough, UK) and all other 
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reagents from Sigma Aldrich. Side chain protecting groups utilised for the Fmoc amino acids were  
t-butyl for Ser, Pbf for Arg, Boc for Lys and Trt for Asn. Temporins A, B and 1Sa were prepared as 
previously described [14]. Temporins A, B, 1Sa, F and L were prepared via manual Fmoc SPPS. 
Peptides were synthesised on a 0.1 mmol scale (127 mg of Rink Amide AM resin). Fmoc amino acids 
(2 equiv.) were coupled using PyBOP (2 equiv.) and DIPEA (4 equiv.) at RT for 1 h on a shaker  
(380 RPM, manual procedure). For the first C-terminus amino acid, double coupling was used. Also all 
amino acids from the 7th position were double coupled to increase the yield. Fmoc deprotection was 
carried out using piperidine/DMF (20% v/v) for 5 and then 10 min at RT. Final peptide cleavage was 
achieved using TFA:TIPS:H2O 95:5:5 (4 mL) at 25 °C with stirring for a minimum of 4 h. The 
cleavage cocktail was collected, the solvent removed in vaccuo, the crude peptides dissolved in 
acidified H2O (0.1% TFA) and lyophilised. Crude peptides were purified by semi-preparative  
RP-HPLC, by use of a Perkin Elmer series 200 LC pump, 785A UV/Vis detector, using a  
250 mm × 10.0 mm, 5 µm SB analytical column; flow rate = 2 mL/min linear gradient elution  
0%–100% B over 60 min (A = 0.1% TFA in 95% H2O and 5% CH3CN, B = 0.1% TFA in 5% H2O and 
95% CH3CN) at λ = 220 or 250 nm. Relevant fractions were collected, lyophilized, and analysed by  
LC–MS, MALDI-TOF MS and analytical HPLC. See Supplemental Materials for analytical data 
(MALDI-TOF MS spectra and analytical HPLC spectra). Temporin A [FLPLIGRVLSGIL-NH2], 
temporin B [LLPIV GNLLKSLL-NH2], temporin 1Sa [FLSGIVGMLGKLF-NH2], temporin F 
[FLPLIGKVLSGIL-NH2], and temporin L [FVQWFSKFLGRIL-NH2]. 
3.3. Antileishmanial Assay 
Leishmania mexicana (MNYC/BZ/62/M379) wild type and LPG mutant parasites (∆lpg1 [23] and 
∆lpg2 [25]) were maintained at 26 °C in Schneider’s Drosophila media (Sigma Aldrich) supplemented 
with heat inactivated foetal bovine sera (15% for promastigotes and mutants, and 20% for amastigotes; 
Biosera). Promastigotes were transformed into axenic amastigotes by a pH and temperature shift as 
previously described [29]. Cells were counted using a Neubauer Improved Haemocytometer. Cytotoxicity 
analyses were performed in 96-well plates (Costar, Corning Inc., Amsterdam, The Netherlands) using 
alamarBlue® (Life Technologies, Paisley, UK) with some modifications to the published, optimized 
protocol [14]. Briefly, to mitigate against the effects of serum on the efficacy of the peptides, 
promastigote and amastigote L. mexicana were preincubated (26 °C for promatastigotes; 33 °C for 
amastigotes) with the temporins (2–100 µM) in 10 µL of serum-free media at 4 × 106 mL−1 for 1 h 
before the addition of 90 µL of complete media. Following incubation at the appropriate temperature 
for 24 h, 10 µL of alamarBlue® was added to each well and the plates incubated for a further 4 h prior to 
assessing cell viability using a fluorescent plate reader (Biotek UK, Potton, UK; 560EX nm/600EM nm). 
All data points were in triplicate, with amphotericin B as positive and DMSO as negative controls. All 
of the experiments described above were carried out on a minimum of three separate occasions to 
ensure a robust data set was collected. 
4. Conclusions 
In summary, L. mexicana amastigotes are generically resistant to the temporin family of AMPs. 
This is not attributably to their lack of LPG when compared to the insect stage promastigote form. 
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However, promastigote L. mexicana lacking both LPG and the other major negatively charged surface 
macromolecule PPG are notably more resistant to the temporin AMPs than either wild type or the LPG 
mutant promastigotes. Given that amastigote L. mexicana lack LPG and surface-associated PPG, it 
may be considered that the cell surface of these mutant promastigotes resembles that of the mammalian 
pathogenic form [26,27], leading to the hypothesis that PPG is at least partly responsible for the 
sensitivity of promastigote compared to amastigote L. mexicana. Notably, for temporin 1Sa, the ED50 
against ∆lpg2 L. mexicana promastigotes (lacking both of LPG and PPG; 31 µM) was closer to that 
established for amastigote form (49 µM) than the wild type promastigote form (4 µM; Table 2;  
Figures 1 and 2). This indicated that, at least for temporin 1Sa, PPG is a major factor in promastigote 
sensitivity. As hypothesized, this could be due to the highly negatively charged PPG attracting the 
cationic temporin peptides towards their site of action, the plasma membrane. However, alternative 
explanations are conceivable. For example, both LPG and cell surface associated PPG are 
glycophosphoinositol lipid-anchored to the Leishmania plasma membrane [30] and their absence may 
significantly alter membrane fluidity and, perhaps, AMP sensitivity. Whatever the mechanism it is 
clear that the loss PPG (together with LPG) increases the resistance of L. mexicana to a range of 
temporin AMPs. Given the lack of these predominant macromolecules in pathogenic amastigote forms 
this may preclude their development as antileishmanials, however secreted PPG associates with  
L. major promastigotes to form a mucin-like coat [31]. Given that intramacrophage (but not axenic)  
L. mexicana amastigotes secrete a form of PPG, aPPG [26,27], it is possible that the presence of this 
macromolecule within the phagolysosome, and its potential association with the parasite cell surface, 
will sensitize the pathogen to the temporin AMPs. 
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Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/02/2775/s1. 
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